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Aims 
 
The study aims were to: 
 provide an evidence base of long-term and short-term health effects of air pollutants in 
Australian children that will contribute to the review of National Environment 
Protection (Ambient Air Quality) Measure (NEPM) standards  
 obtain quantitative effect estimates for the association between children’s historical 
lifetime exposure to the criteria air pollutants contained in the NEPM (O3, PM10, PM2.5, 
NO2, CO, SO2) and (a) the period prevalence of adverse health outcomes such as 
respiratory symptoms (asthma, cough and wheeze), and (b) lung function  
 obtain quantitative estimates of the prospective day-to-day association between the 
criteria air pollutants and (a) incidence of respiratory symptoms, and (b) lung function 
in school children with a history of asthma, aged 7–11 years at baseline 
 determine whether any effects are modified by other factors, such as socio-economic 
disadvantage, geographical area, sex, activity patterns and obesity. 
 
Methods 
 
The target population was Australian school children aged 7–11 years whose exposure to the 
criteria air pollutants was representative of other urban Australian school children of that age.  
The sampling strategy was based on selecting schools, then whole classes within schools.  
Children were not excluded on the basis of race, ethnicity or other socio-demographic factors.   
Exposures of interest were criteria ambient air pollutants measured using standard NEPM air 
quality monitoring stations.  Schools were selected which: 
 were close to NEPM monitors which had been on site for a reasonable number of years  
 were considered to be representative of a larger area around the site  
 could demonstrate the maximum variability of exposures to the various pollutants.    
The cross-sectional study recruited 2,860 children.  Air pollution metrics were average 
exposures over the period of residence of the child near the monitored site.  Hierarchical models 
(with state and school as levels) were used to examine the association between outcome 
variables such as lung function and respiratory symptom and the air pollutant exposures.  
These models were fitted separately for each pollutant.  Confounding variables (such as age and 
sex) were added according to their improvement to the overall model fit.  Finally, 
multi pollutant models were explored in order to estimate which pollutants have the strongest 
independent associations with lung function and asthma. 
 
Within the baseline cross-sectional sample, the nested panel study recruited 270 children with a 
history of asthma, who each provided up to 36 days of data.  Daily air pollution metrics 
corresponding to the averaging periods used in the NEPM were used.  Generalised linear 
models were used, with a random effects mode (random intercepts) to analyse the panel data, 
with adjustments for daily mean temperature and number of hours spent outdoors in vigorous 
physical activity.  Interaction between the air pollutant and mean daily temperature and daily 
number of hours spent outdoors in vigorous physical activity were examined.  
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Findings from cross-sectional study  
 
The cross-sectional study shows consistent evidence of respiratory adverse effects of nitrogen 
dioxide (NO2) for both recent and life-time exposure.  These adverse effects are manifested as 
increased risk of asthma-like symptoms (in particular, wheeze), increased airway inflammation 
and reduced lung volumes.  For current asthma and per ppb recent exposure NO2, the odds 
ratio (OR) was 1.06 (1.02, 1.10), with OR per interquartile range (IQR) NO2 1.26 (1.08, 1.48).  For 
recent wheeze after exercise, the OR was 1.07 (1.03, 1.120) per ppb and 1.32 (1.12, 1.57) per IQR.  
Airways inflammation as measured by exhaled nitric oxide (NO) increased by 3% (1%-5%) and 
lung volume as measured by pre-bronchodilator forced expiratory volume (FEV1) and forced 
vital capacity (FVC) decreased by 7.1 ml (2.8-11.4) and 6.8 ml (2.7-10.9) per ppb respectively. 
Effect estimates were slightly smaller for lifetime exposure. Per IQR decreases in lung function 
measured by FEV1 and FVC pre- and post-bronchodilator ranged from 27.5 to 29 ml. 
 
There was no evidence that the effects were stronger in atopic subjects, apart from sulphur 
dioxide (SO2).  The absence of a greater effect in atopic subjects, the finding that lung volumes, 
rather than airway calibre (reflected in FEV1/FVC ratio), and persistence of the effect after 
bronchodilator, imply that the consequence of NO2 exposure is not typical asthma; instead, 
more non-specific lung effects are implicated.  
 
Particulate matter exposures showed varied results.  Lifetime exposure to PM10 was associated 
with decline in FEV1 post-bronchodilator (decrease of 5.1 ml (0.1-10.1) per g/m3, and  19.3 ml 
(0.23-38.3) per IQR) and increase in exhaled NO (4% (1%-6%) ppb, and 14% (5%-23%) per IQR), 
but did not increase current symptoms.  Recent exposure to PM2.5 was associated with an 
adverse effect on forced vital capacity (FVC) post-bronchodilator (decrease of 43.4 ml (9.3-77.4) 
per g/m3 and , and  46.3 ml (9.95-82.7) per IQR and airways inflammation (increase of 2% ppb 
(2%-3%)) in exhaled NO per g/m3 , with no overall effects on current symptoms.  In non-atopic 
children only, recent exposure to PM2.5 was associated positively with risk of wheezing, asthma, 
and asthma medication, and current asthma, use of beta-agonists and itchy rash in non-atopic 
children. 
 
O3 showed some effects in a beneficial direction (perhaps due to the NO2 effects and the 
negative association between O3 and NO2) but these were eliminated in the joint O3- NO2 
model. 
 
Recent exposure to SO2, after adjustment for O3, showed an adverse effect on lung function 
measures, with a decrease of 30.5 ml (2.2-58.5) per ppb and 24.9 ml (1.79-48.1) per IQR for FEV1 
pre-bronchodilator. SO2 effects on lung function were modified by atopic status, being more 
deleterious in atopic children, and non-significant in non-atopic status.  Reported history of 
wheezing, asthma and asthma medication, and recent itchy rash for six months increased with 
SO2 in non-atopic children, with no effect in atopic children. 
 
Findings from panel study  
 
Single pollutant models produced only few significant adverse effects of air pollutants on 
children's respiratory health.  In particular significant effects on lung function were few, and 
those that occurred showed no consistent pattern. 
 
The most consistent adverse effect was that increased NO2 exposure was associated with an 
increased risk of cough and wheeze during the day and night, and increased use of 
bronchodilators for symptom relief.  Relationships between NO2 and night symptoms and 
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effects were greater for NO2 24-hr than for NO2 1-hr and were more consistent.  For lag 2 NO2 1-
hr the OR (95% CI) was 1.03 (1.01-1.05) per ppb for the association with night cough.  For lag 2 
NO2 24-hr, ORs were 1.06 (1.03-1.09) per ppb for the association with night cough, 1.05 (1.01-
1.10) per ppb for the association with night wheeze, and 1.05 (0.99-1.12) per ppb for the 
association with night shortness of breath.  Effects upon symptoms occurring during the day 
were strongest at lag 0.  For lag 0 NO2 1-hr, the ORs (95% CI) were 1.02 (1.0-1.03), 1.04 (1.01-
1.06), and 1.02 (0.99-1.05) per ppb for associations with day cough, wheeze and shortness of 
breath respectively.  For lag 2 NO2 24-hr, ORs were 1.05 (1.02-1.09), (1.11 (1.07-1.16), and 1.06 
(1.01-1.11) per ppb for the association with day cough, wheeze and shortness of breath 
respectively. 
 
Night symptoms were also adversely associated with 8–hour CO although these effects were 
not consistent or strong.  PM10 24-hr lag 2 was associated with increased risk of night cough: OR 
= 1.03 (1.01-1.05) per g/m3.   
 
There were protective effects for O3 and night wheeze and night shortness of breath and this 
was consistent across all the three metrics for O3.  There was only one significant association 
between air pollution and the use of reliever medication at night (association between SO2 1-hr 
and use of reliever medication at night).   
 
Children were also more likely to use more reliever medications for asthma on days with higher 
NO2 concentrations (OR: 1.05 (1.01-1.10) per ppb for daytime use of medication for symptoms 
and lag 0 NO2 24-hr).  There was one association between air pollution (lag 2 PM10 24-hr) and 
preventer use for symptoms and a single association where higher O3 levels (lag 2 O3 8-hr) were 
associated with decreased use of preventers for symptoms. 
 
In two pollutant models compared to single pollutant models, the effects of NO2 on lung 
function were increased whereas the effects on symptoms slightly decreased.  Further, in the 
two pollutant models compared to single pollutant models, effects on daytime medication use 
were no longer significant.   
 
Also investigated were the effects of PM10 in two pollutant models with each of the gases (O3, 
NO2, SO2 and CO).  Significant negative effects on morning lung function were seen, 
particularly when SO2 was included in the models.  Associations between PM10 and both night 
and daytime symptoms (cough and wheeze) generally persisted when NO2 and CO were added 
to the models.  PM10 was also associated with runny nose when SO2 was included in the 
models.  Significant increased use of daytime reliever medications was only observed in two 
pollutant models with CO.  The odds ratios in all models were consistently greater in the two 
pollutant models compared with single pollutant models especially for lag 1 PM10 and lag 2 
PM10. 
 
A warm season analysis was conducted for O3 as O3 levels are higher in the warmer months. 
The results were similar to those obtained when the analyses were conducted regardless of the 
season.  There were no adverse associations between warm season O3 and lung function, 
symptoms and medication use in this sub-analysis.  There were a few positive associations 
(beneficial effects) with night wheeze; that is, children experienced fewer wheeze symptoms 
during the night when O3 levels were high the previous day.  
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Methodological Issues 
 
Exposure measurement 
 
ACHAPS relied on historical NEPM monitoring for measures of exposure.  There have been 
concerns that the use of such fixed site ambient ozone monitoring stations may not adequately 
characterise the actual personal exposure to ambient air pollutants especially as people spend a 
large proportion of their time indoors where the air pollution concentrations can be much lower 
than ambient concentrations. 
 
While the study differentiated between average lifetime exposure (measured from the time the 
child began living in the area) and recent exposure (averaged over the last year), it remained 
difficult to distinguish between long-term and shorter-term effects, due to correlations of effects 
over time.  While ambient pollution measures were available for many sites, gaps in data were 
left as sites, in general, did not monitor all pollutants over the entire period of the study.  This 
also limited data available to explore multiple-pollutant models. 
 
Sites were chosen according to availability of NEPM monitoring and to maximise variability in 
the targeted pollutants.  A consequence of this choice of sites was that it was difficult to judge 
the representativeness of the sample of children, in relation to the target population of all urban 
primary-school aged children.  The characteristics of the sample in terms of prevalence of 
asthma and other conditions appear to correspond to published estimates from national 
surveys. 
 
Lung function measurement 
 
In the cross-sectional study, lung function was measured, before and after bronchodilator, in 
accordance with the recommendations of the ATS/ERS Task Force performance criteria for 
spirometry.  This measures flow using a pressure transducer and derives volume by integrating 
flow over time was attached to a laptop computer running SpiroScore+ V2.6 for immediate data 
acquisition.  These measures have high reliability and validity. 
In the panel study, lung function (PEF and FEV1) was measured using a Mini-Wright Digital 
electronic peak flow meter. Peak flow meters are widely used in longitudinal studies because 
they are portable and relatively inexpensive, allowing frequent measures of lung function at 
low cost.  It has been demonstrated that the PEF, as measured by a mini Wright peak flow 
meter, is both accurate and reproducible and can be used in epidemiological studies to measure 
lung function. The mini Wright peak flow meter is a convenient and effective tool for 
characterising changes in PEF associated with exposure to ambient air pollution. 
 
Information bias 
 
A challenge for any spatially-constructed study is that of confounding, particularly by spatial-
level confounders.  A major contender for confounding is socio-economic status which is 
spatially distributed, and which may separately relate to both exposure and health outcome.  
The analyses presented in this report have been adjusted at the cluster level for the SEIFA 
indices for relative socio-economic advantage and disadvantage, and for education, and at the 
individual level for parent's education.  Sensitivity analyses which incorporated other spatial 
measures showed, in fact, very few variables (for example, household characteristics) altered 
estimates of effects once the standard variables (age, sex, socio-economic status - as just 
described) were included in models. 
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Questions asking about respiratory symptoms and asthma were derived from existing, widely 
used questionnaires; these included the International Study of Asthma and Allergies in 
Childhood and the Southern California Child Health Study.  Preference was given to the ISAAC 
questionnaire as a source document because of its widespread use (over 300,000 respondents) 
and extensive validation.   
 
Conclusions 
 
Few other studies have been conducted in Australia on the chronic or longer-term health effects 
of outdoor air pollution on children’s health, although a larger number have examined the 
acute effects.   
 
NO2 was the pollutant most consistently associated with adverse effects on children's health.  
These effects were present for both lung function and current symptoms in the cross-sectional 
study, and for symptoms and medication use in the panel study.  The panel study found very 
little evidence of pollutant effects on lung function.  While PM effects on symptoms were seen 
in both the cross-sectional and panel studies, they were more consistent in the latter.   
 
ACHAPS findings of adverse effects of long-term exposure to NO2 on asthma, and other 
respiratory symptoms, are consistent with those of the Southern California Children’s Health 
(SCCHS) Study, although effects are somewhat weaker and apply to current rather than lifetime 
asthma only.  The findings are also consistent in relation to NO2 and PM effects and lung 
function, with little consistent evidence of effect modification by gender.  ACHAPS found 
favourable effects of O3 (contrary to the SCCHS) but these appeared related to negative 
confounding with NO2—assuming the effect is null, the O3 findings are consistent with the 
SCCHS and the Swiss Study on Childhood Allergy and Respiratory Symptoms with respect to 
Air Pollution (SCARPOL).  
 
NO2 is a major constituent of traffic-related pollution and the identified associations are 
consistent with reports in the literature of adverse associations between proximity to traffic and 
respiratory symptoms and lung functions.  Several studies including SCCHS have found 
decreased lung growth in children to be associated with NO2 exposure and proximity to 
roadways.  Unfortunately ACHAPS has no measures of lung function growth, which would 
require a follow-up of ACHAPS sample of children.   
 
A small number of ecological studies have found adverse health effects related to O3; this has 
not been confirmed by large individual studies, including ACHAPS. 
 
The panel study findings of adverse NO2 effects on symptoms are consistent with several other 
panel studies conducted in United States on children with asthma.  The ACHAPS panel study 
did not find any adverse short term effects of PM on lung function in single pollution models 
and a few associations with PM10 and symptoms (mainly cough and wheeze with ORs between 
1.017 to 1.02 for a 1 ug/m3 increase in PM10). These effect estimates are much smaller than the 
pooled estimates from the meta-analysis conducted by Ward and Ayres (Ward and Ayres 2004).   
 
The panel study was not able to demonstrate any adverse effects of ambient O3 on children’s 
lung function, symptoms or medication use.  
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Study background and methods 
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1. INTRODUCTION  
 
1.1. Purpose 
 
The primary purpose of the Australian Child Health and Air Pollution Study (ACHAPS) project 
was to obtain quantitative effect estimates for the association between the criteria air pollutants 
contained in the National Environment Protection (Ambient Air Quality) Measure (ozone (O3), 
particulates as PM10 and PM2.5, nitrogen dioxide (NO2), carbon monoxide (CO), sulphur dioxide 
SO2) and adverse health outcomes such as increases in respiratory symptoms (for example 
cough and wheeze) and decreases in lung function in school-aged children across Australia.  
The study examined both cumulative effects in a representative sample of children and day-to-
day effects of air pollution in a sub-sample of children with asthma. 
The proposed study arose from the scientific needs of the National Environment Protection 
(Ambient Air Quality) Measure review of Australian air quality standards.  Results are critical 
for two stages of the review, specifically: 
 in informing whether the current air quality standards adequately protect the health of 
Australian children from the effects of air pollution 
 to provide quantitative information to inform any amendment of the current standards. 
 
1.2. Background 
1.2.1. Australian air quality standards  
In recognition of the established relationships between air pollution and human health, the 
Australian Government has imposed air pollution controls.  The National Environment 
Protection Council (NEPC) is a statutory body, with its members being Ministers from 
participating jurisdictions (that is, Commonwealth, state and territory governments).  The 
NEPC has two primary functions:  
1. to make national environment protection measures (NEPMs) 
2. to assess and report on the implementation and effectiveness of NEPMs in participating 
jurisdictions. 
 
In 1998, the NEPC created the National Environment Protection (Ambient Air Quality) Measure 
(the NEPM) to protect human health and well-being.  This established, for the first time in 
Australia, air quality standards as maximum ambient concentrations (averaged over certain 
time periods), as well as the maximum number of exceedances allowed for the six criteria air 
pollutants — O3, NO2, SO2, CO, particles (as PM10) and lead ( 
Table 1.1.).  The NEPM was varied in 2003 to include standards for particles such as PM2.5.   
These standards were based on the then available evidence in relation to the adverse effects of 
air pollution.  Any amendment to these standards must, in addition, take account of more 
recent findings from both Australian and international research.  The present report will 
contribute to this evidence base with a particular contribution being the assessment in 
Australian school-aged children. 
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Table 1.1.  Australian air quality standards. 
 
 
POLLUTANT 
 
  
Averaging 
period 
  
WHO 
recommended 
standards 
(2006) 
Concentration 
Goals – 
maximum 
exceedances 
per year 
Carbon 
monoxide (CO) 
8-hours 
9.0 ppm (10,350 
µg/m3) 
1 day 
 
Nitrogen dioxide 
(NO2) 
1 hour 0.12 ppm (226 µg/m3) 1 day 200 µg/m3 
1 year 0.03 ppm (56.4 µg/m3) None 40 µg/m3 
Ozone (O3) 
1 hour 0.10 ppm (196 µg/m3) 1 day 
 
4 hours 0.08 ppm (16 µg/m3) 1 day 
 
8 hours 
  
100 µg/m3 
Sulphur dioxide 
(SO2) 
10 minutes 
  
500 µg/m3 
1 hour 0.20 ppm (524 µg/m3) 1 day 
 
24 hours 0.08 ppm (210 µg/m3) 1 day 20 µg/m3 
1 year 0.02 ppm (52 µg/m3) None 
 
Lead 1 year 0.5  µg/m3 None 
 
Particles as PM 10 
24 hours 50  µg/m3 5 days 50 µg/m3 
1 year 
  
20 µg/m3 
Particles as PM 2.5 
24 hours 25 µg/m3 
 
25 µg/m3 
1 year 8  µg/m3 In review 10 µg/m3 
 
When creating the NEPM, Ministers agreed to a set of future actions that included a full review 
of the NEPM.  To inform this review, the Environment Protection and Heritage Council (EPHC) 
(which incorporates the NEPC) have made a determined effort to address gaps in Australian 
research in this area.  Through a consultative process that included national workshops and the 
release of a discussion paper, a need was identified to conduct studies on more sensitive health 
indicators, such as decreases in lung function and increases in respiratory symptoms.  This was 
to ensure that the review of the ambient air quality NEPM standards is based on Australian, 
rather than overseas, information.   
A priority of these standards is to ensure that sensitive groups within the Australian 
population, including children, are protected and their quality of life is not impacted by air 
pollution.  One key area that was identified and supported through the national consultation 
process was a study into the effects of air pollution on children.   
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A full review of standards started in 2005.  It was essential that this review take account of 
international developments in standard setting - for example, the increasing focus on protecting 
vulnerable groups - but also have access to an Australian evidence base for the standards.  
Noting the importance of this study, EPHC Ministers committed $300,000 toward the 
conduct of this study. 
1.2.2. Relevance of standards to Australia 
 
The current Australian evidence base for long-term health effects of air pollution in children is 
weak, since very few studies have been conducted here.  Australia is different from the overseas 
countries that have provided most of the current evidence base in a number of factors that may 
affect the associations between air pollution and child respiratory health.  Factors such as 
pollutant exposure levels, pollutant compositions, possible higher individual exposures due to 
a different, more outdoor-based lifestyle, and differences in housing and road infrastructure 
(National Heritage Trust, 2003) are likely to be different to overseas countries.  Asthma is the 
leading cause of burden of disease in children aged 0–14 years in Australia, accounting for 
17.9% of the total burden in boys and 18.6% in girls (AIHW Australian Centre for Asthma 
Monitoring, 2005). 
1.2.3. Mechanisms affecting human health 
 
Air pollution is a complex mixture of chemicals that has different implications for the 
atmosphere and human health depending on the type and levels of human exposure.  CO binds 
with haemoglobin in the blood and reduces the capacity of haemoglobin to transport oxygen in 
the blood stream (Maynard and Waller, 1999).  NOX (oxides of nitrogen: NO + NO2) has the 
capacity to impair the function of the alveolar macrophages and epithelial cells, thereby 
increasing the risk of lung infection (Brunekreef and Holgate, 2002).  SO2 is not lethal at levels of 
ambient exposure, but is a chemical irritant, and exposure for more than a few minutes will 
result in irritation of the eyes, mucous membranes, and throat (Schlesinger, 1999).  People with 
asthma are uniquely susceptible to the adverse effects of SO2 exposure.  Brief exposure to 
concentrations as low as 0.25 ppm cause bronchoconstriction (airway narrowing) with resultant 
symptoms of wheezing, chest tightness and/or shortness of breath (Schlesinger, 1999).  
Particulate matter (PM) is divided into two categories: PM10 — coarse particles having an 
aerodynamic diameter less than 10 m, and PM2.5 — fine particles with a diameter less than 
2.5 m.  Exposure to PM is through inhalation and size is relevant to effect.  Particles with a 
diameter of greater than 5 m are often deposited in the upper airways, whereas smaller 
particles reach the small airways (bronchioli) and alveoli, with fine particles able to permeate 
the airway epithelium and vascular walls (Jeffery, 1999).  Particles from diesel exhaust have a 
carbonaceous core to which various hydrocarbons are absorbed, including carcinogenic 
polycyclic aromatic hydrocarbons (PAHs) and nitro-PAHs.  Diesel emissions have also been 
associated with an increased response to allergens (Bates and Vedal, 2002) and it has been 
suggested that this is the link between exposure to traffic and asthma prevalence (Brauer et al., 
2002).  O3 has been shown experimentally to induce inflammation of mucous membranes and, 
in some individuals, induces bronchoconstriction  (Chan-Yeung, 2000;  Schwela, 2000;  Thurston 
and Ito, 1999). 
1.2.4. Exposure measurement 
 
Assessment of exposure may be direct or indirect.  Direct methods are costly, cumbersome for 
the participant, and are usually tolerated only for a short time (especially in children, if feasible 
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at all) so may not be useful as measures of long-term exposures.  Indirect measures are 
obviously not precise measures of actual exposure at a particular point in time, but may be 
obtainable for longer time periods, and therefore more appropriate for long-term exposures.  
Ethical reasons may preclude specimens from children for biomarkers which, in any case, may 
be mainly sensitive to short-term exposures. 
1.2.5. Children are not ‘little adults’ 
 
Children represent a large sub-population susceptible to the adverse health effects of air 
pollution.  They inhale and retain larger amounts of air pollution per unit of body weight than 
adults, and have narrower bronchioles more likely to be constricted in response to 
environmental irritants.  Children’s developing organ systems may be more vulnerable when 
exposed to pollutants at critical periods (Mathieu-Nolf, 2002). 
Children tend to spend more time outdoors than adults, as they participate in more physical 
play and sports activities, perhaps by a three-fold factor (California Air Resources Board, 1991).  
Levels of O3 tend to be higher in the afternoon when school children may be most exposed 
whilst playing or walking home after school (Bates, 1995; Mathieu-Nolf, 2002). 
 
1.2.6. Effects of air pollution on child health 
 
A review of 50 publications over the last 20 years (to 2008) examining long-term health effects of 
ambient air pollution on all ages (Gotschi et al., 2008) concluded that 
there is strong support for air pollution effects on the development of lung function in children and 
adolescents.  It remains unclear whether subjects with slower development of lung function 
compensate by prolonging the growth phase, or whether they end their development at a lower 
plateau, thus entering the decline phase with a reduced lung function.    
The review further concluded that 
[t]here is great diversity in study designs, markers of air pollution, approaches to the measurement 
of exposure, and choices in lung function measures.  These limit the comparability of studies and 
impede quantitative summaries.  New studies should use individual-level exposure assessment to 
clarify the role of traffic and to preclude potential community-level confounding.  Further research 
is needed on the relevance of specific pollution sources, particularly with regard to susceptible 
populations and relevant exposure periods throughout life. 
Cohort studies evaluating the relationship between traffic exposure and respiratory health and 
published between 2002 and October 2008 were reviewed (Braback et al., 2009).  All surveys 
reported associations with at least some of the studied respiratory symptoms.  They concluded 
that '...traffic exhaust contributes to the development of respiratory symptoms in healthy 
children’ and that ’[f]uture studies should also evaluate effects of traffic exhaust on the 
development and long-term outcome of different phenotypes of asthma and wheezing 
symptoms’. 
PUBMED, MEDLINE and EMBASE databases were searched for epidemiological studies, 
published between January 1989 and December 2004, on the adverse health effects of criteria air 
pollutants among Canadian children.  The researchers concluded that  ‘[d]espite inconsistencies 
among study results and data from elsewhere, evidence from Canadian studies suggest that air 
pollution may cause adverse respiratory health effects in children...’ (Koranteng et al., 2007).   
The World Health Organisation has published air quality guidelines (WHO, 2008) for air 
quality targets to protect human health.  These guidelines represent the widely agreed and up-
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to-date assessment of health effects of air pollution, recommending targets for air quality at 
which health risks are significantly reduced.  No specific targets in relation to effects on child 
health have been set, however. 
Research distinguishes long-term effects (resulting from chronic exposure to high levels) from 
short-term effects (within days of an unusually high exposure).  Time series studies of the latter 
have found associations between daily changes in levels of ambient air pollution and increased 
childhood hospital admissions (Braga et al., 1999; Chew et al., 1999; Barnett et al, 2005), 
exacerbation of respiratory symptoms (Lee et al., 2002), and increased infant mortality (Ha et al., 
2003; Loomis et al., 1999; Woodruff et al., 1997).  Panel studies have found associations between 
daily levels of SO2, PM10 and daily decreased lung function (Timonen and Pekkanen, 1997; van 
der Zee et al., 1999) as well as daily CO, PM and daily exacerbation of asthma symptoms (Yu et 
al., 2000). 
The Harvard Six Cities Study of 10,000 children during 1974–1977 involved six cities throughout 
North America, and found a 10 µg/m3 increase in TSP (total suspended particulate matter) 
elevated the risk of chronic cough, bronchitis and lower respiratory illnesses in the previous 
year (Ware et al., 1986), and significant positive associations between PM10 and bronchitis and 
chronic cough, and a positive association between O3 and asthma (Dockery et al., 1989). 
The ongoing Southern California Children’s Health Study (SCCHS) (Peters, 1997) of 3,600 
school children from 12 communities in Southern California provided early information on 
possible chronic effects of air pollution.  Cross-sectional results from the SCCHS show 
prevalence of wheeze and lung function in children were associated with various pollutants 
(Peters et al., 1999a, 1999b).  Sub-cohort analyses of the SCCHS have demonstrated that children 
who moved to areas of lower PM10 showed increased growth in lung function and vice versa for 
children who moved to areas of higher PM10  (Avol et al., 2001).  O3 was strongly associated 
with an increase in respiratory illness-related absences (Gilliland et al., 2001).  Repeated follow-
up data have shown adverse effects of air pollutants on lung function growth (Gauderman 
2000, 2002, 2004, 2007). 
A number of other, mostly European, studies have also shown that relatively low levels of air 
pollution are responsible for increased morbidity and mortality in children (Bates, 1995; 
Mathieu-Nolf, 2002; Nicolai, 1999; Segala, 1999). 
1.2.7. Australian evidence 
 
Very limited research has been performed to establish the long-term effects of ambient air 
pollution on the health of Australian children.  Somewhat more has been done in relation to 
short-term effects but this has, for the most part, been confined to small localised studies.  An 
exception is a time series case-crossover study which examined the association between 
monitored air pollutants and hospital respiratory admissions by children in five Australian (and 
two New Zealand) cities (Barnett et al., 2005).  Increases were found in relation to PM2.5, PM10, 
nephelometry, NO2, and SO2.  The largest association found was a 6.0% increase in asthma 
admissions for children aged 5-14 years old in relation to a 5.1-ppb increase in 24-hour NO2. 
 
An Australian cross-sectional survey on the respiratory health of 3,023 children from industrial 
and non-industrial sites in the Hunter-Illawarra region found a positive association between 
PM10 and both night cough and chest colds in children (Lewis et al., 1998). 
 
Short-term effects have been demonstrated in an Australian panel in 148 children from six 
primary schools in western and south-western Sydney.  A significant negative association 
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between peak expiratory flow rate (PEFR) and same-day mean daytime O3 concentration was 
shown (Jalaludin et al., 2000).  These findings need to be replicated on a national sample. 
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2. STUDY AIMS AND APPROACH 
2.1. Background 
 
Epidemiological studies of the health effects of air pollution can be classified as investigating 
acute effects or chronic effects (Figure 2.1). Studies of acute exposure effects assess relationships 
between day-to-day changes in mortality and morbidity and same day or previous day/s air 
pollution level.  Such studies have found associations between air pollution and acute health 
effects ranging in severity from death, hospital usage, restricted activity days, exacerbations of 
asthma, occurrence of respiratory and other symptoms, and changes in lung function.  Acute 
effects should be distinguished from the way in which long-term exposure to ambient levels of air 
pollution may initiate or promote development of chronic disease.  Such chronic effects may 
eventually lead to increased or earlier hospital usage or to premature death, irrespective of 
whether higher air pollution levels on preceding days had a role in triggering acute health 
effects. 
 
Cross-sectional and cohort studies have been used to examine long- to medium-term exposure 
effects on health.  In cross-sectional studies, current exposure may be measured (for example, 
ambient levels, proximity to roads, indoor sources of pollutants) but is assumed to represent the 
exposure over a significant period in the past (new arrivals to an area may be excluded).  
Alternatively, exposure may be retrospectively estimated by gathering a history of previous 
residences and exposures.  Current health outcomes are measured, and a history of 
development of respiratory symptoms and conditions obtained.  Cohort studies may gather 
both exposures and health outcomes prospectively.  Cohort studies would generally be 
considered more powerful studies since they have the opportunity to gather more accurate and 
detailed data, the temporal sequence between exposure and outcome is clear, and it is possible 
to study changes within individuals as changes in exposure occur.  The chief weakness of cross-
sectional studies in this context is that they may be affected by confounding; for example, socio-
economic class may be related both to exposure (higher socio-economic classes may be able to 
choose to live in lower pollution environments) and exposure (higher socio-economic classes 
may be able to obtain more effective treatment for a child’s early symptoms, therefore 
preventing disease progression).  However, with careful design and analysis, cross-sectional 
studies can provide useful information on the health effects of air pollutants.  Cross-sectional 
and cohort designs have been combined effectively; for example, in the Southern California 
Study of Child Health (Peters et al., 1999a, 199b), with a cross-sectional study providing 
information in its own right as well as being used to identify a cohort of children to be followed 
up over a longer period to provide prospective data.   
 
Ecological studies are population studies where both the risk factor and the outcome factor are 
measured at the population level. Therefore, groups of people rather than individuals are the 
units of analysis.  For each group of people, aggregate measures for the risk factors and health 
outcomes are determined and then examined for associations.  In ecological studies, groups of 
people are often defined by geographical areas or administrative boundaries.  Ecological study 
designs are widely used in environmental epidemiology because environmental factors expose 
large numbers of the population in a similar manner. 
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Figure 2.1 Basic study designs of most epidemiological studies of air pollution (Source: Pope 
and Dockery, 1999). 
 
Two common study designs used in air pollution studies— the time series study and the panel 
study— are types of ecological studies. 
 
In air pollution time series studies, data (both exposures and health outcomes) are aggregated 
over a short period of time (usually one day) and are useful for investigating the acute or short-
term effects of air pollution.  Common outcome measures are deaths, hospital admissions, 
emergency department visits and general practitioner visits.  In these instances, the exposure 
factor will consist of daily air pollution concentrations and the outcome factor will be the daily 
number of deaths (or any of the other health outcomes mentioned above) for a defined 
population.  Time series studies often rely on routinely collected administrative datasets (for 
example, health datasets from health agencies and air pollution data from environmental 
agencies) for analysis. 
 
In panel studies, the air pollution exposure is usually measured at the population or geographic 
level whereas the outcome factor (lung function, respiratory symptoms) is measured at the 
individual level.  Hence, panel studies are also known as semi-ecological studies.  Panel studies 
take a group of subjects and follow them prospectively for a period of time (typically weeks or 
months).  The subjects keep a daily record of their lung function, symptoms and medication use 
in a diary (and therefore panel studies are also often called diary studies).  At the end of the 
study period, data are analysed to determine associations between daily air pollution levels and 
daily measures of symptoms or lung function.  Panel studies are useful for investigating the 
acute or short-term effects of air pollution. 
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2.2. Overall aims of this study 
 
1) To provide an evidence base of long-term and short-term health effects of air pollutants 
in Australian children that will support the review of the NEPM standards 
2) To obtain quantitative effect estimates for the association between children’s historical 
lifetime exposure to the criteria air pollutants contained in the NEPM (O3, PM10, PM2.5, 
NO2, CO, SO2) and (a) the period prevalence of adverse health outcomes such as 
respiratory symptoms (asthma, cough and wheeze), and (b) lung function 
3) To obtain quantitative estimates of the prospective day-to-day association between the 
criteria air pollutants and (a) incidence of respiratory symptoms, and (b) lung function, 
in school children with a history of asthma, aged 7–11 years at baseline 
4) To determine whether the effects described in 2) and 3) are modified by other factors, 
such as socio-economic disadvantage, geographical area, sex, activity patterns and 
obesity. 
 
2.3. Approach 
 
The target population was Australian school children aged 7–11 years whose exposure to the 
criteria air pollutants was representative of other urban Australian school children of that age.  
The sampling strategy was based on selecting schools, then whole classes within schools.  
Children were not excluded on the basis of race, ethnicity or other socio-demographic factors.   
Exposures of interest were criteria ambient air pollutants measured using standard NEPM air 
quality monitoring stations.  It was important to select schools which: 
 were close to NEPM monitors which had been on site for a reasonable number of years  
 were considered to be representative of a larger area around the site  
 could demonstrate the maximum variability of exposures to the various pollutants.    
For Aim 2 (see above in 2.2), the approach used was a cross-sectional study.  Air pollution 
metrics were average exposures over the period of residence of the child near the monitored 
site.  Analyses took into account appropriate confounding variables (other site-specific or 
individual factors) and effect modifiers (for example, gender).   
For Aim 3 (see above in 2.2), the approach used was a nested panel study, which selected a 
vulnerable cohort within the baseline sample.  Daily air pollution metrics corresponding to the 
averaging periods used in the NEPM were used.  Analyses took into account appropriate time-
dependent confounding variables (meteorology, physical activity and effect modifiers (for 
example, gender).   
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3.  REVIEWS AND CLEARANCES 
 
Ethical and administrative reviews were obtained from the universities of Queensland and 
Sydney, departments of education in the Australian Capital Territory (ACT), New South Wales 
(NSW), Queensland (Qld), South Australia (SA), Victoria (Vic) and Western Australia (WA), 
and the Catholic Education Office of Victoria.  Project staff obtained Working with Children 
Checks, and National Police Clearances. 
3.1. University ethics approvals 
 
Approval was sought and given by the University of Queensland’s Human Research Ethics 
Committee on 11 October 2006 (Ref no. 2006000592) as well as the University of Sydney’s 
Human Research Ethics Committee on 18 April 2007 (Ref no. 10050).  The ethics committees 
reviewed study information documents: the letter to school principals (Appendix 1), the 
explanatory letter, information statement and consent form for parents (Appendices 2-4), the 
children’s questionnaire and privacy statement (Appendices 5,6), the diary study consent from 
and information sheet (Appendices 7,8), the peak flow and symptom diary and the time activity 
diary (Appendices 9,10) and the diary study calendar and tracking form (Appendices 11,12).    
3.2. Departments of education approval 
 
The departments of education that were approached by the research team gave approval for the 
study to be conducted.  Details of the relevant state or territory department of education and 
dates of submission and approval to conduct the study are shown in Table 3.1. 
 
Table 3.1. Departments of education submission and approval dates. 
 
Department of education Date of submission Date of approval 
Victorian Department of Education 
and Training 
24 October 2006 
 
9 January 2007 
South Australian Department of 
Education and Children’s Services 
23 November 2006 
 
6 March 2007 
Western Australian Department of 
Education and Training 
5 December 2006 15 December 2006 
ACT Department of Education and 
Training 
6 December 2006 4 January 2007 
Queensland Department of 
Education, Training and the Arts 
6 December 2006 12 March 2007 
New South Wales Department of 
Education and Training 
20 March 2007 14 December 2007 
 
The departments of education in Victoria and New South Wales had special requirements about 
some of the study research forms and therefore they had to be slightly modified.  The New 
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South Wales Department of Education also requested clarification, mostly about general testing 
issues, such as potential risk of the tests, safety measures and confidentiality arrangements.  
Questions about these and other topics were answered by the co-investigators and approval 
was granted after the amendments requested were submitted. 
 
In Victoria, the main consent form was modified allowing parents to choose if they wanted their 
children to have the breathing tests and/or the allergy test.  These changes were implemented 
across the study.  This modification was submitted to the Victorian Department of Education 
and Training on 19 December 2006. 
 
In NSW, modifications were submitted to the New South Wales Department of Education and 
Training on the 2 December 2007.  For the main consent form, a statement was inserted in order 
to give parents the option to request a copy of the website information, in case of no access to 
the internet.  In the main information statement, the sentence, ’The success of the study depends 
on the participation of as many children as possible’, was deleted as requested.  The statement, 
’We ask for your contact details to discuss results, complete missing information or discuss 
further involvement in the study’, was included as a way to explain the reasons for collecting 
contact information.  In the letter to principals, the statement, ’…it is important that we try to 
get information on as many people as possible to improve the accuracy of the study results 
so…’, was deleted. 
3.3. Amendments to ethics approval 
 
After the approval of these modifications by the departments of education in Victoria and New 
South Wales, three amendments were submitted to the University of Queensland’s Human 
Research Ethics Committee: the first one (submission date: 26 February 2007, approval date: 
 5 March 2007) included minor changes made to the principals’ letter, information statement, 
consent form and peak flow and symptom diary.  In addition, some new forms were submitted 
for approval, including an explanatory letter, explanatory form for teachers, school 
characteristics form, time-activity diary, calendar for participants of the panel study, and the 
study website structure. 
The second amendment (submission date: 20 December 2007, approval date: 29 April 2008) 
consisted of slight changes made to the principals’ letter, information statement and main 
consent form.  The last amendment (submission date: 7 February 2008, approval date: 29 
April 2008) incorporated slight changes made to the result sheet. 
3.4. Application to the Catholic Education Office 
 
The Catholic Education Office of Victoria was approached in order to seek approval to conduct 
the study at selected Victorian Catholic primary schools.  This was necessary because of the 
limited number of eligible state government schools at some monitoring sites.  One Catholic 
school from each of these sites was recruited in the study. 
3.5. Working with Children Check 
 
A Working with Children Check was obtained by all research staff involved in the study 
fieldwork in the Australian Capital Territory, Victoria, Queensland, Western Australia, South 
Australia and New South Wales. 
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4. OVERALL STUDY DESIGN 
 
4.1. Site selection 
 
Data for 2004–5 were obtained for all NEPM monitors in the ACT, New South Wales, 
Queensland, South Australia, Victoria and Western Australia from the relevant jurisdictions.  
The Northern Territory and Tasmania were excluded due to lack of sufficient monitored air 
pollution data. 
The first stage of the study involved the selection of potentially useful sites according to the 
following inclusion criteria:  
(i) existence of a NEPM monitor, with at least a five-year history of measurement of criteria 
air pollutants  
(ii)  at least three eligible (see later) primary schools within the monitored area, and  
(iii)  not considered by the relevant environmental protection agency (EPA) jurisdiction to 
be an ‘unrepresentative site’ (such as proximal to a roadway). 
The second stage involved the ranking of selected sites according to average measured 
pollutant levels for each pollutant.  A quota (around six) of the highest and lowest ranked sites 
for each pollutant were then selected so that (allowing for overlap) finally 30 sites were selected.  
This ensured that the study covered maximum variability in air pollution exposures as well as 
diversity of air pollution scenarios (that is, air pollution mixtures/gradients), critical to study 
power and generalisability.  This procedure resulted in at least two sites per jurisdiction being 
chosen to ensure national coverage and relevance. 
4.2. Air pollution exposures  
 
Hourly air pollution data (O3, PM10, PM2.5, CO2 (carbon dioxide), NO2, SO2) from 1995 to 2007 
(2008 for NSW),  for all available pollutants, were supplied by the various jurisdictions for each 
of the selected sites.  
  
Monitoring sites were linked to school sites and, in turn, to children.  For the cross-sectional 
study, exposure metrics based on the number of years of residence of the child in that area or at 
each school were developed.  For the panel study, daily air pollutant levels, corresponding to 
the averaging periods used in the NEPM, were used.  
4.3. Sample size and power 
 
Spatial variability in prevalence of respiratory conditions is evident across cities: a lifetime self-
report of asthma history (not necessarily doctor-diagnosed) varied from 24.9% in Sydney to 
30.4% in Adelaide (AIHW Australian Centre for Asthma Monitoring, 2003). 
Available data on the variability among pollutants across 27 NEPM monitoring stations in 
Brisbane, Melbourne, Perth and Sydney for 1998 to 2001 was examined.  Average 24-hour PM10 
had a mean of 16.4 µg/m3, a between-station standard deviation (SD) of 1.6 µg/m3 and a range 
13.3–19.8 µg/m3.  Power calculations were based on a 30 cluster regression analysis.  Setting 
power to 80% and significance level at 5% (two-sided) a net sample of 1,600 would be able to 
detect an increase of 1.8% in rates of asthma or respiratory symptoms per unit PM10; that is, a 
total increase in prevalence of 13.8% to 15.7% (four capital cities).  A similar calculation based 
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on O3 levels showed that the study is able to detect an increase of 14.0% to 15.8% in prevalence 
of asthma per unit O3.   
Power calculations used the POWER procedure within SAS statistical software. 
The consent rate was expected to be 50–70% based on earlier research on school children 
conducted by the Woolcock Institute of Medical Research.  Thus, the sample size required was 
calculated to be approximately 3,200.  Health outcomes based on continuous measures (peak 
flow) were associated with power exceeding 80%, for the proposed sample size. 
Assuming 15% prevalence of current asthma, and a further consent rate of 70%, the panel study 
was to comprise around 330 participants, or 9,900 person-days.  Examination of variability 
within the four capital cities and over the time period above gives a day-to-day SD of PM10 of 
6 µg/m3.  With a total of 330 persons, and a random effects model, the study was expected to 
have 80% power to detect a decline in standardised peak flow rates (SPFR) of 0.025 per unit 
PM10.  Inter-quartile ranges for daily PM10 in Brisbane and Melbourne respectively were 7.3 and 
8.4 µg/m3 in 2001; other cities would be expected to be similar.  Thus, the panel study could 
detect a decline of at least 0.18 in SPFR at the individual level.  By definition, the SD of an 
individual’s SPFR is unity, yielding a 95% range of 4; thus, the study has the capacity to decline 
a decline of 4.5% of the individual’s range of lung function. 
 
5. LOGISTICS 
5.1. Fieldwork planning 
 
Planning of the study fieldwork began in November 2006 at the Woolcock Institute of Medical 
Research.  The last versions of the forms to be used with participants were created and, along 
with applications to conduct the study, submitted to the departments of education in each state 
and territory.  During this time, fieldwork for 2007 and 2008 was planned and plotted into a 
calendar. 
In February 2007, the project management committee and study staff reached an agreement 
about the times of the year when the study was to be conducted in each state.  At this time, it 
was also decided that the EPA in each jurisdiction would provide local staff members to 
support fieldwork activities as part of the in-kind contribution of the EPHC to the study. 
A weekly calendar was created which specified the tasks to be completed in each state in order 
to run both the cross-sectional and panel components of the study.  These tasks included 
recruitment of the schools, distribution of the questionnaires, processing of data, testing of 
children and recruitment of panel study participants and, finally, completion of follow-up of the 
panel study. 
5.2. EPA staff support 
 
Local EPA staff members assisted with the activities during fieldwork.  A final agreement was 
reached about the tasks to be undertaken and included the following: 
 training for one hour with the study project manager as preparation for fieldwork 
 picking up the sealed envelopes after parents returned completed questionnaires to the 
school, and arranging to courier these bundles back to the Woolcock Institute of 
Medical Research in Sydney 
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 assisting on the testing day with collection of children from classes, measurement of 
height and weight, and crowd control of the testing room. 
 assisting with any panel study home visits. 
 
5.3. Time frame for cross-sectional and panel study 
 
The study fieldwork started in February 2007 and was completed in June 2008.  Victoria and 
New South Wales fieldwork was divided into different stages since they had the greater 
number of air quality monitoring stations.  Table 5.1. and Table 5.2. show details of data 
collection dates across Australia: ‘Prep’ refers to preparation phase (weeks 1 to 8), ‘T’ refers to 
testing period (weeks 9 and 10) and ‘Panel’ refers to follow-up of panel study (weeks 11 to 15). 
 
Table 5.1.  Fieldwork dates for 2007. 
 
Month Jan Feb Mar April May June July Aug Sept Oct Nov Dec 
6.  7.  8.  9.  10. 11. 12. 13. 14. 15. 16. 17. 18. 
ACT   
Prep T Panel 
       
VIC 1  
 Prep T Panel 
      
VIC 2  
   Prep T Panel 
    
QLD  
   Prep T Panel 
    
WA  
    Prep T Panel 
  
SA        Prep T Panel 
 
Table 5.2. Fieldwork dates for 2008. 
 
Month Jan Feb Mar April May June 
19. 20. 21. 22. 23. 24. 25. 26. 
NSW 1  
Prep T Panel 
   
NSW 2  
Prep T Panel 
  
NSW 3  Prep T Panel 
 
The panel study in each monitoring station started from the testing day and lasted for four 
weeks. Weeks were considered as calendar weeks (Monday to Sunday) and the remaining days 
of the first week were also included for data collection.  For example, if a child was tested on a 
Wednesday, the remaining days of that week were included in the study in addition to the next 
four weeks counting from the next Monday. 
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The Australian school year is divided into four terms.  Exact dates for these vary according to 
State/Territory jurisdiction.  The school year itself runs from late January/early February until 
December. There is a short holiday between terms and a long summer holiday in December and 
January. 
The panel study took place only during school terms and not in school holidays since children 
would not be exposed to the air quality in the school area.  The only states and territory that 
had school holidays in the middle of panel study were the ACT, Victoria and Western 
Australia. 
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Part B 
 
The cross-sectional study: 
chronic exposure to air pollution: effects upon children’s health 
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1. STUDY DESIGN AND MEASUREMENT 
1.1. Aims  
 
This section addresses the following aims of the study: 
 to obtain quantitative effect estimates for the association between children’s historical 
lifetime exposure to the criteria air pollutants contained in the NEPM (O3, PM10, PM2.5, 
NO2, CO, SO2) and (a) the period prevalence of adverse health outcomes such as 
respiratory symptoms (asthma, cough and wheeze), and (b) lung function 
 to determine whether the effects are modified by other factors, such as socio-economic 
disadvantage, geographical area, sex, activity patterns and obesity. 
 
1.2. Data collection 
 
Children were tested on school premises during school hours, and parents were asked to 
complete a questionnaire and return it to the project office. 
 
1.2.1. Questionnaire 
 
The questionnaire was designed to include information on relevant respiratory outcomes, 
household sources of pollutants, and covariates.  The sources for items from the questionnaire 
included the International Study of Asthma and Allergies in Childhood (ISAAC) (ISSAC 
Steering Committee and ISAAC Phase Three Study Group, 2000), the SCCHS (Peters et al., 
1999a,b), the Belmont Schoolchildren Study (Toelle et al., 2004), the Childhood Asthma 
Prevention Study (CAPS) (Marks et al., 2006) and the NSW Health Survey (Centre for 
Epidemiology and Research, 2003).  Preference was given to the ISAAC questionnaire as a 
source document because of its widespread use (over 300,000 respondents) and extensive 
validation.  The selection was decided by the investigator team and decisions about each item 
were recorded.  The final questionnaire included 70 items (Appendix 5). 
 
Questions asking about respiratory symptoms and asthma were derived from existing, widely 
used questionnaires; that is, the ISAAC and the SCCHS.  
 
The questionnaire also collected information about eczema, hay fever, upper and lower 
respiratory tract conditions, birth history, parental history of respiratory problems (including 
asthma and atopic diseases), parent smoking history, transport, children’s time-activity 
patterns, past addresses the child has lived, socio-economic factors, and other variables.  These 
questions were derived from questionnaires used in other studies such as the Belmont 
Schoolchildren Study, CAPS, and the NSW Health Survey. 
 
The home environment characteristics (only indoor sources of air pollutants) were collected.   
 
The indoor pollutant levels induced by ambient sources lie in the causal pathway, and do not 
confound the outdoor-health effect association. 
 
Information about school absenteeism in relation to the presence of respiratory symptoms was 
also collected by parent self-report in the questionnaire. 
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1.2.2. Clinical assessments 
 
The main health outcomes for the cross-sectional study included objective lung function 
measurements and, additionally, assessment of exhaled NO and of atopic status.  Collection of 
these measurements occurred at fieldwork in each of the schools.  One day of testing was 
conducted at each school.  These tests were performed if all of the following criteria were met: 
 the consent form was properly completed 
 the child was present at the school at the day of testing 
 the child consented to be tested or the researcher considered it appropriate to carry out 
the tests on the child (that is, tests were not performed where any signs of anxiety were 
present) 
 the child was physically able to perform the tests  
 the testing equipment was functioning properly. 
 
Children who had a recent absence from school and reported having had a respiratory illness or 
who showed signs of respiratory illness did not have spirometry measured.  
 
A brief description of the tests is provided below. 
 
Spirometric lung function  
 
Spirometric function was measured, before and after bronchodilator, in accordance with the 
recommendations of the ATS/ERS Task Force performance criteria for spirometry (Miller et al., 
2005).  A Spirocard spirometer  (QRZ-7000-5636C.1 SpiroCard PC Card, QRS Diagnostics, LLC, 
Plymouth, Minnesota, USA) that measures flow using a pressure transducer and derives 
volume by integrating flow over time was attached to a laptop computer running SpiroScore+ 
V2.6 (supplied by Bird Healthcare, Melbourne, Australia) for immediate data acquisition. 
Participants were requested to withhold short-acting bronchodilators for six hours and long-
acting bronchodilators for 12 hours prior to the baseline measurements.  The procedure was 
explained to the children by the research assistant observing the test.  They stood upright 
during the procedure, which was performed without a nose clip.  Children took a full breath in 
and, with their lips placed around the mouthpiece for sealing, were instructed to blast the air 
out ’as fast and as far as you can‘.  They were encouraged to continue expiration as long as 
possible, while ensuring that they did not bend over during the manoeuvre. 
The procedure was repeated at least three times, or more as required to achieve reproducibility 
of ≤ 100 ml between the best and the second-best FEV1.  The procedure was repeated a 
maximum of 8 times. 
Immediately after the baseline spirometry was completed, participants received salbutamol 
200 µg (Ventolin® 100 µg x 2), administered by a tube spacer, with one minute between doses.  
Post-bronchodilator measurements were made 10 minutes later using the same procedure. 
The following parameters were derived from the spirometric measurements: 
 FVC (forced vital capacity) is the maximum volume of air which can be exhaled during 
a forced manoeuvre  
 FEV1(forced expired volume in one second) is the volume expired in the first second of 
maximal expiration after a maximal inspiration and is a useful measure of airway 
calibre 
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 FEV1
 
/FVC is the FEV1
 
expressed as a percentage of the FVC and gives a clinically useful 
index of airflow limitation  
 FEF25-75% 
 
is the average expired flow between 25% and 75% of FVC and is regarded as a 
more sensitive measure of small airways narrowing than FEV1 , but is less reproducible.  
 
 PEF (peak expiratory flow) is the maximal expiratory flow rate achieved and this occurs 
very early in the forced expiratory manoeuvre. 
 
Predicted lung function, for give sex and height were calculated for each child,  based on 
NHANES III predicted equations for Caucasians males <20 and females <18 (Hankinson et al 
1999).  Percent predicted lung function was calculated as the percentaged ratio of measured 
lung function to predicted lung function. 
 
Exhaled nitric oxide 
 
NO is produced in the airways by a number of different cell types.  Levels of NO in the exhaled 
breath (eNO) are believed to be an indicator of the severity of airway inflammation (Barnes and 
Belvisi, 1993).  In many, but not all, studies, eNO correlates with the number of eosinophils in 
sputum and bronchoalveolar lavage and with the severity of airway hyperresponsiveness.  
Levels of eNO are increased in asthmatic subjects and in many atopic non-asthmatic subjects.  
They are increased following allergen challenge and reduced following treatment with inhaled 
corticosteroids. 
 
NO can be measured in exhaled breath and is a highly reliable measurement in population 
studies (Salome et al., 1999).  A sample of expired air for this study was collected to measure 
NO levels using an offline technique (Massaro and Gaston, 1995; Salome et al., 1999).  Before 
collection, children took three breaths with a scrubber to filter ambient NO.  After filling their 
lungs with air they breathed out against a small resistance to residual volume into an NO 
impermeable polyethylene bag (supplied by Scholle Industries Pty Ltd, SA, Australia) at an 
exhaled flow of 12 litres/min.  The first 2 seconds of the exhalation were diverted from the 
collection bag, using a three-way tap, to exclude dead space air (Paredi and Loukides, 1998).  
The procedure was repeated until there was enough air in the bag to measure. 
The exhaled gas from multiple breaths was analysed within six hours of collection using a 
chemiluminescence analyser (supplied by Thermo Environmental Instruments Model 42i, Lear 
Siegler, Australia) and values for NO, NOX and NO2 were recorded for each participant. 
 
Skin prick tests 
 
Skin testing is a long-established, quick, safe and easy procedure used to diagnose allergies.  It 
has been in use since Charles Blackley performed the first scratch test in 1873.  The four main 
types of skin testing procedures are the intracutaneous (intradermal) (ICT), scratch, puncture 
and prick methods.  In this study, as in previous Australian epidemiological studies, the prick 
method was used, it having an excellent safety record. 
 
For this study, eight common aeroallergens were tested by skin prick test: Dermatophagoidies 
pteronyssinuss (Der p 1), Dermatophagoidies farinae, ryegrass, grass mix, cockroach, cat, Alternaria 
and Aspergillius. 
The participants were asked whether they had taken any antihistamines within the last 48 hours 
and if they were allergic to anything (and, if so, the reaction they experienced).  With their arm 
facing upwards, a stamp was placed and a tiny droplet (2 mm diameter) of each of the allergens 
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was positioned.  For each allergen / control, a lancet was passed through the drop just catching 
the skin at anywhere from a 20° to an 80° angle.  The lancet was then lifted (skin pricked), 
creating a small break in the epidermis so the allergen could enter the dermis. 
The wheal size was measured, 15 minutes after the skin prick test was performed, at the largest 
diameter of the wheal.  Measurements were made to the nearest 1 mm.  The mean wheal size 
was calculated as the average of these two diameters and this result was rounded down.  A 
mean wheal size ≥ 3 mm was classified as positive. 
 
Height and weight 
 
Anthropometric measurements were made with shoes removed.  Standing height and sitting 
height were measured with the participants standing or sitting on a firm, horizontal surface on 
the floor.  The stadiometer (measuring rod) was placed perpendicular (at a 90º angle) to this 
surface.  Weight was measured using digital scales. 
 
Environmental measures 
 
Daily average hourly levels of each air pollutant were averaged over the period of residence of 
the child at the current residence to provide an aggregated measure of exposure.  Period of 
residence was defined as the time between the child's birth and the date of the child's 
assessment if the child had lived at that address all his/her life, or if s/he had not the time 
between the midpoint of the year the child had moved to that address (ascertained in the 
questionnaire) and the date of the child's assessment.  In addition, annual average exposures 
were calculated, as well as average exposures in the last 12 months prior to assessment. 
The following information about classroom and school characteristics was collected: building 
type, proximity to roads, type of heating and cooling, and type of flooring.  Latitude and 
longitude was recorded in each of the classrooms.  The ambient NO of the testing room was 
collected twice in the day and measured no more than six hours later by the chemiluminescence 
analyser. The room temperature and barometric pressure were measured twice daily. 
1.3. Statistical analysis 
 
Standard statistical measures are used to describe the characteristics of the children, their 
respiratory history and the results of clinical tests.   
 
Hierarchical models (with state and school as levels) were used to examine the association 
between outcome variables such as lung function and respiratory symptom and the air 
pollutant exposures.  These models were fitted separately for each pollutant.  Models involving 
lung function also included height and sex.  Confounding variables (such as age, parental 
employment and education, and household variables) were added according to their 
improvement to the overall model fit.  Non-linearity was assessed by incorporating quadratic 
and cubic polynomial terms for the pollutants (after centring), as well as generalised additive 
models.  Multi pollutant models were explored in order to estimate which pollutants have the 
strongest independent associations with lung function and asthma.  The analyses were carried 
out using SAS 9.2 and the procedures SURVEYREG and SURVEYLOGISTIC.  
 
Sensitivity analyses were carried out for two-pollutant models involving NO2 and O3, related to 
the high correlation between these pollutants.  Owing to the presence of one site with high SO2 
values, sensitivity analyses were performed excluding this site from models involving SO2. 
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Interaction terms were added to the models to examine possible effect modification.  Criteria for 
establishing effect modification were the significance of an interaction test (at the 5% level) and 
the existence of one or more significant effects across the levels of the interacting variable. 
 23 
 
 
2. RECRUITMENT 
 
2.1. School recruitment 
 
After the schools were approached, they were classified into different categories:  
 agreed to participate in the study 
 refused to participate in the study  
 ineligible for different reasons, e.g. most parents from non-English speaking background 
and/or not enough children to approach for the study. 
 
The overall response rate was 64% for schools (55 out of 86 eligible schools approached).  Most 
of the recruited schools were within 2.5 km of the air quality monitoring station.  One school 
was 2.8 km from the relevant air quality monitoring station.   
 
2.2. Participant recruitment 
 
Around 100 to 120 questionnaires were distributed per school in the ACT and Victoria.  The 
participant response rate in these jurisdictions was lower than expected.  As a result, it was 
decided to increase the number of children approached from 100 to 150 in order to recruit the 
required number of children in the rest of the states.  In total, 7,618 packages of study materials 
were distributed to the 55 participating schools and 2,880 completed questionnaires were 
returned.  At fieldwork, 2,653 children underwent at least one of the tests and 2,603 completed 
post-bronchodilator spirometry.  Finally, 34% of those approached to participate in the study 
completed post-bronchodilator spirometry. 
 
Reasons for not completing any or all tests on a child for whom a questionnaire was received 
included: 
 no parental consent 
 absent on the day of testing 
 other reason on the moment of testing, e.g. child did not consent or researcher 
considered it not appropriate to conduct the test 
 test was technically unsatisfactory  
 testing equipment malfunction at fieldwork. 
 
Table 2.1.  shows the number of tests completed and not completed for each specific test and 
Table 2.2. shows the reason why the tests were not completed. 
 
A substantial number of participants did not have valid results for exhaled NO measurements 
(35.1%).  This was mainly due to equipment malfunction or the test being technically 
unsatisfactory.  At the beginning of the study, an electronic, automated exhaled breath 
collection device was used.  There was a number of technical problems with this device.  After 
several days of testing, it was evident that the device could not be used for this study.  At this 
time, it was decided to change to the manual rotameter exhaled breath collection device.  This 
was used from the time of the Queensland fieldwork.  A substantial number of samples that 
were collected could not be analysed due to malfunction of the NO chemiluminescence 
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analyser.  This affected some sites in South Australia and Newcastle. While regrettable, these 
lost measurements merely limit the statistical power of the study, since these losses were 
unrelated to the true level of exhaled NO. 
 
Table 2.1.  Description of test completion in ACHAPS. 
 
TEST  
Spirometry 
Pre-
Bronchodilator 
Spirometry 
Post-
Bronchodilator 
Exhaled 
NO 
Skin  
prick test  
 
N 
 
% N % N % N % 
Tests completed 2628 91.3 2603 90.4 1868 64.9 2414 83.8 
Tests NOT 
completed 
252 8.8 277 9.6 1012 35.1 466 16.2 
TOTAL 2880 100 2880 100 2880 100 2880 100 
 
Table 2.2.  Reasons for tests not completed in ACHAPS. 
 
 
TEST  
 
 
Spirometry  
Pre-
Bronchodilator 
Spirometry 
Post-
Bronchodilator 
Exhaled 
NO 
Skin prick 
test 
N % N % N % N % 
No consent 79 31.3 83 30.0 79 7.8 164 35.2 
Absent on testing day 158 62.7 158 57.0 158 15.6 157 33.7 
Another reason 7 2.8 19 6.9 10 1.0 136 29.2 
Technically 
unsatisfactory 
8 3.2 17 6.1 209 20.7 8 1.7 
Equipment 
malfunction 
0 0.0 0 0.0 556 54.9 1 0.2 
TOTAL NOT 
TESTED 
252 100 277 100 1012* 100 466 100 
 
* This large number of tests missed does not affect primary study outcomes 
 
There were some adverse events due to the skin prick test.  Three children experienced a vaso-
vagal syncopal episode after skin prick tests were performed.  This was attributed to anxiety 
and associated hyperventilation.  At the time of the event, first aid was provided to the children.  
No other serious adverse events occurred.  In particular, there were no systemic allergic 
reactions.  After the three episodes of syncope, which occurred in Victoria and Queensland, 
procedures were changed to safeguard against this event.  In particular, children with any 
evidence of anxiety prior to performing the skin prick test did not have this procedure.
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3. RESULTS 
3.1. Demographic characteristics of cross-sectional study participants 
 
The mean age of the sample was 10 years (SD=1.2, 7–12 years); 48.5% were boys.  Most (90%) 
children were born in Australia; 17.7% spoke a language other than English at home.  Most 
parents (72% mothers, 73% fathers) had completed high school education (Table 3.1). 
Table 3.1.Child characteristics (N = 2,860); numbers and per cent unless otherwise specified. 
 
Characteristic   
Age (years)  
  Mean (SD) 9.6  (1.2) 
  Range 7-12 
Gender  
  Female 1462  (51.5) 
  Male 1378  (48.5) 
Born in Australia  
  No 283  (10.1) 
  Yes 2534  (89.9) 
Speak language other than English at home  
  No 2308  (82.3) 
  Yes 495  (17.7) 
Mother’s educational qualification  
   Completed primary school 12  (0.4) 
   Completed 7-9 years 114  (4.1) 
   Completed 10 years 525  (18.8) 
   Completed 12 years 407  (14.6) 
  TAFE Certificate/Diploma 706  (25.3) 
  Tertiary 924  (33.1) 
   Other  100  (3.6) 
Father’s educational qualification  
   Completed primary school 22  (0.4) 
   Completed 7-9 years 115  (4.4) 
  Completed 10 years 466  (17.6) 
  Completed 12 years 367  (13.9) 
  TAFE Certificate/Diploma 682  (25.8) 
  Tertiary 882  (33.3) 
  Other  105  (4.4) 
Mother’s employment (last week)  
  Worked for payment/profit 1820  (66.2) 
  Usually work for payment, but absent last week 67  (2.4) 
  Unpaid work in family business 72  (2.6) 
  Other unpaid work 127  (4.6) 
  No job 471 (17.1) 
  Other 193  (7.0) 
Father’s employment (last week)  
  Worked for payment/profit 2307  (88.8) 
  Usually work for payment, but absent last week 70  (2.7) 
  Unpaid work in family business 22  (0.9) 
  Other unpaid work 14  (0.5) 
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  No job 114 (4.4) 
  Other 72  (2.8) 
3.2. Respiratory conditions of cross-sectional study participants 
 
Twenty-seven per cent of children had a history of asthma, which is consistent with Australian 
estimates for this age group and 14% stated that they still had asthma (Table 3.2.).  Rather more 
(38%) had used medication for asthma, 22% in the last year.   Predominant medications used 
were short-acting beta-agonists (21%) followed by inhaled steroids (9%). 
 
Table 3.2. History of asthma; numbers (n) and per cent (%). 
 
Item N n % 
Diagnosis and treatment    
Ever had asthma diagnosis 2840 781 27.5 
Current asthma 2829 405 14.3 
Medical attention for asthma last 12 months  2591 351 13.5 
       General Practitioner  341 13.1 
       Emergency Department  45 1.8 
       Hospital admission  14 0.5 
Hospital admitted for breathing problems ever 2830 386 13.6 
Asthma/wheezing caused child to miss school last 12 months 2622 227 8.6 
Asthma medication use    
Ever used medication for asthma/wheezing 2703 1,042 38.5 
Any asthma medication  in the last 12 months 2704 250 22.5 
     Short-acting beta-agonist (SABA)  2693 572 21.2 
     Long-acting beta-agonist (LABA) alone 2651 12 0.5 
     All Inhaled steroids 2703 250 9.2 
          Inhaled steroids  alone 2656 130 4.9 
          Combined inhaled steroid and LABA 2659 141 5.3 
     Leukotriene receptor antagonist 2651 24 0.9 
     Oral steroids 2654 609 22.5 
 
Over one-third (34%) of children had has a wheezing episode at some time in their lives with 
about half (16%) in the last 12 months (Table 3.3.).  Seventy-two per cent of children had 
experienced a cough in the last year, with 23% experiencing a dry cough at night (Table 3.4.). 
 
Table 3.3. History of wheezing; numbers (n) and per cent (%). 
 
Item N n % 
Ever had wheezing 2840 987 34.8 
Wheezing in last 12 months 2839 463 16.3 
       After exercise  324 13.2 
       After crying  310 12.6 
       Limiting speech  70 2.8 
 
Asthma/wheezing caused child to miss school last 12 months 
    
Table 3.4. History of cough in the last 12 months; numbers (n) and per cent (%). 
 
Item N n % 
Cough 2860 2,048 71.6 
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Dry cough at night 2851 658 23.1 
Dry cough at night, for more than 2 weeks  2846 160 5.6 
 
 
 
 
Asthma/wheezing caused child to miss school last 12 months 
   
Twenty-three per cent of children's were reported to have experienced an itchy rash for at least 
six months, 29% itchy eyes and 33% problems with sneezing or blocked nose (in the absence of 
a cold) (Table 3.5.).  
 
Table 3.5.  History of itchy rash/eyes or rhinitis; numbers (n) and per cent (%). 
 
Item N n % 
Itchy rash       
       For 6 months ever 2859 662 23.2 
       For 6 months, in the last 12 months 2855 471 16.5 
       Medication in last 12 months 2851 447 15.7 
Itchy eyes       
        Ever 2849 830 29.1 
        In the last 12 months 2847 762 26.8 
        Medication in last 12 months 2848 415 14.6 
Rhinitis       
        Ever 2857 955 33.4 
        In the last 12 months 2856 886 31.0 
        Medication in last 12 months 2856 558 19.5 
 
The most common respiratory or allergic condition diagnosed was otitis media (39%), followed 
by tonsillitis (26%) and eczema or atopic dermatitis (23%) (Table 3.6.).   
 
Table 3.6.  History of diagnosed illnesses ever; numbers (n) and per cent (%) 
 
Item N n % 
Otitis media 2783 1097 39.4 
Tonsillitis 2784 736 26.4 
Eczema/atopic dermatitis 2794 645 23.1 
Croup 2770 518 18.7 
Allergic rhinitis/hay fever 2775 409 14.7 
Bronchitis 2775 361 13.0 
Bronchiolitis 2774 250 9.0 
Pneumonia 2774 169 6.1 
Whooping cough 2758 83 3.0 
 
 
 
 
Asthma/wheezing caused child to miss school last 12 months 
   
Twenty-four per cent of parents reported the child had had an allergic reaction, and 48% of 
those tested had a positive skin prick test (Table 3.7.).  In all, 59% of children either had a 
reported allergic reaction or a positive skin prick test.  The most common parental history of 
allergic conditions was hay fever (48% mothers, 38% fathers), with 21% of mothers and 18% of 
fathers reporting a history of asthma (Table 3.8). 
 
Table 3.7.  Child allergies; numbers (n) and per cent (%). 
 
Item N n % 
History of allergic reaction (reported by parent) 2444 594 24.3 
Positive response to skin prick test  2084 993 47.6 
 28 
 
House dust mite allergy (skin prick test) 2084 807 38.7 
Positive skin prick test or history of allergic reaction 2174 1285 59.1 
    
Table 3.8.  Family history of asthma or allergies; numbers (n) and per cent (%). 
 
Item N n % 
Mother       
       Hay fever 2749 1308 47.6 
       Wheezing 2700 617 22.9 
       Asthma 2733 582 21.3 
       Eczema 2695 567 21.0 
Father       
       Hay fever 2580 970 37.6 
       Wheezing 2557 494 19.3 
       Asthma 2593 460 17.7 
       Eczema 2523 276 10.9 
 
 
 
 
Asthma/wheezing caused child to miss school last 12 months 
   
Mean BMI was 19 kgm-2 (12-38) and mean birthweight was 3.6 kg (0.8-5.8) (Table 3.9). 
 
Table 3.9. Child anthropometry; mean, standard deviation (SD), and range. 
 
Item N Mean  SD  Range  
Birth     
     Birthweight (kg) 2594 3.6  0.6 0.8 - 5.8   
     Born premature (%) 2834 6.5% 
  Measured at time of survey   
     Weight (kg) 2646 37.6 9.9 20 - 91 
     Height (cm) 2648 141.1 9.1 113 - 
174      Body mass index (BMI) kgm-2 2645 18.7 3.3 12 - 38
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3.3. Lung function  
 
Children's  lung function measures were consistent with population values (Table 3.10).   
 
Table 3.10. Child lung function tests; mean, standard deviation (SD), and range. 
 
Item N Mean SD Range 
FEV1  2631          
     Pre-bronchodilator (l)  2.0  0.4 0.8 - 4.1  
     Post-bronchodilator (l)  2.1 0.4 0.8 - 4.0 
     % change: Pre- to post- bronchodilator  3.6 5.3 -50 - 43 
     % predicted: Pre-bronchodilator  97.1 10.8 44 - 147 
     % predicted: Post-bronchodilator  100.5 10.9 41 - 152 
FVC  2498 
        Pre-bronchodilator (l)  2.3  0.5 0.9 - 4.7  
     Post-bronchodilator (l)  2.3 0.5 1.2 - 4.5 
     % predicted: Pre-bronchodilator  110.7  12.6 50 - 164 
     % predicted: Post-bronchodilator  112.0 12.6 52 - 164 
FEV1/FVC ratio  2498 
        Pre-bronchodilator (%)  87.9  6.5 63 - 176  
     Post-bronchodilator (%)  90.0 5.4 56 - 119 
Exhaled NO 1823 
       In ppb 
 
 
 
 9.4  (7.2*) 7.2 0.1 - 67
* Geometric mean 
 
 
 
Asthma/wheezing caused child to miss 
school last 12 months 
    
3.4. Household environment 
 
A high percentage of homes used gas for cooking, either in the child's first year of life (62%) or 
currently (67%) (Table 3.11.).  Thirty-three per cent of homes used gas for heating, about half of 
these unflued.  Sixty-five per cent of homes were air conditioned, largely room air conditioners.  
Eighteen per cent of homes had an internal garage accessible from the home. 
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Table 3.11.  Household exposures; numbers (n) and per cent (%). 
 
Item N n % 
Use gas for cooking     
        In child's first year of life 2774 1732 62.4 
        At present 2840 1904 67.0 
Heating at home in child's first year of life 2859      
        None  208 7.2 
        Gas   946 32.7 
               Unflued gas heater  448 15.5 
       Electric   872 30.1 
       Central   513 17.7 
       Open fire  261 9.0 
       Stove  258 8.9 
       Other  95 3.3 
Heating at home at present 2859      
        None  232 8.0 
        Gas   955 33.0 
               Unflued gas heater  455 15.7 
       Electric   679 23.5 
       Central   605 20.9 
       Open fire  234 8.0 
       Stove  194 6.7 
       Other  106 3.7 
Air conditioning        
        Home air conditioned 2814 1842 65.5 
Use of air conditioning last summer when child home 1801 
          Never used   51 2.8
        Used less than 10 days   326 18.1 
        Used 10-20 days   557 30.9 
        Used 21-40 days   457 25.4 
        Used 41 or more days   410 22.8 
Type of air conditioning 1802 
          Room  1131 62.8
        Ducted    369 20.5 
        Evaporative  302 16.8 
Garage    
        No garage  2734 945 34.6 
        Separate garage  933 34.1 
        Attached garage, no internal access  460 16.8 
        Garage is accessed internally from house  499 18.2 
        Internal garage in child's first year  351 12.6 
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Ninety-one per cent of children lived in a smoking-free house (Table 3.12.), although 19% of 
mothers currently smoked; 15% of mothers reported smoking during pregnancy.   
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Table 3.12.  Smoking exposure of child; numbers (n) and per cent (%). 
 
Item N n % 
Mother smoked during pregnancy  2724 397 14.6 
Mother smoked during child's first year 2728 566 20.7 
Mother smokes regularly at present 2820 546 19.4 
Smoking in house 2854      
     Home is smoke free   2594 90.9 
     People occasionally smoke   177 6.2 
     People frequently smoke   83 2.9 
Number of cigarettes smoked per day in house 2224     
     None   1963 88.3 
     1-10   182 8.2 
     11-20   46 2.0 
     21-40  26 1.2 
     40 or more  7 0.3 
 
Twenty-four percent of children attended day-care in 
the first year of life, with 11% percent attending for 
more than 20 hours per week. 
 
 
 
 
Asthma/wheezing caused child to miss school last 12 
months 
   
Sixty-one per cent of homes had a dog and 36% a cat (Table 3.13). 
 
Table 3.13.  Other exposures: numbers (n) and per cent (%). 
 
Item N n % 
Pets 2830 
       Ever had a cat or dog since child born    2140 75.6 
     Have a cat at present   812 35.5 
     Have a dog at present   1385 60.5 
     Have a cat during child's first year     761 33.8 
     Have a dog during child's firs  year   1138 50.4 
Child care    
     Attend day care in first year 2825 690 24.4 
     Attend day care for more than 20 hrs/week in first year 2789 296 10.6 
 
 
 
 
Asthma/wheezing caused child to miss school last 12 months 
   
3.5. Air pollutant exposures 
 
Not all selected sites monitored all pollutants.  The numbers of sites available for each pollutant 
measure, and pairwise combinations, is shown in Table 3.14. 
 
Table 3.14. Numbers of sites available for pollutant measures. 
 
 Bsp PM2.5 PM10 NO2 O3 CO SO2 
Bsp 46 45 44 46 41 29 24 
PM2.5 45 55 53 55 47 32 32 
PM10 44 53 54 54 45 33 32 
NO2 46 55 54 56 47 33 32 
O3 41 47 45 47 47 26 30 
CO 29 32 33 33 26 33 17 
SO2 24 32 32 32 30 17 32 
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For each pollutant, distributions of lifetime exposures (lifetime = time from first residence in 
area to date of survey) and recent exposures (last year, or lifetime if residence less than one 
year) are shown in Table 3.15. and Table 3.16. respectively.  Correlations among lifetime 
exposures are shown in (Table 3.17.).  
The distributions of lifetime exposures are shown in Figure 3.1.  The outlier for SO2 occurred at 
the Port Pirie site, which hosts the largest lead refinery in the southern hemisphere. 
 
Table 3.15. Mean and variability of lifetime child exposures. 
 
Pollutant N Mean SD Median Lower 
quartile 
Upper 
quartile 
Range Inter-
quartile 
range 
Bsp 10-4 m-1 
PM2.5 g/m3 
PM10 g/m3 
NO2 ppb 
O3 ppb 
CO ppm 
SO2 ppb 
 
2110 
1486 
2545 
2620 
2226 
1641 
1463 
 
0.27 
8.04 
18.47 
9.31 
15.88 
0.30 
1.39 
 
0.09 
1.51 
2.14 
3.34 
2.98 
0.13 
1.43 
 
0.25 
7.76 
18.38 
8.83 
15.20 
0.29 
1.11 
 
0.20 
6.75 
16.59 
7.25 
13.87 
0.24 
0.75 
 
0.28 
8.92 
20.39 
11.57 
16.99 
0.35 
1.49 
 
0.13 - 0.55 
4.90 -13.52 
13.68 - 25.86 
2.83 - 18.30 
10.96 - 22.42 
0.03 - 1.04 
0 - 8.86 
 
0.08 
2.16 
3.80 
4.31 
3.12 
0.11 
0.74 
 
Table 3.16. Mean and variability of recent child exposures. 
 
Pollutant N Mean SD Median Lower 
quartile 
Upper 
quartile 
Range Inter-
quartile 
range 
Bsp 10-4 m-1 
PM2.5 g/m3 
PM10 g/m3 
NO2 ppb 
O3 ppb 
CO ppm 
SO2 ppb 
 
1744 
1237 
2437 
2511 
2120 
1632 
1249 
 
0.29 
7.42 
18.94 
8.78 
16.99 
0.24 
1.53 
 
0.12 
0.75 
2.73 
2.98 
2.84 
0.10 
1.63 
 
0.23 
7.55 
18.75 
7.85 
16.66 
0.24 
1.06 
 
0.18 
6.85 
16.83 
7.11 
14.46 
0.18 
0.77 
 
0.40 
7.92 
20.97 
11.14 
17.94 
0.29 
1.59 
 
0.13 - 0.53 
4.90 - 8.70 
13.68 - 25.86 
3.36 - 15.60 
12.19 - 22.78 
0.03 - 0.47 
0.37 - 8.96 
 
0.22 
1.07 
4.13 
4.03 
3.48 
0.12 
0.82 
 
Table 3.17. Pearson correlations among lifetime child exposures (above diagonal) and among 
recent exposures (below diagonal).   Correlations between lifetime and recent exposures for 
the same pollutant are shown on the diagonal.  Correlations above 0.5 in bold. 
 
 Bsp PM2.5 PM10 NO2 O3 CO SO2 
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Bsp 0.770 0.271 0.251 0.082 0.002 0.005 -0.023 
PM2.5 0.140 0.691 0.520 0.328 -0.235 0.154 0.592 
PM10 0.651 0.431 0.762 0.379 -0.393 0.131 0.194 
NO2 0.212 0.280 0.232 0.963 -0.777 0.692 -0.438 
O3 0.245 -0.426 -0.216 -0.761 0.858 -0.729 0.305 
CO 0.344 0.292 0.185 0.510 -0.453 0.763 -0.501 
SO2 -0.255 0.287 0.227 -0.166 -0.380 -0.189 0.989 
 
Table 3.18. Summary of correlations among child exposures. Correlations above 0.5 in bold. 
 
Lifetime exposure Positively correlated with: Negatively correlated with: 
Bsp PM2.5, PM10, NO2  
PM2.5   Bsp, PM10, NO2, CO, SO2 O3 
PM10 Bsp, PM2.5, NO2, CO, SO2 O3 
NO2 Bsp, PM2.5, PM10, CO O3, SO2 
O3 SO2 PM2.5, PM10, NO2, CO 
CO PM2.5, PM10, NO2 O3, SO2 
SO2 PM2.5, PM10, O3 NO2, CO 
   
Recent exposure Positively correlated with: Negatively correlated with: 
Bsp PM2.5, PM10, NO2, O3, CO SO2 
PM2.5   Bsp, PM10, NO2, CO, SO2 O3 
PM10 Bsp, PM2.5, NO2, CO, SO2 O3, SO2 
NO2 Bsp, PM2.5, PM10, CO PM2.5, PM10, NO2, CO, SO2 
O3 Bsp PM2.5, PM10, NO2, CO, SO2 
CO Bsp, PM2.5, PM10, NO2 O3, SO2 
SO2 PM2.5, PM10 Bsp, NO2, O3, CO 
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Figure 3.1. Distributions of child-based exposures. 
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3.6. SEIFA characteristics 
Socio-economic indexes for areas (SEIFA) of the child's postcode of residence were obtained. 
Each of the four indexes summarises different aspects of the socio-economic conditions of 
people living in an area; each is based upon a different set of social and economic information 
from the 2006 Census (Australian Bureau of Statistics, 2010). The four indexes in SEIFA 2006 
are:  
 Index of relative socio-economic disadvantage (IRSED): is derived from Census 
variables related to disadvantage, such as low income, low educational attainment, 
unemployment, and dwellings without motor vehicles.  
 Index of relative socio-economic advantage and disadvantage (IRSEAD): a continuum 
of advantage (high values) to disadvantage (low values) which is derived from Census 
variables related to both advantage and disadvantage, like household with low income 
and people with a tertiary education.  
 Index of economic resources (IER): focuses on Census variables like the income, 
housing expenditure and assets of households.  
 Index of education and occupation (IEO): includes Census variables relating to the 
educational and occupational characteristics of communities, like the proportion of 
people with a higher qualification or those employed in a skilled occupation. 
The mean and variability of these, over all children, is shown in Table 3.19. 
 
SEIFA indices are standardised to a mean of 1000 and a standard deviation of 100.  The means 
of the sample are slightly above average (by about one-quarter of a standard deviation) on 
IRSEAD, IRSED and IEO, and are somewhat more homogeneous than the Australian 
population (SDs range from 64 to 90).  The latter possibly reflects the urban nature of the 
sample. 
 
Table 3.19.  Mean and variability of SEIFA indices of child's postcode of residence. 
 
Index N Mean SD Median Lower 
quartile 
Upper 
quartile 
Range Inter-
quartile 
range 
IRSEAD 
IRSED 
IER 
IEO 
 
2856 
2856 
2856 
2856 
 
1022 
1013 
1005 
1023 
 
76 
66 
64 
90 
 
1027 
1018 
1001 
1027 
 
788 
781 
808 
800 
 
980 
992 
970 
962 
 
1075-1213 
1059-1149 
1048-1187 
1094-1201 
 
95.14 
66.50 
78.34 
131.78 
 
 
IRSEAD: Index of relative socio-economic advantage and disadvantage 
IRSED: Index of relative socio-economic disadvantage 
IER: Index of economic resources 
IEO: Index of education and occupation 
 
Correlations appear strongest between pollutants and the IRSEAD and IEO indices, with higher 
scores associated with higher NO2 and CO, and lower scores associated with higher SO2, and to 
some extent, O3, PM2.5, and PM10  ( 
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Table 3.20.). 
 
Association between selected respiratory conditions (lifetime or recent asthma or wheeze, 
cough) and SEIFA indices were generally weak.  Statistically significant correlation coefficients 
ranged from -0.04 to -0.09; the lower the SEIFA, the more likely the condition present.   Lung 
function was generally not significantly associated with SEIFA codes.  Exhaled NO was 
significantly correlated with SEIFA indices (correlation coefficients:  -0.05 to -0.09).  
 
Table 3.20. Correlations among child exposures (Pearson coefficients) and SEIFA indices.  
Correlations above 0.3 in bold.  
 Bsp PM2.5 PM10 NO2 O3 CO SO2 
IRSEAD 0.062 -0.226 -0.152 0.340 -0.184 0.361 -0.475 
IRSED 0.149 -0.185 -0.221 0.165 -0.115 0.262 -0.408 
IER 0.160 -0.164 -0.246 0.057 -0.084 0.144 -0.389 
IEO -0.006 -0.239 -0.120 0.433 -0.171 0.443 -0.441 
 
IRSEAD: Index of relative socio-economic advantage and disadvantage 
IRSED: Index of relative socio-economic disadvantage 
IER: Index of economic resources 
IEO: Index of education and occupation 
3.7. Pollutants and lung function 
 
3.7.1. Single pollutant models 
 
Results of all single pollutant models and outcomes considered of clinical importance are 
shown in Table 3.21. and Table 3.22.  These are adjusted for age, gender, height (where 
appropriate), parental education and two SEIFA indices: relative socio-economic advantage and 
disadvantage, and education and occupation.  Effect estimates per unit for the pollutant 
exposures are shown, with 95% confidence intervals (CIs), and P-values.  In this section, 
findings are summarised, by pollutant, for outcomes considered to be of major clinical 
significance.  
 
Bsp 
No significant effects were seen for the outcomes considered in Table 3.21 and 3.22.   
 
PM2.5 
Small but significant increases in FEV1/FVC ratio pre- and post-bronchodilator were found for 
lifetime exposure to PM2.5.  For recent exposure, both FEV1 and FVC post-bronchodilator 
decreased: 0.18  ml ( 0.00, 0.35)  per g/m3 and 0.16 ml ( 0.03, 0.28) per g/m3 respectively.  Per 
interquartile range (IQR) effects were  -24.0 ml (-48.4, 0.33) and 46.3 ml (-82.7, -9.95) 
respectively.  FEV1/FVC ratio post-bronchodilator increased with recent exposure, somewhat 
more strongly than the effect seen with lifetime exposure: 0.58 ( 0.07, 1.10) per g/m3 and 0.62 
(0.07, 1.17) per IQR.  Exhaled NO increased significantly with recent exposure, by about 2% per 
g/m3 and 2% per IQR. 
PM10 
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Post-bronchodilator FEV1 and FVC decreased with increasing lifetime PM10, although only the 
FEV1 effect was statistically significant: effect estimates  were -5.1 ml ( -10.1, -0.1) and -7.1 ml  (-
4.4, 0.3) per g/m3, respectively.  Per IQR effect estimates were 19.3 ml (-38.3,-0.23) and -26.8 ml 
(-54.7, 1.07) respectively.   
Exhaled NO significantly increased with PM10, but this association was statistically significant 
for lifetime exposure only: increases of 4% per g/m3 (1%, 6%) for lifetime exposure and 2% per 
g/m3 (0%, 3%) for recent exposure.  Per IQR effects were  15% (5%, 26%)  and 7% (-1%, 15%), 
respectively. 
NO2 
FEV1 and FVC significantly decreased, both before and after bronchodilator use, ranging from 
5.9 to 6.1 ml per ppb, or 25.3 to 26.4 ml per IQR (about 1.3% drop in mean lung function) for 
lifetime exposure.  Effect estimates were somewhat larger for recent exposure, ranging from 6.8 
to 7. 3ml per ppb, or 27.5 to 29.6 ml per IQR. 
 
Exhaled NO significantly increased with increasing NO2 by 3% (1%, 5%) per ppb for lifetime 
exposure and 2% (1%, 3%) ppb for recent exposure.  Per IQR, these increases are 13% (5%, 21%) 
and 14% (6%, 23%), respectively. 
 
All effects of NO2 were clearly linear with the exception of exhaled NO which increased linearly 
up till about 12 ppb NO2 (approximately the third quartile of NO2 exposure) when the effects 
reached a peak (of about 7 ppb exhaled NO) for both lifetime and recent exposure, and 
decreased somewhat over the remaining range. 
 
O3 
Findings for O3 were generally in a 'protective' direction, which might be related to (a) a true 
protective effect of O3, (b) the effects found for NO2 and strong negative correlation between 
NO2 and O3, or (c) other confounding variables.  For FEV1 post-bronchodilator, O3 showed a 
significant positive effect; 5.2 ml ( 1.2, 9.1)  per ppb for lifetime exposure.  Statistically significant 
and positive effects also existed for recent O3 exposure and FEV1 and FVC post-bronchodilator.  
For exhaled NO, O3 showed significant protective effects.   
 
CO 
CO showed no impact on lung function measures for lifetime exposure, and increasing effects 
on FEV1 and FEV1/FVC ratio pre-bronchodilator for recent exposure.  
SO2 
For exhaled NO, SO2 showed a significant negative effect for both lifetime and recent exposure.  
This effect became non-significant with the exclusion of Port Pirie from the analyses.  Exclusion 
of Port Pirie from the recent SO2 exposure models showed significant decrease in FVC 
pre-bronchodilator: -32.9 ml (--61.5, -4.2) per ppb.  A similar but non-significant decrease 
occurred for FVC post-bronchodilator:  -35.0  ml (-78.1, 8.0) per ppb. 
 
In summary, the most important findings from the single pollutant models are the adverse 
effects of NO2, PM10 and PM2.5 on lung volumes (FEV1 and FVC), which was not reversible with 
bronchodilator, and on airway inflammation (measured as exhaled NO).    
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Table 3.21. Lung function: single pollutant models. Lifetime exposure; effects per unit pollutant.  Bolded entries represent effects significant 
at the p=0.05 level. 
Measure Bsp 
10-4 m-1 
PM2.5 
g/m3 
PM10 
g/m3 
NO2 
ppb 
O3 
ppb 
CO 
ppm 
SO2 
ppb 
 
FEV1 Pre-
bronchodilator/ml 
 
51.3                        
( -54.0, 156.6)           
P = 0.33 
2.1                         
( -4.8, 8.9)                
P = 0.55 
-4.4                          
( -9.8, 1.0)                      
P = 0.11 
-6.1                          
( -9.8, -2.3)                  
P = 0.001 
3.2                              
( -1.4, 7.8)                   
P = 0.16 
44.4                       
( -88.5, 177.3)           
P = 0.49 
-1.0                        
( -10.7, 8.6)            
P = 0.82 
FEV1 Post-
bronchodilator/ml 
 
-58.0                     
(-190.7, 74.6)                  
P = 0.38 
1.7                          
( -5.3, 8.7)                 
P = 0.63 
-5.1                         
( -10.1, -0.1)                  
P = 0.047 
-6.0                        
( -9.6, -2.4)            
P = 0.001 
5.2                          
( 1.2, 9.1)                  
P = 0.011 
-23.7                      
(-141.9, 94.5)       
P = 0.68 
-2.0                        
( -9.2, 5.1)            
P = 0.56 
FVC Pre-
bronchodilator 
 
11.6                      
(-126.2, 149.3)           
P = 0.86 
-1.4                          
( -7.7, 5.0)                  
P = 0.66 
-3.5                          
( -9.5, 2.5)                    
P = 0.24 
-5.9                          
( -9.4, -2.3)                  
P = 0.001 
2.7                            
( -2.0, 7.5)                       
P = 0.24 
-33.6                     
(-159.7, 92.5)           
P = 0.58 
-4.1                        
( -16.1, 7.9)               
P = 0.49 
FVC Post-
bronchodilator/ml 
 
-109.4                       
(-275.6, 56.7)             
P = 0.19 
-1.8                          
( -10.3, 6.7)                 
P = 0.67 
-7.1                        
( -14.4, 0.3)               
P = 0.05 
-5.9                        
( -10.3, -1.6)               
P = 0.008 
3.9                          
( -2.3, 10.1)                
P = 0.21 
-79.4                       
(-220.2, 61.3)            
P = 0.25 
-7.0                         
( -18.6, 4.7)                
P = 0.22 
FEV1/FVC Ratio 
Pre-bronchodilator 
(%) 
1.42                         
( -1.25, 4.08)           
P = 0.28 
0.18                        
( 0.00, 0.35)                 
P = 0.046 
-0.05                              
( -0.27, 0.16)             
P = 0.63 
-0.05                              
( -0.17, 0.08)              
P = 0.46 
0.03                       
( -0.11, 0.17)                  
P = 0.66 
2.62                        
( -1.94, 7.18)                 
P = 0.24 
0.11                        
( -0.22, 0.45)              
P = 0.49 
FEV1/FVC Ratio 
Post-bronchodilator 
(%) 
0.68                       
( -2.09, 3.44)            
P = 0.62 
0.16                       
( 0.03, 0.28)                   
P = 0.015 
0.08                         
( -0.10, 0.26)                 
P = 0.35 
-0.01                      
( -0.10, 0.08)             
P = 0.87 
0.06                           
( -0.05, 0.16)                 
P = 0.27 
2.19                         
( -0.78, 5.16)                
P = 0.14 
0.08                             
( -0.25, 0.41)                   
P = 0.63 
Exhaled NO* 
 
 
1.02                       
( 0.59, 1.77)                
P = 0.92 
0.99                         
( 0.96, 1.01)                   
P = 0.35 
1.04                        
( 1.01, 1.06)                
P = 0.004 
1.03                       
( 1.01, 1.05)              
P = 0.002 
0.96                        
( 0.94, 0.98)                    
P < 0.0001 
0.74                        
( 0.50, 1.11)                
P = 0.13 
0.98                             
( 0.96, 0.99)                  
P = 0.009 
 
* Coefficient represents relative increase in exhaled NO, per unit pollutant
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Table 3.22. Lung function: single pollutant models.  Recent exposure; effects per unit pollutant. Bolded entries represent effects significant at 
the p=0.05 level. 
Measure Bsp 
10-4 m-1 
PM2.5 
g/m3 
PM10 
g/m3 
NO2 
ppb 
O3 
ppb 
CO 
ppm 
SO2 
ppb 
 
FEV1 Pre-
bronchodilator/ml 
 
55.1                          
( -38.7, 148.9)                       
P = 0.23 
6.6                           
( -7.9, 21.1)                 
P = 0.35 
-1.1                            
( -4.8, 2.7)                       
P = 0.57 
-7.1                         
( -11.4, -2.8)                    
P = 0.001 
4.1                         
( -0.9, 9.2)            
P = 0.10 
181.6                     
( 43.8, 319.5)          
P = 0.011 
-3.4                           
( -16.1, 9.3)            
P = 0.58 
FEV1 Post-
bronchodilator/ml 
 
-43.2                               
(-164.1, 77.7)                  
P = 0.47 
-22.5                             
( -45.2, 0.3)                  
P = 0.05 
-3.0                          
( -6.9, 0.8)                       
P = 0.11 
-7.3                            
( -11.4, -3.3)              
P = 0.0007 
5.8                           
( 1.8, 9.8)                      
P = 0.005 
74.7                       
(-106.6, 256.0)            
P = 0.40 
-5.0                             
( -14.9, 4.8)           
P = 0.29 
FVC Pre-
bronchodilator 
 
39.2                            
( -89.7, 168.0)                  
P = 0.53 
-12.4                          
( -36.1, 11.3)                
P = 0.28 
-0.5                           
( -4.1, 3.1)                      
P = 0.78 
-6.8                          
( -10.9, -2.7)                 
P = 0.001 
4.6                         
( -0.6, 9.8)                 
P = 0.08 
59.9                                 
(-101.8, 221.7)             
P = 0.45 
-7.0                                
( -20.4, 6.5)             
P = 0.29 
FVC Post-
bronchodilator/ml 
 
-34.4                         
(-196.3, 127.5)                    
P = 0.66 
-43.4                       
( -77.4, -9.3)            
P = 0.015 
-3.1                            
( -8.1, 1.8)                    
P = 0.20 
-6.9                         
( -12.1, -1.6)                 
P = 0.011  
6.6                             
( 0.9, 12.3)                   
P = 0.024 
45.3                               
(-181.1, 271.6)               
P = 0.68 
-8.8                          
( -22.5, 5.0)             
P = 0.19 
FEV1/FVC Ratio 
Pre-bronchodilator 
(%) 
0.27                          
( -2.45, 2.99)               
P = 0.84 
0.68                        
( -0.16, 1.52)                
P = 0.10 
-0.03                           
( -0.18, 0.12)               
P = 0.67 
-0.06                       
( -0.19, 0.08)              
P = 0.42 
-0.00                       
( -0.14, 0.14)             
P = 0.97 
5.40                               
( 0.85, 9.94)                 
P = 0.021*I 
0.12                               
( -0.26, 0.50)                 
P = 0.50 
FEV1/FVC Ratio 
Post-bronchodilator 
(%) 
-1.32                           
( -4.63, 1.99)                    
P = 0.42 
0.58                        
( 0.07, 1.10)                  
P = 0.027 
-0.01                               
( -0.14, 0.11)                 
P = 0.82 
-0.05                        
( -0.14, 0.05)                 
P = 0.32 
-0.02                           
( -0.13, 0.08)            
P = 0.64 
0.95                       
( -3.40, 5.29)               
P = 0.65 
0.03                               
( -0.35, 0.42)            
P = 0.85 
Exhaled NO 
 
 
1.25                            
( 0.97, 1.62)                      
P = 0.08 
1.02                       
( 1.02, 1.02)         
P <  0.0001 
1.02                               
( 1.00, 1.03)                     
P = 0.07 
1.03                          
( 1.01, 1.05)             
P = 0.0008 
0.96                           
( 0.94, 0.98)           
P = 0.0001   
0.89                                  
( 0.48, 1.66)             
P = 0.70 
0.98                                  
( 0.96, 0.99)               
P = 0.011   
 
* Coefficient represents relative increase in exhaled NO, per unit pollutant
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3.7.2. Joint pollutant models 
 
Detailed results are given in Appendices - Part B. 
 
Joint NO2 - O3 model 
NO2 and O3 are strongly negatively correlated (r = -0.78 and -0.76 for lifetime and recent 
respectively) and where effects on lung function are demonstrated these are in opposite 
directions.  A joint pollutant model was therefore fitted to health outcomes for these pollutants.  
The difficulty of separating effects of NO2 and O3 is illustrated in Figure 3.2., showing mean 
exposures, by school, for NO2 and O3.  The small number of schools in locations with high mean 
O3 levels for lifetime and recent exposures were in locations with the lowest NO2 levels.  
Figure 3.2. Scatter plots of NO2 and O3 exposures. 
 
To minimise the influence of the high-ozone sites, a sensitivity analysis examined single and 
joint pollutant models, restricting analyses to sites with mean exposure less than 20 ppb. This 
resulted in the omission of 10 schools (one in Queensland,  two at one site in South Australia 
and seven at three sites in Western Australia) 
Joint pollutant NO2-O3 model including all sites (Table 3.23., Table 3.24.):  Effects of NO2 noted 
above reduced only slightly in magnitude (some effects becoming just non-significant) or 
strengthened.  Effects of O3 reduced considerably, to non-significance in most cases, with only 
exhaled NO remaining a significant effect. 
Joint pollutant NO2-O3 model excluding high-ozone schools (Table 3.25., Table 3.26.):  These 
analyses largely confirmed the NO2 effects.  While effect sizes remained consistent with the 
unrestricted analyses, in some cases significance was reduced, perhaps due to the smaller 
sample size.  O3 effects for FEV1/FVC ratio post-bronchodilator and exhaled NO were 
consistent with the unrestricted model.  Other spirometry measures were either non-significant 
or showed a significant decline with increasing O3 (FVC post-bronchodilator - lifetime exposure 
- and percent change in FEV1 - recent exposure). 
 
In summary, joint pollutant and restricted O3 models largely confirmed the NO2 findings with 
(from the joint model) decreases in lung volume of 6.3 to 10 ml per ppb of NO2 in FEV1 and FVC 
pre- and post-bronchodilator and 26.3 to 43.1 ml per IQR.  These effects showed no evidence of 
non-linearity in either the polynomial or nonparametric models.  The significant protective O3 
effects seen in the single pollutant unrestricted analysis appear related to the large negative 
correlation with NO2.  A 'paradoxical' effect remains for O3, however, for exhaled NO. 
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Table 3.23. Lifetime exposure: effects per unit pollutant, all schools.  Bolded entries represent 
effects significant at the p=0.05 level. 
 
 
NO2 (ppb): 
One pollutant 
model 
NO2 (ppb): 
Joint pollutant 
model 
O3 (ppb):     
One pollutant 
model 
O3 (ppb):    
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-6.1 ( -9.8, -2.3)    
P = 0.001 
-6.3 ( -13.2, 0.7)  
P = 0.07 
3.2 ( -1.4, 7.8)      
P = 0.16 
-1.2 ( -7.9, 5.6)    
P = 0.72 
FEV1 Post- 
bronchodilator (ml) 
-6.0 ( -9.6, -2.4)   
P = 0.001 
-6.1 ( -13.1, 0.9)  
P = 0.08 
5.2 ( 1.2, 9.1)       
P = 0.011 
0.9 ( -6.1, 7.9)      
P = 0.79 
FVC Pre- 
bronchodilator (ml) 
-5.9 ( -9.4, -2.3)   
P = 0.001 
-10.0 ( -16.7, -3.3) 
P = 0.004 
2.7 ( -2.0, 7.5)      
P = 0.24 
-4.3 ( -11.1, 2.6)   
P = 0.21 
FVC Post- 
bronchodilator (ml) 
-5.9 ( -10.3, -1.6) 
P = 0.008 
-9.8 ( -17.5, -2.1) 
P = 0.013 
3.9 ( -2.3, 10.1)     
P = 0.21 
-3.0 ( -13.1, 7.1)   
P = 0.55 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.05 ( -0.17, 0.08) 
P = 0.46 
0.07 ( -0.20, 0.33) 
P = 0.60 
0.03 ( -0.11, 0.17) 
P = 0.66 
0.08 ( -0.16, 0.32) 
P = 0.51 
FEV1/FVC Ratio - 
Post-bronchodilator 
-0.01 ( -0.10, 0.08) 
P = 0.87 
0.14 ( -0.08, 0.37) 
P = 0.20 
0.06 ( -0.05, 0.16) 
P = 0.27 
0.16 ( -0.05, 0.36) 
P = 0.13 
Exhaled NO (ppb)        1.03 ( 1.01, 1.05) 
P = 0.002 
1.02 ( 1.00, 1.04) 
P = 0.046 
0.96 ( 0.94, 0.98) 
P < 0.0001 
0.97 ( 0.95, 0.99) 
P = 0.003 
 
Table 3.24. Recent exposure: effects per unit pollutant, all schools.  Bolded entries represent 
effects significant at the p=0.05 level. 
 
 
NO2 (ppb): 
One pollutant 
model 
NO2 (ppb): 
Joint pollutant 
model 
O3 (ppb):      
One pollutant 
model 
O3 (ppb):    
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-7.1 ( -11.4, -2.8) 
P = 0.001 
-6.0 ( -14.4, 2.4)   
P = 0.15 
4.1 ( -0.9, 9.2)      
P = 0.10 
0.2 ( -7.4, 7.7)      
P = 0.96 
FEV1 Post- 
bronchodilator (ml) 
-7.3 ( -11.4, -3.3) 
P = 0.0007 
-8.6 ( -17.0, -0.2) 
P = 0.045 
5.8 ( 1.8, 9.8)       
P = 0.005*I 
0.2 ( -6.2, 6.5)      
P = 0.96 
FVC Pre- 
bronchodilator (ml) 
-6.8 ( -10.9, -2.7) 
P = 0.001 
-7.5 ( -17.0, 2.0)   
P = 0.11 
4.6 ( -0.6, 9.8)      
P = 0.08 
-0.4 ( -8.5, 7.7)     
P = 0.92 
FVC Post- 
bronchodilator (ml) 
-6.9 ( -12.1, -1.6) 
P = 0.011 
-6.7 ( -16.7, 3.4)   
P = 0.18 
6.6 ( 0.9, 12.3)      
P = 0.024*I 
2.2 ( -6.5, 10.8)     
P = 0.61 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.06 ( -0.19, 0.08) 
P = 0.42 
-0.03 ( -0.24, 0.18) 
P = 0.74 
-0.00 ( -0.14, 0.14) 
P = 0.97 
-0.02 ( -0.19, 0.15) 
P = 0.77 
FEV1/FVC Ratio - 
Post-bronchodilator 
-0.05 ( -0.14, 0.05) 
P = 0.32 
-0.15 ( -0.37, 0.07) 
P = 0.16 
-0.02 ( -0.13, 0.08) 
P = 0.64 
-0.12 ( -0.30, 0.06) 
P = 0.17 
Exhaled NO (ppb) 1.03 ( 1.01, 1.05) 
P = 0.0008*I 
1.02 ( 1.00, 1.05) 
P = 0.05 
0.96 ( 0.94, 0.98) 
P = 0.0001 
0.98 ( 0.95, 1.00) 
P = 0.026 
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Table 3.25. Lifetime exposure: effects per unit pollutant, 10 high-O3 schools omitted.  Bolded 
entries represent effects significant at the p=0.05 level. 
 
 NO2 (ppb):    
One pollutant 
model 
NO2(ppb): 
Joint pollutant 
model 
O3 (ppb):    
One pollutant 
model 
O3 (ppb):    
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-6.6 ( -11.2, -2.0)   
P = 0.005 
-7.1 ( -14.5, 0.4) 
P = 0.06 
1.0 ( -7.1, 9.1)     
P = 0.80 
-4.0 ( -14.6, 6.6)    
P = 0.44 
FEV1 Post- 
bronchodilator (ml) 
-5.2 ( -9.9, -0.6)     
P = 0.028 
-8.6 ( -15.6, -1.5) 
P = 0.019 
0.1 ( -8.9, 9.1)     
P = 0.98 
-5.9 ( -17.0, 5.2)   
P = 0.28 
FVC Pre- 
bronchodilator (ml) 
-7.4 ( -11.8, -3.0)   
P = 0.001 
-11.9 ( -19.1, -4.7) 
P = 0.002 
0.0 ( -11.0, 11.1) 
P = 0.99 
-8.3 ( -21.2, 4.6)   
P = 0.19 
FVC Post- 
bronchodilator (ml) 
-5.7 ( -10.9, -0.5)   
P = 0.032 
-13.4 ( -20.6, -6.3) 
P = 0.0005 
-5.7 ( -17.9, 6.6) 
P = 0.35 
-15.1 ( -29.1, -1.0) 
P = 0.036 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.04 ( -0.19, 0.11) 
P = 0.56 
0.11 ( -0.17, 0.39) 
P = 0.44 
0.11 ( -0.12, 0.34) 
P = 0.32 
0.19 ( -0.12, 0.49) 
P = 0.21 
FEV1/FVC Ratio - 
Post-bronchodilator 
0.00 ( -0.12, 0.12)  
P = 0.98 
0.16 ( -0.07, 0.40) 
P = 0.17 
0.23 ( 0.06, 0.40) 
P = 0.008 
0.35 ( 0.11, 0.58) 
P = 0.004 
Exhaled NO (ppb) 1.01 ( 1.00, 1.03)   
P = 0.14 
1.01 ( 1.00, 1.03) 
P = 0.13 
0.95 ( 0.92, 0.98) 
P = 0.005 
0.96 ( 0.93, 1.00) 
P = 0.037 
 
 
Table 3.26. Recent exposure: effects per unit pollutant, 10 high-O3 schools omitted.  Bolded 
entries represent effects significant at the p=0.05 level. 
 
 NO2(ppb):   
One pollutant 
model 
NO2 (ppb) 
Joint pollutant 
model 
O3(ppb):     
One pollutant 
model 
O3(ppb)       
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-7.3 ( -12.6, -1.9) 
P = 0.008 
-5.0 ( -12.8, 2.8) 
P = 0.20 
4.3 ( -2.9, 11.4)   
P = 0.23 
1.6 ( -6.9, 10.1)    
P = 0.70 
FEV1 Post- 
bronchodilator (ml) 
-5.6 ( -10.8, -0.4) 
P = 0.036 
-8.1 ( -16.6, 0.3) 
P = 0.05 
1.0 ( -6.3, 8.3)     
P = 0.77 
-3.3 ( -11.5, 4.8)   
P = 0.41 
FVC Pre- 
bronchodilator (ml) 
-7.7 ( -12.9, -2.5) 
P = 0.004 
-7.7 ( -17.1, 1.7) 
P = 0.10 
5.5 ( -3.6, 14.6)    
P = 0.22 
1.4 ( -9.4, 12.1)    
P = 0.79 
FVC Post- 
bronchodilator (ml) 
-4.9 ( -11.0, 1.2) 
P = 0.11 
-7.2 ( -17.4, 3.1) 
P = 0.16 
2.0 ( -7.1, 11.1)   
P = 0.65 
-1.8 ( -12.5, 8.9)    
P = 0.72 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.06 ( -0.21, 0.1) 
P = 0.40 
-0.00 ( -0.22, 
0.21) P = 0.96 
0.01 ( -0.22, 0.23) 
P = 0.94 
0.01 ( -0.21, 0.22) 
P = 0.95 
FEV1/FVC Ratio - 
Post-bronchodilator 
-0.06 ( -0.18, 0.1) 
P = 0.30 
-0.13 ( -0.35, 0.1) 
P = 0.26 
-0.08 ( -0.31, 0.1) 
P = 0.48 
-0.14 ( -0.41, 0.12) 
P = 0.26 
Exhaled NO (ppb) 1.02 ( 1.00, 1.04) 
P = 0.05 
1.02 ( 1.00, 1.04) 
P = 0.10 
0.97 ( 0.94, 0.99) 
P = 0.020 
0.98 ( 0.95, 1.01) 
P = 0.19 
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Joint NO2-PM2.5 model 
NO2 and PM2.5 exposures are positively correlated, more strongly for lifetime exposure than 
recent exposure (Figure 3.3). 
Figure 3.3. Scatterplot of NO2 and PM2.5 exposures. 
 
A joint-NO2-PM2.5 model (Table 3.27.,  
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Table 3.28.) provided very similar estimates to the respective single pollutant models, providing 
some evidence of independent effects of these two pollutants. 
 
Table 3.27. Lifetime exposure: effects per unit pollutant.  Bolded entries represent effects 
significant at the p=0.05 level. 
 
 NO2 (ppb):  
One pollutant 
model 
NO2(ppb):   
Joint pollutant 
model 
PM2.5(g/m3):  
One pollutant 
model 
PM2.5 (g/m3): 
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-6.1 ( -9.8, -2.3)    
P = 0.001 
-6.2 ( -10.2, -2.3)   
P = 0.002 
2.1 ( -4.8, 8.9)       
P = 0.55 
0.4 ( -5.8, 6.7)       
P = 0.88 
FEV1 Post- 
bronchodilator (ml) 
-6.0 ( -9.6, -2.4)    
P = 0.001 
-6.1 ( -10.1, -2.2)   
P = 0.003 
1.7 ( -5.3, 8.7)       
P = 0.63 
0.2 ( -6.5, 7.0)       
P = 0.94 
FVC Pre- 
bronchodilator (ml) 
-5.9 ( -9.4, -2.3)    
P = 0.001 
-6.2 ( -9.9, -2.4)    
P = 0.001 
-1.4 ( -7.7, 5.0)      
P = 0.66 
-3.0 ( -9.0, 2.9)      
P = 0.30 
FVC Post- 
bronchodilator (ml) 
-5.9 ( -10.3, -1.6)   
P = 0.008 
-6.2 ( -11.0, -1.4)   
P = 0.013 
-1.8 ( -10.3, 6.7)    
P = 0.67 
-3.4 ( -11.8, 5.0)    
P = 0.42 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.05 ( -0.17, 
0.08) P = 0.46 
-0.03 ( -0.2, 0.10) 
P = 0.65 
0.18 ( 0.00, 0.35)   
P = 0.046 
0.17 ( -0.01, 0.35) 
P = 0.06 
FEV1/FVC Ratio - 
Post-bronchodilator 
-0.01 ( -0.10, 
0.08) P = 0.87 
-0.00 ( -0.09, 
0.08) P = 0.96 
0.16 ( 0.03, 0.28)   
P = 0.015 
0.16 ( 0.03, 0.29)   
P = 0.019 
Exhaled NO 1.03 ( 1.01, 1.05)   
P = 0.002 
1.03 ( 1.02, 1.05)   
P < 0.0001 
0.99 ( 0.96, 1.01)   
P = 0.35 
0.99 ( 0.96, 1.01)   
P = 0.17 
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Table 3.28. Recent exposure: effects per unit pollutant.  Bolded entries represent effects 
significant at the p=0.05 level. 
 
 NO2 (ppb):              
One pollutant 
model 
NO2 (ppb):           
Joint pollutant 
model 
PM2.5(g/m3):          
One pollutant 
model 
PM2.5(g/m3):           
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-7.1 ( -11.4, -2.8) 
P = 0.001 
-4.8 ( -10.8, 1.2)  
P = 0.11 
6.6 ( -7.9, 21.1)   
P = 0.35 
11.8 ( -4.9, 28.6) 
P = 0.15 
FEV1 Post- 
bronchodilator (ml) 
-7.3 ( -11.4, -3.3) 
P = 0.0007 
-7.2 ( -13.2, -1.2) 
P = 0.020 
-22.5 ( -45.2, 0.3) 
P = 0.05 
-14.5 ( -34.4, 5.4) 
P = 0.14 
FVC Pre- 
bronchodilator (ml) 
-6.8 ( -10.9, -2.7) 
P = 0.001 
-7.4 ( -14.6, -0.3) 
P = 0.042 
-12.4 ( -36, 11.3) 
P = 0.28 
-4.2 ( -26.9, 18.6) 
P = 0.70 
FVC Post- 
bronchodilator (ml) 
-6.9 ( -12.1, -1.6) 
P = 0.011 
-6.9 ( -14.2, 0.5)   
P = 0.06 
-43.4 ( -77.4, -9.3) 
P = 0.015 
-35.8 ( -65.2, -6.3) 
P = 0.019 
FEV1/FVC Ratio - 
Pre-bronchodilator 
-0.06 ( -0.19, 0.1) 
P = 0.42 
0.05 ( -0.11, 0.21) 
P = 0.54 
0.68 ( -0.16, 1.52) 
P = 0.10 
0.63 ( -0.17, 1.42) 
P = 0.11 
FEV1/FVC Ratio - 
Post-bronchodilator 
-0.05 ( -0.14, 
0.05) P = 0.32 
-0.06 ( -0.2, 0.03) 
P = 0.18 
0.58 ( 0.07, 1.10) 
P = 0.027 
0.66 ( 0.15, 1.16) 
P = 0.013 
Exhaled NO (ppb) 1.03 ( 1.01, 1.05) 
P = 0.0008 
1.05 ( 1.05, 1.05) 
P < 0.0001 
1.02 ( 1.02, 1.02) 
P < 0.0001 
0.94 ( 0.94, 0.94) 
P < 0.0001 
 
Joint SO2-O3 Model 
SO2 and O3 were negatively correlated for lifetime exposure, but positively correlated for recent 
exposure (Figure 3.4. Scatterplot of SO2 and O3 exposures.).   A joint SO2 - O3 model (Table 3.30. 
Recent exposure) showed declining effects in FEV1 and FVC pre- and post-bronchodilator with 
increasing lifetime SO2 and no effects for these lung function measures with lifetime O3.  For 
recent exposures, effects of SO2 were similar, although only the pre-bronchodilator effects were 
statistically significant; additionally, FEV1/FVC ratio post-bronchodilator significantly 
increased with recent SO2.  FEV1 and FVC post-bronchodilator decreased significantly with 
recent O3, reversing the increasing effects seen in the single pollutant O3 model. 
Figure 3.4. Scatterplot of SO2 and O3 exposures. 
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Table 3.29. Lifetime exposure: effects per unit pollutant. Bolded entries represent effects 
significant at the p=0.05 level. 
 
 SO2 (ppb):   
One pollutant 
model 
SO2 (ppb): 
Joint pollutant 
model 
O3 (ppb):    
One pollutant 
model 
O3 (ppb):    
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-1.0 ( -10.7, 8.6)   
P = 0.82 
-8.9 ( -16.5, -1.3) 
P = 0.023 
3.2 ( -1.4, 7.8)     
P = 0.16 
2.9 ( -2.8, 8.6)     
P = 0.29 
FEV1 Post- 
bronchodilator (ml) 
-2.0 ( -9.2, 5.1)    
P = 0.56 
-8.3 ( -15.2, -1.5) 
P = 0.019 
5.2 ( 1.2, 9.1)      
P = 0.011 
2.6 ( -3.0, 8.1)     
P = 0.35 
FVC Pre- 
bronchodilator (ml) 
-4.1 ( -16.1, 7.9)   
P = 0.49 
-11.3 ( -21.7, -0.9) 
P = 0.034 
2.7 ( -2.0, 7.5)     
P = 0.24 
0.7 ( -7.0, 8.3)     
P = 0.86 
FVC Post- 
bronchodilator (ml) 
-7.0 ( -18.6, 4.7)   
P = 0.22 
-12.5 ( -21.9, -3.1) 
P = 0.011 
3.9 ( -2.3, 10.1)    
P = 0.21 
-0.2 ( -7.3, 6.9) P 
= 0.95 
FEV1/FVC Ratio - 
Pre-bronchodilator 
0.11 ( -0.22, 0.45) 
P = 0.49 
0.06 ( -0.33, 0.45) 
P = 0.75 
0.03 ( -0.11, 0.17) 
P = 0.66 
0.11 ( -0.05, 0.27) 
P = 0.18 
FEV1/FVC Ratio - 
Post-bronchodilator 
0.08 ( -0.25, 0.41) 
P = 0.63 
0.04 ( -0.34, 0.43) 
P = 0.81 
0.06 ( -0.05, 0.16) 
P = 0.27 
0.08 ( -0.03, 0.20) 
P = 0.14 
Exhaled NO (ppb)  0.98 ( 0.96, 0.99) 
P = 0.009 
0.99 ( 0.98, 1.01) 
P = 0.32 
0.96 ( 0.94, 0.98) 
P < 0.0001 
0.95 ( 0.93, 0.97) 
P < 0.0001 
 
Table 3.30.  Recent exposure: effects per unit pollutant.  Bolded entries represent effects 
significant at the p=0.05 level. 
 
 SO2 (ppb): 
One pollutant 
model 
SO2 (ppb): 
Joint pollutant 
model 
O3 (ppb):   
One pollutant 
model 
O3 (ppb):   
Joint pollutant 
model 
FEV1 Pre- 
bronchodilator (ml) 
-3.4 ( -16.1, 9.3)  
P = 0.58 
-30.5 ( -58.7, -2.2) 
P = 0.036 
4.1 ( -0.9, 9.2) P = 
0.10 
-6.2 ( -16.4, 4.1)  
P = 0.22 
FEV1 Post- 
bronchodilator (ml) 
-5.0 ( -14.9, 4.8)  
P = 0.29 
-25.4 ( -66, 15.2) 
P = 0.20 
5.8 ( 1.8, 9.8)      
P = 0.005 
-10.7 ( -19.6, -1.8) 
P = 0.021 
FVC Pre- 
bronchodilator (ml) 
-7.0 ( -20.4, 6.5)  
P = 0.29 
-46.8 ( -78, -15.1) 
P = 0.006 
4.6 ( -0.6, 9.8)     
P = 0.08 
-3.8 ( -12.6, 5.0)    
P = 0.37 
FVC Post- 
bronchodilator (ml) 
-8.8 ( -22.5, 5.0)  
P = 0.19 
-46.7 ( -97.2, 3.9) 
P = 0.06 
6.6 ( 0.9, 12.3)    
P = 0.024 
-9.7 ( -17.5, -1.9) 
P = 0.018 
FEV1/FVC Ratio - 
Pre-bronchodilator 
0.12 ( -0.26, 0.50) 
P = 0.50 
0.54 ( -0.32, 1.40) 
P = 0.20 
-0.0 ( -0.14, 0.14) 
P = 0.97 
-0.1 ( -0.41, 0.19) 
P = 0.46 
FEV1/FVC Ratio - 
Post-bronchodilator 
0.03 ( -0.35, 0.42) 
P = 0.85 
0.93 ( 0.30, 1.56) 
P = 0.006 
-0.0 ( -0.13, 0.08) 
P = 0.64 
-0.1 ( -0.37, 0.19) 
P = 0.51 
Exhaled NO (ppb) 0.98 ( 0.96, 0.99) 
P = 0.011 
1.01 ( 0.92, 1.11) 
P = 0.76 
0.96 ( 0.94, 0.98) 
P = 0.0001 
1.00 ( 0.98, 1.02) 
P = 0.89 
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3.7.3. Interaction models 
 
Models were extended to incorporate interaction terms to allow for the detection of 
modification of pollutant effects by atopy (a positive response to one or more of the eight 
allergens tested), current asthma and gender.  Evidence of an interactive effect was assumed 
when the interaction was significant and at least one subgroup effect was significant at the 5% 
level.   
Atopy 
No significant effect modification was found in relation to Bsp, NO2, and O3.  Effect 
modification was most marked for SO2 (Table 3.31.), with atopic children having significant 
decreases in lung function on many measures, and non-atopic children showing no effects, for 
both lifetime and recent exposure.  Effects persisted when Port Pirie was excluded.   
Other pollutants showed evidence of interactive effects, but these were somewhat inconsistent. 
For recent exposure, the increase in exhaled NO with Bsp and PM10 was significantly greater in 
atopic children, and non-significant within non-atopic children.  Exhaled NO increased by 2% 
(1%, 3%) per g/m3 recent PM10  exposure in atopic children, with virtually no effect in non-
atopic children, with P = 0.003 for interaction).  The relationship between exhaled NO and 
recent Bsp exposure was consistent with this pattern (effect estimate 28% per 10-4 m-1 (1%, 65%) 
in atopic children, and no effect in  non-atopic children, with P = 0.014 for interaction), but the 
effect in atopic children fell just short of significance (P=0.053). 
Conversely, adverse effects of lifetime CO on FVC post-bronchodilator were greater in non-
atopic children and non-significant in atopic children (decrease of 12.3 ml per ppm (-142, 166) 
for atopic children, and -172 ml per ppm (-305, -40) for non-atopic children, with P = 0.01 for 
interaction).  No effect modification of CO effects was seen for recent exposure. 
FEV1/FVC ratio post-bronchodilator was not significantly related to recent PM2.5 in atopic 
children but increased significantly with PM2.5 in non-atopic children (effect estimate 0.03 per 
g/m3 PM2.5  (-0.47, 1.08) in atopic children, 1.28 (0.83, 1.73) for non-atopic children, with P = 
0.036 for interaction).   
Gender 
Atopic status was included in the interaction models for gender. 
No significant effect modification by gender was found in relation to CO.  Where evidence of 
effect modification occurred, it was predominantly males who showed the greater (or only) 
effects.  The evidence for male specific effects (in terms of interaction tests) was stronger than 
that for the female specific effects. 
Females showed some specific effects for particulate matter and O3; males showed specific 
effects for NO2 and SO2.  
For FEV1 post-bronchodilator, the effect estimates for lifetime NO2 were -7.0 ml (-11.6, -2.4) per 
ppb for males, -3.4 ml  (-8.5, 1.8) per ppb for females, with P =0.057 for interaction, and for 
recent NO2, were -9.6 ml (-14.7, -4.4) per ppb for males, -4.7 ml (-10.2, 0.8) per ppb for females, 
with P =0.018 for interaction.   
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FVC pre- and post-bronchodilator decreased with lifetime and recent SO2, for males only (Table 
3.32.).  For FVC post-bronchodilator, effect estimates for lifetime SO2 were -16.1 (-25.2,--7.0) for 
males, -2.7 (-18.1, 12.6) for females, with P =0.012 for interaction, and for recent SO2, were --16.3 
(-26.3,-6.3) for males, -2.4 (-19.6, 14.9) for females, with P =0.019 for interaction.  For FVC pre-
bronchodilator, effect estimates were consistent with this pattern, but effect estimates were not 
quite significant.    
Table 3.31. Modification of SO2 (ppb) effects by atopic status. Bolded entries represent 
effects significant at the p=0.05 level. 
 
Outcome Lifetime exposure P Recent exposure P 
FEV1 Pre-bronchodilator (ml)     
  Atopic -17.0 ( -30.3, -3.6) 0.014 -20.0 ( -35.11, -4.89) 0.012 
  Non-atopic -1.0 ( -9.5, 7.4) 0.80 -2.0 ( -14.00, 10.01) 0.73 
  Interaction 16.0 ( 6.9, 25.1) 0.001 18.0 ( 10.04, 25.96) 0.0001 
FEV1 Post-bronchodilator (ml)     
  Atopic -19.4 ( -29.5, -9.3) 0.0006 -23.1 ( -34.83, -11.45) 0.0005 
  Non-atopic -0.2 ( -6.7, 6.3) 0.95 -2.2 ( -11.29, 6.82) 0.61 
  Interaction 19.2 ( 11.0, 27.4) < 0.0001 20.9 ( 14.27, 27.54) < 0.0001 
FVC Pre-bronchodilator (ml)     
  Atopic -33.8 ( -56.3, -11.3) 0.005 -38.0 ( -61.98, -14.06) 0.003 
  Non-atopic 2.1 ( -6.0, 10.1) 0.60 -1.6 ( -9.86, 6.58) 0.68 
  Interaction 35.9 ( 15.9, 55.8) 0.001 36.4 ( 15.10, 57.66) 0.002 
FVC Post-bronchodilator (ml)     
  Atopic -27.7 ( -49.4, -6.0) 0.014 -27.8 ( -51.3, -4.2) 0.023 
  Non-atopic 1.25 ( -4.7, 7.2) 0.66 1.33 ( -4.6, 7.3) 0.64 
  Interaction 29.0 ( 10.0, 47.9) 0.004 29.1 ( 9.0, 49.2) 0.006 
FEV1/FVC Ratio Pre-
bronchodilator (%) 
   
 
  Atopic 0.62 ( 0.15, 1.09) 0.011 0.66 ( 0.18, 1.14) 0.009 
  Non-atopic -0.15 ( -0.46, 0.15) 0.31 -0.05 ( -0.36, 0.26) 0.72 
  Interaction -0.77 ( -1.17, -0.37)   0.0005 -0.71 ( -1.05, -0.37) 0.0003 
FEV1/FVC Ratio Post-
bronchodilator (%) 
   
 
  Atopic 0.31 ( -0.30, 0.92) 0.29 0.26 ( -0.44, 0.96) 0.44 
  Non-atopic -0.06 ( -0.31, 0.18) 0.58 -0.04 ( -0.33, 0.25) 0.76 
  Interaction -0.38 ( -0.91, 0.16) 0.15 -0.30 ( -0.91, 0.31) 0.31 
Exhaled NO (ppb)     
  Atopic 0.99 ( 0.96, 1.01) 0.26 0.99 ( 0.96, 1.01) 0.28 
  Non-atopic 0.98 ( 0.96, 1.00) 0.044 0.98 ( 0.96, 1.00) 0.038 
  Interaction -0.01 ( -0.04, 0.03) 0.67 -0.01 ( -0.04, 0.03) 0.68 
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Table 3.32. Modification of SO2 (ppb)  effects by gender.  Bolded entries represent effects 
significant at the p=0.05 level. 
 
Outcome Lifetime exposure P Recent exposure P 
FEV1 Pre-bronchodilator (ml)     
  Males -7.7 ( -16.5, 1.1) 0.08 -10.6 ( -23.1, 1.8) 0.09 
  Females -6.0 ( -19.4, 7.5) 0.36 -6.4 ( -22.9, 10.0) 0.42 
  Interaction 1.7 ( -10.5, 13.9) 0.77 4.2 ( -9.3, 17.6) 0.52 
FEV1 Post-bronchodilator (ml)     
  Males -9.4 ( -16.0, -2.73) 0.007 -13.0 ( -22.9, -3.1) 0.0126 
  Females -4.9 ( -15.6, 5.7) 0.34 -6.7 ( -19.4, 6.0) 0.284 
  Interaction 4.4 ( -6.3, 15.1) 0.4 6.3 ( -5.3, 17.9) 0.2709 
FVC Pre-bronchodilator (ml)     
  Males -16.7 ( -26.5, -6.9) 0.001 -20.8 ( -31.7, -9.8) 0.0008 
  Females -6.3 ( -24.2, 11.5) 0.46 -10.1 ( -29.3, 9.2) 0.28 
  Interaction 10.4  ( -0.9, 21.6) 0.06 10.7 ( -0.7, 22.0) 0.06 
FVC Post-bronchodilator (ml)     
  Males -16.1 ( -25.2, -7.0) 0.001 -16.3 ( -26.3, -6.3) 0.003 
  Females -2.7 ( -18.1, 12.6) 0.71 -2.4 ( -19.6, 14.9) 0.77 
  Interaction 13.4 ( 3.2, 23.5) 0.011 13.9 ( 2.5, 25.3) 0.019 
FEV1/FVC Ratio Pre-
bronchodilator (%) 
    
  Males 0.41 ( 0.03, 0.79) 0.036 0.43 ( -0.01, 0.87) 0.05 
  Females -0.12 ( -0.49, 0.25) 0.5 0.02 ( -0.35, 0.38) 0.93 
  Interaction -0.53 ( -0.75, -0.31) < 0.0001 -0.41 ( -0.63, -0.19) 0.0008 
FEV1/FVC Ratio Post-
bronchodilator (%) 
    
  Males 0.30 ( -0.05, 0.65) 0.08 0.25 ( -0.17, 0.67) 0.2274 
  Females -0.15 ( -0.53, 0.24) 0.43 -0.10 ( -0.53, 0.32) 0.614 
  Interaction -0.45 ( -0.61, -0.28) < 0.0001 -0.36 ( -0.53, -0.18) 0.0003 
Expired NO (ppb)     
  Males 0.98 ( 0.97, 1.00)  0.016 0.98 ( 0.97, 1.00) 0.024 
  Females 0.98 ( 0.97, 1.00)  0.035 0.98 ( 0.96, 1.00) 0.037 
  Interaction -0.00 ( -0.01, 0.01) 0.87 -0.00 ( -0.01, 0.01) 0.81 
 
FEV1/FVC ratio pre- and post-bronchodilator decreased with lifetime O3 in females, but not in 
males. 
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Females showed a significant increase in FEV1 pre-bronchodilator and FEV1/FVC ratio pre-
bronchodilator with lifetime Bsp: FEV1 pre-bronchodilator effect estimates were -28.3 ml (-180, 
123) per 10-4 m-1 for males, 138 (0.1, 276) per 10-4 m-1 for females, with P =0.041 for interaction 
and for FEV1/FVC ratio pre-bronchodilator were -0.94 ml (-5.0, 3.1) per 10-4 m-1 for males 7.6 
(3.4,11.7) per 10-4 m-1 for females, with P =0.0008 for interaction.  The pattern for FEV1/FVC 
ratio pre-bronchodilator was similar for recent exposure, and held for Bsp, PM2.5 and PM10. 
3.8. Pollutants and respiratory symptoms 
3.8.1. Single pollutant models 
 
Results of all single pollutant models and outcomes considered of clinical importance are 
shown in Table 3.33 and Table 3.34.   These are adjusted for age and gender, parental education 
and two SEIFA indices: relative socio-economic advantage and disadvantage, and education 
and occupation.  Effect estimates per unit pollutant exposures are shown, with 95% CIs, and P-
values.  Findings are summarised in this section. 
 
Bsp 
The only symptom which was significantly linearly related to Bsp (recent exposure only) was 
recent wheeze after exercise which showed an increased risk: odds ratio (OR) and 95% CI: 5.88 
(1.56, 22.2) per 10-4 m-1  and 1.45 (1.10, 1.91) per inter-quartile range (IQR) . 
 
 
PM2.5 
No symptoms showed any linear association with lifetime or recent PM2.5. 
 
PM10 
Recent cough significantly declined with both lifetime and recent exposure to PM10. 
 
NO2 
Current asthma, recent wheeze, and recent wheeze after exercise were associated with 
increasing NO2, for both lifetime and recent exposure, with effects slightly greater for recent 
exposure.  For current asthma and per ppb recent exposure NO2, the OR was 1.06 (1.02, 1.10), 
with OR per IQR NO2 1.26 (1.08, 1.48).   For recent wheeze after exercise, the OR was 1.07 (1.03, 
1.120) per ppb and 1.32 (1.12, 1.57) per IQR. 
 
O3 
Symptom prevalence for wheezing and asthma decreased with lifetime exposure to O3.  No 
significant associations were found for recent exposure, except for an increase in prevalence of 
recent cough with increasing O3. 
 
CO 
No associations between CO and symptoms were detected. 
SO2 
Recent wheeze after exercise, and use of beta-agonists declined with increasing SO2, for both 
lifetime and recent measures.  These effects became non-significant with the exclusion of Port 
Pirie from the models. 
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In summary, the most important adverse effects noted in these single pollutant models were the 
effects of NO2 exposure on risk of asthma-related symptoms. 
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Table 3.33. Symptoms: single pollutant models, lifetime exposure; effects per unit pollutant. Bolded entries represent effects significant at the 
p=0.05 level. 
Symptom Bsp 
10-4 m-1 
PM2.5 
g/m3 
PM10 
g/m3 
NO2 
ppb 
O3 
ppb 
CO 
ppm 
SO2 
ppb 
Ever had wheezing 0.93 ( 0.25, 3.50) 
P = 0.91 
1.02 ( 0.96, 1.08) 
P = 0.54 
0.98 ( 0.94, 1.02) 
P = 0.35 
1.02 ( 0.99, 1.05) 
P = 0.13 
0.97 ( 0.95, 1.00) 
P = 0.047 
0.81 ( 0.25, 2.65) 
P = 0.73 
0.97 ( 0.91, 1.03) 
P = 0.32 
Ever had asthma 1.60 ( 0.51, 5.05) 
P = 0.42 
1.00 ( 0.95, 1.06) 
P = 0.95 
0.99 ( 0.95, 1.03) 
P = 0.54 
1.02 ( 1.00, 1.04) 
P = 0.08 
0.97 ( 0.95, 1.00) 
P = 0.021 
1.11 ( 0.33, 3.68) 
P = 0.86 
0.96 ( 0.89, 1.02) 
P = 0.19 
Ever had medication 
for asthma/wheezing 
1.05 ( 0.19, 5.68) 
P = 0.95 
1.02 ( 0.96, 1.08) 
P = 0.53 
0.99 ( 0.94, 1.04) 
P = 0.58 
1.02 ( 0.99, 1.05) 
P = 0.20 
0.98 ( 0.96, 1.01) 
P = 0.13 
0.60 ( 0.19, 1.89) 
P = 0.37 
1.00 ( 0.94, 1.05) 
P = 0.87 
Ever had rhinitis  1.23 ( 0.26, 5.86) 
P = 0.79 
1.03 ( 0.96, 1.11) 
P = 0.36 
0.99 ( 0.94, 1.04) 
P = 0.72 
0.99 ( 0.95, 1.03) 
P = 0.60 
1.00 ( 0.97, 1.04) 
P = 0.85 
0.66 ( 0.25, 1.73) 
P = 0.39 
0.97 ( 0.90, 1.05) 
P = 0.48 
        
Recent wheeze 1.34 ( 0.34, 5.24) 
P = 0.67 
0.98 ( 0.91, 1.04) 
P = 0.50 
0.99 ( 0.94, 1.04) 
P = 0.65 
1.03 ( 1.00, 1.07) 
P = 0.042 
0.96 ( 0.92, 1.00) 
P = 0.031 
0.66 ( 0.21, 2.10) 
P = 0.48 
0.97 ( 0.92, 1.02) 
P = 0.26 
Recent wheeze 
after exercise 
3.25 ( 0.58,18.11) 
P = 0.17 
1.00 ( 0.92, 1.08) 
P = 0.94 
1.01 ( 0.95, 1.08) 
P = 0.74 
1.06 ( 1.02, 1.09) 
P = 0.001 
0.94 ( 0.89, 0.99) 
P = 0.012 
0.73 ( 0.22, 2.36) 
P = 0.59 
0.81 ( 0.74, 0.89) 
P < 0.0001 
Current asthma 1.56 ( 0.33, 7.33) 
P = 0.57 
0.97 ( 0.90, 1.05) 
P = 0.43 
0.99 ( 0.94, 1.04) 
P = 0.75 
1.05 ( 1.01, 1.09) 
P = 0.010 
0.94 ( 0.90, 0.98) 
P = 0.001 
1.68 ( 0.40, 7.15) 
P = 0.48 
0.91 ( 0.82, 1.00) 
P = 0.059 
Recent visit to 
GP/ED/hospital 
0.91 ( 0.31, 2.70) 
P = 0.86 
0.99 ( 0.92, 1.06) 
P = 0.68 
0.96 ( 0.90, 1.03) 
P = 0.29 
1.03 ( 0.98, 1.08) 
P = 0.24 
0.99 ( 0.94, 1.05) 
P = 0.84 
0.22 ( 0.04, 1.22) 
P = 0.08 
0.96 ( 0.83, 1.12) 
P = 0.63 
Recent use of beta-
agonist (short-term)  
1.58 ( 0.42, 5.91) 
P = 0.49 
0.97 ( 0.92, 1.03) 
P = 0.32 
0.99 ( 0.94, 1.03) 
P = 0.61 
1.02 ( 0.99, 1.06) 
P = 0.15 
0.97 ( 0.95, 1.00) 
P = 0.038 
0.68 ( 0.25, 1.86) 
P = 0.45 
0.93 ( 0.88, 0.97) 
P = 0.003 
Recent cough 0.61 ( 0.13, 2.79) 
P = 0.52 
0.98 ( 0.92, 1.05) 
P = 0.61 
0.93 ( 0.88, 0.98) 
P = 0.008 
1.00 ( 0.96, 1.03) 
P = 0.89 
1.04 ( 1.00, 1.08) 
P = 0.038 
0.50 ( 0.09, 2.85) 
P = 0.43 
1.02 ( 0.95, 1.11) 
P = 0.53 
Recent rhinitis  1.52 ( 0.30, 7.65) 
P = 0.61 
1.05 ( 0.97, 1.12) 
P = 0.21 
0.99 ( 0.94, 1.05) 
P = 0.79 
0.99 ( 0.95, 1.03) 
P = 0.67 
1.00 ( 0.96, 1.04) 
P = 0.96 
0.87 ( 0.32, 2.36) 
P = 0.78 
0.98 ( 0.92, 1.05) 
P = 0.53 
Recent itchy rash for 6 
months 
1.18 ( 0.22, 6.36) 
P = 0.84 
1.01 ( 0.93, 1.10) 
P = 0.76 
0.99 ( 0.94, 1.05) 
P = 0.83 
1.00 ( 0.96, 1.04) 
P = 0.96 
1.00 ( 0.96, 1.04) 
P = 0.88 
0.81 ( 0.36, 1.81) 
P = 0.61 
1.04 ( 0.95, 1.14) 
P = 0.44 
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Table 3.34. Symptoms: single pollutant models, recent exposure; effects per unit pollutant.  Bolded entries represent effects significant at the 
p=0.05 level. 
Symptom Bsp 
10-4 m-1 
PM2.5 
g/m3 
PM10 
g/m3 
NO2 
ppb 
O3 
ppb 
CO 
ppm 
SO2 
ppb 
Recent wheeze 2.22 ( 0.78, 6.32) 
P = 0.13 
0.96 ( 0.72, 1.28) 
P = 0.78 
1.00 ( 0.96, 1.04) 
P = 0.99 
1.04 ( 1.01, 1.08) 
P = 0.013 
0.97 ( 0.93, 1.01) 
P = 0.14 
0.68 ( 0.15, 3.06) 
P = 0.61 
0.95 ( 0.89, 1.02) 
P = 0.18 
Recent wheeze  
after exercise 
5.88 ( 1.56,22.19) 
P = 0.008 
0.97 ( 0.65, 1.45) 
P = 0.88 
1.03 ( 0.98, 1.09) 
P = 0.20 
1.07 ( 1.03, 1.12) 
P = 0.001 
0.96 ( 0.91, 1.02) 
P = 0.20 
1.22 ( 0.16, 9.57) 
P = 0.84 
0.81 ( 0.75, 0.89) 
P < 0.0001 
Current asthma 3.33 ( 0.85,13.01) 
P = 0.08 
1.04 ( 0.76, 1.41) 
P = 0.82 
1.01 ( 0.97, 1.06) 
P = 0.56 
1.06 ( 1.02, 1.10) 
P = 0.003 
0.96 ( 0.92, 1.00) 
P = 0.07 
2.77 ( 0.54,14.36) 
P = 0.22 
0.92 ( 0.83, 1.03) 
P = 0.14 
Recent visit to 
GP/ED/hospital 
1.80 ( 0.45, 7.09) 
P = 0.40 
1.00 ( 0.79, 1.26) 
P = 0.97 
0.97 ( 0.92, 1.02) 
P = 0.21 
1.04 ( 0.99, 1.10) 
P = 0.15 
1.01 ( 0.95, 1.06) 
P = 0.85 
0.20 ( 0.02, 1.92) 
P = 0.16 
0.97 ( 0.81, 1.16) 
P = 0.72 
Recent use of beta-
agonist (short-term) 
1.64 ( 0.58, 4.67) 
P = 0.35 
0.97 ( 0.75, 1.25) 
P = 0.79 
1.00 ( 0.97, 1.04) 
P = 0.84 
1.03 ( 1.00, 1.06) 
P = 0.08 
0.98 ( 0.96, 1.01) 
P = 0.30 
0.69 ( 0.21, 2.23) 
P = 0.53 
0.92 ( 0.86, 0.97) 
P = 0.004 
Recent cough 0.54 ( 0.17, 1.74) 
P = 0.30 
0.84 ( 0.61, 1.17) 
P = 0.30 
0.93 ( 0.89, 0.97) 
P = 0.001 
1.00 ( 0.96, 1.04) 
P = 0.97 
1.05 ( 1.00, 1.10) 
P = 0.059 
0.16 ( 0.02, 1.23) 
P = 0.07 
1.05 ( 0.96, 1.14) 
P = 0.30 
Recent rhinitis 1.43 ( 0.47, 4.40) 
P = 0.52 
1.08 ( 0.75, 1.56) 
P = 0.67 
0.99 ( 0.94, 1.04) 
P = 0.66 
0.99 ( 0.94, 1.03) 
P = 0.50 
1.00 ( 0.96, 1.05) 
P = 0.89 
0.99 ( 0.27, 3.67) 
P = 0.99 
0.98 ( 0.89, 1.07) 
P = 0.61 
Recent itchy rash for 
6 months 
2.12 ( 0.50, 8.97) 
P = 0.30 
0.83 ( 0.64, 1.09) 
P = 0.18 
1.01 ( 0.96, 1.07) 
P = 0.63 
1.00 ( 0.96, 1.05) 
P = 0.87 
1.02 ( 0.97, 1.06) 
P = 0.47 
0.99 ( 0.22, 4.45) 
P = 0.99 
1.08 ( 0.96, 1.21) 
P = 0.22 
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3.8.2. Joint pollutant models 
 
More details are given in Appendices - Part B 
 
NO2 and O3 joint model 
 
Joint pollutant model including all sites (Table 3.35. and Table 3.36.):  Effects of lifetime NO2 
were generally reduced in the joint pollutant model, although a significant increase in urgent 
asthma care was identified.  However, effects of recent NO2 were increased in magnitude with 
increased risks for recent wheeze, wheeze after exercise, current asthma, and urgent asthma 
care.  O3 effects were largely unchanged in the joint pollutant models, with the exception of an 
increased risk of urgent medical care with recent O3 exposure. 
 
Joint pollutant model excluding high-ozone schools ( 
Table 3.37. and Table 3.38.): No effects of lifetime exposures were identified, except for a 
protective effect of O3 on current asthma, in both single and joint pollutant models.  Recent NO2 
effects were reduced compared to the unrestricted models, with recent wheeze after exercise 
and urgent asthma care remaining significant in the restricted two pollutant model.  Recent O3 
exposure was associated with increased risk of recent wheeze after exercise and recent rhinitis. 
 
Table 3.35. Lifetime exposure: effects per unit pollutant; unrestricted O3.  Bolded entries 
represent effects significant at the p=0.05 level. 
Measure NO2 (ppb):     
One pollutant 
model 
NO2 (ppb):      
Two pollutant 
model 
O3 (ppb):        
One pollutant 
model 
O3 (ppb):        
Two  pollutant 
model 
Recent wheeze 1.03 ( 1.00, 1.07)      
P = 0.042 
1.01 ( 0.95, 1.08)      
P = 0.66 
0.96 ( 0.92, 1.00)      
P = 0.031 
0.97 ( 0.91, 1.03)      
P = 0.28 
Recent wheeze 
after exercise 
1.06 ( 1.02, 1.09)      
P = 0.001 
1.02 ( 0.95, 1.10)      
P = 0.51 
0.94 ( 0.89, 0.99)      
P = 0.012 
0.95 ( 0.88, 1.03)      
P = 0.21 
Current asthma 1.05 ( 1.01, 1.09)      
P = 0.010 
0.98 ( 0.92, 1.05)      
P = 0.57 
0.94 ( 0.90, 0.98)      
P = 0.001 
0.92 ( 0.87, 0.98)      
P = 0.013 
Recent visit to  
GP/ED/hospital 
1.03 ( 0.98, 1.08)      
P = 0.24 
1.10 ( 1.01, 1.20)      
P = 0.028 
0.99 ( 0.94, 1.05)      
P = 0.84 
1.06 ( 0.98, 1.15)      
P = 0.12 
Recent use of beta-
agonist (short-term)  
1.02 ( 0.99, 1.06)      
P = 0.15 
1.00 ( 0.94, 1.06)       
P = 0.92 
0.97 ( 0.95, 1.00)      
P = 0.038 
0.97 ( 0.92, 1.02)      
P = 0.23 
Recent cough 1.00 ( 0.96, 1.03)         
P = 0.89 
1.03 ( 0.97, 1.08)      
P = 0.32 
1.04 ( 1.00, 1.08)      
P = 0.038 
1.06 ( 1.00, 1.12)      
P = 0.034 
Recent rhinitis  0.99 ( 0.95, 1.03)      
P = 0.67 
1.02 ( 0.96, 1.09)      
P = 0.45 
1.00 ( 0.96, 1.04)       
P = 0.96 
1.02 ( 0.96, 1.08)      
P = 0.54 
Recent itchy rash 
for 6 months 
1.00 ( 0.96, 1.04)       
P = 0.96 
1.04 ( 0.97, 1.12)      
P = 0.28 
1.00 ( 0.96, 1.04)      
P = 0.88 
1.03 ( 0.96, 1.11)      
P = 0.37 
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Table 3.36. Recent exposure: effects per unit pollutant: unrestricted O3.  Bolded entries 
represent effects significant at the p=0.05 level. 
Measure NO2 (ppb):     
One pollutant 
model 
NO2 (ppb):      
Two pollutant 
model 
O3 (ppb):        
One pollutant 
model 
O3 (ppb):        
Two  pollutant 
model 
Recent wheeze 1.04 ( 1.01, 1.08)      
P = 0.013 
1.08 ( 1.00, 1.17)      
P = 0.048I 
0.90 ( 0.79, 1.04)      
P = 0.1463 
1.02 ( 0.96, 1.09)      
P = 0.47 
Recent wheeze 
after exercise 
1.07 ( 1.03, 1.12)      
P = 0.001 
1.15 ( 1.08, 1.22)      
P < 0.0001 
0.88 ( 0.73, 1.07)      
P = 0.2074 
1.06 ( 0.98, 1.14)      
P = 0.13 
Current asthma 1.06 ( 1.02, 1.10)      
P = 0.003 
1.06 ( 0.98, 1.16)       
P = 0.14 
0.87 ( 0.75, 1.01)      
P = 0.0717 
1.00 ( 0.94, 1.07)      
P = 0.94 
Recent visit to 
GP/ED/hospital 
1.04 ( 0.99, 1.10)      
P = 0.15 
1.18 ( 1.04, 1.33)      
P = 0.008 
1.02 ( 0.85, 1.22)      
P = 0.8529 
1.12 ( 1.03, 1.23)      
P = 0.012 
Recent use of beta-
agonist (short-term)  
1.03 ( 1.00, 1.06)      
P = 0.08 
1.03 ( 0.97, 1.10)       
P = 0.29 
0.95 ( 0.85, 1.05)      
P = 0.3077 
1.01 ( 0.96, 1.05)       
P = 0.81 
Recent cough 1.00 ( 0.96, 1.04)       
P = 0.97 
1.03 ( 0.97, 1.09)       
P = 0.29 
1.17 ( 0.99, 1.37)      
P = 0.0598 
1.07 ( 1.00, 1.14)      
P = 0.052 
Recent rhinitis  0.99 ( 0.94, 1.03)      
P = 0.50 
1.01 ( 0.95, 1.08)       
P = 0.71 
1.01 ( 0.87, 1.17)      
P = 0.8998 
1.01 ( 0.96, 1.07)      
P = 0.69 
Recent itchy rash 
for 6 months 
1.00 ( 0.96, 1.05)      
P = 0.87 
1.07 ( 0.96, 1.20)       
P = 0.21 
1.06 ( 0.91, 1.23)      
P = 0.4730 
1.07 ( 0.96, 1.18)      
P = 0.21 
 
Table 3.37. Lifetime exposure: effects per unit pollutant: restricted O3.  Bolded entries 
represent effects significant at the p=0.05 level. 
Measure NO2 (ppb):     
One pollutant 
model 
NO2 (ppb):      
Two pollutant 
model 
O3 (ppb):        
One pollutant 
model 
O3 (ppb):        
Two  pollutant 
model 
Recent wheeze 1.01 ( 0.97, 1.06)      
P = 0.65 
1.01 ( 0.95, 1.08)      
P = 0.73 
0.97 ( 0.89, 1.06)      
P = 0.52 
0.98 ( 0.89, 1.08)      
P = 0.69 
Recent wheeze 
after exercise 
1.03 ( 0.99, 1.07)      
P = 0.17 
1.02 ( 0.96, 1.09)      
P = 0.47 
0.95 ( 0.88, 1.02)      
P = 0.17 
0.97 ( 0.88, 1.06)      
P = 0.49 
Current asthma 1.03 ( 0.98, 1.08)      
P = 0.28 
0.98 ( 0.92, 1.05)      
P = 0.55 
0.91 ( 0.84, 0.99)      
P = 0.026 
0.90 ( 0.82, 0.99)      
P = 0.029 
Recent visit to 
GP/ED/hospital 
1.04 ( 0.97, 1.11)      
P = 0.24 
1.10 ( 1.01, 1.20)      
P = 0.037 
0.96 ( 0.87, 1.05)      
P = 0.38 
1.02 ( 0.91, 1.15)      
P = 0.68 
Recent use of beta-
agonist (short-term)  
1.01 ( 0.96, 1.06)      
P = 0.70 
0.99 ( 0.93, 1.06)       
P = 0.78 
0.98 ( 0.92, 1.04)      
P = 0.52 
0.97 ( 0.90, 1.05)      
P = 0.47 
Recent cough 1.03 ( 0.99, 1.07)      
P = 0.16 
1.01 ( 0.96, 1.07)       
P = 0.65 
1.00 ( 0.94, 1.07)      
P = 0.96 
1.01 ( 0.94, 1.08)      
P = 0.77 
Recent rhinitis  0.99 ( 0.93, 1.04)      
P = 0.58 
1.04 ( 0.97, 1.10)      
P = 0.26 
1.03 ( 0.95, 1.12)      
P = 0.46 
1.06 ( 0.96, 1.16)      
P = 0.23 
Recent itchy rash 
for 6 months 
1.03 ( 0.97, 1.09)       
P = 0.41 
1.04 ( 0.96, 1.13)      
P = 0.29 
0.96 ( 0.88, 1.04)      
P = 0.34 
0.99 ( 0.90, 1.09)      
P = 0.83 
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Table 3.38. Recent exposure: effects per unit pollutant: restricted O3.  Bolded entries 
represent effects significant at the p=0.05 level. 
Measure NO2 (ppb):     
One pollutant 
model 
NO2 (ppb):      
Two pollutant 
model 
O3 (ppb):        
One pollutant 
model 
O3 (ppb):        
Two  pollutant 
model 
Recent wheeze 1.03 ( 0.98, 1.08)      
P = 0.29 
1.07 ( 0.99, 1.17)      
P = 0.08 
1.01 ( 0.94, 1.08)      
P = 0.74 
1.05 ( 0.97, 1.14)       
P = 0.22 
Recent wheeze 
after exercise 
1.06 ( 1.01, 1.11)      
P = 0.025 
1.15 ( 1.08, 1.23)      
P < 0.0001 
1.03 ( 0.96, 1.11)      
P = 0.41 
1.12 ( 1.03, 1.22)       
P = 0.006 
Current asthma 1.05 ( 0.99, 1.10)      
P = 0.10 
1.07 ( 0.98, 1.16)       
P = 0.14 
0.99 ( 0.91, 1.07)      
P = 0.75 
1.02 ( 0.93, 1.12)      
P = 0.60 
Recent visit to 
GP/ED/hospital 
1.06 ( 0.99, 1.14)      
P = 0.08 
1.18 ( 1.04, 1.34)      
P = 0.012 
0.99 ( 0.89, 1.10)      
P = 0.83 
1.09 ( 0.96, 1.24)      
P = 0.19 
Recent use of beta-
agonist (short-term)  
1.02 ( 0.97, 1.07)      
P = 0.46 
1.02 ( 0.96, 1.10)      
P = 0.46 
1.01 ( 0.94, 1.08)      
P = 0.83 
1.02 ( 0.95, 1.10)      
P = 0.56 
Recent cough 1.05 ( 1.00, 1.09)      
P = 0.049 
1.03 ( 0.98, 1.09)       
P = 0.25 
1.00 ( 0.92, 1.08)      
P = 0.95 
1.01 ( 0.93, 1.10)      
P = 0.72 
Recent rhinitis  0.97 ( 0.91, 1.03)      
P = 0.29 
1.01 ( 0.94, 1.09)      
P = 0.74 
1.05 ( 0.96, 1.14)      
P = 0.27 
1.05 ( 0.97, 1.14)      
P = 0.19 
Recent itchy rash 
for 6 months 
1.03 ( 0.96, 1.11)                                                       
P = 0.38 
1.07 ( 0.95, 1.22)    
P = 0.27 
1.01 ( 0.93, 1.10)      
P = 0.78 
1.05 ( 0.92, 1.21)      
P = 0.46 
3.8.3. Interaction models 
 
Models were extended to incorporate interaction terms to allow for the detection of 
modification of pollutant effects by atopy, current asthma and gender.  Evidence of an 
interactive effect was assumed when the interaction was significant and at least one subgroup 
effect was significant at the 5% level.   
Atopy 
Where effect modification occurred, effects were greater in non-atopic children.  This occurred 
most noticeably for lifetime exposure of PM2.5 and history of wheezing, asthma, and asthma 
medications and recent asthma, use of beta-agonists and recent itchy rash for six months (Table 
3.39).   Other specific effects for non-atopic children included lifetime CO exposure and current 
asthma, lifetime SO2 exposure and history of wheezing, asthma and asthma medication, and 
recent itchy rash for 6 months, recent Bsp exposure and current asthma, recent PM10 exposure 
and current asthma and recent cough, and recent SO2 exposure and recent itchy rash for 6 
months. 
Gender 
 
Atopic status was included in the interaction models for gender. 
No consistent effects appeared. 
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Table 3.39.  Modification of PM2.5 (g/m3) effects by atopic status.  Bolded entries represent 
effects significant at the p=0.05 level 
Outcome Lifetime exposure P Recent exposure P 
Ever had wheezing 
  Atopic 1.04 ( 0.98, 1.10) 0.19   
  Non-Atopic 1.12 ( 1.02, 1.23) 0.018   
  Interaction 1.07 ( 1.02, 1.13) 0.007   
Ever had Asthma 
  Atopic 1.02 ( 0.97, 1.08) 0.45   
  Non-Atopic 1.14 ( 1.07, 1.23) 0.0001   
   Interaction 1.12 ( 1.07, 1.17) < 0.0001   
Ever had medication for asthma/wheezing 
  Atopic 1.02 ( 0.95, 1.10) 0.55   
  Non-Atopic 1.11 ( 1.02, 1.21) 0.021   
  Interaction 1.09 ( 1.04, 1.14) 0.0002   
Ever had rhinitis 
  Atopic 1.05 ( 0.98, 1.13) 0.16   
  Non-Atopic 1.10 ( 1.02, 1.19) 0.013   
  Interaction 1.05 ( 0.99, 1.10) 0.08   
Recent wheeze 
  Atopic 1.05 ( 0.97, 1.13) 0.23 1.10 ( 0.80, 1.52) 0.55 
  Non-Atopic 1.13 ( 0.97, 1.32) 0.11 1.15 ( 0.72, 1.84) 0.56 
  Interaction 1.08 ( 0.98, 1.19) 0.12 1.04 ( 0.85, 1.28) 0.68 
Recent wheeze after exercise 
  Atopic 1.04 ( 0.94, 1.15) 0.44 0.94 ( 0.65, 1.36) 0.75 
  Non-Atopic 1.09 ( 0.91, 1.31) 0.35 0.82 ( 0.48, 1.41) 0.47 
  Interaction 1.05 ( 0.95, 1.16) 0.37 0.87 ( 0.67, 1.14) 0.31 
Current asthma 
  Atopic 1.10 ( 0.86, 1.42) 0.4395 1.23 ( 0.83, 1.81) 0.30 
  Non-Atopic 1.63 ( 1.13, 2.35) 0.0082 1.56 ( 0.87, 2.79) 0.13 
  Interaction 1.48 ( 1.24, 1.76) < 0.0001 1.27 ( 0.99, 1.63) 0.058 
Recent visit to GP/ED/hospital 
  Atopic 1.00 ( 0.92, 1.08) 0.92 1.04 ( 0.80, 1.35) 0.77 
  Non-Atopic 1.02 ( 0.91, 1.13) 0.78 1.03 ( 0.71, 1.50) 0.86 
  Interaction 1.02 ( 0.96, 1.09) 0.56 0.99 ( 0.79, 1.25) 0.96 
Recent use of beta-agonist (short-term) 
  Atopic 1.02 ( 0.95, 1.09) 0.65 1.04 ( 0.78, 1.39) 0.08 
  Non-Atopic 1.12 ( 1.02, 1.23) 0.021 1.07 ( 0.73, 1.56) 0.73 
  Interaction 1.10 ( 1.05, 1.16) 0.0002 1.03 ( 0.86, 1.24) 0.75 
Recent cough     
  Atopic 0.98 ( 0.89, 1.07) 0.6 0.89 ( 0.61, 1.31) 0.56 
  Non-Atopic 0.93 ( 0.84, 1.03) 0.16 0.91 ( 0.59, 1.40) 0.66 
  Interaction 0.95 ( 0.90, 1.01) 0.11 1.02 ( 0.84, 1.24) 0.84 
Recent rhinitis     
  Atopic 1.07 ( 0.99, 1.15) 0.09 1.11 ( 0.82, 1.49) 0.50 
  Non-Atopic 1.11 ( 1.02, 1.21) 0.017 1.09 ( 0.79, 1.51) 0.60 
  Interaction 1.04 ( 0.99, 1.09) 0.14 0.98 ( 0.85, 1.14) 0.83 
Recent itchy rash for 6 months 
  Atopic 1.02 ( 0.93, 1.11) 0.72 0.94 ( 0.71, 1.25) 0.68 
  Non-Atopic 1.12 ( 1.03, 1.23) 0.008 1.24 ( 0.87, 1.77) 0.23 
  Interaction 1.11 ( 1.02, 1.20) 0.01 1.32 ( 0.91, 1.90) 0.14 
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4. DISCUSSION  
 
The cross-sectional component of ACHAPS involved a national sample of approximately 2,900 
children, in six jurisdictions in Australia.   
4.1. Summary of findings  
 
The cross-sectional study showed consistent evidence of respiratory adverse effects of NO2, 
associated with both recent and life-time exposure.  These adverse effects were manifested as 
increased risk of asthma-like symptoms (in particular, wheeze), increased airway inflammation, 
and reduced lung volumes.  There was no evidence that the effects were stronger in atopic 
subjects, apart from SO2.  The absence of a greater effect in atopic subjects, the finding that lung 
volumes, rather than airway calibre (reflected in FEV1/FVC ratio), and persistence of the effect 
after bronchodilator imply that the consequence of NO2 exposure is not typical asthma; rather, 
more non-specific lung effects are implicated.  
Particulate matter exposures showed varied results.  PM10 was associated with decline in FEV1 
post-bronchodilator and increase in exhaled NO, but no overall increase in current symptoms.  
PM2.5 was associated with an adverse effect on FVC post-bronchodilator and on exhaled NO, 
with no overall effects on current symptoms, but showed increased risk of lifetime wheezing, 
asthma, and asthma medication, and current asthma, use of beta-agonists and itchy rash in non-
atopic children.  Bsp was associated with a decline in change in FEV1 post-bronchodilator and 
an increased risk of recent cough.  Females had an increase in FEV1/FVC ratio pre-
bronchodilator for lifetime and recent Bsp, recent PM2.5, and recent PM10, with non-significant 
effects in males.  Despite the absence of effect on current symptoms, a reduction in lung volume 
at this age may have longer-term adverse consequences if it persists into later life. 
O3 showed some effects in a beneficial direction (perhaps due to the NO2 effects and the 
negative association between O3 and NO2) but these were eliminated in the joint O3- NO2 
model.  FEV1/FVC ratio decreased significantly with lifetime O3 exposure in females, with no 
effect in males. 
Exposure to SO2 in the last year, after adjustment for O3, showed an adverse effect on lung 
function measures.   SO2 effects on lung function were modified by atopic status, being more 
deleterious in atopic children, and non-significant in non-atopic status.  Males had greater 
adverse effects of SO2, for FVC post-bronchodilator and FEV1/FVC ratio pre-bronchodilator.  
Reported history of wheezing, asthma and asthma medication, and recent itchy rash for 6 
months increased with SO2 in non-atopic children, with no effect in atopic children. 
4.2. Comparison with other studies of chronic exposure in school children 
 
Australia 
 
Few other studies have been conducted in Australia on the chronic or longer-term health effects 
of outdoor air pollution on children’s health, although a larger number have examined the 
acute effects.  The latter will be discussed in Section C of this report. 
A cross-sectional survey of the respiratory health of 3,023 children aged 8-10 years from 
industrial and non-industrial sites in the Hunter and Illawarra regions in New South Wales 
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examined the relationship between outside air quality (PM10, TSP and SO2) and respiratory 
symptoms (asthma, wheeze, cough, chest colds, hay fever, and eczema) (Lewis et al, 1998).  A 
positive association was found between PM10 and both night cough and chest colds.  An 
increase of 10 µg/m3  PM10 was associated with an increase in chest colds (OR 1.43, 95%CI 1.12-
1.82), and night time cough (OR 1.34, CI 1.19-1.53).  No associations were found between SO2 
and night cough, chest colds, and wheeze.  No association was found between PM10 and 
wheeze. 
 
Measured air pollution cross-sectional studies 
 
Raizenne et al. (1996) examined the health effects of exposure to acidic air pollution on 
pulmonary function among 10,251 white children aged 8-12 years living in 24 communities 
throughout the United States and Canada.  Pulmonary function was measured by FVC, FEV1, 
FEV0.75, FEF25-75%, and PEFR.  Measures of PM10, PM2.5, fine particle strong acidity, fine particle 
sulphate, gaseous acids, and O3 were collected for one year prior to the pulmonary tests. 
Particle strong acidity was associated with a 3.5% decrement in FVC (CI: -4.9 to -2.0) and a 3.1% 
decrement in FEV1 (CI: 1.6-4.6%).  PM10 was also associated with a 2.4% (CI: 0.5-4.3%) 
decrement in FVC.  Stratified analyses showed no differences in the associations with regard to 
geography, year of study, gender, and exercise levels.  Further results showed that O3 was 
associated with a decrease in pulmonary function with mean daytime O3 having the strongest 
association.  
 
Dockery et al. (1996) examined respiratory symptoms among 13,369 white children within the 
same study.  Particle strong acidity and fine particulate sulphate were associated with 
significantly higher reporting of bronchitis (1.64, CI 1.12-2.42 & 1.65, CI 1.12-2.42, respectively). 
Gaseous acids were associated with a higher risk of asthma and asthma symptoms (OR 2.00, CI 
1.14-3.53).  There was no association between O3 and any of the respiratory symptoms. No 
subgroups were more sensitive to particle strong acidity than the overall sample. 
 
The cross-sectional sub-study of the  SCCHS  examined the prevalence of respiratory diseases 
within a sample of 3,676 school children (Peters et al., 1999a), and also the effects on pulmonary 
function in a sample of 3,293 school children (Peters et al., 1999b).  The main respiratory 
symptoms that were examined were asthma, wheeze, cough, and bronchitis.  Results showed 
that only the prevalence of wheeze (OR 1.26, CI 1.01-1.57) in all subjects was associated with 
acid vapour.  Exposure to NO2 and acid vapour was associated with wheeze in boys only (OR 
1.47, CI 1.04-2.09).  No other associations were found between air pollutants and respiratory 
symptoms and the overall results showed no consistent or large excesses of morbidity in 
subjects who lived in the most polluted communities.  The authors stated that this might 
indicate 
…1) little effect of even the most severe outdoor pollution; 2) an increase of uncontrolled risk 
factors in cleaner communities; 3) our inability to detect important effects, because of exposure 
misclassification, inadequate sensitivity of health measures, or bias in diagnostic practices 
between communities; or 4) effects of self selection of place of residence inherent in cross-
sectional comparisons. 
 
In the baseline SCCHS, PM10, PM2.5, and NO2 were each significantly associated with lower 
FVC, FEV1, and maximal midexpiratory flow (MMEF); acid vapour with lower FVC, FEV1,  
PEFR, and MMEF; and O3 with lower PEFR and MMEF.  Effects were generally larger in those 
girls spending more time outdoors.  Stepwise regression of adjusted pulmonary function values 
for girls in the 12 communities showed that NO2 was most strongly associated with lower FVC 
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(r = -0.74, p < 0.01), PM2.5 with FEV1 (r = -0.72, p < 0.01), O3 with PEFR (r = -0.75, p < 0.005), and 
PM2.5 with MMEF (r = -0.80, p < 0.005).  There was a statistically significant association between 
O3 exposure and decreased FVC and FEV1 in girls with asthma. For boys, significant 
associations were seen between peak O3 exposures and lower FVC and FEV1, but only in those 
spending more time outdoors (Peters et al., 1999b). 
 
However, among SCCHS children with asthma, positive associations were found between air 
pollution and bronchitis and phlegm (McConnell et al., 1999).  As PM10 increased across 
communities, risk of bronchitis increased: per IQR OR 1.4/19 g/m3; 95% CI:  1.1-1.8).  
Increased prevalence of phlegm was significantly associated with increasing exposure to all 
ambient pollutants except O3.  The strongest association was for NO2, based on relative risk per 
IQR in the 12 communities (OR 2.7 per 24 ppb; CI, 1.4-5.3).  
 
To examine evidence relating to traffic-related pollution and asthma, a sample of children was 
randomly selected from participants in the SCCHS, a prospective cohort designed to investigate 
associations between air pollution and respiratory health in children 10-18 years of age 
(Gauderman et al., 2005; Peters et al., 1999a).   Lifetime history of doctor-diagnosed asthma was 
associated with outdoor NO2; the OR was 1.83 (95% CI: 1.04-3.22) per increase of 1 IQR 
(IQR=5.7 ppb) in exposure.   Increased asthma was associated with closer residential distance to 
a freeway (1.89 per IQR; 1.19-3.02) and with model-based estimates of outdoor pollution from a 
freeway (2.22 per IQR; 1.36-3.63).  These two indicators of freeway exposure and measured NO2 
concentrations were also associated with wheezing and use of asthma medication.  Asthma was 
not associated with traffic volume on roadways within 150 m of homes or with model-based 
estimates of pollution from non-freeway roads. 
A sample of 217 children was selected from participants in the SCCHS.  NO2 monitors were 
placed outside children's homes for two weeks in the summer and two weeks in the fall-winter 
season as a marker of traffic-related air pollution (Jerrett et al., 2008).  Incident asthma was 
positively associated with traffic pollution, with a hazard ratio (HR) of 1.29 (95% CI: 1.07-1.56) 
across the average within-community IQR of 6.2 ppb in annual residential NO2.  Using the total 
IQR for all measurements of 28.9 ppb increased the HR to 3.25 (95% CI, 1.35-7.85). 
A cross-sectional study of current asthma and other respiratory symptoms recruited 1,080 
children living at varying distances from high-traffic roads in the San Francisco Bay Area, 
California, a highly urbanised region characterised by good regional air quality (Kim et al., 
2008).  Exposure was assessed using residential proximity to traffic and major roads.  Traffic-
related pollutants (NOX) were measured for a subset of households.  Children whose residences 
were in the highest quintile of exposure had approximately twice the adjusted odds of current 
asthma (that is, asthma episode in the preceding 12 months) compared with children whose 
residences were within the lowest quintile.  The highest risks were among those living within 
75 m of a freeway/highway. 
The 2001 California Health Interview Survey was linked to air monitoring and traffic data to 
estimate associations between traffic density or outdoor air pollutant concentrations and 
childhood asthma morbidity (Wilhelm et al, 2008).  Children with asthma living in high O3 
areas and areas with high concentrations of PM10 experienced symptoms more frequently, and 
those living close to heavy traffic reported more emergency department visits or 
hospitalisations. 
Results from the pulmonary function tests showed significant associations between air 
pollution levels and lung function in females only.  Negative associations were found between 
peak O3 and MMEF and PEFR (β= -69.5; p < 0.01 & β= -128.3; p < 0.01 respectively).  Adjusted 
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pulmonary function values in girls showed that NO2 was associated with FVC (r = -0.74; p < 
0.01), PM2.5 with FEV1 (r = -0.72; p < 0.01), O3 with PEFR (r = -0.75; p < 0.005), and PM2.5 with 
MMEFR (r = -0.80; p < 0.005).  It is interesting to note that associations were found with males 
only with regard to prevalence of wheeze, and associations were found with females only with 
regard to pulmonary function.  
The Swiss Study on Childhood Allergy and Respiratory Symptoms with respect to Air 
POLlution (SCARPOL) was conducted throughout 10 communities during 1992/1993 and 
involved a sample of 4,470 children aged 6-15 years.   Questionnaires were used to collect 
information about respiratory and allergic symptoms (Braun-Fahrlander et al., 1997).  Ambient 
measures of SO2, NO2, O3 and PM10 were collected continuously throughout the study period in 
each of the 10 communities.  Results showed associations between PM10 and chronic cough (OR 
3.07, CI 1.62-5.81) and nocturnal dry cough (OR 2.88, CI 1.69-4.89).  Smaller associations were 
also observed between chronic cough and NO2 (OR 1.58, CI 1.14-2.18), nocturnal dry cough and 
NO2 (OR 1.99, CI 1.51-2.61), SO2 (OR 1.57, CI 1.02-2.42) and PM10 (OR 2.88, CI 1.69-4.89).  PM10 
was also associated with bronchitis (OR 2.17, CI 1.21-3.87).   No associations were found with 
asthma, current wheeze, sneezing attacks during pollen season, and hay fever.  Furthermore, no 
associations were found between O3 and symptom rates when annual mean concentrations 
were considered.  However, when peak O3 hours were considered, there were small positive 
associations with nocturnal dry cough, bronchitis, and conjunctivitis.  Stratified analyses 
showed stronger associations in children with a reported family history of respiratory, 
bronchitis and conjunctivitis symptoms.  
 
The cross-sectional Health Effects of School Environment Study, based in Norway, Sweden, 
Denmark, France and Italy found PM10 and CO2 levels in a day of normal classroom activity 
were related to wheezing, dry cough at night and rhinitis in 654 children aged 10 years (Simoni 
et al., 2010).   Disorders were more prevalent in children in poorly ventilated classrooms.  
 
ACHAPS findings of adverse effects of NO2 in relation to history of asthma, and other 
respiratory symptoms, are consistent with the SCCHS, although effects are somewhat weaker 
and apply to current rather than lifetime asthma only.  The findings are also consistent in 
relation to NO2 and PM effects and lung function, with little consistent evidence of effect 
modification by gender.  ACHAPS found favourable effects of O3 (contrary to the SCCHS) but 
these appeared related to negative confounding with NO2 - assuming the effect is null, the O3 
findings are consistent with the SCCHS and the SCARPOL. 
 
 
Comparative high-low pollution/proxy studies 
Many cross-sectional studies conducted throughout the world have examined associations 
between road traffic-related air pollution and lung function and prevalence of respiratory 
symptoms in children.  Studies investigating road traffic-related air pollution often use 
residential and school proximity to major roads, and traffic counts as proxies for exposure.  
A European study found mixed results when investigating associations between road traffic 
density and child respiratory symptoms.  In 10 areas of northern and central Italy varying in 
size, latitude, climate, and level of urbanisation, 39, 275 children aged 6-7 years and 13-14 years 
were surveyed (Cicconne et al., 1998).   Children’s parents reported on medical diagnosis of 
asthma, occurrences of other respiratory symptoms, and medical history of respiratory diseases 
in the first two years of life (if the children had never changed residence).  Parents were also 
asked to give a subjective evaluation of traffic density in the zone of residence.  The validity of 
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the subjective traffic density data was further evaluated with NO2 sampling at various locations 
and objective measures of traffic density.  Overall, the results showed only weak and 
inconsistent associations between respiratory symptoms and traffic density.  However, in areas 
of high truck traffic density, positive associations with respiratory symptoms were found. The 
strongest associations were found with lower respiratory tract infections early in life (OR 1.39, 
CI 1.19-1.62) and current respiratory problems (OR 1.29, CI 1.15-1.45).  No relevant differences 
were found between age groups and sexes.  A second phase of this study (Migliore et al., 2009) 
found that overall traffic density was weakly associated with asthma symptoms, but there was 
a stronger association with cough or phlegm production (OR 1.24; 95% CI (1.04-1.49).   
Other studies have used traffic density counts and proximity to major roads and freeways as air 
pollution exposure variables.  Van Vliet et al. (1997) examined whether motor vehicle exhaust 
from freeways has an effect on respiratory symptoms in children.  A sample of 1,068 primary 
school children was recruited from six residential areas in South Holland where a large number 
of houses were located within 300 m of a major freeway.  The study measured the distance from 
children’s homes and schools from the freeways and also the traffic density of the freeways.  Of 
the 1,068 children, 878 were living within 1,000 m of a freeway.  In two of the six areas, 
measures of PM10, PM2.5, black smoke, and NO2 were collected.  Levels of black smoke and NO2 
decreased with increasing distances from the freeways.  Measures of PM10 and NO2 were also 
collected from within 12 of the 13 participating primary schools.  Results showed that chronic 
cough, wheeze, and rhinitis were more prevalent in children living within 100 m of the 
freeways.  The same respiratory symptoms, with the addition of asthma attacks, were also more 
prevalent in areas of high truck traffic density.  When the analysis was restricted to children 
living within 300 m of the freeway, associations were found between truck traffic density and 
bronchitis (OR 3.52, CI 0.91-13.6, p=0.10), and also between chronic cough (OR 2.94, CI 0.98-8.89, 
p<0.10), rhinitis (OR 5.84, CI 1.43-20.0) and black smoke in schools.  The effects were stronger in 
girls than boys. 
The same study also analysed lung function (FEV, FEV1 and FEF25-75%) of the children living 
near freeways (Brunekreef et al., 1997).  For all the children living within 1,000 m of the 
freeways, results showed an association between truck traffic density and FEV1, PEF, and 
FEF25-75%.  When the analysis included only children living within 300 m of the freeways, the 
association was stronger.  Lung function was also found to be associated with black smoke 
measured in schools.  Similar to the respiratory symptom analysis, all the associations were 
stronger in girls than boys. 
Residential proximity to major roads was also used as a traffic-related air pollution exposure 
variable in an English study (Venn et al., 2001) on wheezing in children.  Spatial analysis 
techniques in a geographical information system were used to establish the distance from 
children’s homes to the closest main road.  A total of 6,147 primary school children and 3,709 
secondary children from Nottingham, England were surveyed about respiratory symptoms. 
Results for the overall sample of primary school children showed that the distance to the main 
road was not significantly associated with the risk of wheeze.  However, of the 1,541 primary 
school children living within 150 m of a main road, there was a trend toward an increase in risk 
of wheeze (OR 1.08, CI 1.00-1.16) per 30 m increase in proximity to the road.  The effect was 
more prominent in girls than boys.  Similar results were reported for the secondary school 
children (OR 1.16, CI 1.02-1.32).  A positive association between risk of wheeze and proximity to 
a main road was only found for children living within 150 m of a main road.  Effects were 
slightly stronger for secondary school girls than boys. 
It should be noted that the Venn et al. (2001) study was a nested study within a much larger 
cross-sectional/longitudinal study (Venn et al., 2000) that investigated the prevalence, severity, 
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and persistence of wheeze in a sample of 22, 968 primary school children and 27,826 secondary 
school children.  The exposure variable was traffic density in the locality of the schools the 
children attended.  It is interesting to note that in the cross-sectional data analysis there were no 
significant associations found between the prevalence of wheeze in both primary and secondary 
school children and traffic density. In contrast, there were associations between wheeze and the 
proximity of children’s homes to freeways.  The longitudinal data analysis used follow-up data 
from a survey conducted in 1988.  Results showed a weak linear correlation between persistence 
of wheeze and traffic density. 
 
Oosterlee and colleagues (Oosterlee et al., 1996) used only traffic density counts as an air 
pollution exposure variable.  They examined whether children and adults living along streets 
with high traffic density had a higher prevalence of chronic respiratory symptoms.  Results 
showed a higher prevalence for wheeze (OR 2.10, CI 0.99-4.4) and respiratory medication use 
(OR 2.2, CI 1.10-4.60) among children living in the high traffic areas when compared to children 
living in the control areas.  The effect was much greater for girls than boys.  It is interesting to 
note that mild dyspnoea was the only self-reported respiratory symptom in adults that was 
significantly higher among adults living in the high traffic density area.  These results support 
the argument that children are more susceptible than adults. 
 
Cross-sectional studies have also found associations between traffic-related air pollution and 
atopic sensitisation in children.  Kramer and colleagues (Kramer et al., 2000) studied 317 
children who lived near major roads in Dusseldorf, Germany.  Data regarding respiratory and 
allergy symptoms were collected via questionnaires, skin prick tests, serum tests for IgE 
antibodies, and a symptom diary (completed by the parents for a period of one year).  Outdoor 
NO2 was measured at 158 sampling points in three selected areas.  Personal monitoring of NO2 
was also conducted; 191 children agreed to wear personal air samplers during two non-
consecutive months of the study period.  The mean values of personal NO2 were below 50% of 
the outdoor NO2 measurements and there was only a weak correlation.  Results showed an 
association between allergic rhinitis and outdoor NO2 (OR 1.81, CI 1.02-3.21).  The observed 
effects were more pronounced in girls than boys.  No associations were found between indoor 
NO2 and allergic symptoms.  
 
A similar study by Duhme and colleagues (Duhme et al., 1996) examined the self-reported 
symptoms of asthma and allergic rhinitis in 3,703 students aged 12-15 years in association with 
self-reported exposure to road traffic density.  Results showed a positive association between 
symptoms of ‘frequent’ and ‘constant’ wheeze (OR 1.53, CI 1.15-2.05 and OR 2.15, CI 1.44-3.21 
respectively) and allergic rhinitis (OR 1.71, CI 1.36-2.15 and OR 1.96, CI 1.40-2.76 respectively) 
and self-reported frequency of truck traffic density. 
 
School children aged 8-12 years were recruited from two areas in Hong Kong with differing 
levels of air pollution (Yu et al., 2001).  Parents of 1,660 children completed questionnaires on 
respiratory symptoms and 1,294 children participated in spirometric tests (FEV1, FVC, 
FEF25-75%).  Routine monitoring was done for SO2, NO2, and respirable suspended particulate 
(RSP) in the two areas.  Results showed that children from the more polluted area had higher 
crude rates for all respiratory symptoms than children in the low polluted area, except 
bronchitis in boys. After adjusting for age, gender, and other covariates, the ORs for frequent 
cough (OR 1.74, CI 1.28-2.38), frequent sputum (OR 1.87, CI 1.28-2.78), chronic sputum (OR 1.84, 
CI 1.06-3.19), and asthma (OR 1.98, CI 1.24-3.18) were all statistically significant.  Boys had a 
higher risk than girls for frequent sputum, wheezing with shortness of breath, and asthma.  
Results from the lung function tests showed that the adjusted means for both sexes were higher 
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in the lower polluted area.  Significant differences between the two areas were found for all 
spirometric tests except for FVC in boys.  The differences in lung function between the two 
districts were greater in girls than boys. 
 
A study of southern Californian communities exposed to high levels of traffic emissions, 
including truck and ship emissions arising from port activity, found that approximately 1,600 
(9%) of all childhood asthma cases in Long Beach and 690 (6%) in Riverside were attributed to 
traffic proximity (Perez et al., 2009).  Ship emissions accounted for 1,400 (21%) bronchitis 
episodes and, in more modest proportions, health care visits for asthma.  Considerably greater 
reductions in asthma morbidity could be obtained by reducing NO2 and O3 concentrations to 
levels found in clean coastal communities. 
 
A large English cross-sectional study, based on the Health Survey of England, made findings 
that contrasted with those of the southern Californian study. They found that distance to main 
roads did not predict risk of wheeze, asthma, eczema, or hay fever or level of serum 
immunoglobulin E (an indicator of allergy) or forced expiratory volume in one second (FEV1, 
an indicator of airflow obstruction).   (Pujades-Rodriguez, 2009). 
 
A school-based cross-sectional study in France used a validated dispersion model combining 
data on traffic conditions, topography, meteorology and background pollution to relate 3-yrs 
averaged concentrations of major urban pollutants at the sites of schools to skin prick tests, 
exercise-induced asthma and reported asthma and allergies in 6,683 children (9-11 yrs) 
attending 108 randomly selected schools in six French communities (Penard-Morand et al., 
2005, 2010).  Asthma (exercise induced, past year and lifetime) was significantly positively 
associated with benzene, SO2, PM10, NOX and CO.   Eczema (lifetime and past year) was 
significantly positively associated with benzene, PM10, NO2, NOX and CO, lifetime allergic 
rhinitis with PM10 and sensitisation to pollens with benzene and PM10. 
  
A Dutch study correlated air pollution exposures at the birth address (estimated using land use 
regression models) with reported asthma, hay fever and related symptoms during the first 8 
years of life in a sample of 3,863 children (Gehring et al., 2010).  PM2.5 levels were associated 
with a significant increase in incidence of asthma, (OR 1.28; 95% CI, 1.10-1.49), prevalence of 
asthma (OR 1.26; 1.04-1.51), and prevalence of asthma symptoms (OR 1.15; 1.02-1.28).  Findings 
were similar for NO2 and soot.  No associations were found with atopic eczema, allergic 
sensitisation, and bronchial hyperresponsiveness. 
 
In Rome, 2,107 children aged 9-14 years from 40 schools in Rome in 2000-2001 were included in 
a cross-sectional survey (Rosenlund et al., 2009).  Respiratory symptoms were assessed in 1,760 
children by parental questionnaires, while allergic sensitisation was measured by skin prick 
tests and lung function was measured by spirometry on 1,359 children.  Three indicators of 
traffic-related air pollution exposure were assessed: self-reported heavy traffic outside the 
child's home; the measured distance between the child's home and busy roads; and the 
residential NO2 levels estimated by a land use regression model.   There was a strong 
association between estimated NO2 exposure per 10 µg/m3 and lung function, especially 
expiratory flows, in linear regression models adjusted for age, gender, height and weight: -
0.62% (95% CI -1.05 to -0.19) for FEV1 as a percentage of VC, -62 ml/s (95% CI -102 to -21) for 
FEF25-75, and  -85 ml/s (95% CI -135 to -35) for PEF.  The other two exposure indicators 
showed similar but weaker associations.  The associations appeared stronger in girls, older 
children, in children of high socio-economic status and in those exposed to parental smoking. 
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There was not a consistent association between traffic-related air pollution exposure and 
prevalence of respiratory symptoms or allergic sensitisation. 
 
In order to assess repeated hospital presentations for asthma in children, and its association 
with traffic-related air pollution near the residence, hospital records for 2,768 Californian 
children aged 0–18 years were obtained for a catchment area of two hospitals in northern 
Orange County, California (Delfino et al., 2009).  A line source dispersion model was used to 
estimate individual seasonal exposures to local traffic-generated pollutants (NOx and CO) 
longitudinally, beginning with the first hospital encounter.  Adjusted HRs for IQR increases in 
NOx (4.00 ppb) and CO (0.056 ppm) were 1.10 (95% CI, 1.03-1.16) and 1.07 (1.01-1.14), 
respectively.  The study concluded that locally generated air pollution near the home affects 
asthma severity in children.  
 
A hospital-based longitudinal study of a southern California urban catchment area around two 
adjacent children's hospitals examined the association between nearby traffic and repeated 
hospital encounters among children with asthma (Chang et al., 2009).   Living within 300 m of 
arterial roads or freeways increased risk of repeated hospital encounters in 3,297 children age 18 
years or less.  At highest risk were children in the top quintile of traffic density (HR = 1.21; 95% 
CL 0.99 to 1.49) and those who had 750 m or more of arterial road and freeway length within 
300 m of their residence (HR = 1.18; 95% CL 0.99 to 1.41).  
 
The consistent findings of adverse associations between proximity to traffic and respiratory 
symptoms and lung functions support ACHAPS findings in relation to NO2, a major constituent 
of traffic-related pollution. 
 
 
Prospective studies 
A four-year follow-up cohort of 1,678 children from the SCCHS found significant deficits in 
lung function growth rate were associated with exposure to acid vapour, NO2, PM2.5, and 
elemental carbon (Gauderman et al., 2002).  Exposure to acid vapour was also associated with 
reductions in the ratio of MMEF to FVC (P = 0.02), whereas exposure to O3 was correlated with 
reduced growth in peak flow rate (P = 0.006).  Larger deficits in lung function growth rate were 
observed in children who reported spending more time outdoors.   In children with asthma, 
respiratory symptoms were associated with the yearly variability of PM2.5 (OR 1.09 per µg/m3, 
95% CI 1.01-1.17), organic carbon (OR 1.41per g/m3, 95% CI 1.12-1.78), NO2 (OR 1.07 per ppb, 
95% CI 1.02-1.13), and O3  (OR 1.06 per ppb, 95% CI 1.00-1.12)  (McConnell et al, 2003). 
A five-year follow-up cohort of 3,535 children from the SCCHS, with no history of asthma at 
recruitment, found that children living in communities with high O3 concentrations and playing 
three or more sports had an increased risk of developing asthma: OR  3.3 (95% CI 1.9-5.8), 
compared to children in the same communities playing no sports (RR 3.3, 95% CI 1.9-5.8) 
(McConnell et al., 2002). Sports had no effect in areas of low O3 concentration (0.8, 0.4-1.6). Time 
spent outside was associated with a higher incidence of asthma in areas of high O3 (1.4, 1.0-2.1), 
but not in areas of low O3.  Exposure to pollutants other than O3 did not alter the effect of team 
sports. 
 
An eight-year follow-up of 1,759 children from the SCCHS (average age, 10 years) measured 
lung function annually for eight years (Gauderman et al.,  2004).  Over the eight-year period, 
deficits in the growth of FEV1 were associated with exposure to NO2 (P=0.005), acid vapour 
(P=0.004), PM2.5 (P=0.04), and elemental carbon (P=0.007), even after adjustment for several 
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potential confounders and effect modifiers.  Associations were also observed for other 
spirometric measures.  Exposure to pollutants was associated with clinically and statistically 
significant deficits in the FEV1 attained at the age of 18 years. 
 
A further follow-up study of 3,677 children from the SCCHS examined lung function growth 
from 10–18 years and its association with traffic exposure (Gauderman et al., 2007).  Children 
who lived within 500 m of a freeway had substantial deficits in eight-year growth of forced 
expiratory volume in 1 s (FEV(1), -81 ml, p=0.01 [95% CI -143 to -18]) and MMEF rate (MMEF, -
127 ml/s, p=0.03 [-243 to -11), compared with children who lived at least 1,500 m from a 
freeway.  Local exposure to freeways and regional air pollution had detrimental, and 
independent, effects on lung-function growth.  Pronounced deficits in attained lung function at 
age 18 years were recorded for those living within 500 m of a freeway, with mean per cent-
predicted 97.0% for FEV1 (p=0.013, relative to >1500 m [95% CI 94.6-99.4]) and 93.4% for MMEF 
(p=0.006 [95% CI 89.1-97.7]). 
 
Lin et al. (2008) followed a birth cohort born in New York State during 1995-1999 to first asthma 
admission or until 31 December 2000 and linked these data with ambient O3 data (8-hr 
maximum).  Asthma admissions were significantly associated with increased O3 levels for all 
chronic exposure indicators (ORs, 1.16-1.68), with a positive dose-response relationship. 
Stronger associations were found among younger children and low socio-demographic groups. 
 
ACHAPS has no measures of lung function growth, which would require a follow-up of 
ACHAPS sample of children.  However, again, it appears that NO2 and PM are implicated in 
poorer lung development. 
 
 
Ecological studies 
 
The 2001-2004 National Health Interview Survey included 34,073 children aged 3-17 years in US 
metropolitan areas (Akinbami et al., 2010).  Reported asthma history was linked to monitored 
air quality (SO2, NO2, O3, PM) in their county of residence over the recent 12 months.  Results 
suggested that chronic (12 month) exposure to O3 increased the risk of asthma in children with 
an OR for current asthma of 1.56 (95% CI  1.15-2.10), comparing highest and lowest quartiles of 
exposure, and a corresponding OR for recent asthma of 1.38 (0.99-1.91).  No associations were 
found for SO2 and NO2, while results for PM were suggestive. 
 
A similar analysis was based on approximately 70,000 children from the 1999-2005 National 
Health Interview Survey and ambient pollution monitoring data from the US Environmental 
Protection Agency (Parker et al., 2009).  Increased respiratory allergy or hay fever was 
associated with increased summer O3 levels: (adjusted OR 1.20 per 10 ppb, 95% CI 1.15-1.2) and 
increased PM2.5 (OR 1.23 per 10 µg/m3,  95% CI 1.10-1.38).  These associations persisted after 
stratification by urban-rural status, inclusion of multiple pollutants, and definition of exposures 
by differing exposure radii. No associations between the other pollutants and the reporting 
respiratory allergy/hay fever were apparent. 
 
The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One showed up 
to 10 to 20-fold worldwide variability in the prevalence of symptoms of asthma, 
rhinoconjunctivitis and eczema.  Ecological analyses at city level demonstrated a weak inverse 
relationship between city-level PM10 and symptoms of the three conditions, after controlling for 
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Gross National Product, while multi-centre meta-analyses of data from countries with multiple 
centres found a consistent pattern of weak positive associations.      
  
 
These studies largely link O3 to adverse health effects on children, contrary to the large 
individual studies. 
 
 
4.2.1. Methodological issues 
 
ACHAPS is cross-sectional and relies on historical NEPM monitoring for measures of exposure.  
While the study differentiated between average lifetime exposure (measured from the time the 
child began living in the area) and recent exposure (averaged over the last year), it remained 
difficult to distinguish between long-term and shorter-term effects, due to correlations of effects 
over time.   In addition, the study relied on the availability of routine monitored air pollutants.  
While this was considerable for many sites, gaps in data were left as sites, in general, did not 
monitor all pollutants over the entire period of the study.  This also limited data available to 
explore multiple-pollutant models. 
 
Each child had an individual exposure metric calculated for each pollutant.  However, due to 
the cluster design and the dependence on the NEPM monitoring stations for measures of air 
quality, exposure variability within sites was limited.  Thus, the study relied very much on 
variability among sites for its power to detect associations.  This variability was optimised in the 
original selection of sites; sites were purposefully chosen to maximise the range of pollutant 
levels (based on historic data prior to the start of the study) and with NEPM stations with the 
greatest number of criterion air pollutants measured. 
 
A consequence of this choice of sites was that it was difficult to judge the representativeness of 
the sample of children, in relation to the target population of all urban primary-school aged 
children.  The characteristics of the sample in terms of prevalence of asthma and other 
conditions appear to correspond to published estimates from national surveys (AIHW, 2007).   
 
However, as the study was essentially a comparative one, examining the way in which the 
health of this sample of children varied with exposure to air pollutants, and based in 
community samples, it is argued that the presence of a factor likely to modify the observed 
associations is unlikely. 
 
However, a challenge for any spatially-constructed study is that of confounding, particularly by 
spatial-level confounders.  A major contender for confounding is socio-economic status which is 
spatially distributed, and which may separately relate to both exposure and health outcome.  
The analyses presented in this report have been adjusted at the cluster level for the SEIFA 
indices for relative socio-economic advantage and disadvantage, and for education, and at the 
individual level for parent's education.  Sensitivity analyses which incorporated other spatial 
measures showed, in fact, very few variables (for example, household characteristics) altered 
estimates of effects once the standard variables (age, sex, socio-economic status - as just 
described) were included in models.  
  
Health outcomes were determined in multiple ways to enhance the reliability and validity of 
the findings. We performed lung function tests, which have acknowledged validity and 
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reliability, along with administering validated questionnaires used in previous studies to 
ascertain parental reports of diagnoses and symptoms.  
 
Determining the temporal sequence of exposure and outcomes in a cross-sectional study such 
as this one may be problematic.  The examination of effects by lifetime outcomes and lifetime 
exposures, and, separately, by recent outcomes and recent and lifetime outcomes was an 
attempt to clarify this — an association of a recent health effect with recent exposure that is 
stronger than, but consistent with, the association of the same recent health effect with lifetime 
exposure, would support an argument for a causal effect.  
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Part C 
 
The panel study: 
acute exposure to air pollution: effects upon children’s health 
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1. PANEL STUDY DESIGN AND MEASUREMENT 
1.1. Aims and objectives 
 
1) To obtain quantitative estimates of the prospective day-to-day association between the 
criteria air pollutants and (a) incidence of respiratory symptoms, and (b) lung function, 
in school children with a history of asthma, aged 7–11 years at baseline; and, 
2) To determine whether the effects are modified by other factors, such as socioeconomic 
disadvantage, geographical area, sex, activity patterns and obesity. 
 
1.2. Methods 
 
1.2.1. Participant selection 
 
Children for the panel study were selected from those who had participated in the cross-
sectional study.  Criteria for panel study eligibility included the following: 
(i) answering ‘yes’ to Q11: ‘Have you ever been told by a doctor or nurse that your child 
has asthma?” AND 
(ii) answering ‘yes’ to: 
a.  Q4: ‘Has your child had wheezing or whistling in the chest in the past 12 
months?’ OR  
b. Q13: ‘Does he/she still have asthma?’ OR 
c. Q16: ‘In the past 12 months, has your child had an asthma attack, episode of 
wheezing or episode of bronchitis for which he/she: 
i. Visited your family doctor (GP) or medical centre’ OR 
ii. Attended a hospital’s Emergency Department (casualty)?’ OR 
iii. Was admitted to hospital?’ 
d. Q22: ‘In the past 12 months, has your child had any cough?’ OR 
(iii) answering ‘some days’, ‘more than once a month’, ‘more than once a week’ to: 
a. Q15: ‘In the past 12 months, has asthma, wheezing or bronchitis limited your 
child’s activities?’ OR 
b. Q17: ‘In the past 12 months, has your child missed school because he/she had 
asthma or wheezed?’ AND 
(iv) living within a 3 km radius from the corresponding monitoring station. 
The distance from the corresponding monitoring station to their home addresses was calculated 
using Metroview Version: 2.50 (c) (Metroview Systems Pty Limited, Sydney, Australia).  Parents 
of symptomatic children living within the specified radius were asked to consent to their child’s 
participation in the panel study.  One week prior to the school testing day, parents were 
contacted by telephone to seek consent to participate in the panel study.  The target number of 
panel study participants was 11 at each site. 
1.2.2. Panel study measurements 
 
Information about lung function measurements, symptoms and time-activity patterns were 
collected in paper diaries and in electronic peak flow devices (Miniwright Digital, MWD, 
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Clement Clarke, Essex, UK).  The paper diaries were designed to facilitate easy recording of 
data (Peak Flow and Symptom Diary and the Time-Activity Diary, see Appendices, Part A). 
Peak expiratory flow measurements 
Children were instructed to conduct lung function measurements every morning and evening 
for 30 days. Lung function was measured using an electronic peak flow meter, before any 
inhaled medication was used. Peak expiratory flow rate (PEF; litres/minute) and forced 
expiratory volume in one second (FEV1; litres) were measured. The electronic peak flow meters 
were given to each child and they recorded three successive measurements in the morning and 
three successive measurements in the evening. The highest PEF and FEV1 from these three 
successive measurements were automatically stored in the electronic peak flow device with a 
date and time stamp.  
Symptoms and medication use measurements 
Children were instructed to complete a paper symptom and medication use diary every 
morning and evening for 30 days.  This diary collected information about: 
 
(i) presence of the following respiratory symptoms during the night:  
a. cough and/or phlegm; 
b. wheeze and/or chest tightness; and, 
c. shortness of breath.  
 
This information was recorded in the morning. Each of these symptoms was recorded 
on a zero to four scale (0=no symptoms during the night, 1=symptoms, but did not 
disturb sleep, 2=symptoms that disturbed part of child’s sleep, 4=symptoms that 
disturbed all or most of child’s sleep). In the panel study analysis, symptoms were 
categorized as either ‘No symptoms’ or ‘Any symptoms’. 
 
(ii) presence of any cough and/or phlegm, wheeze and/or chest tightness, and shortness of 
breath during the night (categorized as ‘Yes’ or’ No’). 
 
(iii) Whether any asthma reliever medication was used during the night (categorized as 
‘Yes’ or ‘No’). 
 
(iv) presence of the following respiratory symptoms during the day:  
a. cough and/or phlegm; 
b. wheeze and/or chest tightness; 
c. shortness of breath; 
d. runny/blocked nose; 
e. eye irritation; and, 
f. fever/sore throat.  
 
This information was recorded in the evening. Each of these symptoms was recorded on 
a zero to four scale (0=no symptoms during the day, 1=symptoms, but did not disturb 
child’s daily activities, 2=symptoms that disturbed part of child’s daily activities, 
4=symptoms that disturbed all or most of child’s daily activities). In the panel study 
analysis, symptoms were categorized as either ‘No symptoms’ or ‘Any symptoms’. 
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(v) presence of any cough and/or phlegm, wheeze and/or chest tightness, shortness of 
breath, runny/blocked nose, eye irritation and fever/sore throat during the day 
(categorized as ‘Yes’ or’ No’). 
 
(vi) use of any asthma reliever and asthma preventer medication during the day. 
Medication use was categorized as ‘Yes’ and’ No’ and also whether the asthma 
medications (relievers and preventers) were taken as part of the child’s normal 
medication routine or because of symptoms. 
 
(vii) use of oral corticosteroids in the previous 24 hours (categorized as ‘Yes’ or ‘No’).  
 
Outdoor physical activity 
 
The time of the day the child spent time outdoors at home, school or elsewhere and the amount 
of time they did any vigorous physical activity during these periods of time were also collected 
for the panel study. Vigorous physical activity was defined as any activity which made the 
child breathe heavily, for example, playing tennis, cycling, running and swimming. Parents and 
children were asked to complete this time-activity diary once in the evenings. This diary was 
collected on the same days the peak flow and symptom diaries were collected. In absence of any 
pre-existing suitable format, we designed our own time-activity diary to record this 
information.  
 
The total amount of time spent outdoors engaging in any vigorous physical activity was 
calculated for each child. This information was used in the panel study analyses. 
 
Air pollution measures 
The air pollution measures of interest for the panel study included: 
1. particulate matter less than 2.5 microns in diameter  (PM2.5) - 24-hour average (PM2.5 24-
hr) 
2. particulate matter less than 10 microns in diameter (PM10) - 24-hour average (PM10 24-hr) 
3. nitrogen dioxide (NO2)  - 1-hour maximum (NO2 1-hr) and 24-hour average (NO2 24-hr) 
4. ozone (O3) - 1-hour maximum (O3 1-hr), 4-hour rolling average (O3 4-hr) and 8-hour 
rolling average (O3 8-hr) 
5. carbon monoxide (CO) – 8-hour rolling average (CO 8-hr)  
6. sulphur dioxide (SO2) – 1-hour maximum (SO2 1-hr) and 24-hour average (SO2 24-hr) 
 
Particulates were measured as micrograms per meter squared (ug/m3). NO2, O3 and SO2 were 
measured in parts per billion (ppb) and CO was measured in parts per million (ppm). 
1.2.3. Panel study adherence maintenance procedures 
 
Initial meeting with parents and children 
Research staff made face to face appointments with parents and children after school or at their 
home to discuss the panel study. During this face-to-face meetings, parents were informed in 
detail about the panel study and signed a written consent form. Research staff explained the use 
of the electronic peak flow meter and taught parents and children how to fill out the peak flow 
and symptom diary and the time-activity diary. 
 
 75 
 
Follow-up procedures 
Weekly contact was instituted to keep participants and their parents motivated during the 
study.  During the panel study, diaries were completed daily by the participants’ 
parent/guardian. Diaries were posted to the study centre weekly and research staff reviewed 
the diaries and telephoned the parents to thank them for filling out the diary. At this telephone 
call, missing data pertaining to the week as a whole was sought. However, no attempt was 
made to obtain data that were missing on a day-by-day basis. This process was followed until 
all diaries were completed and the final diaries and peak flow meters were posted back to the 
research team. 
 
1.3. Statistical analyses 
 
Descriptive analyses (frequencies, means and medians, correlation coefficients and cross-
tabulations) of the panel, air pollution and diary data were initially conducted.  
 
We used generalized linear models to analyse the panel data (identity link function for 
continuous outcomes using Proc Mixed and logit link function for binary outcomes using Proc 
Glimmix). We centered daily mean temperature at 20 degrees Centigrade and number of hours 
spent outdoors in vigorous physical activity at two hours. All regression models then included 
the centered values for mean daily temperature and number of hours spent outdoors in 
vigorous physical activity.  
Mean daily temperature, daily number of hours spent outdoors in vigorous physical activity, 
and interaction terms between the air pollutant and mean daily temperature and daily number 
of hours spent outdoors in vigorous physical activity were included in all models. Child and 
school specific intercepts were included as random effects in all models with continuous 
outcomes. For binary outcomes, only the child specific intercepts were included as a random 
effect. All regression models also included a first order autoregressive term. 
 
In the models with morning reported outcomes (children measured their lung function in the 
morning and recorded whether they had symptoms and any reliever use during the night) as 
the dependent variable, air pollutants and time varying covariates (temperature and number of 
hours spent outdoors engaged in vigorous physical activity) were lagged by one day.  
 
In models with evening reported outcomes (children measured their lung function in the 
evening and recorded symptoms and reliever/preventer use during the day) as the dependent 
variable, the same day (lag zero) air pollutant concentrations and covariates were used.  
 
In all analyses, we excluded the first three days of PEF recordings to minimize any learning 
effects. Only children with seven or more days of diary data were included in the regression 
analyses.  
 
All analyses were conducted using SAS v9.2 statistical software (SAS Institute Inc., Cary, NC, 
USA). Associations between air pollutants and outcomes were deemed to be statistically 
significant if the p-value was less than 0.05. 
 
Results of the regression models (beta coefficients and odds ratios and their associated ninety 
five percent confidence intervals) are presented for a one unit increase in the air pollutant. All 
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results should be interpreted at a daily mean temperature of 20 degrees Centigrade and two 
hours spent outdoors in vigorous physical activity. 
 
2. RESULTS 
 
2.1. Demographic and baseline data 
 
Two hundred and seventy subjects met the inclusion criteria for the panel study and their data 
are presented in this section. These 270 children are from SA (n=36; 13.3%), QLD (n=38; 14.1%), 
ACT (n=11; 4.1%), VIC (n=81; 30.0%), WA (n=40; 14.8%) and NSW (n=64; 23.7%). These subjects 
came from 51 different schools. 
 
Demographic and clinical characteristics of the 270 subjects are presented in Table 2.1Error! 
Reference source not found..  
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Table 2.1.  Demographic and clinical characteristics of the subjects meeting the inclusion 
criteria for the panel study 
 
 Total 
Number 
Number 
positive 
% 
Sex    
 Females 269 123 45.7 
Symptoms    
 Ever wheezed 270 235 87.0 
 Wheezed in the past 12 months 269 138 51.3 
 Doctor diagnosed asthma 270 270 100 
 Current asthma 266 156 58.7 
 Cough in last 12 months 269 252 93.7 
 Visit GP last 12 months for asthma 245 102 45.6 
 Visit ED last 12 months for asthma 235 14 6.0 
 Admitted to hospital last 12 months for 
asthma 
235 3 1.3 
 Asth a limited activities in last 12 months 244 102 41.8 
 Missed school due to asthma in last 12 months 247 76 30.8 
Atopy status    
 Any atopy 255 137 53.7 
 House dust mite atopy 255 120 47.1 
Use of medicines for asthma    
 Any medications ever 268 259 96.6 
 Short-acting bronchodilators last 12 
months 
265 181 68.3 
 Long-acting bronchodilators (alone) last 
12 months 
254 5 2.0 
 Inhaled corticosteroids (alone) last 12 
months 
257 54 21.0 
 Combined Inhaled corticosteroids and 
Long-acting bronchodilators last 12 
months 
258 50 19.4 
 eukotrie e receptor antagonist last 12 
t s 
255 13 5.1 
 Oral steroids last 12 months 254 31 12.2 
Environmental exposures    
Smoking inside the house 
(occassionally/frequently) 
269 11 4.9 
Types of heating    
 Unflued gas heating 270 46 17.0 
 Open fire 270 38 14.1 
Gas for cooking 268 198 73.9 
Pets (cats/dogs) in the home 236 195 82.6 
  Mean SD 
Age (years) 258 10.0 1.21 
Weight (kg) 260 37.0 10.56 
Height (cm) 261 140.9 9.52 
 
2.2. Diary data 
 
The panel study was conducted in six jurisdictions - (Australian Capital Territory (ACT), 
Victoria (VIC), Queensland (QLD), South Australia (SA), Western Australia (WA) and New 
South Wales (NSW).  The panel study was conducted in 2007, except for NSW, where the panel 
study was conducted in 2008, with start and completion dates as shown in Table 2.2. 
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Table 2.2.  Timing of panel study in each jurisdiction 
 
Jurisdiction Start Date Completion Date 
ACT 3/4/2007 to 4/4/2007 27/4/2007 
NSW 28/2/2008 to 9/5/2008 30/3/2008 to 8/6/2008 
Qld 24/7/2007 to 2/8/2007 26/8/2007 to 21/10/2007 
SA 31/10/2007 to 8/11/2007 2/12/2007 to 9/12/2007 
Vic 21/5/2007 to 28/06/2007 24/6/2007 to 12/8/2007 
WA 28/8/2007 to 6/9/2007 30/9/2007-2/9/2007 
 
The final sample included 270 children and  8,691 diary days for analyses after excluding those 
not eligible for inclusion in the panel study (n=5 children; 116 records) and those diary days 
with missing or out of range dates (157 records). 
 
The mean and median number of diary days were 32.8 and 35 respectively (range=7-49 days).  
Eighty percent (n=216) of the children kept a diary for between 35 and 40 days. About 94% of 
the children kept a diary for at least four weeks.  
 
There were at least seven days of diary recordings (n=237 children) for morning and evening 
PEF and morning and evening FEV1. Eighteen children did not have recordings for PEF and 
FEV1. At least 7 days of diary entries were made by 260 children for evening symptoms and by 
259 children for evening reliever medication use. At least 7 days of diary entries were made by 
257 children for morning symptoms.  
 
Table 2.3Error! Reference source not found. shows the available data (diary days) for each of 
the outcome variables. The mean number of diary days for recorded lung function was less than 
the mean number of diary days for recorded symptoms. For example, morning FEV1 was 
recorded on 19.6 days on average whereas morning and evening symptoms were recorded on 
an average of about 26 days.  
 
Table 2.4 presents descriptive statistics for selected outcome variables. 
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Table 2.3.  Available diary days per child (N = 270) for selected outcome variables 
 
Health outcomes Mean SD Median Range 
Morning FEV1 19.61 9.38 22 0-34 
Evening FEV1 19.61 9.37 21 0-35 
Within-subject residual morning 
FEV1 
19.81 9.48 22 0-34 
Within-subject residual evening 
FEV1 
19.87 9.52 21 0-35 
Amplitude difference of FEV1 15.05 9.05 15 0-32 
Morning PEF 19.61 9.38 22 0-34 
Evening PEF 19.56 9.35 21 0-35 
Within-subject residual morning PEF 19.81 9.48 22 0-34 
Within-subject residual evening PEF 19.87 9.52 21 0-35 
Amplitude difference of PEF 15.00 9.03 15 0-33 
Any day time symptom 26.21 7.89 29 2-35 
Mean of day time score of cough, 
wheeze, shortness of breath, runny 
nose, eye irritation and fever 
26.12 7.87 29 2-35 
Mean of day time score of runny 
nose, eye irritation and fever (upper 
respiratory symptoms) 
26.11 7.88 29 2-35 
Day time cough 26.11 7.87 29 2-35 
Day time wheeze 26.11 7.88 29 2-35 
Day time shortness of breath 26.11 7.88 29 2-35 
Day time runny nose 26.11 7.88 29 2-35 
Day time eye irritation 26.11 7.88 29 2-35 
Day time fever 26.11 7.88 29 2-35 
Used reliever for symptoms during 
the day 
26.58 8.07 30 0-36 
Used preventers for symptoms 
during the day 
26.26 8.35 30 0-35 
Used any medications for symptoms 
during the day 
26.70 8.12 30 0-36 
Any chest symptoms during the 
night  
26.11 7.73 29 2-36 
Night cough 26.05 7.71 29 2-36 
Night wheeze 26.04 7.72 29 2-36 
Night shortness of breath 26.04 7.72 29 2-36 
Mean of night  score of cough, 
wheeze and shortness of breath 
26.05 7.71 29 2-36 
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Table 2.4.  Summary statistics for selected continuous outcome variables 
 
Health outcomes N Mean SD Median Range 
Morning PEF (litres/min) 252 260.87 57.54 255.52 120-467 
Evening PEF (litres/min) 252 275.9 56.71 269.52 143-470 
Within-subject residual morning 
PEF (litres/min) 
252 0 0.09 0 -0.4 - 0.67 
Within-subject residual evening 
PEF (litres/min) 
252 -0.01 0.11 0 -0.93-0.4 
Amplitude difference of PEF 
(litres/min) 
251 -0.04 0.07 -0.03 -0.38-0.24 
Morning FEV1 (litres) 252 1.81 0.42 1.74 0.86-3.52 
Evening FEV1 (litres) 252 1.87 0.41 1.8 0.93-3.53 
Within-subject residual morning 
FEV1 (litres) 
252 -0.01 0.08 0 -0.59-0.29 
Within-subject residual evening 
FEV1 (litres) 
252 0 0.08 0 -0.45-0.55 
Amplitude difference of FEV1 
(litres) 
251 -0.02 0.08 -0.01 -0.38-0.48 
Mean of day time cough, wheeze, 
shortness of breath, runny nose, 
eye irritation and fever 
270 0.18 0.26 0.11 0-1.85 
Mean of day time runny nose, 
eye irritation and fever (upper 
respiratory symptoms) 
270 0.18 0.27 0.08 0-1.57 
Mean of night cough, wheeze 
and shortness of breath 
270 0.16 0.24 0.08 0-1.97 
*Total diary days=8,848 days 
 
Table 2.5, Table 2.6 and Table 2.7show the summary distribution of numbers of days with night 
symptoms, day time symptoms and medication use respectively. 
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Table 2.5.  Number of children by percentage of diary days with night symptoms 
 
% of diary days N Percent Cumulative Cumulative 
Frequency Percent 
Any night symptoms 
 
 
    
Less than 20% 148 54.81 148 54.81 
20 to 39% 55 20.37 203 75.19 
40-to 59% 25 9.26 228 84.44 
60 to 79%  18 6.67 246 91.11 
80% or more 24 8.89 270 100 
Night cough     
Less than 20% 162 60 162 60 
20 to 39% 50 18.52 212 78.52 
40-to 59% 21 7.78 233 86.3 
60 to 79%  19 7.04 252 93.33 
80% or more 18 6.67 270 100 
Night wheeze     
Less than 20% 229 84.81 229 84.81 
20 to 39% 22 8.15 251 92.96 
40-to 59% 10 3.7 261 96.67 
60 to 79%  3 1.11 264 97.78 
80% or more 6 2.22 270 100 
Night shortness of breath     
Less than 20% 253 93.7 253 93.7 
20 to 39% 8 2.96 261 96.67 
40-to 59% 7 2.59 268 99.26 
60 to 79%  1 0.37 269 99.63 
80% or more 1 0.37 270 100 
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Table 2.6.  Number of children by percentage of diary days with day time symptoms  
 
 
% of diary days 
N Percent Cumulative Cumulative 
Frequency Percent 
Any day time symptoms 
 
    
Less than 20% 96 35.56 96 35.56 
20 to 39% 63 23.33 159 58.89 
40-to 59% 39 14.44 198 73.33 
60 to 79%  30 11.11 228 84.44 
80% or more 42 15.56 270 100 
Day time cough 
% of diary days 
    
Less than 20% 142 52.59 142 52.59 
20 to 39% 53 19.63 195 72.22 
40-to 59% 32 11.85 227 84.07 
60 to 79%  19 7.04 246 91.11 
80% or more 24 8.89 270 100 
Day time wheeze 
% of diary days 
    
Less than 20% 213 78.89 213 78.89 
20 to 39% 34 12.59 247 91.48 
40-to 59% 10 3.7 257 95.19 
60 to 79%  8 2.96 265 98.15 
80% or more 5 1.85 270 100 
Day time shortness of breath 
% of diary days 
    
Less than 20% 239 88.52 239 88.52 
20 to 39% 18 6.67 257 95.19 
40-to 59% 5 1.85 262 97.04 
60 to 79%  6 2.22 268 99.26 
80% or more 2 0.74 270 100 
Day time runny nose 
% of diary days 
    
Less than 20% 160 59.26 160 59.26 
20 to 39% 49 18.15 209 77.41 
40-to 59% 24 8.89 233 86.3 
60 to 79%  19 7.04 252 93.33 
80% or more 18 6.67 270 100 
Day time eye irritation 
% of diary days 
    
Less than 20% 234 86.67 234 86.67 
20 to 39% 22 8.15 256 94.81 
40-to 59% 2 0.74 258 95.56 
60 to 79%  8 2.96 266 98.52 
80% or more 4 1.48 270 100 
Day time fever 
% of diary days 
    
Less than 20% 233 86.3 233 86.3 
20 to 39% 17 6.3 250 92.59 
40-to 59% 10 3.7 260 96.3 
60 to 79%  5 1.85 265 98.15 
80% or more 5 1.85 270 100 
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Table 2.7.  Number of children by percentage of diary days with medication use  
 
 
% of diary days 
N Percent Cumulative Cumulative 
Frequency Percent 
Use of preventers during the day for symptoms  
% of diary days 
    
Less than 20% 253 94.05 253 94.05 
20 to 39% 8 2.97 261 97.03 
40-to 59% 2 0.74 263 97.77 
60 to 79%  5 1.86 268 99.63 
80% or more 1 0.37 269 100 
Use of any medications during the day for 
symptoms 
    
Less than 20% 230 85.5 230 85.5 
20 to 39% 22 8.18 252 93.68 
40-to 59% 7 2.6 259 96.28 
60 to 79%  7 2.6 266 98.88 
80% or more 3 1.12 269 100 
Use of routine relievers during the day     
Less than 20% 252 93.68 252 93.68 
20 to 39% 4 1.49 256 95.17 
40-to 59% 6 2.23 262 97.4 
60 to 79%  7 2.6 269 100 
Use of routine preventers during the day               
Less than 20%    
    
230 85.5 230 85.5 
20 to 39% 3 1.12 233 86.62 
40-to 59% 4 1.49 237 88.1 
60 to 79%  10 3.72 247 91.82 
80% or more 22 8.18 269 100 
 
2.3. Air pollution data 
 
Air pollution and data from 27 air quality monitors (AQMs) were used in the panel study. The 
AQMs were located in SA (n=4), QLD (n=4), ACT (n=1), VIC (n=8), WA (n=3) and NSW (n=7). 
 
All AQMs except those from NSW provided data from 1 January 2007 to 31 December 2007.  
NSW AQMs provided data from January 2008 to 30 September 2008. PM2.5 data were provided 
by 15 AQMs, PM10 data by 27 AQMs, ozone by 23 AQMs, NO2 by 26 AQMs, CO by 17 AQMs 
and SO2 by 14 AQMs. 
 
Across all the 27 AQMs, mean PM10 24-hr and PM2.5 24-hr concentrations were 17.6 ug/m3 
(range: 1.2-166.7 ug/m3) and 7.2 ug/m3 (range: 0.1-131.9 ug/m3) respectively; the mean 1-hr, 4-
hr and 8-hr ozone concentrations were 30.5 ppb (range: 0-127 ppb), 28.8 ppb (range: 0.3-115 
ppb) and 26.4 ppb (range: 0.4-99 ppb) respectively; mean 1-hr and 24-hr NO2 concentrations 
were 18.7 ppb (range: 0-69 ppb) and 7.9 ppb (range: 0-30.8 ppb) respectively; mean CO 8-hr was 
0.45 ppm (range: 0.01-2.9 ppm); and, mean SO2 1-hr and SO2 24-hr concentrations were 9.8 ppb 
(range: 0-594 ppb) and 1.9 ppb (range: 0-59.7 ppb) respectively. Descriptive data for each of the 
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air quality monitoring stations and by each State/Territory and season are presented in 
Appendices Part C.  
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2.4. Associations between air pollutants and lung function, symptoms and 
medication use 
 
We conducted seven sets of analyses on the panel data: 
 
1. All air pollutants and all outcomes. For the morning recorded lung function (PEF, FEV1) 
and night symptoms and night  reliever medication use, analyses were conducted using 
air pollution concentrations at lag 1, lag 2 and lag 3. For the evening recorded lung 
function (PEF, FEV1) and day time symptoms and day time reliever and preventer 
medication use, analyses were conducted using air pollution concentrations at lag 0, lag 
1 and lag 2. 
2. A sub-analysis for the effects of ozone during the warm months (November to April). 
3. A sub-analysis for the effects of SO2 after excluding children from Port Pirie. 
4. A sub-analysis for the effects of SO2 in two pollutant models with  PM10 .  
5. A sub-analysis for the effects of NO2 in two pollutant models with ozone. 
6. A sub-analysis for the effects of NO2 in the subgroup of children who have unflued gas 
heating in their home. 
7. A sub-analysis for the effects of PM10 in two pollutant models (ie. PM10 plus the gaseous 
air pollutants). 
 
Lung function effects are presented as the beta coefficients with the associated 95% confidence 
intervals and the p-values. Effects of air pollution on symptoms and medication use are 
presented as odds ratios and association 95% confidence intervals and the p-values.  
 
Across all the 27 AQMs, there was moderate correlation between PM10 and PM2.5 (r=0.65). There 
were very high correlations among the three metrics for ozone (r=0.94-0.99), the two metrics for 
SO2 (r=0.90) and the two metrics for NO2 (r=0.84). Otherwise, the correlations between air 
pollutants were generally weak. Correlation coefficients by State/Territory are presented in 
Appendices Part C. 
2.4.1. Associations between any air pollutants and lung function, symptoms and 
medication use 
 
There were few associations between air pollutants and lung function (Table 2.8). These were 
mainly positive associations between 1-hr NO2 and morning lung function, and 24-hr SO2 with 
lung function. 
 
Tables 2.9- 2.11 and present the findings for air pollutants and symptoms and medication use. 
Negative effects are seen mainly with CO, NO2 and PM10 whereas positive effects are generally 
seen with ozone and SO2. More adverse effects were observed with 24-hr NO2 compared to 1-hr 
NO2. Similarly, more adverse effects were seen with PM10 than with PM2.5.  
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Table 2.8.   Associations between air pollutants and lung function 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM2.5 24-hr 
lag0 
-0.2076 (-1.7232 to 
1.3080), p=0.79 
-0.0022 (-0.0119 to 
0.0076), p=0.66 
    
lag1 
0.8534 (-0.5868 to 
2.2936), p=0.25 
0.0058 (-0.0036 to 
0.0151), p=0.23 
0.1960 (-0.8843 to 
1.2762), p=0.72 
0.0024 (-0.0056 to 
0.0103), p=0.56 
lag2 
0.3709 (-1.0164 to 
1.7583), p=0.60 
0.0001 (-0.0091 to 
0.0092), p=0.99 
0.2315 (-0.8657 to 
1.3286), p=0.68 
0.0037 (-0.0043 to 
0.0118), p=0.37 
lag3     
-0.8327 (-1.9529 to 
0.2874), p=0.15 
-0.0035 (-0.0116 to 
0.0046), p=0.40 
PM10 24-hr 
lag0 
-0.0619 (-0.3833 to 
0.2595), p=0.71 
0.0004 (-0.0018 to 
0.0025), p=0.74 
    
lag1 
0.1204 (-0.2078 to 
0.4487), p=0.47 
0.0008 (-0.0013 to 
0.0030), p=0.46 
0.1880 (-0.0564 to 
0.4324), p=0.13 
0.0011 (-0.0006 to 
0.0028), p=0.21 
lag2 
-0.0279 (-0.3741 to 
0.3183), p=0.87 
-0.0001 (-0.0025 to 
0.0022), p=0.91 
-0.0155 (-0.2834 to 
0.2523), p=0.91 
0.0001 (-0.0018 to 
0.0020), p=0.94 
lag3     
-0.0899 (-0.3755 to 
0.1957), p=0.54 
-0.0006 (-0.0026 to 
0.0014), p=0.57 
NO2 1-hr 
lag0 
0.0586 (-0.3451 to 
0.4623), p=0.78 
-0.0003 (-0.0030 to 
0.0024), p=0.81 
    
lag1 
0.0155 (-0.3831 to 
0.4140), p=0.94 
0.0011 (-0.0015 to 
0.0038), p=0.41 
0.2165 (-0.0772 to 
0.5101), p=0.15 
0.0016 (-0.0006 to 
0.0037), p=0.15 
lag2 
0.1877 (-0.2250 to 
0.6003), p=0.37 
0.0009 (-0.0019 to 
0.0037), p=0.52 
-0.3102 (-0.6241 to 
0.0038), p=0.053 
-0.0030 (-0.0052 to  
-0.0008), p=0.007 
lag3     
0.3541 (0.0439 to 
0.6642), p=0.025 
0.0017 (-0.0005 to 
0.0039), p=0.13 
NO2 24-hr 
lag0 
0.2562 (-0.5916 to 
1.1041), p=0.55 
0.0022 (-0.0035 to 
0.0078), p=0.45 
    
lag1 
-0.2076 (-1.0393 to 
0.6242), p=0.62 
0.0008 (-0.0047 to 
0.0064), p=0.77 
0.0037 (-0.6227 to 
0.6301), p=0.99 
-0.0026 (-0.0070 to 
0.0019), p=0.26 
lag2 
0.3475 (-0.4809 to 
1.1759), p=0.41 
0.0016 (-0.0040 to 
0.0073), p=0.57 
-0.0702 (-0.7089 to 
0.5685), p=0.83 
-0.0026 (-0.0071 to 
0.0019), p=0.26 
lag3     
0.2670 (-0.3603 to 
0.8943), p=0.40 
0.0017 (-0.0028 to 
0.0061), p=0.46 
O3 1-hr 
lag0 
-0.1139 (-0.4480 to 
0.2201), p=0.50 
-0.0005 (-0.0027 to 
0.0018), p=0.68 
    
lag1 
-0.0409 (-0.3590 to 
0.2772), p=0.80 
-0.0009 (-0.0031 to 
0.0012), p=0.39 
0.1636 (-0.0668 to 
0.3939), p=0.16 
0.0007 (-0.0009 to 
0.0023), p=0.39 
lag2 
0.1639 (-0.1568 to 
0.4847), p=0.32 
0.0009 (-0.0013 to 
0.0030), p=0.42 
-0.0331 (-0.2679 to 
0.2018), p=0.78 
-0.0005 (-0.0021 to 
0.0011), p=0.57 
lag3     -0.1207 (-0.3520 to -0.0003 (-0.0018 to 
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Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
0.1106), p=0.31 0.0013), p=0.75 
O3 4-hr 
lag0 
-0.2039 (-0.5728 to 
0.1649), p=0.28 
-0.0012 (-0.0037 to 
0.0013), p=0.34 
    
lag1 
-0.0249 (-0.3744 to 
0.3247), p=0.89 
-0.0007 (-0.0030 to 
0.0016), p=0.56 
0.1664 (-0.0902 to 
0.4230), p=0.20 
0.0007 (-0.0011 to 
0.0025), p=0.43 
lag2 
0.2023 (-0.1484 to 
0.5530), p=0.26 
0.0009 (-0.0015 to 
0.0032), p=0.46 
0.0000 (-0.2594 to 
0.2595), p=1.00 
-0.0003 (-0.0020 to 
0.0015), p=0.75 
lag3     
-0.1383 (-0.3921 to 
0.1156), p=0.29 
-0.0003 (-0.0020 to 
0.0014), p=0.74 
O3 8-hr 
lag0 
-0.2220 (-0.6396 to 
0.1956), p=0.30 
-0.0018 (-0.0046 to 
0.0010), p=0.20 
    
lag1 
0.0069 (-0.3950 to 
0.4088), p=0.97 
-0.0004 (-0.0031 to 
0.0023), p=0.77 
0.1783 (-0.1197 to 
0.4764), p=0.24 
0.0008 (-0.0013 to 
0.0028), p=0.46 
lag2 
0.2517 (-0.1579 to 
0.6613), p=0.23 
0.0012 (-0.0016 to 
0.0040), p=0.40 
0.0006 (-0.3077 to 
0.3089), p=1.00 
-0.0000 (-0.0021 to 
0.0021), p=0.98 
lag3     
-0.1043 (-0.4105 to 
0.2019), p=0.50 
-0.0006 (-0.0027 to 
0.0015), p=0.58 
CO 8-hr 
lag0 
0.5490 (-13.762 to 
14.8604), p=0.94 
0.0228 (-0.0756 to 
0.1212), p=0.65 
    
lag1 
5.3164 (-8.8404 to 
19.4732), p=0.46 
0.0443 (-0.0526 to 
0.1413), p=0.37 
1.9066 (-8.6810 to 
12.4943), p=0.72 
-0.0319 (-0.1088 to 
0.0450), p=0.42 
lag2 
0.5428 (-13.935 to 
15.0201), p=0.94 
-0.0027 (-0.1016 to 
0.0962), p=0.96 
-5.4271 (-15.771 to 
4.9173), p=0.30 
-0.0295 (-0.1052 to 
0.0463), p=0.45 
lag3     
4.8370 (-4.6149 to 
14.2889), p=0.32 
0.0140 (-0.0552 to 
0.0832), p=0.69 
SO2 1-hr 
lag0 
0.2848 (-0.0329 to 
0.6026), p=0.079 
0.0011 (-0.0011 to 
0.0033), p=0.31 
    
lag1 
-0.0750 (-0.3208 to 
0.1708), p=0.55 
0.0007 (-0.0010 to 
0.0025), p=0.40 
0.0362 (-0.1621 to 
0.2345), p=0.72 
0.0002 (-0.0011 to 
0.0015), p=0.76 
lag2 
-0.0810 (-0.3682 to 
0.2062), p=0.58 
-0.0014 (-0.0034 to 
0.0006), p=0.18 
0.1137 (-0.0906 to 
0.3179), p=0.28 
0.0005 (-0.0009 to 
0.0018), p=0.47 
lag3     
-0.1482 (-0.3499 to 
0.0536), p=0.15 
0.0001 (-0.0013 to 
0.0014), p=0.94 
SO2 24-hr 
lag0 
1.6181 (0.1404 to 
3.0958), p=0.032 
0.0052 (-0.0049 to 
0.0154), p=0.31 
    
lag1 
-1.0652 (-2.5482 to 
0.4179), p=0.16 
0.0022 (-0.0081 to 
0.0125), p=0.68 
-0.6026 (-1.7145 to 
0.5094), p=0.29 
-0.0044 (-0.0119 to 
0.0031), p=0.25 
lag2 
0.4314 (-1.1946 to 
2.0575), p=0.60 
-0.0009 (-0.0122 to 
0.0104), p=0.87 
1.2686 (0.0857 to 
2.4514), p=0.036 
0.0078 (0.0000 to 
0.0157), p=0.050 
lag3     
-1.0547 (-2.2404 to 
0.1310), p=0.081 
-0.0048 (-0.0127 to 
0.0032), p=0.24 
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Table 2.9.  Associations between air pollutants and night symptoms and medication use 
 
Lag Night cough Night wheeze 
Night shortness of 
breath 
Any night symptoms 
Any night reliever 
medications use 
PM2.5 24-hr 
lag1 
1.0285 (0.9539 to 1.1088), 
p=0.46 
1.0401 (0.9333 to 1.1592), 
p=0.48 
0.9944 (0.8520 to 1.1606), 
p=0.94 
1.0180 (0.9493 to 1.0918), 
p=0.62 
0.9286 (0.8274 to 1.0421), 
p=0.21 
lag2 
1.0767 (0.9998 to 1.1596), 
p=0.051 
1.0222 (0.9145 to 1.1425), 
p=0.70 
1.0503 (0.8938 to 1.2343), 
p=0.55 
1.0553 (0.9844 to 1.1313), 
p=0.13 
0.9342 (0.8334 to 1.0472), 
p=0.24 
lag3 
1.0718 (0.9928 to 1.1570), 
p=0.076 
0.9851 (0.8803 to 1.1025), 
p=0.79 
1.0302 (0.8824 to 1.2027), 
p=0.71 
1.0418 (0.9703 to 1.1186), 
p=0.26 
0.9544 (0.8537 to 1.0669), 
p=0.41 
PM10 24-hr 
lag1 
1.0187 (1.0047 to 1.0329), 
p=0.009 
1.0190 (0.9988 to 1.0396), 
p=0.065 
1.0034 (0.9725 to 1.0354), 
p=0.83 
1.0131 (0.9994 to 1.0269), 
p=0.060 
1.0013 (0.9776 to 1.0255), 
p=0.92 
lag2 
1.0180 (1.0041 to 1.0322), 
p=0.011 
1.0238 (1.0036 to 1.0444), 
p=0.021 
1.0166 (0.9862 to 1.0479), 
p=0.29 
1.0163 (1.0029 to 1.0298), 
p=0.017 
0.9813 (0.9542 to 1.0092), 
p=0.19 
lag3 
1.0173 (1.0024 to 1.0325), 
p=0.023 
1.0151 (0.9938 to 1.0368), 
p=0.17 
1.0112 (0.9772 to 1.0464), 
p=0.52 
1.0138 (0.9996 to 1.0282), 
p=0.057 
0.9948 (0.9679 to 1.0225), 
p=0.71 
NO2 1-hr 
lag1 
1.0164 (0.9984 to 1.0347), 
p=0.074 
1.0116 (0.9868 to 1.0371), 
p=0.36 
1.0304 (0.9961 to 1.0660), 
p=0.083 
1.0165 (0.9996 to 1.0338), 
p=0.056 
1.0102 (0.9828 to 1.0383), 
p=0.47 
lag2 
1.0282 (1.0096 to 1.0473), 
p=0.003 
1.0180 (0.9923 to 1.0445), 
p=0.17 
1.0104 (0.9746 to 1.0474), 
p=0.57 
1.0244 (1.0067 to 1.0424), 
p=0.007 
0.9968 (0.9689 to 1.0255), 
p=0.83 
lag3 
1.0257 (1.0066 to 1.0451), 
p=0.008 
1.0201 (0.9934 to 1.0474), 
p=0.14 
1.0110 (0.9725 to 1.0509), 
p=0.58 
1.0227 (1.0047 to 1.0410), 
p=0.013 
1.0110 (0.9824 to 1.0404), 
p=0.45 
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Lag Night cough Night wheeze 
Night shortness of 
breath 
Any night symptoms 
Any night reliever 
medications use 
NO2 24-hr 
lag1 
1.0504 (1.0175 to 1.0844), 
p=0.002 
1.0640 (1.0186 to 1.1114), 
p=0.005 
1.0771 (1.0183 to 1.1392), 
p=0.010 
1.0442 (1.0126 to 1.0768), 
p=0.006 
1.0459 (0.9973 to 1.0969), 
p=0.064 
lag2 
1.0599 (1.0261 to 1.0948), 
p=0.0004 
1.0545 (1.0083 to 1.1028), 
p=0.020 
1.0545 (0.9923 to 1.1207), 
p=0.087 
1.0577 (1.0250 to 1.0915), 
p=0.0005 
1.0358 (0.9867 to 1.0873), 
p=0.16 
lag3 
1.0757 (1.0407 to 1.1118), 
p=0.0000 
1.0581 (1.0124 to 1.1057), 
p=0.012 
1.0283 (0.9658 to 1.0947), 
p=0.38 
1.0682 (1.0349 to 1.1026), 
p=0.0000 
1.0439 (0.9943 to 1.0959), 
p=0.083 
O3 1-hr 
lag1 
0.9935 (0.9783 to 1.0089), 
p=0.40 
0.9805 (0.9598 to 1.0017), 
p=0.071 
0.9598 (0.9277 to 0.9929), 
p=0.018 
0.9924 (0.9786 to 1.0064), 
p=0.28 
0.9945 (0.9715 to 1.0181), 
p=0.64 
lag2 
0.9999 (0.9840 to 1.0161), 
p=0.99 
0.9753 (0.9523 to 0.9988), 
p=0.039 
0.9675 (0.9326 to 1.0038), 
p=0.078 
1.0005 (0.9859 to 1.0153), 
p=0.95 
0.9927 (0.9684 to 1.0176), 
p=0.56 
lag3 
0.9946 (0.9782 to 1.0114), 
p=0.53 
0.9636 (0.9404 to 0.9874), 
p=0.003 
0.9613 (0.9256 to 0.9984), 
p=0.041 
0.9892 (0.9742 to 1.0045), 
p=0.17 
0.9891 (0.9635 to 1.0154), 
p=0.41 
O3 4-hr 
lag1 
0.9931 (0.9770 to 1.0095), 
p=0.41 
0.9751 (0.9533 to 0.9975), 
p=0.029 
0.9558 (0.9223 to 0.9905), 
p=0.013 
0.9911 (0.9765 to 1.0060), 
p=0.24 
0.9932 (0.9688 to 1.0183), 
p=0.59 
lag2 
0.9990 (0.9821 to 1.0162), 
p=0.91 
0.9703 (0.9460 to 0.9951), 
p=0.019 
0.9616 (0.9248 to 0.9998), 
p=0.049 
0.9985 (0.9830 to 1.0143), 
p=0.85 
0.9919 (0.9660 to 1.0185), 
p=0.55 
lag3 
0.9941 (0.9766 to 1.0119), 
p=0.51 
0.9604 (0.9359 to 0.9855), 
p=0.002 
0.9581 (0.9204 to 0.9972), 
p=0.036 
0.9892 (0.9732 to 1.0054), 
p=0.19 
0.9844 (0.9575 to 1.0120), 
p=0.27 
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Lag Night cough Night wheeze 
Night shortness of 
breath 
Any night symptoms 
Any night reliever 
medications use 
O3 8-hr 
lag1 
0.9906 (0.9728 to 1.0087), 
p=0.31 
0.9619 (0.9383 to 0.9862), 
p=0.002 
0.9519 (0.9162 to 0.9890), 
p=0.011 
0.9882 (0.9722 to 1.0043), 
p=0.15 
0.9899 (0.9632 to 1.0174), 
p=0.47 
lag2 
0.9949 (0.9762 to 1.0140), 
p=0.60 
0.9562 (0.9299 to 0.9832), 
p=0.002 
0.9537 (0.9139 to 0.9952), 
p=0.029 
0.9933 (0.9763 to 1.0107), 
p=0.45 
0.9846 (0.9560 to 1.0141), 
p=0.30 
lag3 
0.9926 (0.9732 to 1.0125), 
p=0.46 
0.9530 (0.9263 to 0.9805), 
p=0.0009 
0.9536 (0.9129 to 0.9960), 
p=0.032 
0.9883 (0.9707 to 1.0062), 
p=0.20 
0.9750 (0.9454 to 1.0055), 
p=0.11 
CO 8-hr 
lag1 
1.6304 (0.9819 to 2.7073), 
p=0.059 
1.8501 (0.9353 to 3.6594), 
p=0.077 
2.3444 (1.0130 to 5.4260), 
p=0.047 
1.5380 (0.9296 to 2.5445), 
p=0.094 
1.1206 (0.5303 to 2.3680), 
p=0.77 
lag2 
1.9233 (1.1552 to 3.2020), 
p=0.012 
1.8100 (0.9163 to 3.5751), 
p=0.088 
1.9437 (0.8032 to 4.7034), 
p=0.14 
1.9502 (1.1704 to 3.2498), 
p=0.010 
0.7411 (0.3443 to 1.5955), 
p=0.44 
lag3 
1.0988 (0.6760 to 1.7862), 
p=0.70 
1.0803 (0.5623 to 2.0754), 
p=0.82 
1.5933 (0.6735 to 3.7691), 
p=0.29 
1.0118 (0.6273 to 1.6320), 
p=0.96 
1.0453 (0.5199 to 2.1016), 
p=0.90 
SO2 1-hr 
lag1 
1.0048 (0.9915 to 1.0184), 
p=0.48 
1.0027 (0.9795 to 1.0264), 
p=0.82 
0.9401 (0.8725 to 1.0129), 
p=0.10 
1.0055 (0.9928 to 1.0184), 
p=0.40 
1.0255 (1.0033 to 1.0482), 
p=0.024 
lag2 
0.9939 (0.9797 to 1.0084), 
p=0.41 
0.9995 (0.9743 to 1.0252), 
p=0.97 
0.9192 (0.8480 to 0.9964), 
p=0.041 
0.9974 (0.9839 to 1.0111), 
p=0.71 
1.0195 (0.9977 to 1.0417), 
p=0.080 
lag3 
1.0046 (0.9904 to 1.0190), 
p=0.52 
0.9966 (0.9697 to 1.0241), 
p=0.80 
0.9199 (0.8452 to 1.0013), 
p=0.054 
1.0042 (0.9904 to 1.0181), 
p=0.56 
0.9509 (0.8986 to 1.0062), 
p=0.081 
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Lag Night cough Night wheeze 
Night shortness of 
breath 
Any night symptoms 
Any night reliever 
medications use 
SO2 24-hr 
lag1 
0.9787 (0.9053 to 1.0582), 
p=0.59 
0.9786 (0.8575 to 1.1168), 
p=0.75 
0.8482 (0.6143 to 1.1711), 
p=0.32 
0.9843 (0.9142 to 1.0597), 
p=0.67 
1.1044 (0.9660 to 1.2627), 
p=0.15 
lag2 
0.9506 (0.8750 to 1.0327), 
p=0.23 
1.0062 (0.8813 to 1.1488), 
p=0.93 
0.8827 (0.6656 to 1.1706), 
p=0.39 
0.9785 (0.9054 to 1.0575), 
p=0.58 
1.0571 (0.9146 to 1.2217), 
p=0.45 
lag3 
0.9948 (0.9184 to 1.0776), 
p=0.90 
0.9068 (0.7682 to 1.0704), 
p=0.25 
0.6063 (0.4053 to 0.9069), 
p=0.015 
0.9850 (0.9110 to 1.0652), 
p=0.71 
0.8244 (0.6575 to 1.0336), 
p=0.094 
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Table 2.10.  Associations between air pollutants and day time symptoms 
 
Lag Day cough Day wheeze 
Day shortness of 
breath 
Day runny nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM2.5 24-hr 
lag0 
1.0409 (0.9753 to 
1.1109), p=0.23 
1.0096 (0.9198 to 
1.1082), p=0.84 
0.9747 (0.8678 to 
1.0948), p=0.67 
1.0873 (1.0143 to 
1.1656), p=0.018 
0.9982 (0.8895 to 
1.1201), p=0.98 
0.9002 (0.8026 to 
1.0096), p=0.072 
1.0285 (0.9707 to 
1.0897), p=0.34 
lag1 
1.0188 (0.9516 to 
1.0908), p=0.59 
0.9512 (0.8642 to 
1.0470), p=0.31 
0.9956 (0.8768 to 
1.1304), p=0.95 
1.0375 (0.9657 to 
1.1147), p=0.31 
1.0968 (0.9787 to 
1.2293), p=0.11 
0.9341 (0.8336 to 
1.0466), p=0.24 
1.0053 (0.9467 to 
1.0676), p=0.86 
lag2 
1.0460 (0.9759 to 
1.1210), p=0.20 
0.9668 (0.8778 to 
1.0649), p=0.49 
1.0152 (0.8952 to 
1.1512), p=0.81 
1.0210 (0.9490 to 
1.0985), p=0.58 
1.0759 (0.9562 to 
1.2106), p=0.22 
0.9723 (0.8707 to 
1.0858), p=0.62 
1.0229 (0.9624 to 
1.0873), p=0.47 
PM10 24-hr 
lag0 
1.0058 (0.9922 to 
1.0197), p=0.40 
1.0211 (1.0034 to 
1.0392), p=0.019 
1.0070 (0.9850 to 
1.0294), p=0.54 
1.0040 (0.9888 to 
1.0194), p=0.61 
0.9847 (0.9603 to 
1.0097), p=0.23 
1.0054 (0.9851 to 
1.0261), p=0.60 
0.9990 (0.9869 to 
1.0112), p=0.87 
lag1 
1.0092 (0.9943 to 
1.0243), p=0.23 
1.0082 (0.9885 to 
1.0284), p=0.42 
1.0222 (0.9987 to 
1.0463), p=0.064 
0.9992 (0.9823 to 
1.0165), p=0.93 
0.9980 (0.9726 to 
1.0241), p=0.88 
0.9982 (0.9759 to 
1.0211), p=0.88 
1.0048 (0.9919 to 
1.0179), p=0.47 
lag2 
1.0177 (1.0028 to 
1.0327), p=0.019 
1.0137 (0.9936 to 
1.0341), p=0.18 
1.0118 (0.9874 to 
1.0367), p=0.35 
0.9984 (0.9817 to 
1.0154), p=0.85 
1.0034 (0.9778 to 
1.0296), p=0.80 
1.0086 (0.9873 to 
1.0304), p=0.43 
1.0070 (0.9944 to 
1.0198), p=0.28 
NO2 1-hr 
lag0 
1.0150 (0.9984 to 
1.0318), p=0.077 
1.0356 (1.0130 to 
1.0586), p=0.002 
1.0212 (0.9949 to 
1.0483), p=0.11 
1.0008 (0.9840 to 
1.0179), p=0.93 
0.9863 (0.9605 to 
1.0129), p=0.31 
0.9998 (0.9762 to 
1.0239), p=0.98 
1.0052 (0.9910 to 
1.0197), p=0.47 
lag1 
1.0144 (0.9976 to 
1.0316), p=0.094 
1.0230 (1.0007 to 
1.0458), p=0.043 
1.0208 (0.9927 to 
1.0497), p=0.15 
1.0040 (0.9866 to 
1.0216), p=0.66 
0.9895 (0.9636 to 
1.0161), p=0.44 
0.9862 (0.9626 to 
1.0105), p=0.26 
1.0045 (0.9899 to 
1.0192), p=0.55 
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Lag Day cough Day wheeze 
Day shortness of 
breath 
Day runny nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
lag2 
1.0186 (1.0013 to 
1.0362), p=0.035 
1.0040 (0.9816 to 
1.0269), p=0.73 
1.0101 (0.9828 to 
1.0382), p=0.47 
0.9893 (0.9719 to 
1.0069), p=0.23 
0.9985 (0.9715 to 
1.0262), p=0.91 
0.9921 (0.9679 to 
1.0169), p=0.53 
0.9995 (0.9847 to 
1.0145), p=0.94 
NO2 24-hr 
lag0 
1.0535 (1.0219 to 
1.0861), p=0.0008 
1.1107 (1.0681 to 
1.1550), p=0.0000 
1.0594 (1.0134 to 
1.1075), p=0.011 
1.0153 (0.9835 to 
1.0481), p=0.35 
0.9825 (0.9325 to 
1.0352), p=0.51 
1.0112 (0.9689 to 
1.0552), p=0.61 
1.0387 (1.0109 to 
1.0673), p=0.006 
lag1 
1.0387 (1.0071 to 
1.0713), p=0.016 
1.0730 (1.0320 to 
1.1155), p=0.0004 
1.0557 (1.0075 to 
1.1063), p=0.023 
1.0141 (0.9815 to 
1.0477), p=0.40 
0.9792 (0.9302 to 
1.0308), p=0.42 
0.9799 (0.9385 to 
1.0232), p=0.36 
1.0212 (0.9933 to 
1.0499), p=0.14 
lag2 
1.0494 (1.0170 to 
1.0829), p=0.003 
1.0402 (1.0002 to 
1.0818), p=0.049 
1.0426 (0.9950 to 
1.0925), p=0.080 
0.9966 (0.9641 to 
1.0303), p=0.84 
0.9971 (0.9456 to 
1.0513), p=0.91 
0.9878 (0.9454 to 
1.0320), p=0.58 
1.0202 (0.9921 to 
1.0491), p=0.16 
O3 1-hr 
lag0 
0.9899 (0.9762 to 
1.0039), p=0.16 
0.9980 (0.9789 to 
1.0175), p=0.84 
1.0118 (0.9889 to 
1.0352), p=0.31 
1.0023 (0.9881 to 
1.0166), p=0.76 
0.9985 (0.9750 to 
1.0225), p=0.90 
0.9910 (0.9712 to 
1.0111), p=0.38 
0.9948 (0.9833 to 
1.0065), p=0.38 
lag1 
0.9923 (0.9778 to 
1.0070), p=0.30 
0.9855 (0.9661 to 
1.0053), p=0.15 
1.0096 (0.9842 to 
1.0357), p=0.46 
0.9981 (0.9833 to 
1.0132), p=0.81 
0.9988 (0.9755 to 
1.0227), p=0.92 
0.9922 (0.9718 to 
1.0130), p=0.46 
0.9945 (0.9824 to 
1.0067), p=0.37 
lag2 
0.9942 (0.9791 to 
1.0096), p=0.46 
0.9830 (0.9622 to 
1.0042), p=0.12 
0.9978 (0.9720 to 
1.0243), p=0.87 
0.9954 (0.9800 to 
1.0110), p=0.56 
1.0025 (0.9760 to 
1.0297), p=0.86 
0.9922 (0.9709 to 
1.0141), p=0.48 
0.9907 (0.9782 to 
1.0034), p=0.15 
O3 4-hr 
lag0 
0.9891 (0.9745 to 
1.0039), p=0.15 
0.9959 (0.9758 to 
1.0165), p=0.70 
1.0126 (0.9886 to 
1.0372), p=0.30 
1.0022 (0.9872 to 
1.0174), p=0.78 
1.0034 (0.9788 to 
1.0287), p=0.79 
0.9923 (0.9715 to 
1.0137), p=0.48 
0.9940 (0.9818 to 
1.0064), p=0.34 
lag1 
0.9910 (0.9756 to 
1.0066), p=0.26 
0.9804 (0.9601 to 
1.0012), p=0.065 
1.0103 (0.9838 to 
1.0374), p=0.45 
0.9974 (0.9817 to 
1.0133), p=0.75 
1.0010 (0.9764 to 
1.0262), p=0.94 
0.9930 (0.9715 to 
1.0150), p=0.53 
0.9939 (0.9811 to 
1.0069), p=0.36 
lag2 0.9910 (0.9749 to 0.9826 (0.9607 to 0.9987 (0.9714 to 0.9951 (0.9788 to 1.0042 (0.9763 to 0.9934 (0.9708 to 0.9884 (0.9751 to 
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Lag Day cough Day wheeze 
Day shortness of 
breath 
Day runny nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
1.0074), p=0.28 1.0049), p=0.13 1.0267), p=0.93 1.0117), p=0.56 1.0330), p=0.77 1.0166), p=0.57 1.0020), p=0.094 
O3 8-hr 
lag0 
0.9869 (0.9711 to 
1.0029), p=0.11 
0.9944 (0.9729 to 
1.0164), p=0.61 
1.0138 (0.9880 to 
1.0403), p=0.30 
1.0064 (0.9902 to 
1.0230), p=0.44 
1.0071 (0.9799 to 
1.0350), p=0.61 
0.9923 (0.9698 to 
1.0153), p=0.51 
0.9953 (0.9821 to 
1.0086), p=0.49 
lag1 
0.9850 (0.9684 to 
1.0020), p=0.083 
0.9737 (0.9518 to 
0.9961), p=0.022 
1.0065 (0.9781 to 
1.0357), p=0.66 
0.9971 (0.9802 to 
1.0144), p=0.74 
1.0023 (0.9749 to 
1.0305), p=0.87 
0.9928 (0.9697 to 
1.0165), p=0.55 
0.9919 (0.9781 to 
1.0059), p=0.25 
lag2 
0.9825 (0.9648 to 
1.0006), p=0.057 
0.9755 (0.9518 to 
0.9998), p=0.048 
0.9929 (0.9628 to 
1.0240), p=0.65 
0.9942 (0.9762 to 
1.0126), p=0.54 
1.0078 (0.9771 to 
1.0394), p=0.62 
0.9900 (0.9654 to 
1.0151), p=0.43 
0.9839 (0.9693 to 
0.9989), p=0.035 
CO 8-hr 
lag0 
1.5407 (0.9323 to 
2.5461), p=0.092 
2.7767 (1.5451 to 
4.9897), p=0.0006 
1.3386 (0.6802 to 
2.6343), p=0.40 
1.2845 (0.7714 to 
2.1388), p=0.34 
0.4708 (0.1950 to 
1.1365), p=0.094 
0.8095 (0.3938 to 
1.6642), p=0.57 
1.5834 (1.0025 to 
2.5008), p=0.049 
lag1 
1.2686 (0.7630 to 
2.1092), p=0.36 
1.6562 (0.9086 to 
3.0192), p=0.100 
1.1589 (0.5752 to 
2.3351), p=0.68 
1.1641 (0.6912 to 
1.9608), p=0.57 
0.6731 (0.2932 to 
1.5450), p=0.35 
0.7040 (0.3427 to 
1.4459), p=0.34 
1.2596 (0.7916 to 
2.0044), p=0.33 
lag2 
1.5223 (0.9179 to 
2.5245), p=0.10 
1.4512 (0.7972 to 
2.6416), p=0.22 
1.1550 (0.5763 to 
2.3149), p=0.68 
1.2208 (0.7202 to 
2.0693), p=0.46 
0.9836 (0.4286 to 
2.2574), p=0.97 
0.8661 (0.4185 to 
1.7924), p=0.70 
1.1934 (0.7480 to 
1.9040), p=0.46 
SO2 1-hr 
lag0 
0.9993 (0.9875 to 
1.0113), p=0.91 
0.9736 (0.9327 to 
1.0162), p=0.22 
0.9806 (0.9377 to 
1.0256), p=0.39 
1.0092 (0.9961 to 
1.0225), p=0.17 
0.9634 (0.9140 to 
1.0156), p=0.17 
1.0007 (0.9767 to 
1.0252), p=0.96 
1.0034 (0.9938 to 
1.0130), p=0.49 
lag1 
0.9974 (0.9856 to 
1.0093), p=0.66 
0.9900 (0.9584 to 
1.0225), p=0.54 
0.9922 (0.9491 to 
1.0373), p=0.73 
1.0051 (0.9925 to 
1.0178), p=0.43 
0.9995 (0.9669 to 
1.0332), p=0.98 
1.0017 (0.9838 to 
1.0199), p=0.86 
0.9975 (0.9873 to 
1.0079), p=0.63 
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Lag Day cough Day wheeze 
Day shortness of 
breath 
Day runny nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
lag2 
0.9939 (0.9810 to 
1.0069), p=0.35 
0.9577 (0.9194 to 
0.9976), p=0.038 
0.9866 (0.9482 to 
1.0266), p=0.51 
1.0068 (0.9928 to 
1.0210), p=0.34 
0.9208 (0.8535 to 
0.9933), p=0.033 
0.9765 (0.9462 to 
1.0078), p=0.14 
0.9925 (0.9809 to 
1.0042), p=0.21 
SO2 24-hr 
lag0 
1.0047 (0.9405 to 
1.0733), p=0.89 
0.8608 (0.7185 to 
1.0313), p=0.10 
0.9327 (0.7679 to 
1.1330), p=0.48 
1.0551 (0.9808 to 
1.1351), p=0.15 
0.9959 (0.8530 to 
1.1627), p=0.96 
0.9275 (0.8004 to 
1.0749), p=0.32 
1.0250 (0.9693 to 
1.0838), p=0.39 
lag1 
0.9634 (0.8934 to 
1.0389), p=0.33 
0.8705 (0.7374 to 
1.0275), p=0.10 
0.9225 (0.7358 to 
1.1567), p=0.48 
1.0413 (0.9654 to 
1.1232), p=0.29 
0.9675 (0.8120 to 
1.1529), p=0.71 
0.9665 (0.8599 to 
1.0862), p=0.57 
0.9860 (0.9256 to 
1.0503), p=0.66 
lag2 
0.9907 (0.9191 to 
1.0678), p=0.81 
0.7680 (0.6165 to 
0.9568), p=0.019 
0.9026 (0.7501 to 
1.0860), p=0.28 
1.0825 (0.9979 to 
1.1743), p=0.056 
0.8742 (0.6405 to 
1.1932), p=0.40 
0.8463 (0.7231 to 
0.9905), p=0.038 
0.9889 (0.9251 to 
1.0572), p=0.74 
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Table 2.11.  Associations between air pollutants and day time medication use 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM2.5 24-hr 
lag0 
0.9464 (0.8549 to 1.0478), 
p=0.29 
0.9475 (0.8186 to 1.0967), 
p=0.47 
0.9734 (0.8870 to 1.0682), 
p=0.57 
lag1 
0.9671 (0.8738 to 1.0703), 
p=0.52 
1.0494 (0.9014 to 1.2216), 
p=0.53 
1.0170 (0.9263 to 1.1166), 
p=0.72 
lag2 
0.9250 (0.8329 to 1.0273), 
p=0.15 
0.9841 (0.8408 to 1.1518), 
p=0.84 
0.9771 (0.8879 to 1.0752), 
p=0.63 
PM10 24-hr 
lag0 
1.0031 (0.9832 to 1.0235), 
p=0.76 
1.0060 (0.9797 to 1.0331), 
p=0.66 
0.9963 (0.9771 to 1.0160), 
p=0.71 
lag1 
1.0124 (0.9909 to 1.0345), 
p=0.26 
1.0206 (0.9913 to 1.0508), 
p=0.17 
1.0103 (0.9899 to 1.0311), 
p=0.33 
lag2 
1.0110 (0.9887 to 1.0338), 
p=0.34 
1.0335 (1.0012 to 1.0669), 
p=0.042 
1.0132 (0.9922 to 1.0347), 
p=0.22 
NO2 1-hr 
lag0 
1.0117 (0.9879 to 1.0361), 
p=0.34 
1.0088 (0.9739 to 1.0450), 
p=0.63 
1.0097 (0.9878 to 1.0321), 
p=0.39 
lag1 
1.0065 (0.9829 to 1.0306), 
p=0.59 
1.0173 (0.9816 to 1.0543), 
p=0.35 
1.0096 (0.9878 to 1.0320), 
p=0.39 
lag2 
1.0034 (0.9796 to 1.0278), 
p=0.78 
0.9905 (0.9542 to 1.0282), 
p=0.62 
1.0051 (0.9832 to 1.0274), 
p=0.65 
NO2 24-hr 
lag0 
1.0537 (1.0110 to 1.0983), 
p=0.013 
1.0339 (0.9714 to 1.1005), 
p=0.29 
1.0480 (1.0080 to 1.0897), 
p=0.018 
lag1 
1.0480 (1.0058 to 1.0920), 
p=0.025 
1.0430 (0.9797 to 1.1104), 
p=0.19 
1.0473 (1.0079 to 1.0883), 
p=0.018 
lag2 
1.0478 (1.0049 to 1.0925), 
p=0.029 
1.0410 (0.9763 to 1.1100), 
p=0.22 
1.0570 (1.0166 to 1.0990), 
p=0.005 
O3 1-hr 
lag0 
0.9887 (0.9682 to 1.0096), 
p=0.29 
1.0157 (0.9871 to 1.0452), 
p=0.29 
0.9925 (0.9732 to 1.0123), 
p=0.46 
lag1 
0.9959 (0.9752 to 1.0171), 
p=0.70 
1.0217 (0.9912 to 1.0531), 
p=0.16 
0.9999 (0.9802 to 1.0200), 
p=0.99 
lag2 
0.9854 (0.9638 to 1.0074), 
p=0.19 
0.9848 (0.9530 to 1.0177), 
p=0.36 
0.9840 (0.9631 to 1.0053), 
p=0.14 
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Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
O3 4-hr 
lag0 
0.9884 (0.9669 to 1.0104), 
p=0.30 
1.0180 (0.9879 to 1.0490), 
p=0.24 
0.9929 (0.9725 to 1.0137), 
p=0.50 
lag1 
0.9916 (0.9698 to 1.0139), 
p=0.46 
1.0163 (0.9847 to 1.0489), 
p=0.31 
0.9961 (0.9753 to 1.0174), 
p=0.72 
lag2 
0.9814 (0.9586 to 1.0047), 
p=0.12 
0.9846 (0.9515 to 1.0188), 
p=0.37 
0.9801 (0.9581 to 1.0027), 
p=0.084 
O3 8-hr 
lag0 
0.9858 (0.9628 to 1.0095), 
p=0.24 
1.0145 (0.9824 to 1.0477), 
p=0.38 
0.9900 (0.9681 to 1.0123), 
p=0.38 
lag1 
0.9838 (0.9601 to 1.0080), 
p=0.19 
1.0048 (0.9709 to 1.0399), 
p=0.79 
0.9887 (0.9663 to 1.0117), 
p=0.33 
lag2 
0.9751 (0.9501 to 1.0008), 
p=0.058 
0.9820 (0.9460 to 1.0194), 
p=0.34 
0.9748 (0.9507 to 0.9996), 
p=0.046 
CO 8-hr 
lag0 
1.2503 (0.6416 to 2.4365), 
p=0.51 
1.2708 (0.4472 to 3.6110), 
p=0.65 
1.3906 (0.7427 to 2.6037), 
p=0.30 
lag1 
1.1383 (0.5806 to 2.2318), 
p=0.71 
1.5484 (0.5742 to 4.1751), 
p=0.39 
1.4509 (0.7824 to 2.6907), 
p=0.24 
lag2 
1.4964 (0.7654 to 2.9257), 
p=0.24 
1.2664 (0.4780 to 3.3549), 
p=0.63 
1.8111 (0.9774 to 3.3557), 
p=0.059 
SO2 1-hr 
lag0 
0.9820 (0.9503 to 1.0147), 
p=0.28 
0.9921 (0.9530 to 1.0328), 
p=0.70 
1.8111 (0.9774 to 3.3557), 
p=0.059 
lag1 
0.9951 (0.9655 to 1.0255), 
p=0.75 
1.0178 (0.9888 to 1.0475), 
p=0.23 
1.0074 (0.9847 to 1.0306), 
p=0.53 
lag2 
0.9978 (0.9669 to 1.0297), 
p=0.89 
0.9441 (0.8827 to 1.0097), 
p=0.093 
0.9933 (0.9613 to 1.0265), 
p=0.69 
SO2 24-hr 
lag0 
0.9259 (0.7974 to 1.0751), 
p=0.31 
0.9962 (0.8375 to 1.1849), 
p=0.97 
0.9470 (0.8321 to 1.0779), 
p=0.41 
lag1 
0.9469 (0.8104 to 1.1063), 
p=0.49 
1.0256 (0.8695 to 1.2097), 
p=0.76 
0.9740 (0.8558 to 1.1085), 
p=0.69 
lag2 
0.9250 (0.7760 to 1.1025), 
p=0.38 
0.9632 (0.7259 to 1.2781), 
p=0.79 
0.9059 (0.7555 to 1.0862), 
p=0.29 
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2.4.2. Associations between ozone and lung function, symptoms and medication use in the 
warm season  
 
There were no adverse associations between ozone and lung function, symptoms and 
medication use in this sub-analysis (Table 2.12, Table 2.13, Table 2.14, Table 2.15). There were a 
few positive associations (beneficial effects) with night wheeze, that is, children experienced less 
wheeze symptoms during the night when ozone levels were high the previous day (Table 2.13). 
 
Table 2.12. Associations between warm season ozone and lung function 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
O3 1-hr 
lag0 
-0.0889 (-0.3522 to 
0.1743), p=0.51 
-0.0003 (-0.0022 to 
0.0016), p=0.75 
    
lag1 
-0.0390 (-0.2803 to 
0.2023), p=0.75 
-0.0006 (-0.0024 to 
0.0012), p=0.52 
-0.0073 (-0.2975 to 
0.2829), p=0.96 
0.0000 (-0.0018 to 
0.0019), p=0.96 
lag2 
0.1515 (-0.0980 to 
0.4011), p=0.23 
0.0005 (-0.0013 to 
0.0024), p=0.55 
0.0033 (-0.2891 to 
0.2957), p=0.98 
-0.0004 (-0.0023 to 
0.0014), p=0.64 
lag3     
-0.0792 (-0.3745 to 
0.2161), p=0.60 
0.0001 (-0.0017 to 
0.0019), p=0.88 
O3 4-hr 
lag0 
-0.1657 (-0.4680 to 
0.1366), p=0.28 
-0.0009 (-0.0031 to 
0.0012), p=0.40 
    
lag1 
-0.0091 (-0.2811 to 
0.2628), p=0.95 
-0.0001 (-0.0022 to 
0.0020), p=0.93 
0.0170 (-0.3116 to 
0.3456), p=0.92 
0.0001 (-0.0020 to 
0.0021), p=0.94 
lag2 
0.1953 (-0.0849 to 
0.4755), p=0.17 
0.0003 (-0.0017 to 
0.0023), p=0.78 
-0.0026 (-0.3302 to 
0.3251), p=0.99 
-0.0005 (-0.0025 to 
0.0016), p=0.64 
lag3     
-0.0512 (-0.3788 to 
0.2763), p=0.76 
0.0003 (-0.0017 to 
0.0023), p=0.75 
O3 8-hr 
lag0 
-0.1718 (-0.5828 to 
0.2392), p=0.41 
-0.0014 (-0.0041 to 
0.0013), p=0.31 
    
lag1 
0.0495 (-0.3137 to 
0.4128), p=0.79 
0.0005 (-0.0020 to 
0.0031), p=0.69 
0.0559 (-0.3518 to 
0.4635), p=0.79 
0.0005 (-0.0021 to 
0.0030), p=0.71 
lag2 
0.2832 (-0.0611 to 
0.6275), p=0.11 
0.0005 (-0.0021 to 
0.0032), p=0.69 
-0.0586 (-0.4664 to 
0.3491), p=0.78 
-0.0006 (-0.0032 to 
0.0019), p=0.63 
lag3     
0.0419 (-0.3708 to 
0.4546), p=0.84 
0.0003 (-0.0022 to 
0.0028), p=0.83 
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Table 2.13.  Associations between warm season ozone and night symptoms and 
medication use 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
O3 1-hr 
lag1 
0.9984 (0.9779 
to 1.0195), 
p=0.88 
0.9745 (0.9443 
to 1.0057), 
p=0.11 
0.9517 (0.9023 
to 1.0039), 
p=0.069 
0.9961 (0.9774 
to 1.0151), 
p=0.69 
0.9997 (0.9673 
to 1.0331), 
p=0.98 
lag2 
1.0088 (0.9871 
to 1.0309), 
p=0.43 
0.9874 (0.9528 
to 1.0233), 
p=0.49 
0.9623 (0.9069 
to 1.0211), 
p=0.20 
1.0142 (0.9942 
to 1.0346), 
p=0.17 
1.0004 (0.9668 
to 1.0352), 
p=0.98 
lag3 
1.0086 (0.9864 
to 1.0313), 
p=0.45 
0.9520 (0.9182 
to 0.9870), 
p=0.008 
0.9597 (0.9019 
to 1.0212), 
p=0.19 
0.9995 (0.9793 
to 1.0201), 
p=0.96 
1.0055 (0.9666 
to 1.0460), 
p=0.79 
O3 4-hr 
lag1 
0.9980 (0.9756 
to 1.0208), 
p=0.86 
0.9691 (0.9364 
to 1.0029), 
p=0.073 
0.9471 (0.8941 
to 1.0031), 
p=0.064 
0.9943 (0.9741 
to 1.0150), 
p=0.59 
0.9988 (0.9634 
to 1.0355), 
p=0.95 
lag2 
1.0098 (0.9861 
to 1.0340), 
p=0.42 
0.9837 (0.9464 
to 1.0226), 
p=0.41 
0.9594 (0.9001 
to 1.0227), 
p=0.20 
1.0134 (0.9917 
to 1.0356), 
p=0.23 
1.0024 (0.9652 
to 1.0410), 
p=0.90 
lag3 
1.0107 (0.9866 
to 1.0355), 
p=0.39 
0.9466 (0.9097 
to 0.9849), 
p=0.007 
0.9546 (0.8926 
to 1.0209), 
p=0.17 
1.0013 (0.9793 
to 1.0238), 
p=0.91 
1.0086 (0.9654 
to 1.0537), 
p=0.70 
O3 8-hr 
lag1 
0.9968 (0.9701 
to 1.0242), 
p=0.82 
0.9573 (0.9192 
to 0.9971), 
p=0.036 
0.9512 (0.8906 
to 1.0159), 
p=0.14 
0.9932 (0.9693 
to 1.0176), 
p=0.58 
0.9975 (0.9559 
to 1.0410), 
p=0.91 
lag2 
1.0068 (0.9787 
to 1.0357), 
p=0.64 
0.9768 (0.9342 
to 1.0214), 
p=0.30 
0.9711 (0.9028 
to 1.0446), 
p=0.43 
1.0111 (0.9857 
to 1.0371), 
p=0.39 
0.9972 (0.9532 
to 1.0432), 
p=0.90 
lag3 
1.0154 (0.9867 
to 1.0449), 
p=0.30 
0.9369 (0.8942 
to 0.9817), 
p=0.006 
0.9568 (0.8852 
to 1.0342), 
p=0.27 
1.0051 (0.9793 
to 1.0317), 
p=0.70 
1.0093 (0.9589 
to 1.0623), 
p=0.72 
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Table 2.14.  Associations between warm season ozone and day time symptoms 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
O3 1-hr 
lag0 
0.9863 
(0.9676 to 
1.0054), 
p=0.16 
0.9993 
(0.9717 to 
1.0276), 
p=0.96 
1.0250 
(0.9912 to 
1.0601), 
p=0.15 
1.0111 
(0.9905 to 
1.0321), 
p=0.29 
0.9846 
(0.9509 to 
1.0194), 
p=0.38 
1.0030 
(0.9736 to 
1.0334), 
p=0.84 
0.9982 
(0.9824 to 
1.0142), 
p=0.82 
lag1 
0.9974 
(0.9771 to 
1.0180), 
p=0.80 
0.9864 
(0.9586 to 
1.0150), 
p=0.35 
0.9918 
(0.9552 to 
1.0298), 
p=0.67 
1.0022 
(0.9809 to 
1.0239), 
p=0.84 
0.9957 
(0.9622 to 
1.0305), 
p=0.81 
1.0186 
(0.9883 to 
1.0497), 
p=0.23 
1.0020 
(0.9854 to 
1.0188), 
p=0.82 
lag2 
1.0002 
(0.9788 to 
1.0221), 
p=0.98 
0.9831 
(0.9522 to 
1.0150), 
p=0.29 
0.9827 
(0.9459 to 
1.0209), 
p=0.37 
1.0140 
(0.9917 to 
1.0368), 
p=0.22 
1.0223 
(0.9808 to 
1.0655), 
p=0.30 
1.0141 
(0.9808 to 
1.0486), 
p=0.41 
1.0002 
(0.9830 to 
1.0176), 
p=0.99 
O3 4-hr 
lag0 
0.9845 
(0.9641 to 
1.0054), 
p=0.14 
0.9968 
(0.9674 to 
1.0272), 
p=0.84 
1.0269 
(0.9903 to 
1.0649), 
p=0.15 
1.0125 
(0.9902 to 
1.0353), 
p=0.28 
0.9897 
(0.9534 to 
1.0273), 
p=0.58 
1.0071 
(0.9750 to 
1.0403), 
p=0.67 
0.9977 
(0.9805 to 
1.0152), 
p=0.80 
lag1 
0.9956 
(0.9736 to 
1.0181), 
p=0.70 
0.9841 
(0.9544 to 
1.0147), 
p=0.30 
0.9889 
(0.9494 to 
1.0301), 
p=0.59 
1.0027 
(0.9797 to 
1.0261), 
p=0.82 
0.9987 
(0.9622 to 
1.0365), 
p=0.94 
1.0224 
(0.9896 to 
1.0562), 
p=0.18 
1.0008 
(0.9829 to 
1.0191), 
p=0.93 
lag2 
0.9973 
(0.9740 to 
1.0211), 
p=0.82 
0.9839 
(0.9508 to 
1.0182), 
p=0.35 
0.9824 
(0.9421 to 
1.0244), 
p=0.40 
1.0173 
(0.9930 to 
1.0422), 
p=0.16 
1.0244 
(0.9794 to 
1.0715), 
p=0.29 
1.0195 
(0.9832 to 
1.0571), 
p=0.30 
0.9988 
(0.9801 to 
1.0179), 
p=0.90 
O3 8-hr 
lag0 
0.9826 
(0.9585 to 
1.0074), 
p=0.17 
0.9988 
(0.9648 to 
1.0341), 
p=0.95 
1.0372 
(0.9933 to 
1.0830), 
p=0.098 
1.0226 
(0.9958 to 
1.0500), 
p=0.099 
0.9899 
(0.9479 to 
1.0337), 
p=0.65 
1.0202 
(0.9817 to 
1.0603), 
p=0.31 
1.0017 
(0.9814 to 
1.0224), 
p=0.87 
lag1 
0.9909 
(0.9652 to 
1.0173), 
p=0.50 
0.9820 
(0.9480 to 
1.0173), 
p=0.31 
0.9858 
(0.9398 to 
1.0341), 
p=0.56 
1.0059 
(0.9790 to 
1.0336), 
p=0.67 
0.9966 
(0.9543 to 
1.0408), 
p=0.88 
1.0352 
(0.9964 to 
1.0755), 
p=0.076 
1.0018 
(0.9807 to 
1.0234), 
p=0.87 
lag2 
0.9898 
(0.9626 to 
1.0178), 
p=0.47 
0.9821 
(0.9440 to 
1.0218), 
p=0.37 
0.9775 
(0.9293 to 
1.0282), 
p=0.38 
1.0270 
(0.9979 to 
1.0568), 
p=0.069 
1.0301 
(0.9789 to 
1.0840), 
p=0.25 
1.0279 
(0.9859 to 
1.0717), 
p=0.20 
0.9988 
(0.9767 to 
1.0214), 
p=0.92 
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Table 2.15.  Associations between warm season ozone and day time medication use 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
O3 1-hr 
lag0 
0.9968 (0.9672 to 1.0273), 
p=0.83 
1.0196 (0.9781 to 1.0628), 
p=0.36 
1.0020 (0.9735 to 1.0313), 
p=0.89 
lag1 
1.0018 (0.9716 to 1.0329), 
p=0.91 
1.0171 (0.9736 to 1.0625), 
p=0.45 
1.0132 (0.9836 to 1.0437), 
p=0.38 
lag2 
0.9844 (0.9522 to 1.0176), 
p=0.35 
0.9863 (0.9390 to 1.0361), 
p=0.58 
0.9846 (0.9529 to 1.0172), 
p=0.35 
O3 4-hr 
lag0 
0.9969 (0.9649 to 1.0301), 
p=0.85 
1.0222 (0.9772 to 1.0693), 
p=0.34 
1.0031 (0.9723 to 1.0349), 
p=0.84 
lag1 
0.9986 (0.9662 to 1.0322), 
p=0.94 
1.0164 (0.9697 to 1.0654), 
p=0.50 
1.0126 (0.9807 to 1.0455), 
p=0.44 
lag2 
0.9818 (0.9468 to 1.0182), 
p=0.32 
0.9905 (0.9387 to 1.0452), 
p=0.73 
0.9831 (0.9485 to 1.0189), 
p=0.35 
O3 8-hr 
lag0 
1.0036 (0.9663 to 1.0423), 
p=0.85 
1.0248 (0.9732 to 1.0792), 
p=0.35 
1.0066 (0.9707 to 1.0438), 
p=0.72 
lag1 
0.9933 (0.9559 to 1.0321), 
p=0.73 
1.0077 (0.9560 to 1.0622), 
p=0.77 
1.0099 (0.9735 to 1.0478), 
p=0.60 
lag2 
0.9725 (0.9315 to 1.0154), 
p=0.21 
0.9933 (0.9335 to 1.0571), 
p=0.83 
0.9791 (0.9386 to 1.0214), 
p=0.33 
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2.4.3. Associations between SO2 and lung function, symptoms and medication use after 
excluding children from Port Pirie 
 
A significant negative association is now seen between 1-hr SO2 and morning PEF (Table 2.16). 
There was no association for night time symptoms (Table 2.17).  The beneficial effects on day 
time symptoms are no longer apparent when children from Port Pirie were excluded from the 
analyses (Table 2.18). In fact, there are now adverse effects especially with cough and runny 
nose. Children also tended to use more day time preventer medication for symptoms on days 
with higher 1-hr SO2 levels (Table 2.19).   
 
Table 2.16.  Associations between SO2 and lung function after excluding children from 
Port Pirie 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
SO2 1-hr 
lag0 
0.1918 (-0.5797 to 
0.9633), p=0.63 
-0.0010 (-0.0063 to 
0.0043), p=0.72 
    
lag1 
-0.1427 (-0.8951 to 
0.6096), p=0.71 
0.0014 (-0.0039 to 
0.0066), p=0.61 
0.2526 (-0.2815 to 
0.7868), p=0.35 
0.0015 (-0.0020 to 
0.0051), p=0.40 
lag2 
0.0179 (-0.7337 to 
0.7695), p=0.96 
-0.0007 (-0.0059 to 
0.0046), p=0.81 
0.1762 (-0.3372 to 
0.6896), p=0.50 
0.0014 (-0.0020 to 
0.0047), p=0.43 
lag3     
-0.6132 (-1.1394 to  
-0.0871), p=0.022 
-0.0034 (-0.0069 to 
0.0001), p=0.057 
SO2 24-hr 
lag0 
0.3566 (-2.9728 to 
3.6860), p=0.83 
-0.0110 (-0.0339 to 
0.0119), p=0.35 
    
lag1 
-0.8262 (-4.0907 to 
2.4383), p=0.62 
0.0088 (-0.0140 to 
0.0316), p=0.45 
0.3566 (-1.9700 to 
2.6832), p=0.76 
-0.0022 (-0.0177 to 
0.0134), p=0.78 
lag2 
-0.1299 (-3.5071 to 
3.2473), p=0.94 
-0.0031 (-0.0266 to 
0.0204), p=0.80 
0.7237 (-1.6062 to 
3.0536), p=0.54 
0.0067 (-0.0086 to 
0.0221), p=0.39 
lag3     
-2.3497 (-4.7141 to 
0.0146), p=0.051 
-0.0139 (-0.0297 to 
0.0018), p=0.083 
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Table 2.17.  Associations between SO2 and night symptoms and medication use after 
excluding children from Port Pirie 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
SO2 1-hr 
lag1 
1.0124 (0.9764 
to 1.0498), 
p=0.50 
1.0082 (0.9575 
to 1.0615), 
p=0.76 
0.9844 (0.9039 
to 1.0720), 
p=0.72 
1.0118 (0.9774 
to 1.0473), 
p=0.51 
1.0161 (0.9617 
to 1.0735), 
p=0.57 
lag2 
1.0049 (0.9677 
to 1.0435), 
p=0.80 
1.0219 (0.9697 
to 1.0769), 
p=0.42 
1.0093 (0.9299 
to 1.0955), 
p=0.82 
1.0236 (0.9881 
to 1.0603), 
p=0.20 
1.0237 (0.9705 
to 1.0798), 
p=0.39 
lag3 
1.0068 (0.9682 
to 1.0470), 
p=0.73 
0.9771 (0.9179 
to 1.0400), 
p=0.47 
0.9577 (0.8710 
to 1.0530), 
p=0.37 
1.0019 (0.9648 
to 1.0405), 
p=0.92 
0.9901 (0.9274 
to 1.0570), 
p=0.76 
SO2 24-hr 
lag1 
0.9884 (0.8380 
to 1.1657), 
p=0.89 
1.0129 (0.7995 
to 1.2833), 
p=0.92 
0.9029 (0.6232 
to 1.3081), 
p=0.59 
0.9933 (0.8484 
to 1.1629), 
p=0.93 
1.0070 (0.7790 
to 1.3018), 
p=0.96 
lag2 
0.9977 (0.8422 
to 1.1819), 
p=0.98 
1.1035 (0.8710 
to 1.3981), 
p=0.41 
0.9723 (0.6733 
to 1.4040), 
p=0.88 
1.0977 (0.9359 
to 1.2874), 
p=0.25 
1.1241 (0.8728 
to 1.4476), 
p=0.36 
lag3 
0.9648 (0.8115 
to 1.1471), 
p=0.69 
0.8261 (0.6334 
to 1.0774), 
p=0.16 
0.8321 (0.5652 
to 1.2248), 
p=0.35 
0.9370 (0.7928 
to 1.1075), 
p=0.45 
0.9228 (0.6884 
to 1.2372), 
p=0.59 
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Table 2.18.  Associations between SO2 and day time symptoms after excluding children 
from Port Pirie 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
SO2 1-hr 
lag0 
1.0405 
(1.0053 to 
1.0769), 
p=0.024 
0.9830 
(0.9338 to 
1.0347), 
p=0.51 
0.9991 
(0.9412 to 
1.0606), 
p=0.98 
1.0323 
(0.9976 to 
1.0683), 
p=0.068 
1.0182 
(0.9571 to 
1.0831), 
p=0.57 
0.9693 
(0.9198 to 
1.0215), 
p=0.24 
1.0289 
(0.9992 to 
1.0596), 
p=0.056 
lag1 
1.0155 
(0.9786 to 
1.0538), 
p=0.42 
1.0175 
(0.9667 to 
1.0710), 
p=0.51 
1.0075 
(0.9416 to 
1.0780), 
p=0.83 
1.0428 
(1.0047 to 
1.0823), 
p=0.027 
1.0504 
(0.9845 to 
1.1206), 
p=0.14 
0.9889 
(0.9396 to 
1.0408), 
p=0.67 
1.0437 
(1.0105 to 
1.0780), 
p=0.010 
lag2 
1.0191 
(0.9809 to 
1.0588), 
p=0.33 
0.9577 
(0.9018 to 
1.0170), 
p=0.16 
1.0187 
(0.9581 to 
1.0832), 
p=0.55 
1.0311 
(0.9949 to 
1.0685), 
p=0.093 
0.9865 
(0.9096 to 
1.0698), 
p=0.74 
0.9717 
(0.9194 to 
1.0270), 
p=0.31 
1.0030 
(0.9720 to 
1.0350), 
p=0.85 
SO2 24-hr 
lag0 
1.1816 
(1.0145 to 
1.3764), 
p=0.032 
0.9593 
(0.7620 to 
1.2077), 
p=0.72 
1.0304 
(0.7973 to 
1.3317), 
p=0.82 
1.1779 
(1.0117 to 
1.3714), 
p=0.035 
1.2340 
(0.9427 to 
1.6153), 
p=0.13 
0.8708 
(0.6914 to 
1.0967), 
p=0.24 
1.1261 
(0.9890 to 
1.2821), 
p=0.073 
lag1 
1.0290 
(0.8720 to 
1.2142), 
p=0.74 
1.0108 
(0.7985 to 
1.2797), 
p=0.93 
1.0140 
(0.7497 to 
1.3714), 
p=0.93 
1.2176 
(1.0312 to 
1.4377), 
p=0.020 
1.1907 
(0.8882 to 
1.5962), 
p=0.24 
0.9202 
(0.7279 to 
1.1634), 
p=0.49 
1.1629 
(1.0085 to 
1.3408), 
p=0.038 
lag2 
1.0072 
(0.8499 to 
1.1936), 
p=0.93 
0.7745 
(0.5939 to 
1.0100), 
p=0.059 
1.0773 
(0.8155 to 
1.4233), 
p=0.60 
1.1474 
(0.9785 to 
1.3455), 
p=0.090 
0.9007 
(0.6366 to 
1.2745), 
p=0.55 
0.8416 
(0.6589 to 
1.0749), 
p=0.17 
0.9714 
(0.8444 to 
1.1174), 
p=0.68 
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Table 2.19.  Associations between SO2 and day time medication use after excluding 
children from Port Pirie 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
SO2 1-hr 
lag0 
1.0154 (0.9661 to 1.0673), 
p=0.55 
1.0256 (0.9538 to 1.1029), 
p=0.49 
1.0133 (0.9655 to 1.0636), 
p=0.59 
lag1 
1.0312 (0.9813 to 1.0837), 
p=0.22 
1.0792 (1.0057 to 1.1581), 
p=0.034 
1.0366 (0.9877 to 1.0879), 
p=0.14 
lag2 
1.0283 (0.9766 to 1.0827), 
p=0.29 
1.0382 (0.9607 to 1.1220), 
p=0.34 
1.0203 (0.9696 to 1.0735), 
p=0.44 
SO2 24-hr 
lag0 
1.0602 (0.8468 to 1.3274), 
p=0.61 
1.0686 (0.7697 to 1.4836), 
p=0.69 
1.0622 (0.8531 to 1.3225), 
p=0.59 
lag1 
1.0977 (0.8741 to 1.3786), 
p=0.42 
1.2795 (0.9223 to 1.7751), 
p=0.14 
1.1418 (0.9143 to 1.4259), 
p=0.24 
lag2 
1.0278 (0.8115 to 1.3017), 
p=0.82 
0.9953 (0.7033 to 1.4084), 
p=0.98 
0.9925 (0.7860 to 1.2532), 
p=0.95 
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2.4.4. Associations between SO2 and lung function, symptoms and medication use in two 
pollutant models with PM10 
 
In these two pollutant models with PM10, the SO2 effects were similar to the effect estimates 
from single pollutant models (Table 2.20, Table 2.21, Table 2.22, Table 2.23). Three estimates that 
were significant in the single pollutant models were no longer significant in the two pollutant 
models (lag 2 SO2 24-hr and morning PEF and FEV1; lag 2 SO2 1-hr and night shortness of 
breath).  
 
One estimate that was non-significant in the single pollutant model was significant in the two 
pollutant model (lag 1 SO2 24-hr and day wheeze); however, the OR were similar (OR single 
pollutant model=0.8705, 95%CI: 0.7374-1.0275; OR two pollutant model=0.8131, 95%CI: 0.6681-
0.9896) (Table 2.22). 
 
 
Table 2.20.  Associations between SO2 and lung function in two pollutant models with 
PM10  
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
SO2 1-hr 
lag0 
0.2929 (-0.0282 to 
0.6140), p=0.074 
0.0012 (-0.0010 to 
0.0034), p=0.28 
    
lag1 
-0.0408 (-0.3117 to 
0.2301), p=0.77 
0.0006 (-0.0013 to 
0.0024), p=0.53 
0.0257 (-0.1738 to 
0.2252), p=0.80 
0.0002 (-0.0012 to 
0.0015), p=0.83 
lag2 
-0.0282 (-0.2986 to 
0.2423), p=0.84 
-0.0013 (-0.0031 to 
0.0006), p=0.19 
-0.0263 (-0.2469 to 
0.1942), p=0.81 
-0.0011 (-0.0026 to 
0.0004), p=0.14 
lag3     
-0.1879 (-0.3893 to 
0.0134), p=0.067 
-0.0011 (-0.0024 to 
0.0003), p=0.12 
SO2 24-hr 
lag0 
1.6946 (0.1918 to 
3.1973), p=0.027 
0.0057 (-0.0046 to 
0.0161), p=0.28 
    
lag1 
-0.7056 (-2.2275 to 
0.8163), p=0.36 
0.0050 (-0.0054 to 
0.0154), p=0.34 
-0.7361 (-1.8649 to 
0.3926), p=0.20 
-0.0051 (-0.0127 to 
0.0025), p=0.18 
lag2 
0.1860 (-1.2380 to 
1.6100), p=0.80 
-0.0023 (-0.0121 to 
0.0075), p=0.64 
0.5679 (-0.5765 to 
1.7123), p=0.33 
0.0022 (-0.0056 to 
0.0100), p=0.57 
lag3     
-0.8858 (-2.0003 to 
0.2287), p=0.12 
-0.0051 (-0.0126 to 
0.0024), p=0.18 
 
 
 
 107 
 
 
Table 2.21.  Associations between SO2 and night symptoms and medication use in two 
pollutant models with PM10 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
SO2 1-hr 
lag1 
1.0031 (0.9890 
to 1.0174), 
p=0.67 
1.0038 (0.9807 
to 1.0274), 
p=0.75 
0.9839 (0.9109 
to 1.0627), 
p=0.68 
1.0043 (0.9911 
to 1.0176), 
p=0.53 
1.0247 (1.0021 
to 1.0478), 
p=0.032 
lag2 
0.9894 (0.9728 
to 1.0061), 
p=0.21 
1.0109 (0.9854 
to 1.0371), 
p=0.41 
0.9956 (0.9508 
to 1.0426), 
p=0.85 
0.9980 (0.9831 
to 1.0130), 
p=0.79 
1.0237 (1.0027 
to 1.0453), 
p=0.027 
lag3 
1.0035 (0.9913 
to 1.0159), 
p=0.57 
1.0061 (0.9836 
to 1.0290), 
p=0.60 
0.9624 (0.8912 
to 1.0393), 
p=0.33 
1.0043 (0.9924 
to 1.0163), 
p=0.48 
0.9947 (0.9681 
to 1.0220), 
p=0.70 
SO2 24-hr 
lag1 
0.9575 (0.8802 
to 1.0415), 
p=0.31 
0.9869 (0.8635 
to 1.1278), 
p=0.85 
0.8515 (0.6110 
to 1.1866), 
p=0.34 
0.9694 (0.8967 
to 1.0480), 
p=0.43 
1.0990 (0.9583 
to 1.2604), 
p=0.18 
lag2 
0.9232 (0.8468 
to 1.0065), 
p=0.070 
1.0045 (0.8726 
to 1.1564), 
p=0.95 
0.8943 (0.6734 
to 1.1877), 
p=0.44 
0.9606 (0.8880 
to 1.0391), 
p=0.32 
1.0742 (0.9452 
to 1.2208), 
p=0.27 
lag3 
1.0093 (0.9435 
to 1.0797), 
p=0.79 
0.9434 (0.8040 
to 1.1070), 
p=0.48 
0.6138 (0.4186 
to 0.9000), 
p=0.012 
1.0071 (0.9430 
to 1.0756), 
p=0.83 
0.9099 (0.7890 
to 1.0494), 
p=0.19 
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Table 2.22.  Associations between SO2 and day time symptoms in two pollutant models 
with PM10 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
SO2 1-hr 
lag0 
0.9979 
(0.9856 to 
1.0104), 
p=0.74 
0.9674 
(0.9236 to 
1.0132), 
p=0.16 
0.9847 
(0.9426 to 
1.0288), 
p=0.49 
1.0071 
(0.9933 to 
1.0210), 
p=0.32 
0.9847 
(0.9446 to 
1.0266), 
p=0.47 
0.9997 
(0.9749 to 
1.0251), 
p=0.98 
1.0026 
(0.9929 to 
1.0125), 
p=0.60 
lag1 
1.0019 
(0.9894 to 
1.0146), 
p=0.76 
0.9798 
(0.9406 to 
1.0207), 
p=0.33 
0.9960 
(0.9583 to 
1.0352), 
p=0.84 
1.0117 
(0.9998 to 
1.0238), 
p=0.054 
1.0054 
(0.9750 to 
1.0367), 
p=0.73 
1.0046 
(0.9863 to 
1.0233), 
p=0.62 
1.0064 
(0.9965 to 
1.0164), 
p=0.20 
lag2 
0.9974 
(0.9846 to 
1.0104), 
p=0.70 
0.9531 
(0.9085 to 
0.9999), 
p=0.049 
0.9808 
(0.9404 to 
1.0229), 
p=0.37 
1.0061 
(0.9926 to 
1.0198), 
p=0.37 
0.9768 
(0.9254 to 
1.0311), 
p=0.40 
0.9859 
(0.9618 to 
1.0107), 
p=0.26 
0.9984 
(0.9875 to 
1.0093), 
p=0.77 
SO2 24-hr 
lag0 
0.9905 
(0.9247 to 
1.0610), 
p=0.79 
0.8314 
(0.6833 to 
1.0116), 
p=0.065 
0.9515 
(0.7846 to 
1.1538), 
p=0.61 
1.0352 
(0.9587 to 
1.1177), 
p=0.38 
0.9724 
(0.8243 to 
1.1471), 
p=0.74 
0.9166 
(0.7852 to 
1.0700), 
p=0.27 
1.0145 
(0.9581 to 
1.0743), 
p=0.62 
lag1 
0.9580 
(0.8904 to 
1.0308), 
p=0.25 
0.8131 
(0.6681 to 
0.9896), 
p=0.039 
0.9332 
(0.7625 to 
1.1421), 
p=0.50 
1.0434 
(0.9686 to 
1.1240), 
p=0.26 
0.9731 
(0.8213 to 
1.1530), 
p=0.75 
1.0067 
(0.8991 to 
1.1272), 
p=0.91 
0.9900 
(0.9319 to 
1.0517), 
p=0.74 
lag2 
0.9984 
(0.9358 to 
1.0652), 
p=0.96 
0.7317 
(0.5829 to 
0.9186), 
p=0.007 
0.9127 
(0.7592 to 
1.0973), 
p=0.33 
1.0463 
(0.9730 to 
1.1251), 
p=0.22 
0.9396 
(0.7610 to 
1.1601), 
p=0.56 
0.8811 
(0.7705 to 
1.0076), 
p=0.064 
0.9951 
(0.9400 to 
1.0534), 
p=0.87 
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Table 2.23.  Associations between SO2 and day time medication use in two pollutant 
models with PM10 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
SO2 1-hr 
lag0 
0.9791 (0.9362 to 1.0241), 
p=0.36 
0.9936 (0.9608 to 1.0276), 
p=0.71 
0.9854 (0.9577 to 1.0140), 
p=0.31 
lag1 
1.0074 (0.9813 to 1.0343), 
p=0.58 
1.0095 (0.9805 to 1.0395), 
p=0.52 
1.0139 (0.9941 to 1.0341), 
p=0.17 
lag2 
0.9912 (0.9621 to 1.0213), 
p=0.56 
0.9950 (0.9643 to 1.0267), 
p=0.75 
0.9994 (0.9748 to 1.0246), 
p=0.96 
SO2 24-hr 
lag0 
0.9141 (0.7824 to 1.0679), 
p=0.26 
0.9901 (0.8301 to 1.1810), 
p=0.91 
0.9432 (0.8260 to 1.0770), 
p=0.39 
lag1 
0.9859 (0.8576 to 1.1333), 
p=0.84 
1.0009 (0.8529 to 1.1744), 
p=0.99 
1.0038 (0.8932 to 1.1280), 
p=0.95 
lag2 
0.8813 (0.7428 to 1.0455), 
p=0.15 
0.9213 (0.7732 to 1.0978), 
p=0.36 
0.9301 (0.8198 to 1.0552), 
p=0.26 
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2.4.5. Associations between NO2 and lung function, symptoms and medication use in two 
pollutant models with ozone 
 
There were far fewer significant associations for NO2 when ozone was included in the models. 
Many of the effects of NO2 on symptoms and medication that were observed in single pollutant 
models were no longer apparent when ozone was included in two pollutant models.  
 
In two pollutant models compared to single pollutant models, the effects on the lung function 
were increased whereas the effects on symptoms slightly decreased. Further, in the two 
pollutant models compared to single pollutant models, there were no longer any significant 
effects on day time medication use. 
 
Associations between NO2 and lung function, symptoms and medication use when ozone was 
included in the models are presented in Table 2.24, Table 2.25, Table 2.26, Table 2.27 for 1-hr 
ozone, Table 2.28, Table 2.29, Table 2.30, Table 2.31 for 4-hr ozone and Table 2.32, Table 2.33, 
Table 2.34, Table 2.35 for 8-hr ozone. 
 
2.4.5.1. Associations between NO2 and lung function, symptoms and 
medication use in two pollutant models with 1-hour ozone 
 
Table 2.24.  Associations between NO2 and lung function in two pollutant models with 1-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
NO2 1-hr 
lag0 
0.0614 (-0.3823 to 
0.5051), p=0.79 
-0.0002 (-0.0032 to 
0.0027), p=0.89 
    
lag1 
0.1370 (-0.3030 to 
0.5769), p=0.54 
0.0013 (-0.0016 to 
0.0042), p=0.38 
0.2729 (-0.0492 to 
0.5951), p=0.097 
0.0022 (-0.0000 to 
0.0045), p=0.050 
lag2 
0.0327 (-0.4360 to 
0.5013), p=0.89 
-0.0002 (-0.0033 to 
0.0030), p=0.92 
-0.4042 (-0.7318 to -
0.0767), p=0.016 
-0.0025 (-0.0047 to -
0.0002), p=0.031 
lag3     
0.3025 (-0.0521 to 
0.6571), p=0.094 
0.0007 (-0.0017 to 
0.0032), p=0.56 
NO2 24-hr 
lag0 
0.3493 (-0.6369 to 
1.3355), p=0.49 
0.0007 (-0.0058 to 
0.0073), p=0.83 
    
lag1 
0.2638 (-0.7250 to 
1.2526), p=0.60 
0.0035 (-0.0031 to 
0.0101), p=0.30 
0.0434 (-0.6808 to 
0.7677), p=0.91 
-0.0016 (-0.0066 to 
0.0034), p=0.53 
lag2 
0.2870 (-0.6955 to 
1.2694), p=0.57 
0.0006 (-0.0060 to 
0.0073), p=0.85 
-0.3414 (-1.0614 to 
0.3786), p=0.35 
-0.0027 (-0.0077 to 
0.0022), p=0.28 
lag3     -0.1246 (-0.8626 to -0.0031 (-0.0082 to 
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0.6134), p=0.74 0.0020), p=0.24 
 
 
Table 2.25.  Associations between NO2 and night symptoms and medication use in two 
pollutant models with 1-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
NO2 1-hr 
lag1 
1.0020 (0.9801 
to 1.0244), 
p=0.86 
1.0107 (0.9798 
to 1.0426), 
p=0.50 
0.9928 (0.9440 
to 1.0441), 
p=0.78 
1.0049 (0.9849 
to 1.0254), 
p=0.63 
0.9988 (0.9637 
to 1.0350), 
p=0.95 
lag2 
1.0141 (0.9926 
to 1.0361), 
p=0.20 
1.0120 (0.9815 
to 1.0435), 
p=0.45 
0.9642 (0.9166 
to 1.0142), 
p=0.16 
1.0112 (0.9915 
to 1.0312), 
p=0.27 
0.9920 (0.9580 
to 1.0272), 
p=0.65 
lag3 
1.0121 (0.9905 
to 1.0342), 
p=0.28 
1.0104 (0.9785 
to 1.0434), 
p=0.53 
0.9772 (0.9278 
to 1.0292), 
p=0.38 
1.0115 (0.9915 
to 1.0320), 
p=0.26 
1.0061 (0.9715 
to 1.0419), 
p=0.73 
NO2 24-hr 
lag1 
1.0146 (0.9705 
to 1.0608), 
p=0.52 
1.0634 (0.9990 
to 1.1319), 
p=0.054 
1.0011 (0.9112 
to 1.0999), 
p=0.98 
1.0100 (0.9690 
to 1.0526), 
p=0.64 
1.0137 (0.9459 
to 1.0864), 
p=0.70 
lag2 
1.0326 (0.9882 
to 1.0790), 
p=0.15 
1.0369 (0.9746 
to 1.1032), 
p=0.25 
0.9828 (0.8944 
to 1.0798), 
p=0.72 
1.0254 (0.9846 
to 1.0678), 
p=0.23 
1.0084 (0.9417 
to 1.0798), 
p=0.81 
lag3 
1.0447 (1.0015 
to 1.0898), 
p=0.042 
1.0409 (0.9805 
to 1.1051), 
p=0.19 
0.9494 (0.8657 
to 1.0412), 
p=0.27 
1.0301 (0.9906 
to 1.0712), 
p=0.14 
1.0203 (0.9541 
to 1.0911), 
p=0.56 
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Table 2.26.  Associations between NO2 and day time symptoms in two pollutant models 
with 1-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
 Day 
fever 
Any day 
symptoms 
NO2 1-hr 
lag0 
1.0046 
(0.9851 to 
1.0246), 
p=0.64 
1.0155 
(0.9872 to 
1.0445), 
p=0.29 
1.0161 
(0.9817 to 
1.0517), 
p=0.36 
0.9896 
(0.9699 to 
1.0096), 
p=0.31 
0.9833 
(0.9526 to 
1.0149), 
p=0.30 
0.9888 
(0.9595 to 
1.0189), 
p=0.46 
0.9942 
(0.9778 to 
1.0108), 
p=0.49 
lag1 
1.0037 
(0.9853 to 
1.0225), 
p=0.69 
1.0070 
(0.9799 to 
1.0347), 
p=0.62 
1.0138 
(0.9804 to 
1.0483), 
p=0.42 
0.9950 
(0.9763 to 
1.0141), 
p=0.61 
0.9804 
(0.9516 to 
1.0102), 
p=0.19 
0.9798 
(0.9523 to 
1.0081), 
p=0.16 
0.9920 
(0.9765 to 
1.0078), 
p=0.32 
lag2 
1.0048 
(0.9859 to 
1.0241), 
p=0.62 
0.9917 
(0.9647 to 
1.0194), 
p=0.55 
0.9835 
(0.9514 to 
1.0167), 
p=0.33 
0.9822 
(0.9635 to 
1.0013), 
p=0.068 
0.9832 
(0.9540 to 
1.0133), 
p=0.27 
0.9769 
(0.9488 to 
1.0059), 
p=0.12 
0.9921 
(0.9762 to 
1.0082), 
p=0.34 
NO2 24-hr 
lag0 
1.0216 
(0.9811 to 
1.0638), 
p=0.30 
1.0722 
(1.0130 to 
1.1348), 
p=0.016 
1.0434 
(0.9762 to 
1.1152), 
p=0.21 
0.9929 
(0.9518 to 
1.0358), 
p=0.74 
0.9731 
(0.9076 to 
1.0432), 
p=0.44 
0.9719 
(0.9137 to 
1.0338), 
p=0.37 
1.0033 
(0.9688 to 
1.0391), 
p=0.85 
lag1 
1.0128 
(0.9737 to 
1.0535), 
p=0.53 
1.0360 
(0.9807 to 
1.0944), 
p=0.21 
1.0245 
(0.9608 to 
1.0925), 
p=0.46 
0.9913 
(0.9516 to 
1.0326), 
p=0.67 
0.9467 
(0.8835 to 
1.0144), 
p=0.12 
0.9545 
(0.8987 to 
1.0137), 
p=0.13 
0.9908 
(0.9579 to 
1.0249), 
p=0.59 
lag2 
1.0191 
(0.9807 to 
1.0589), 
p=0.34 
0.9961 
(0.9448 to 
1.0501), 
p=0.88 
1.0200 
(0.9585 to 
1.0856), 
p=0.53 
0.9764 
(0.9385 to 
1.0158), 
p=0.24 
0.9597 
(0.8982 to 
1.0254), 
p=0.22 
0.9661 
(0.9114 to 
1.0241), 
p=0.25 
0.9916 
(0.9594 to 
1.0248), 
p=0.62 
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Table 2.27. Associations between NO2 and day time medication use in two pollutant models 
with 1-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
NO2 1-hr 
lag0 
1.0057 (0.9761 to 1.0363), 
p=0.71 
0.9720 (0.9286 to 1.0174), 
p=0.22 
1.0000 (0.9722 to 1.0286), 
p=1.00 
lag1 
1.0071 (0.9787 to 1.0363), 
p=0.63 
0.9877 (0.9463 to 1.0310), 
p=0.57 
1.0052 (0.9782 to 1.0329), 
p=0.71 
lag2 
0.9924 (0.9643 to 1.0213), 
p=0.60 
0.9732 (0.9310 to 1.0174), 
p=0.23 
0.9944 (0.9677 to 1.0218), 
p=0.69 
NO2 24-hr 
lag0 
1.0448 (0.9842 to 1.1090), 
p=0.15 
0.9640 (0.8805 to 1.0554), 
p=0.43 
1.0356 (0.9778 to 1.0968), 
p=0.23 
lag1 
1.0330 (0.9752 to 1.0943), 
p=0.27 
1.0174 (0.9335 to 1.1090), 
p=0.69 
1.0315 (0.9761 to 1.0901), 
p=0.27 
lag2 
1.0282 (0.9725 to 1.0871), 
p=0.33 
1.0067 (0.9238 to 1.0972), 
p=0.88 
1.0350 (0.9812 to 1.0918), 
p=0.21 
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2.4.5.2 Associations between NO2 and lung function, symptoms and medication use in 
two pollutant models with 4-hour ozone 
 
Table 2.28.  Associations between NO2 and lung function in two pollutant models with 4-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
NO2 1-hr 
lag0 
0.0639 (-0.3788 to 
0.5066), p=0.78 
-0.0002 (-0.0031 to 
0.0028), p=0.90 
    
lag1 
0.1481 (-0.2911 to 
0.5873), p=0.51 
0.0014 (-0.0016 to 
0.0043), p=0.36 
0.2795 (-0.0421 to 
0.6011), p=0.088 
0.0023 (0.0000 to 
0.0045), p=0.048 
lag2 
0.0275 (-0.4410 to 
0.4959), p=0.91 
-0.0002 (-0.0034 to 
0.0030), p=0.90 
-0.3963 (-0.7236 to  
-0.0690), p=0.018 
-0.0025 (-0.0047 to  
-0.0002), p=0.032 
lag3     
0.2962 (-0.0585 to 
0.6509), p=0.10 
0.0007 (-0.0018 to 
0.0032), p=0.57 
NO2 24-hr 
lag0 
0.3326 (-0.6544 to 
1.3197), p=0.51 
0.0006 (-0.0059 to 
0.0072), p=0.85 
    
lag1 
0.2695 (-0.7189 to 
1.2579), p=0.59 
0.0035 (-0.0030 to 
0.0101), p=0.29 
0.0538 (-0.6714 to 
0.7791), p=0.88 
-0.0015 (-0.0066 to 
0.0035), p=0.55 
lag2 
0.2753 (-0.7067 to 
1.2573), p=0.58 
0.0005 (-0.0061 to 
0.0072), p=0.87 
-0.3356 (-1.0556 to 
0.3844), p=0.36 
-0.0027 (-0.0077 to 
0.0023), p=0.28 
lag3     
-0.1388 (-0.8768 to 
0.5992), p=0.71 
-0.0031 (-0.0082 to 
0.0020), p=0.23 
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Table 2.29.  Associations between NO2 and night symptoms and medication use in two 
pollutant models with 4-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
NO2 1-hr 
lag1 
1.0014 ( 0.9796 
to 1.0237), 
p=0.90 
1.0110 ( 0.9803 
to 1.0427), 
p=0.49 
0.9914 ( 0.9429 
to 1.0423), 
p=0.73 
1.0046 ( 0.9847 
to 1.0250), 
p=0.65 
0.9985 ( 0.9637 
to 1.0345), 
p=0.93 
lag2 
1.0138 ( 0.9924 
to 1.0357), 
p=0.21 
1.0127 ( 0.9821 
to 1.0442), 
p=0.42 
0.9647 ( 0.9170 
to 1.0148), 
p=0.16 
1.0111 ( 0.9915 
to 1.0311), 
p=0.27 
0.9920 ( 0.9581 
to 1.0272), 
p=0.65 
lag3 
1.0121 ( 0.9905 
to 1.0342), 
p=0.28 
1.0108 ( 0.9789 
to 1.0439), 
p=0.51 
0.9778 ( 0.9283 
to 1.0300), 
p=0.40 
1.0116 ( 0.9916 
to 1.0320), 
p=0.26 
1.0062 ( 0.9716 
to 1.0420), 
p=0.73 
NO2 24-hr 
lag1 
1.0134 ( 0.9693 
to 1.0596), 
p=0.56 
1.0605 ( 0.9964 
to 1.1288), 
p=0.065 
0.9950 ( 0.9054 
to 1.0935), 
p=0.92 
1.0086 ( 0.9678 
to 1.0512), 
p=0.68 
1.0122 ( 0.9446 
to 1.0846), 
p=0.73 
lag2 
1.0321 ( 0.9878 
to 1.0785), 
p=0.16 
1.0361 ( 0.9737 
to 1.1025), 
p=0.26 
0.9814 ( 0.8930 
to 1.0785), 
p=0.70 
1.0250 ( 0.9842 
to 1.0674), 
p=0.23 
1.0079 ( 0.9413 
to 1.0793), 
p=0.82 
lag3 
1.0447 ( 1.0015 
to 1.0898), 
p=0.042 
1.0400 ( 0.9796 
to 1.1042), 
p=0.20 
0.9483 ( 0.8647 
to 1.0401), 
p=0.26 
1.0300 ( 0.9904 
to 1.0710), 
p=0.14 
1.0203 ( 0.9541 
to 1.0910), 
p=0.56 
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Table 2.30.  Associations between NO2 and day time symptoms in two pollutant models 
with 4-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
NO2 1-hr 
lag0 
1.0044 
(0.9849 to 
1.0242), 
p=0.66 
1.0158 
(0.9877 to 
1.0447), 
p=0.27 
1.0166 
(0.9824 to 
1.0520), 
p=0.34 
0.9898 
(0.9702 to 
1.0098), 
p=0.32 
0.9821 
(0.9516 to 
1.0136), 
p=0.26 
0.9877 
(0.9586 to 
1.0177), 
p=0.42 
0.9941 
(0.9778 to 
1.0106), 
p=0.48 
lag1 
1.0037 
(0.9853 to 
1.0225), 
p=0.69 
1.0075 
(0.9804 to 
1.0352), 
p=0.59 
1.0142 
(0.9809 to 
1.0486), 
p=0.41 
0.9952 
(0.9765 to 
1.0142), 
p=0.62 
0.9796 
(0.9508 to 
1.0093), 
p=0.18 
0.9791 
(0.9517 to 
1.0074), 
p=0.15 
0.9921 
(0.9766 to 
1.0078), 
p=0.32 
lag2 
1.0049 
(0.9860 to 
1.0242), 
p=0.61 
0.9919 
(0.9649 to 
1.0197), 
p=0.56 
0.9836 
(0.9515 to 
1.0168), 
p=0.33 
0.9822 
(0.9635 to 
1.0013), 
p=0.068 
0.9833 
(0.9541 to 
1.0134), 
p=0.27 
0.9771 
(0.9490 to 
1.0061), 
p=0.12 
0.9922 
(0.9763 to 
1.0083), 
p=0.34 
NO2 24-hr 
lag0 
1.0202 
(0.9797 to 
1.0623), 
p=0.33 
1.0720 
(1.0129 to 
1.1345), 
p=0.016 
1.0439 
(0.9767 to 
1.1157), 
p=0.21 
0.9926 
(0.9515 to 
1.0355), 
p=0.73 
0.9720 
(0.9067 to 
1.0421), 
p=0.42 
0.9705 
(0.9122 to 
1.0324), 
p=0.34 
1.0026 
(0.9681 to 
1.0383), 
p=0.89 
lag1 
1.0125 
(0.9734 to 
1.0531), 
p=0.54 
1.0362 
(0.9809 to 
1.0945), 
p=0.20 
1.0249 
(0.9611 to 
1.0929), 
p=0.45 
0.9913 
(0.9517 to 
1.0326), 
p=0.67 
0.9461 
(0.8830 to 
1.0138), 
p=0.12 
0.9541 
(0.8984 to 
1.0133), 
p=0.13 
0.9908 
(0.9578 to 
1.0249), 
p=0.59 
lag2 
1.0191 
(0.9807 to 
1.0590), 
p=0.33 
0.9959 
(0.9446 to 
1.0500), 
p=0.88 
1.0201 
(0.9584 to 
1.0856), 
p=0.53 
0.9762 
(0.9383 to 
1.0156), 
p=0.23 
0.9603 
(0.8988 to 
1.0260), 
p=0.23 
0.9666 
(0.9119 to 
1.0245), 
p=0.25 
0.9916 
(0.9594 to 
1.0248), 
p=0.62 
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Table 2.31.  Associations between NO2 and day time medication use in two pollutant 
models with 4-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
NO2 1-hr 
lag0 
1.0051 (0.9757 to 1.0354), 
p=0.74 
0.9724 (0.9292 to 1.0175), 
p=0.23 
0.9996 (0.9720 to 1.0280), 
p=0.98 
lag1 
1.0069 (0.9785 to 1.0360), 
p=0.64 
0.9875 (0.9461 to 1.0307), 
p=0.57 
1.0050 (0.9781 to 1.0327), 
p=0.72 
lag2 
0.9924 (0.9643 to 1.0213), 
p=0.60 
0.9727 (0.9304 to 1.0169), 
p=0.22 
0.9944 (0.9677 to 1.0218), 
p=0.68 
NO2 24-hr 
lag0 
1.0432 (0.9829 to 1.1073), 
p=0.16 
0.9664 (0.8829 to 1.0578), 
p=0.46 
1.0347 (0.9770 to 1.0958), 
p=0.24 
lag1 
1.0327 (0.9749 to 1.0939), 
p=0.27 
1.0182 (0.9342 to 1.1098), 
p=0.68 
1.0313 (0.9759 to 1.0898), 
p=0.27 
lag2 
1.0282 (0.9726 to 1.0871), 
p=0.33 
1.0067 (0.9237 to 1.0972), 
p=0.88 
1.0351 (0.9812 to 1.0918), 
p=0.21 
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2.4.5.3. Associations between NO2 and lung function, symptoms and medication use in 
two pollutant models with 8-hour ozone 
 
 
Table 2.32.  Associations between NO2 and lung function in two pollutant models with 8-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
NO2 1-hr 
lag0 
0.0534 (-0.3885 to 
0.4952), p=0.81 
-0.0002 (-0.0032 to 
0.0027), p=0.87 
    
lag1 
0.1247 (-0.3144 to 
0.5638), p=0.58 
0.0012 (-0.0017 to 
0.0041), p=0.43 
0.2831 (-0.0380 to 
0.6042), p=0.084 
0.0023 (0.0001 to 
0.0045), p=0.045 
lag2 
-0.0133 (-0.4876 to 
0.4610), p=0.96 
-0.0003 (-0.0034 to 
0.0029), p=0.87 
-0.3986 (-0.7269 to   
-0.0702), p=0.017 
-0.0024 (-0.0047 to  
-0.0002), p=0.033 
lag3     
0.3112 (-0.0439 to 
0.6663), p=0.086 
0.0007 (-0.0018 to 
0.0031), p=0.59 
NO2 24-hr 
lag0 
0.1645 (-0.8381 to 
1.1671), p=0.75 
0.0001 (-0.0065 to 
0.0067), p=0.98 
    
lag1 
0.1651 (-0.8363 to 
1.1666), p=0.75 
0.0034 (-0.0032 to 
0.0100), p=0.31 
0.1216 (-0.6110 to 
0.8543), p=0.74 
-0.0013 (-0.0064 to 
0.0037), p=0.61 
lag2 
0.1322 (-0.8630 to 
1.1273), p=0.79 
0.0001 (-0.0066 to 
0.0068), p=0.97 
-0.3357 (-1.0620 to 
0.3905), p=0.36 
-0.0026 (-0.0076 to 
0.0024), p=0.31 
lag3     
-0.1235 (-0.8672 to 
0.6201), p=0.74 
-0.0031 (-0.0082 to 
0.0020), p=0.23 
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Table 2.33.  Associations between NO2 and night symptoms and medication use in two 
pollutant models with 8-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
NO2 1-hr 
lag1 
1.0011 (0.9794 
to 1.0232), 
p=0.92 
1.0115 (0.9808 
to 1.0431), 
p=0.47 
0.9882 (0.9401 
to 1.0388), 
p=0.64 
1.0043 (0.9845 
to 1.0246), 
p=0.67 
0.9990 (0.9644 
to 1.0348), 
p=0.96 
lag2 
1.0141 (0.9927 
to 1.0359), 
p=0.20 
1.0140 (0.9834 
to 1.0455), 
p=0.38 
0.9642 (0.9166 
to 1.0142), 
p=0.16 
1.0115 (0.9920 
to 1.0315), 
p=0.25 
0.9932 (0.9591 
to 1.0284), 
p=0.70 
lag3 
1.0131 (0.9916 
to 1.0352), 
p=0.23 
1.0131 (0.9810 
to 1.0461), 
p=0.43 
0.9727 (0.9245 
to 1.0234), 
p=0.29 
1.0114 (0.9915 
to 1.0317), 
p=0.26 
1.0070 (0.9724 
to 1.0428), 
p=0.70 
NO2 24-hr 
lag1 
1.0134 (0.9692 
to 1.0596), 
p=0.56 
1.0519 (0.9881 
to 1.1197), 
p=0.11 
0.9772 (0.8888 
to 1.0743), 
p=0.63 
1.0054 (0.9647 
to 1.0479), 
p=0.80 
1.0106 (0.9430 
to 1.0830), 
p=0.77 
lag2 
1.0327 (0.9884 
to 1.0791), 
p=0.15 
1.0312 (0.9692 
to 1.0973), 
p=0.33 
0.9723 (0.8853 
to 1.0678), 
p=0.56 
1.0235 (0.9829 
to 1.0657), 
p=0.26 
1.0078 (0.9411 
to 1.0792), 
p=0.82 
lag3 
1.0455 (1.0022 
to 1.0905), 
p=0.039 
1.0378 (0.9774 
to 1.1019), 
p=0.22 
0.9434 (0.8609 
to 1.0338), 
p=0.21 
1.0289 (0.9895 
to 1.0698), 
p=0.15 
1.0208 (0.9545 
to 1.0917), 
p=0.55 
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Table 2.34. Associations between NO2 and day time symptoms in two pollutant models with 
8-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
NO2 1-hr 
lag0 
1.0035 
(0.9842 to 
1.0233), 
p=0.72 
1.0161 
(0.9882 to 
1.0449), 
p=0.26 
1.0167 
(0.9827 to 
1.0519), 
p=0.34 
0.9891 
(0.9696 to 
1.0089), 
p=0.28 
0.9817 
(0.9514 to 
1.0131), 
p=0.25 
0.9869 
(0.9579 to 
1.0167), 
p=0.39 
0.9934 
(0.9772 to 
1.0098), 
p=0.43 
lag1 
1.0034 
(0.9851 to 
1.0221), 
p=0.72 
1.0086 
(0.9816 to 
1.0363), 
p=0.54 
1.0147 
(0.9814 to 
1.0491), 
p=0.39 
0.9950 
(0.9763 to 
1.0139), 
p=0.60 
0.9793 
(0.9505 to 
1.0090), 
p=0.17 
0.9791 
(0.9516 to 
1.0073), 
p=0.14 
0.9920 
(0.9766 to 
1.0077), 
p=0.32 
lag2 
1.0048 
(0.9861 to 
1.0240), 
p=0.62 
0.9930 
(0.9659 to 
1.0208), 
p=0.62 
0.9845 
(0.9524 to 
1.0178), 
p=0.36 
0.9835 
(0.9648 to 
1.0026), 
p=0.090 
0.9834 
(0.9542 to 
1.0135), 
p=0.28 
0.9781 
(0.9500 to 
1.0071), 
p=0.14 
0.9928 
(0.9770 to 
1.0088), 
p=0.38 
NO2 24-hr 
lag0 
1.0177 
(0.9774 to 
1.0597), 
p=0.39 
1.0729 
(1.0137 to 
1.1354), 
p=0.015 
1.0411 
(0.9742 to 
1.1125), 
p=0.23 
0.9943 
(0.9532 to 
1.0373), 
p=0.79 
0.9729 
(0.9075 to 
1.0430), 
p=0.44 
0.9680 
(0.9098 to 
1.0300), 
p=0.30 
1.0019 
(0.9675 to 
1.0376), 
p=0.91 
lag1 
1.0113 
(0.9723 to 
1.0518), 
p=0.58 
1.0375 
(0.9822 to 
1.0959), 
p=0.19 
1.0225 
(0.9590 to 
1.0903), 
p=0.50 
0.9920 
(0.9524 to 
1.0332), 
p=0.70 
0.9465 
(0.8833 to 
1.0143), 
p=0.12 
0.9526 
(0.8970 to 
1.0116), 
p=0.11 
0.9905 
(0.9577 to 
1.0244), 
p=0.58 
lag2 
1.0189 
(0.9806 to 
1.0586), 
p=0.34 
0.9965 
(0.9451 to 
1.0506), 
p=0.90 
1.0191 
(0.9576 to 
1.0845), 
p=0.55 
0.9773 
(0.9395 to 
1.0167), 
p=0.26 
0.9607 
(0.8992 to 
1.0265), 
p=0.24 
0.9669 
(0.9123 to 
1.0247), 
p=0.26 
0.9921 
(0.9600 to 
1.0252), 
p=0.64 
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Table 2.35.  Associations between NO2 and day time medication use in two pollutant 
models with 8-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
NO2 1-hr 
lag0 
1.0049 (0.9757 to 1.0350), 
p=0.74 
0.9737 (0.9308 to 1.0186), 
p=0.25 
0.9998 (0.9723 to 1.0280), 
p=0.99 
lag1 
1.0064 (0.9782 to 1.0354), 
p=0.66 
0.9871 (0.9463 to 1.0296), 
p=0.54 
1.0049 (0.9781 to 1.0324), 
p=0.72 
lag2 
0.9909 (0.9631 to 1.0196), 
p=0.53 
0.9701 (0.9289 to 1.0131), 
p=0.17 
0.9934 (0.9669 to 1.0206), 
p=0.63 
NO2 24-hr 
lag0 
1.0406 (0.9805 to 1.1043), 
p=0.19 
0.9687 (0.8858 to 1.0595), 
p=0.49 
1.0335 (0.9760 to 1.0943), 
p=0.26 
lag1 
1.0319 (0.9744 to 1.0929), 
p=0.28 
1.0209 (0.9373 to 1.1119), 
p=0.63 
1.0314 (0.9762 to 1.0898), 
p=0.27 
lag2 
1.0276 (0.9721 to 1.0863), 
p=0.34 
1.0073 (0.9250 to 1.0968), 
p=0.87 
1.0350 (0.9813 to 1.0916), 
p=0.21 
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2.4.6. Associations between NO2 and lung function, symptoms and medication use in 
children with unflued gas heating in the home 
 
There were stronger adverse effects of NO2 on children with unflued gas heating in the home 
compared to all children in the study. These stronger effects were seen for morning PEF, 
symptoms and medication use (Table 2.36, Table 2.37, Table 2.38, Table 2.39).  
 
Table 2.36.  Associations between NO2 and lung function in children with unflued gas 
heating in the home 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
NO2 1-hr 
lag0 
-0.6089 (-1.7861 to 
0.5683), p=0.31 
-0.0041 (-0.0122 to 
0.0040), p=0.32 
    
lag1 
-0.6411 (-1.8515 to 
0.5693), p=0.30 
0.0001 (-0.0081 to 
0.0082), p=0.98 
0.0833 (-0.6371 to 
0.8038), p=0.82 
0.0016 (-0.0037 to 
0.0069), p=0.55 
lag2 
0.0350 (-1.2237 to 
1.2937), p=0.96 
0.0017 (-0.0067 to 
0.0101), p=0.70 
-1.0481 (-1.8306 to  
-0.2655), p=0.009 
-0.0046 (-0.0105 to 
0.0013), p=0.12 
lag3     
-0.4617 (-1.2757 to 
0.3524), p=0.27 
-0.0017 (-0.0079 to 
0.0045), p=0.59 
NO2 24-hr 
lag0 
-0.3496 (-2.5388 to 
1.8397), p=0.75 
-0.0033 (-0.0179 to 
0.0114), p=0.66 
    
lag1 
-1.9496 (-4.2067 to 
0.3074), p=0.090 
-0.0073 (-0.0223 to 
0.0076), p=0.34 
0.3852 (-1.0634 to 
1.8337), p=0.60 
0.0035 (-0.0071 to 
0.0141), p=0.52 
lag2 
0.0713 (-2.3798 to 
2.5224), p=0.95 
-0.0020 (-0.0180 to 
0.0140), p=0.81 
-1.1664 (-2.6869 to 
0.3542), p=0.13 
-0.0091 (-0.0204 to 
0.0022), p=0.12 
lag3     
-0.5003 (-2.0914 to 
1.0908), p=0.54 
-0.0013 (-0.0132 to 
0.0107), p=0.83 
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Table 2.37.  Associations between NO2 and night symptoms and medication use in 
children with unflued gas heating in the home 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
NO2 1-hr 
lag1 
1.0056 (0.9538 
to 1.0601), 
p=0.84 
1.0724 (0.9939 
to 1.1571), 
p=0.072 
1.1189 (0.9586 
to 1.3060), 
p=0.15 
1.0071 (0.9587 
to 1.0579), 
p=0.78 
1.1016 (1.0204 
to 1.1893), 
p=0.013 
lag2 
1.0555 (1.0014 
to 1.1126), 
p=0.044 
1.0081 (0.9341 
to 1.0879), 
p=0.84 
1.0911 (0.9341 
to 1.2744), 
p=0.27 
1.0248 (0.9768 
to 1.0752), 
p=0.32 
1.0378 (0.9616 
to 1.1200), 
p=0.34 
lag3 
1.0752 (1.0190 
to 1.1345), 
p=0.008 
1.0269 (0.9539 
to 1.1055), 
p=0.48 
1.0080 (0.8321 
to 1.2212), 
p=0.93 
1.0516 (1.0011 
to 1.1047), 
p=0.045 
1.0366 (0.9550 
to 1.1253), 
p=0.39 
NO2 24-hr 
lag1 
1.0402 (0.9579 
to 1.1296), 
p=0.35 
1.1939 (1.0525 
to 1.3545), 
p=0.006 
1.1178 (0.8883 
to 1.4066), 
p=0.34 
1.0434 (0.9649 
to 1.1282), 
p=0.29 
1.2156 (1.0699 
to 1.3811), 
p=0.003 
lag2 
1.0787 (0.9949 
to 1.1695), 
p=0.066 
1.0907 (0.9636 
to 1.2345), 
p=0.17 
1.1103 (0.8574 
to 1.4379), 
p=0.43 
1.0467 (0.9695 
to 1.1300), 
p=0.24 
1.1289 (0.9976 
to 1.2775), 
p=0.055 
lag3 
1.1339 (1.0443 
to 1.2313), 
p=0.003 
1.0977 (0.9657 
to 1.2478), 
p=0.15 
1.0123 (0.7499 
to 1.3666), 
p=0.94 
1.1113 (1.0274 
to 1.2022), 
p=0.009 
1.1144 (0.9699 
to 1.2804), 
p=0.13 
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Table 2.38.  Associations between NO2 and day time symptoms in children with unflued 
gas heating in the home 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
NO2 1-hr 
lag0 
1.0126 
(0.9641 to 
1.0635), 
p=0.62 
1.0385 
(0.9783 to 
1.1024), 
p=0.21 
1.1094 
(1.0218 to 
1.2045), 
p=0.013 
1.0269 
(0.9710 to 
1.0860), 
p=0.35 
0.9254 
(0.8155 to 
1.0501), 
p=0.23 
1.0380 
(0.9621 to 
1.1200), 
p=0.34 
0.9961 
(0.9537 to 
1.0404), 
p=0.86 
lag1 
1.0080 
(0.9586 to 
1.0599), 
p=0.76 
1.0610 
(0.9994 to 
1.1263), 
p=0.052 
1.0978 
(1.0109 to 
1.1922), 
p=0.027 
1.0335 
(0.9782 to 
1.0920), 
p=0.24 
0.9555 
(0.8535 to 
1.0697), 
p=0.43 
1.0224 
(0.9506 to 
1.0996), 
p=0.55 
1.0015 
(0.9584 to 
1.0465), 
p=0.95 
lag2 
1.0276 
(0.9774 to 
1.0803), 
p=0.29 
0.9910 
(0.9328 to 
1.0529), 
p=0.77 
1.0536 
(0.9719 to 
1.1422), 
p=0.20 
1.0341 
(0.9788 to 
1.0925), 
p=0.23 
0.9206 
(0.7962 to 
1.0645), 
p=0.26 
1.0019 
(0.9286 to 
1.0810), 
p=0.96 
0.9938 
(0.9498 to 
1.0397), 
p=0.79 
NO2 24-hr 
lag0 
1.0523 
(0.9711 to 
1.1404), 
p=0.21 
1.1134 
(1.0073 to 
1.2307), 
p=0.036 
1.1653 
(1.0323 to 
1.3154), 
p=0.013 
1.0730 
(0.9796 to 
1.1752), 
p=0.13 
0.9887 
(0.7533 to 
1.2977), 
p=0.93 
1.0447 
(0.9214 to 
1.1845), 
p=0.49 
1.0294 
(0.9568 to 
1.1076), 
p=0.44 
lag1 
1.0106 
(0.9324 to 
1.0955), 
p=0.80 
1.1350 
(1.0244 to 
1.2576), 
p=0.016 
1.1763 
(1.0370 to 
1.3343), 
p=0.012 
1.0641 
(0.9745 to 
1.1620), 
p=0.17 
1.0091 
(0.8222 to 
1.2384), 
p=0.93 
1.0394 
(0.9225 to 
1.1711), 
p=0.53 
1.0035 
(0.9321 to 
1.0802), 
p=0.93 
lag2 
1.0518 
(0.9692 to 
1.1414), 
p=0.23 
1.0626 
(0.9621 to 
1.1737), 
p=0.23 
1.1815 
(1.0346 to 
1.3493), 
p=0.014 
1.0909 
(0.9972 to 
1.1934), 
p=0.057 
0.9192 
(0.7386 to 
1.1439), 
p=0.45 
0.9795 
(0.8661 to 
1.1076), 
p=0.74 
1.0099 
(0.9373 to 
1.0881), 
p=0.80 
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Table 2.39.  Associations between NO2 and day time medication use in children with 
unflued gas heating in the home 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use for 
symptoms 
Any day time medication 
use for symptoms 
NO2 1-hr 
lag0 
1.0099 ( 0.9375 to 1.0879), 
p=0.80 
1.0257 ( 0.8944 to 1.1762), 
p=0.72 
0.9920 ( 0.9241 to 1.0649), 
p=0.82 
lag1 
1.0276 ( 0.9528 to 1.1083), 
p=0.48 
1.1265 ( 1.0029 to 1.2654), 
p=0.045 
1.0216 ( 0.9537 to 1.0943), 
p=0.54 
lag2 
0.9795 ( 0.9069 to 1.0579), 
p=0.60 
1.0509 ( 0.9356 to 1.1804), 
p=0.40 
0.9832 ( 0.9167 to 1.0545), 
p=0.63 
NO2 24-hr 
lag0 
1.0532 ( 0.9381 to 1.1825), 
p=0.38 
1.0138 ( 0.8062 to 1.2748), 
p=0.91 
1.0140 ( 0.9082 to 1.1321), 
p=0.80 
lag1 
1.0735 ( 0.9547 to 1.2072), 
p=0.24 
1.2068 ( 0.9964 to 1.4617), 
p=0.055 
1.0822 ( 0.9707 to 1.2066), 
p=0.15 
lag2 
1.0510 ( 0.9344 to 1.1822), 
p=0.41 
1.0965 ( 0.9113 to 1.3195), 
p=0.33 
1.0670 ( 0.9572 to 1.1895), 
p=0.24 
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2.4.7. Associations between PM10 and lung function, symptoms and medication use in two 
pollutant models 
 
In this section, results are presented for the associations between PM10 and lung function, 
symptoms and medication use from two pollutant models: 1-hr NO2 (Table 2.40, Table 
2.41, Table 2.42, Table 2.43), 24-hr NO2 (Table 2.44, Table 2.45, Table 2.46, Table 2.47), 1-hr ozone 
(Table 2.48, Table 2.49, Table 2.50, Table 2.51), 4-hr ozone (Table 2.52, Table 2.53, Table 2.54, 
Table 2.55), 8-hr ozone (Table 2.56, Table 2.57, Table 2.58, Table 2.59), 8-hr CO (Table 2.60, Table 
2.61, Table 2.62, Table 2.63), 1-hr SO2 (Table 2.64, Table 2.65, Table 2.66, Table 2.67) and 24-hr 
SO2 (Table 2.68, Table 2.69, Table 2.70, Table 2.71).  
 
In two pollutant models, changes in the effects were seen with evening lung function. The 
adverse effects were greatly increased when 1-hr ozone (Table 2.48) and SO2 (Table 2.64) for 1-
hr SO2 and Table 2.68 for 24-hr SO2) were added to the model.   
 
Associations between PM10 and both night  and day time symptoms generally persisted when 
NO2, CO and SO2 were added to the models (Table 2.41,Table 2.42 for 1-hr NO2, Table 2.45, 
Table 2.46 for 24-hr NO2, Table 2.61, Table 2.62 for 8-hr CO, Table 2.65, Table 2.66 for 1-hr SO2 
and Table 2.69, Table 2.70 for 24-hr SO2). The odds ratios were generally greater in the two 
pollutant models compared to the single pollutant models.  
 
There were no significant associations when ozone was added to the models (Table 2.49, Table 
2.50, Table 2.53, Table 2.54, Table 2.57, Table 2.58 for 1-hr ozone, 4-hr ozone and 8-hr ozone 
respectively).  
 
Significant increased use of day time medication use was only observed in two pollutant 
models with CO (Table 2.63).  However, the odds ratios in all models were consistently greater 
in the two pollutant models compared with single pollutant models especially for lag 1 PM10 
and lag 2 PM10. 
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2.4.7.1 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 1-hour NO2 
 
 
Table 2.40.  Associations between PM10 and lung function in two pollutant models with 1-
hour NO2 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.0322 (-0.4865 to 
0.4221), p=0.89 
0.0010 (-0.0020 to 
0.0040), p=0.50 
    
lag1 
-0.0569 (-0.5126 to 
0.3987), p=0.81 
-0.0001 (-0.0031 to 
0.0030), p=0.97 
0.2559 (-0.0742 to 
0.5860), p=0.13 
0.0019 (-0.0005 to 
0.0043), p=0.11 
lag2 
-0.0603 (-0.5152 to 
0.3945), p=0.79 
-0.0001 (-0.0031 to 
0.0029), p=0.96 
-0.1348 (-0.4815 to 
0.2120), p=0.45 
-0.0007 (-0.0032 to 
0.0018), p=0.58 
lag3     
-0.0427 (-0.3972 to 
0.3117), p=0.81 
-0.0012 (-0.0038 to 
0.0013), p=0.33 
 
 
 
 
Table 2.41.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 1-hour NO2 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0164 (0.9962 
to 1.0370), 
p=0.11 
1.0267 (1.0000 
to 1.0543), 
p=0.050 
0.9948 (0.9587 
to 1.0324), 
p=0.78 
1.0127 (0.9939 
to 1.0318), 
p=0.19 
0.9987 (0.9682 
to 1.0301), 
p=0.93 
lag2 
1.0220 (1.0017 
to 1.0428), 
p=0.033 
1.0260 (0.9991 
to 1.0536), 
p=0.058 
1.0271 (0.9925 
to 1.0629), 
p=0.13 
1.0171 (0.9981 
to 1.0364), 
p=0.078 
0.9876 (0.9583 
to 1.0179), 
p=0.42 
lag3 
1.0096 (0.9897 
to 1.0299), 
p=0.35 
1.0223 (0.9963 
to 1.0491), 
p=0.093 
1.0003 (0.9648 
to 1.0372), 
p=0.99 
1.0111 (0.9927 
to 1.0299), 
p=0.24 
0.9975 (0.9685 
to 1.0274), 
p=0.87 
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Table 2.42.  Associations between PM10 and day time symptoms in two pollutant models 
with 1-hour NO2 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0097 
(0.9914 to 
1.0284), 
p=0.30 
1.0288 
(1.0049 to 
1.0534), 
p=0.018 
1.0089 
(0.9802 to 
1.0383), 
p=0.55 
1.0073 
(0.9881 to 
1.0269), 
p=0.46 
0.9930 
(0.9635 to 
1.0233), 
p=0.65 
1.0065 
(0.9807 to 
1.0329), 
p=0.63 
1.0042 
(0.9883 to 
1.0204), 
p=0.61 
lag1 
1.0157 
(0.9970 to 
1.0347), 
p=0.10 
1.0091 
(0.9856 to 
1.0331), 
p=0.45 
1.0193 
(0.9911 to 
1.0482), 
p=0.18 
0.9969 
(0.9777 to 
1.0165), 
p=0.76 
1.0153 
(0.9862 to 
1.0453), 
p=0.31 
1.0062 
(0.9804 to 
1.0326), 
p=0.64 
1.0110 
(0.9949 to 
1.0273), 
p=0.18 
lag2 
1.0227 
(1.0042 to 
1.0416), 
p=0.016 
1.0115 
(0.9881 to 
1.0355), 
p=0.34 
1.0231 
(0.9950 to 
1.0520), 
p=0.11 
0.9897 
(0.9704 to 
1.0093), 
p=0.30 
1.0121 
(0.9835 to 
1.0417), 
p=0.41 
1.0083 
(0.9829 to 
1.0344), 
p=0.52 
1.0071 
(0.9914 to 
1.0231), 
p=0.38 
 
 
 
 
 
Table 2.43.  Associations between PM10 and day time medication use in two pollutant 
models with 1-hour NO2 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
1.0067 (0.9807 to 1.0334), 
p=0.61 
1.0138 (0.9781 to 1.0508), 
p=0.45 
0.9971 (0.9726 to 1.0222), 
p=0.82 
lag1 
1.0218 (0.9963 to 1.0479), 
p=0.095 
1.0302 (0.9947 to 1.0670), 
p=0.096 
1.0167 (0.9925 to 1.0415), 
p=0.18 
lag2 
1.0233 (0.9974 to 1.0498), 
p=0.078 
1.0239 (0.9882 to 1.0609), 
p=0.19 
1.0218 (0.9973 to 1.0468), 
p=0.081 
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2.4.7.2 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 24-hour NO2 
 
Table 2.44.  Associations between PM10 and lung function in two pollutant models with 
24-hour NO2 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.1596 (-0.6289 to 
0.3096), p=0.50 
0.0001 (-0.0030 to 
0.0032), p=0.96 
    
lag1 
-0.1021 (-0.5604 to 
0.3561), p=0.66 
-0.0003 (-0.0033 to 
0.0028), p=0.87 
0.3079 (-0.0302 to 
0.6460), p=0.074 
0.0027 (0.0003 to 
0.0051), p=0.030 
lag2 
-0.1057 (-0.5638 to 
0.3524), p=0.65 
-0.0005 (-0.0035 to 
0.0025), p=0.74 
-0.1284 (-0.4756 to 
0.2188), p=0.47 
-0.0007 (-0.0031 to 
0.0018), p=0.60 
lag3     
-0.0208 (-0.3761 to 
0.3345), p=0.91 
-0.0010 (-0.0035 to 
0.0015), p=0.44 
 
 
 
 
Table 2.45.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 24-hour NO2 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0160 (0.9953 
to 1.0371), 
p=0.13 
1.0181 (0.9910 
to 1.0460), 
p=0.19 
0.9774 (0.9412 
to 1.0150), 
p=0.24 
1.0104 (0.9912 
to 1.0299), 
p=0.29 
0.9870 (0.9558 
to 1.0192), 
p=0.42 
lag2 
1.0218 (1.0013 
to 1.0426), 
p=0.037 
1.0211 (0.9942 
to 1.0487), 
p=0.13 
1.0160 (0.9819 
to 1.0513), 
p=0.36 
1.0149 (0.9959 
to 1.0342), 
p=0.12 
0.9824 (0.9527 
to 1.0130), 
p=0.26 
lag3 
1.0094 (0.9895 
to 1.0297), 
p=0.36 
1.0188 (0.9929 
to 1.0454), 
p=0.16 
0.9920 (0.9571 
to 1.0282), 
p=0.66 
1.0096 (0.9912 
to 1.0282), 
p=0.31 
0.9936 (0.9646 
to 1.0235), 
p=0.67 
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Table 2.46.  Associations between PM10 and day time symptoms in two pollutant models 
with 24-hour NO2 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0086 
(0.9901 to 
1.0274), 
p=0.37 
1.0243 
(0.9999 to 
1.0492), 
p=0.051 
1.0049 
(0.9759 to 
1.0347), 
p=0.75 
1.0068 
(0.9873 to 
1.0266), 
p=0.50 
1.0007 
(0.9703 to 
1.0321), 
p=0.96 
1.0095 
(0.9832 to 
1.0366), 
p=0.48 
1.0021 
(0.9860 to 
1.0184), 
p=0.80 
lag1 
1.0148 
(0.9961 to 
1.0337), 
p=0.12 
1.0056 
(0.9820 to 
1.0297), 
p=0.65 
1.0158 
(0.9876 to 
1.0448), 
p=0.27 
0.9960 
(0.9768 to 
1.0155), 
p=0.68 
1.0191 
(0.9900 to 
1.0491), 
p=0.20 
1.0073 
(0.9815 to 
1.0337), 
p=0.58 
1.0090 
(0.9931 to 
1.0253), 
p=0.27 
lag2 
1.0218 
(1.0034 to 
1.0405), 
p=0.020 
1.0086 
(0.9853 to 
1.0325), 
p=0.47 
1.0205 
(0.9926 to 
1.0492), 
p=0.15 
0.9886 
(0.9695 to 
1.0081), 
p=0.25 
1.0148 
(0.9861 to 
1.0444), 
p=0.31 
1.0092 
(0.9840 to 
1.0351), 
p=0.48 
1.0053 
(0.9897 to 
1.0212), 
p=0.51 
 
 
 
 
Table 2.47.  Associations between PM10 and day time medication use in two pollutant 
models with 24-hour NO2 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
0.9988 (0.9724 to 1.0259), 
p=0.93 
1.0113 (0.9754 to 1.0485), 
p=0.54 
0.9902 (0.9653 to 1.0157), 
p=0.45 
lag1 
1.0183 (0.9927 to 1.0444), 
p=0.16 
1.0282 (0.9933 to 1.0645), 
p=0.11 
1.0133 (0.9891 to 1.0381), 
p=0.28 
lag2 
1.0202 (0.9945 to 1.0465), 
p=0.12 
1.0222 (0.9870 to 1.0586), 
p=0.22 
1.0183 (0.9941 to 1.0431), 
p=0.14 
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2.4.7.3 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 1-hour ozone 
 
 
 
Table 2.48.  Associations between PM10 and lung function in two pollutant models with 1-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.0801 (-0.4549 to 
0.2947), p=0.68 
-0.0001 (-0.0026 to 
0.0024), p=0.95 
    
lag1 
-0.0212 (-0.4704 to 
0.4280), p=0.93 
-0.0003 (-0.0033 to 
0.0027), p=0.84 
0.1000 (-0.1915 to 
0.3915), p=0.50 
0.0000 (-0.0020 to 
0.0020), p=0.98 
lag2 
0.0553 (-0.3831 to 
0.4938), p=0.80 
0.0000 (-0.0029 to 
0.0029), p=0.99 
-0.3674 (-0.7291 to -
0.0057), p=0.046 
-0.0017 (-0.0042 to 
0.0008), p=0.18 
lag3     
0.1716 (-0.1923 to 
0.5354), p=0.36 
0.0013 (-0.0012 to 
0.0038), p=0.32 
 
 
 
 
 
Table 2.49.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 1-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0012 (0.9814 
to 1.0214), 
p=0.91 
1.0184 (0.9942 
to 1.0432), 
p=0.14 
0.9905 (0.9507 
to 1.0321), 
p=0.65 
1.0000 (0.9819 
to 1.0185), 
p=1.00 
0.9958 (0.9638 
to 1.0289), 
p=0.80 
lag2 
1.0116 (0.9892 
to 1.0345), 
p=0.31 
1.0290 (0.9995 
to 1.0594), 
p=0.054 
1.0195 (0.9798 
to 1.0609), 
p=0.34 
1.0071 (0.9867 
to 1.0280), 
p=0.50 
0.9869 (0.9516 
to 1.0235), 
p=0.48 
lag3 
1.0002 (0.9779 
to 1.0230), 
p=0.99 
1.0271 (0.9991 
to 1.0559), 
p=0.058 
0.9831 (0.9396 
to 1.0286), 
p=0.46 
1.0014 (0.9815 
to 1.0217), 
p=0.89 
1.0026 (0.9685 
to 1.0379), 
p=0.88 
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Table 2.50.  Associations between PM10 and day time symptoms in two pollutant models 
with 1-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0061 
(0.9891 to 
1.0233), 
p=0.48 
1.0135 
(0.9920 to 
1.0355), 
p=0.22 
0.9962 
(0.9672 to 
1.0260), 
p=0.80 
0.9986 
(0.9798 to 
1.0178), 
p=0.88 
0.9817 
(0.9533 to 
1.0109), 
p=0.22 
0.9857 
(0.9603 to 
1.0119), 
p=0.28 
0.9947 
(0.9799 to 
1.0097), 
p=0.49 
lag1 
1.0044 
(0.9845 to 
1.0247), 
p=0.67 
0.9947 
(0.9679 to 
1.0222), 
p=0.70 
1.0008 
(0.9680 to 
1.0346), 
p=0.96 
0.9930 
(0.9724 to 
1.0141), 
p=0.51 
0.9977 
(0.9667 to 
1.0296), 
p=0.88 
0.9961 
(0.9677 to 
1.0253), 
p=0.79 
0.9947 
(0.9778 to 
1.0118), 
p=0.54 
lag2 
1.0154 
(0.9957 to 
1.0355), 
p=0.13 
0.9927 
(0.9660 to 
1.0201), 
p=0.60 
1.0075 
(0.9747 to 
1.0414), 
p=0.66 
0.9867 
(0.9662 to 
1.0077), 
p=0.21 
1.0010 
(0.9710 to 
1.0319), 
p=0.95 
1.0091 
(0.9823 to 
1.0365), 
p=0.51 
0.9957 
(0.9792 to 
1.0124), 
p=0.61 
 
 
 
 
Table 2.51.  Associations between PM10 and day time medication use in two pollutant 
models with 1-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
0.9980 (0.9749 to 1.0217), 
p=0.87 
1.0004 (0.9688 to 1.0330), 
p=0.98 
0.9926 (0.9697 to 1.0161), 
p=0.53 
lag1 
1.0172 (0.9885 to 1.0469), 
p=0.24 
1.0257 (0.9858 to 1.0672), 
p=0.21 
1.0100 (0.9823 to 1.0386), 
p=0.48 
lag2 
1.0093 (0.9806 to 1.0389), 
p=0.53 
1.0273 (0.9870 to 1.0691), 
p=0.19 
1.0059 (0.9782 to 1.0343), 
p=0.68 
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2.4.7.4 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 4-hour ozone 
 
 
 
Table 2.52.  Associations between PM10 and lung function in two pollutant models with 4-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.0810 (-0.4555 to 
0.2934), p=0.67 
-0.0001 (-0.0026 to 
0.0024), p=0.95 
    
lag1 
-0.0198 (-0.4684 to 
0.4288), p=0.93 
-0.0003 (-0.0033 to 
0.0027), p=0.85 
0.1070 (-0.1840 to 
0.3981), p=0.47 
0.0000 (-0.0020 to 
0.0021), p=0.96 
lag2 
0.0539 (-0.3844 to 
0.4922), p=0.81 
0.0000 (-0.0029 to 
0.0029), p=1.00 
-0.3599 (-0.7212 to 
0.0015), p=0.051 
-0.0017 (-0.0042 to 
0.0008), p=0.19 
lag3     
0.1683 (-0.1956 to 
0.5321), p=0.36 
0.0013 (-0.0012 to 
0.0038), p=0.32 
 
 
 
 
Table 2.53.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 4-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0011 (0.9812 
to 1.0213), 
p=0.92 
1.0177 (0.9937 
to 1.0423), 
p=0.15 
0.9894 (0.9498 
to 1.0306), 
p=0.61 
1.0000 (0.9819 
to 1.0184), 
p=1.00 
0.9957 (0.9639 
to 1.0286), 
p=0.80 
lag2 
1.0115 (0.9891 
to 1.0344), 
p=0.32 
1.0288 (0.9994 
to 1.0592), 
p=0.055 
1.0190 (0.9792 
to 1.0604), 
p=0.36 
1.0070 (0.9866 
to 1.0279), 
p=0.50 
0.9870 (0.9517 
to 1.0235), 
p=0.48 
lag3 
1.0002 (0.9779 
to 1.0230), 
p=0.99 
1.0267 (0.9987 
to 1.0554), 
p=0.062 
0.9823 (0.9387 
to 1.0279), 
p=0.44 
1.0013 (0.9814 
to 1.0217), 
p=0.90 
1.0026 (0.9685 
to 1.0379), 
p=0.88 
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Table 2.54.  Associations between PM10 and day time symptoms in two pollutant models 
with 4-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0058 
(0.9889 to 
1.0229), 
p=0.51 
1.0137 
(0.9922 to 
1.0357), 
p=0.21 
0.9968 
(0.9681 to 
1.0264), 
p=0.83 
0.9989 
(0.9802 to 
1.0180), 
p=0.91 
0.9816 
(0.9530 to 
1.0111), 
p=0.22 
0.9856 
(0.9601 to 
1.0118), 
p=0.28 
0.9947 
(0.9799 to 
1.0097), 
p=0.49 
lag1 
1.0042 
(0.9843 to 
1.0245), 
p=0.68 
0.9950 
(0.9684 to 
1.0225), 
p=0.72 
1.0013 
(0.9687 to 
1.0351), 
p=0.94 
0.9934 
(0.9728 to 
1.0144), 
p=0.53 
0.9975 
(0.9666 to 
1.0295), 
p=0.88 
0.9959 
(0.9675 to 
1.0252), 
p=0.78 
0.9947 
(0.9780 to 
1.0118), 
p=0.54 
lag2 
1.0153 
(0.9956 to 
1.0354), 
p=0.13 
0.9927 
(0.9660 to 
1.0201), 
p=0.60 
1.0075 
(0.9747 to 
1.0414), 
p=0.66 
0.9867 
(0.9661 to 
1.0077), 
p=0.21 
1.0016 
(0.9715 to 
1.0325), 
p=0.92 
1.0092 
(0.9824 to 
1.0366), 
p=0.51 
0.9957 
(0.9792 to 
1.0124), 
p=0.61 
 
 
 
 
Table 2.55.  Associations between PM10 and day time medication use in two pollutant 
models with 4-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
0.9977 (0.9746 to 1.0213), 
p=0.85 
1.0015 (0.9698 to 1.0342), 
p=0.93 
0.9924 (0.9694 to 1.0158), 
p=0.52 
lag1 
1.0170 (0.9882 to 1.0466), 
p=0.25 
1.0266 (0.9866 to 1.0681), 
p=0.20 
1.0099 (0.9822 to 1.0384), 
p=0.49 
lag2 
1.0093 (0.9805 to 1.0389), 
p=0.53 
1.0276 (0.9873 to 1.0695), 
p=0.18 
1.0058 (0.9782 to 1.0342), 
p=0.68 
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2.4.7.5 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 8-hour ozone 
 
 
Table 2.56.  Associations between PM10 and lung function in two pollutant models with 8-
hour ozone 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.1386 (-0.5181 to 
0.2408), p=0.47 
-0.0003 (-0.0028 to 
0.0022), p=0.80 
    
lag1 
-0.0544 (-0.5075 to 
0.3987), p=0.81 
-0.0003 (-0.0033 to 
0.0026), p=0.82 
0.1263 (-0.1661 to 
0.4187), p=0.40 
0.0001 (-0.0019 to 
0.0021), p=0.89 
lag2 
0.0271 (-0.4167 to 
0.4709), p=0.90 
-0.0001 (-0.0030 to 
0.0029), p=0.97 
-0.3413 (-0.7038 to 
0.0213), p=0.065 
-0.0016 (-0.0041 to 
0.0009), p=0.21 
lag3     
0.1722 (-0.1935 to 
0.5380), p=0.36 
0.0013 (-0.0012 to 
0.0038), p=0.32 
 
 
 
 
 
Table 2.57.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 8-hour ozone 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0027 (0.9832 
to 1.0226), 
p=0.79 
1.0151 (0.9915 
to 1.0393), 
p=0.21 
0.9812 (0.9417 
to 1.0223), 
p=0.36 
1.0001 (0.9823 
to 1.0182), 
p=0.99 
0.9961 (0.9646 
to 1.0286), 
p=0.81 
lag2 
1.0131 (0.9909 
to 1.0359), 
p=0.25 
1.0274 (0.9981 
to 1.0576), 
p=0.067 
1.0126 (0.9731 
to 1.0537), 
p=0.54 
1.0071 (0.9868 
to 1.0278), 
p=0.49 
0.9877 (0.9524 
to 1.0242), 
p=0.50 
lag3 
1.0016 (0.9794 
to 1.0243), 
p=0.89 
1.0254 (0.9975 
to 1.0541), 
p=0.074 
0.9782 (0.9347 
to 1.0238), 
p=0.34 
1.0016 (0.9818 
to 1.0218), 
p=0.88 
1.0027 (0.9685 
to 1.0381), 
p=0.88 
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Table 2.58.  Associations between PM10 and day time symptoms in two pollutant models 
with 8-hour ozone 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0053 
(0.9885 to 
1.0224), 
p=0.54 
1.0150 
(0.9936 to 
1.0369), 
p=0.17 
0.9965 
(0.9680 to 
1.0259), 
p=0.81 
1.0012 
(0.9826 to 
1.0201), 
p=0.90 
0.9824 
(0.9536 to 
1.0120), 
p=0.24 
0.9860 
(0.9606 to 
1.0121), 
p=0.29 
0.9956 
(0.9809 to 
1.0104), 
p=0.56 
lag1 
1.0042 
(0.9844 to 
1.0243), 
p=0.68 
0.9971 
(0.9706 to 
1.0245), 
p=0.84 
1.0001 
(0.9677 to 
1.0337), 
p=0.99 
0.9951 
(0.9747 to 
1.0160), 
p=0.64 
0.9980 
(0.9670 to 
1.0299), 
p=0.90 
0.9958 
(0.9676 to 
1.0248), 
p=0.78 
0.9954 
(0.9788 to 
1.0123), 
p=0.59 
lag2 
1.0153 
(0.9957 to 
1.0354), 
p=0.13 
0.9941 
(0.9674 to 
1.0216), 
p=0.67 
1.0066 
(0.9739 to 
1.0403), 
p=0.70 
0.9883 
(0.9678 to 
1.0092), 
p=0.27 
1.0021 
(0.9720 to 
1.0331), 
p=0.89 
1.0093 
(0.9827 to 
1.0367), 
p=0.50 
0.9964 
(0.9800 to 
1.0131), 
p=0.67 
 
 
 
 
Table 2.59.  Associations between PM10 and day time medication use in two pollutant 
models with 8-hour ozone 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
0.9958 (0.9727 to 1.0193), 
p=0.72 
0.9997 (0.9681 to 1.0323), 
p=0.99 
0.9912 (0.9684 to 1.0144), 
p=0.45 
lag1 
1.0155 (0.9870 to 1.0449), 
p=0.29 
1.0236 (0.9846 to 1.0642), 
p=0.24 
1.0092 (0.9818 to 1.0375), 
p=0.51 
lag2 
1.0079 (0.9793 to 1.0374), 
p=0.59 
1.0241 (0.9847 to 1.0650), 
p=0.23 
1.0050 (0.9775 to 1.0333), 
p=0.72 
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2.4.7.6 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 8-hour CO 
 
 
Table 2.60.  Associations between PM10 and lung function in two pollutant models with 8-
hour CO 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.1877 (-0.6581 to 
0.2826), p=0.43 
-0.0001 (-0.0033 to 
0.0032), p=0.97 
    
lag1 
-0.1537 (-0.7169 to 
0.4094), p=0.59 
-0.0014 (-0.0052 to 
0.0025), p=0.49 
0.3708 (-0.0045 to 
0.7460), p=0.053 
0.0028 (0.0001 to 
0.0056), p=0.042 
lag2 
-0.0218 (-0.5751 to 
0.5314), p=0.94 
-0.0002 (-0.0040 to 
0.0035), p=0.90 
-0.0382 (-0.4827 to 
0.4063), p=0.87 
-0.0005 (-0.0037 to 
0.0028), p=0.78 
lag3     
0.0252 (-0.4326 to 
0.4829), p=0.91 
-0.0011 (-0.0044 to 
0.0022), p=0.50 
 
 
 
 
 
Table 2.61.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 8-hour CO 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0163 (0.9960 
to 1.0370), 
p=0.12 
1.0408 (1.0140 
to 1.0682), 
p=0.003 
1.0207 (0.9854 
to 1.0572), 
p=0.25 
1.0152 (0.9953 
to 1.0355), 
p=0.14 
0.9991 (0.9640 
to 1.0355), 
p=0.96 
lag2 
1.0194 (0.9972 
to 1.0420), 
p=0.087 
1.0453 (1.0143 
to 1.0774), 
p=0.004 
1.0417 (1.0031 
to 1.0819), 
p=0.034 
1.0206 (0.9990 
to 1.0426), 
p=0.062 
0.9941 (0.9580 
to 1.0316), 
p=0.75 
lag3 
1.0114 (0.9896 
to 1.0336), 
p=0.31 
1.0361 (1.0062 
to 1.0670), 
p=0.018 
1.0319 (0.9927 
to 1.0726), 
p=0.11 
1.0178 (0.9969 
to 1.0391), 
p=0.095 
0.9921 (0.9561 
to 1.0294), 
p=0.67 
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Table 2.62.  Associations between PM10 and day time symptoms in two pollutant models 
with 8-hour CO 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
0.9991 
(0.9799 to 
1.0187), 
p=0.93 
1.0242 
(1.0016 to 
1.0473), 
p=0.036 
1.0178 
(0.9922 to 
1.0441), 
p=0.17 
1.0032 
(0.9830 to 
1.0239), 
p=0.76 
0.9912 
(0.9629 to 
1.0204), 
p=0.55 
1.0233 
(0.9991 to 
1.0480), 
p=0.060 
0.9988 
(0.9818 to 
1.0160), 
p=0.89 
lag1 
1.0229 
(1.0006 to 
1.0456), 
p=0.044 
1.0230 
(0.9952 to 
1.0515), 
p=0.11 
1.0269 
(0.9954 to 
1.0594), 
p=0.094 
0.9945 
(0.9723 to 
1.0172), 
p=0.63 
1.0114 
(0.9798 to 
1.0440), 
p=0.49 
1.0225 
(0.9947 to 
1.0511), 
p=0.11 
1.0175 
(0.9983 to 
1.0371), 
p=0.073 
lag2 
1.0179 
(0.9962 to 
1.0402), 
p=0.11 
1.0269 
(1.0002 to 
1.0543), 
p=0.049 
1.0269 
(0.9958 to 
1.0588), 
p=0.090 
0.9917 
(0.9697 to 
1.0142), 
p=0.47 
0.9963 
(0.9645 to 
1.0292), 
p=0.82 
1.0149 
(0.9875 to 
1.0431), 
p=0.29 
1.0085 
(0.9900 to 
1.0272), 
p=0.37 
 
 
 
 
 
Table 2.63.  Associations between PM10 and day time medication use in two pollutant 
models with 8-hour CO 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
1.0158 (0.9906 to 1.0418), 
p=0.22 
1.0271 (0.9928 to 1.0627), 
p=0.12 
1.0082 (0.9843 to 1.0327), 
p=0.51 
lag1 
1.0349 (1.0043 to 1.0664), 
p=0.025 
1.0621 (1.0176 to 1.1086), 
p=0.006 
1.0292 (1.0005 to 1.0587), 
p=0.046 
lag2 
1.0508 (1.0203 to 1.0823), 
p=0.001 
1.0567 (1.0133 to 1.1020), 
p=0.010 
1.0499 (1.0211 to 1.0795), 
p=0.0006 
 
 139 
 
 
2.4.7.7 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 1-hour SO2 
 
 
 
Table 2.64.  Associations between PM10 and lung function in two pollutant models with 1-
hour SO2 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.0118 (-0.5283 to 
0.5048), p=0.96 
-0.0003 (-0.0038 to 
0.0033), p=0.88 
    
lag1 
0.2130 (-0.4689 to 
0.8949), p=0.54 
0.0016 (-0.0031 to 
0.0063), p=0.51 
0.1153 (-0.2669 to 
0.4974), p=0.55 
0.0007 (-0.0019 to 
0.0032), p=0.62 
lag2 
-0.2673 (-0.9349 to 
0.4002), p=0.43 
0.0001 (-0.0045 to 
0.0047), p=0.95 
-0.7972 (-1.3148 to  
-0.2796), p=0.003 
-0.0041 (-0.0076 to  
-0.0006), p=0.023 
lag3     
0.1646 (-0.3440 to 
0.6732), p=0.53 
0.0028 (-0.0006 to 
0.0062), p=0.11 
 
 
 
 
 
Table 2.65.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 1-hour SO2 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0246 (1.0016 
to 1.0482), 
p=0.036 
0.9793 (0.9398 
to 1.0204), 
p=0.32 
0.9805 (0.9241 
to 1.0402), 
p=0.51 
1.0173 (0.9954 
to 1.0396), 
p=0.12 
0.9924 (0.9506 
to 1.0361), 
p=0.73 
lag2 
1.0269 (0.9993 
to 1.0552), 
p=0.056 
1.0229 (0.9827 
to 1.0648), 
p=0.27 
1.0317 (0.9756 
to 1.0912), 
p=0.27 
1.0256 (0.9992 
to 1.0528), 
p=0.058 
0.9594 (0.9135 
to 1.0077), 
p=0.098 
lag3 
1.0199 (0.9928 
to 1.0478), 
p=0.15 
0.9811 (0.9380 
to 1.0261), 
p=0.40 
1.0019 (0.9381 
to 1.0701), 
p=0.95 
1.0060 (0.9797 
to 1.0329), 
p=0.66 
0.9946 (0.9496 
to 1.0416), 
p=0.82 
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Table 2.66. Associations between PM10 and day time symptoms in two pollutant models with 
1-hour SO2 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0156 
(0.9919 to 
1.0398), 
p=0.20 
1.0153 
(0.9820 to 
1.0498), 
p=0.37 
0.9926 
(0.9506 to 
1.0364), 
p=0.74 
1.0244 
(1.0007 to 
1.0487), 
p=0.044 
1.0262 
(0.9800 to 
1.0745), 
p=0.27 
0.9971 
(0.9599 to 
1.0357), 
p=0.88 
1.0124 
(0.9922 to 
1.0329), 
p=0.23 
lag1 
1.0176 
(0.9899 to 
1.0462), 
p=0.21 
0.9953 
(0.9581 to 
1.0338), 
p=0.81 
1.0028 
(0.9563 to 
1.0515), 
p=0.91 
1.0395 
(1.0106 to 
1.0692), 
p=0.007 
1.0481 
(0.9972 to 
1.1015), 
p=0.064 
1.0082 
(0.9680 to 
1.0501), 
p=0.69 
1.0257 
(1.0018 to 
1.0502), 
p=0.035 
lag2 
1.0134 
(0.9854 to 
1.0422), 
p=0.35 
0.9999 
(0.9585 to 
1.0432), 
p=1.00 
1.0183 
(0.9668 to 
1.0725), 
p=0.49 
1.0223 
(0.9953 to 
1.0500), 
p=0.11 
1.0600 
(1.0020 to 
1.1214), 
p=0.042 
1.0238 
(0.9820 to 
1.0674), 
p=0.27 
1.0137 
(0.9912 to 
1.0367), 
p=0.23 
 
 
 
 
Table 2.67.  Associations between PM10 and day time medication use in two pollutant 
models with 1-hour SO2 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
1.0193 (0.9821 to 1.0578), 
p=0.31 
1.0111 (0.9588 to 1.0662), 
p=0.68 
1.0031 (0.9673 to 1.0403), 
p=0.87 
lag1 
1.0281 (0.9868 to 1.0712), 
p=0.18 
1.0318 (0.9764 to 1.0903), 
p=0.27 
1.0108 (0.9711 to 1.0522), 
p=0.60 
lag2 
1.0124 (0.9682 to 1.0586), 
p=0.59 
1.0447 (0.9896 to 1.1029), 
p=0.11 
1.0043 (0.9629 to 1.0475), 
p=0.84 
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2.4.7.8 Associations between PM10 and lung function, symptoms and medication use in 
two pollutant models with 24-hour SO2 
 
 
 
Table 2.68.  Associations between PM10 and lung function in two pollutant models with 
24-hour SO2 
 
Lag Evening PEF Evening FEV1 Morning PEF Morning FEV1 
PM10 24-hr 
lag0 
-0.0552 (-0.5757 to 
0.4652), p=0.84 
-0.0004 (-0.0040 to 
0.0031), p=0.81 
    
lag1 
0.2011 (-0.4789 to 
0.8810), p=0.56 
0.0015 (-0.0032 to 
0.0062), p=0.53 
0.1253 (-0.2592 to 
0.5098), p=0.52 
0.0007 (-0.0019 to 
0.0033), p=0.59 
lag2 
-0.2763 (-0.9362 to 
0.3837), p=0.41 
0.0001 (-0.0044 to 
0.0047), p=0.96 
-0.8187 (-1.3325 to  
-0.3048), p=0.002 
-0.0043 (-0.0078 to  
-0.0008), p=0.015 
lag3     
0.1926 (-0.3152 to 
0.7004), p=0.46 
0.0030 (-0.0004 to 
0.0064), p=0.083 
 
 
 
 
Table 2.69.  Associations between PM10 and night symptoms and medication use in two 
pollutant models with 24-hour SO2 
 
Lag Night cough Night wheeze 
Night 
shortness of 
breath 
Any night 
symptoms 
Any night 
reliever 
medications 
use 
PM10 24-hr 
lag1 
1.0267 (1.0033 
to 1.0507), 
p=0.025 
0.9800 (0.9400 
to 1.0217), 
p=0.34 
0.9841 (0.9270 
to 1.0448), 
p=0.60 
1.0188 (0.9965 
to 1.0416), 
p=0.098 
0.9911 (0.9491 
to 1.0349), 
p=0.68 
lag2 
1.0277 (1.0003 
to 1.0559), 
p=0.047 
1.0228 (0.9827 
to 1.0645), 
p=0.27 
1.0326 (0.9762 
to 1.0922), 
p=0.26 
1.0263 (1.0000 
to 1.0533), 
p=0.050 
0.9579 (0.9124 
to 1.0058), 
p=0.084 
lag3 
1.0197 (0.9926 
to 1.0476), 
p=0.16 
0.9812 (0.9378 
to 1.0266), 
p=0.41 
1.0022 (0.9382 
to 1.0706), 
p=0.95 
1.0055 (0.9793 
to 1.0325), 
p=0.68 
0.9925 (0.9478 
to 1.0392), 
p=0.75 
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Table 2.70.  Associations between PM10 and day time symptoms in two pollutant models 
with 24-hour SO2 
 
Lag 
Day 
cough 
Day 
wheeze 
Day 
shortness 
of breath 
Day 
runny 
nose 
Day eye 
irritation 
Day fever 
Any day 
symptoms 
PM10 24-hr 
lag0 
1.0158 
(0.9919 to 
1.0404), 
p=0.20 
1.0183 
(0.9843 to 
1.0535), 
p=0.29 
0.9907 
(0.9484 to 
1.0348), 
p=0.67 
1.0223 
(0.9985 to 
1.0468), 
p=0.067 
1.0252 
(0.9789 to 
1.0738), 
p=0.29 
1.0006 
(0.9628 to 
1.0398), 
p=0.98 
1.0117 
(0.9913 to 
1.0325), 
p=0.26 
lag1 
1.0180 
(0.9903 to 
1.0465), 
p=0.21 
0.9962 
(0.9588 to 
1.0350), 
p=0.84 
1.0025 
(0.9557 to 
1.0516), 
p=0.92 
1.0369 
(1.0082 to 
1.0664), 
p=0.012 
1.0481 
(0.9970 to 
1.1017), 
p=0.065 
1.0097 
(0.9693 to 
1.0517), 
p=0.64 
1.0253 
(1.0015 to 
1.0496), 
p=0.037 
lag2 
1.0122 
(0.9845 to 
1.0406), 
p=0.39 
1.0009 
(0.9595 to 
1.0441), 
p=0.97 
1.0164 
(0.9672 to 
1.0681), 
p=0.52 
1.0199 
(0.9927 to 
1.0479), 
p=0.15 
1.0547 
(1.0004 to 
1.1120), 
p=0.048 
1.0261 
(0.9833 to 
1.0708), 
p=0.24 
1.0119 
(0.9893 to 
1.0349), 
p=0.30 
 
 
 
 
 
Table 2.71.  Associations between PM10 and day time medication use in two pollutant 
models with 24-hour SO2 
 
Lag 
Day time reliever use for 
symptoms 
Day time preventer use 
for symptoms 
Any day time medication 
use for symptoms 
PM10 24-hr 
lag0 
1.0206 (0.9829 to 1.0598), 
p=0.29 
1.0112 (0.9595 to 1.0657), 
p=0.68 
1.0046 (0.9682 to 1.0424), 
p=0.81 
lag1 
1.0287 (0.9872 to 1.0720), 
p=0.18 
1.0305 (0.9754 to 1.0887), 
p=0.28 
1.0111 (0.9713 to 1.0526), 
p=0.59 
lag2 
1.0122 (0.9684 to 1.0579), 
p=0.59 
1.0476 (0.9907 to 1.1077), 
p=0.10 
1.0052 (0.9634 to 1.0487), 
p=0.81 
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3. DISCUSSION 
 
ACHAPS is the largest panel study on ambient air pollution and children’s respiratory health 
conducted anywhere in Australia. Two hundred and seventy primary school aged children 
from six cities (Sydney, Melbourne, Brisbane, Adelaide, Perth and Canberra) participated in this 
panel study.  
 
We investigated the effects of six air pollutants – PM10 (24-hr average), PM2.5 (24-hr average), 
ozone (1-hr maximum, 4-hr average, 8-hr average), NO2 (1-hr maximum, 24-hr average), SO2 (1-
hr maximum, 2 4-hr average) and CO (8-hr average) – on children’s respiratory health. Health 
outcomes considered included lung function, respiratory and non-respiratory symptoms, and 
medication use for asthma. 
3.1. Single pollutant models 
 
Single pollutant models produced only few significant adverse effects of air pollutants on 
children's respiratory health.  Many associations showed a beneficial effect of air pollutants on 
respiratory health.  The most consistent adverse effect was that increased NO2 exposure was 
associated with an increased risk of cough and wheeze, during the day and night, and increased 
use of bronchodilators for symptom relief. These findings are consistent with worsening asthma 
or asthma-like illness. The absence of a measurable impact on lung function may be due to the 
relief of bronchoconstriction due to the use of bronchodilators 
 
Morning and evening lung function 
 
There was only one significant adverse effect on lung function (lag 2 NO2 1-hr and morning 
FEV1).   
 
Night symptoms and use of asthma medications for symptoms 
 
Night symptoms were associated with CO, NO2 and PM10 with higher pollutant levels 
associated with greater risk of night symptoms, especially night cough.  Relationships between 
NO2 and night symptoms and effects were greater for NO2 24-hr than for NO2 1-hr were more 
consistent. There were protective effects for ozone and night wheeze and night shortness of 
breath and this was consistent across all the three metrics for ozone. There was only one 
significant association between air pollution and the use of reliever medication at night 
(association between SO2 1-hr and use of reliever medication at night).   
 
Day symptoms and use of asthma medications for symptoms 
 
Day time symptoms were more likely to be associated with NO2 (cough, wheeze and shortness 
of breath) and less likely to be associated with ozone (wheeze). Again, as was seen with night 
symptoms, there were more consistent relationships between NO2 and day time  symptoms and 
effects were greater for NO2 24-hr than for NO2 1-hr. Children were also more likely to use more 
reliever medications for asthma on days with higher NO2 concentrations. There was one 
association between air pollution (lag 2 PM10 24-hr) and preventer use for symptoms and a 
single association where higher ozone levels (lag 2 O3 8-hr) were associated with decreased use 
of preventers for symptoms. 
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3.2. Two pollutant models 
 
NO2 and ozone 
 
In two pollutant models compared to single pollutant models, the effects of NO2 on the lung 
function were increased whereas the effects on symptoms slightly decreased. Further, in the 
two pollutant models compared to single pollutant models, effects on day time medication use 
were no longer significant. 
 
PM10 and gases 
 
We also investigated the effects of PM10 in two pollutant models with each of the gases (O3, 
NO2, SO2 and CO). Significant negative effects on morning lung function were seen particularly 
when SO2 was included in the models. Associations between PM10 and both night and day time 
symptoms (cough and wheeze) generally persisted when NO2 and CO were added to the 
models. PM10 was also associated with runny nose when SO2 was included in the models. 
Significant increased use of day time reliever medications was only observed in two pollutant 
models with CO. The odds ratios in all models were consistently greater in the two pollutant 
models compared with single pollutant models especially for  
lag 1 PM10 and lag 2 PM10. 
 
SO2 and PM10 
 
In these two pollutant models with PM10, the SO2 effects were similar to the effect estimates 
from single pollutant models. Mainly protective effects were observed. 
3.3. Restricted models 
 
Warm season ozone models 
 
A warm season analysis was conducted for ozone as ozone levels are higher in the warmer 
months. The results were similar to those obtained when the analyses were conducted 
regardless of the season. There were no adverse associations between warm season ozone and 
lung function, symptoms and medication use in this sub-analysis. There were a few positive 
associations (beneficial effects) with night wheeze, that is, children experienced less wheeze 
symptoms during the night when ozone levels were high the previous day.  
 
SO2 analysis excluding Port Pirie 
 
We also conducted a sub-analysis for the effects of SO2 after excluding children from Port Pirie 
as Port Pirie has high ambient levels of SO2. A significant negative association is now seen 
between SO2 1-hr and morning PEF. The beneficial effects on day time symptoms are no longer 
apparent when children from Port Pirie were excluded from the analyses. In fact, there are now 
adverse effects especially with cough and runny nose. Children also tended to use more 
preventer medication for symptoms on days with higher SO2 1-hr levels.   
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3.4. Comparisons with other studies 
3.4.1. Particulate matter 
 
In a recent systematic review of particulate matter and panel studies (daily data for at least 
eight weeks) in children, Ward and Ayres (2004) reviewed 22 studies on the effects of 
particulate matter on PEF, cough and lower respiratory symptoms. In the 14 studies of PM10 
and PEF, all studies, but one, showed adverse effects. For a 1 ug/m3 increase in PM10, there was 
a 0.012 litre/min (95%CI: 0.008-0.017 litre/min) decrease in PEF. All five studies of PM2.5 and 
PEF showed adverse effects on PEF. A 1 ug/m3 increase in PM2.5, was associated with 0.063 
litre/min (95%CI: 0.034-0.094 litre/min) decrease in PEF. In the case of PM10, the pooled effect 
estimates for cough and lower respiratory symptoms were 1.000 (95%CI: 0.999-1.001) and 1.001 
(95%CI: 1.000-1.001) for a 1 ug/m3 increase respectively. For PM2.5, the pooled effect estimates 
for cough and lower respiratory symptoms were 1.005 (95%CI: 1.003-1.007) and 1.004 (95%CI: 
1.002-1.006) for a 1 ug/m3 increase respectively. However, the significant heterogeneity 
detected between the panel studies results raises questions about the transferability of the 
estimated pooled results. There was also evidence of publication bias especially for PM10 and 
PEF, again raising concerns about the validity of the pooled results. 
 
In a re-analysis of five panel studies, Hoek et al (Hoek, Dockery et al. 1998) found that the 
prevalence of decrements in PEF>10% significantly increased by 2.7% for every 10 ug/m3 
increase in PM10 and the population mean PEF significantly decreased by about 0.07 litres.  
 
In an eight city analysis, Schildcrout et al (Schildcrout, Sheppard et al. 2006) investigated 
associations between ambient air pollutants and asthma exacerbations (symptoms and 
medication use). There were no associations between PM10 and either asthma symptoms or the 
use of asthma medications.  
 
Mortimer et al (Mortimer, Neas et al. 2002) studied 846 children with asthma recruited from 
eight US urban centres focusing on the effects of ozone on lung function and symptoms.  
However, in subsidiary analysis, they demonstrated associations between cumulative lag 1-2 
PM10 and incidence of any morning asthma symptoms of cough, chest tightness or wheeze 
(OR=1.26, 95%CI: 1.00-1.59) in single pollutant models for a 10 ug/m3 change in PM10. In two 
pollutant models (with ozone) and in four pollutant models (with ozone, SO2 and NO2), 
although the effects were of similar magnitude, they were no longer significant. There were no 
significant effects on morning or evening PEF (except at lag 8) or evening symptoms. As the 
PM10 analyses were restricted to only three of the centres with PM10 data, the lack of an effect 
could be due to smaller sample sizes. 
 
A panel study  of 133 children in Seattle, Washington found increases in PM2.5 and PM10 to be 
significantly associated with an increased risk of more severe asthma attacks and medication 
use in children with asthma (Slaughter et al, 2003). 
 
Lewis et al (Lewis, Robins et al. 2005) studied 86 children with asthma with daily diaries. There 
were no associations between PM10 and PM2.5 and FEV1 for the children who were not taking 
maintenance corticosteroids. In those children taking maintenance corticosteroids for their 
asthma, there was a significant decrease in FEV1 with PM10 (beta=-2.21, 95%CI: -3.97 to -0.46; lag 
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2 PM10) but not with PM2.5. Adverse effects of both PM10 and PM2.5 seen at lag 3-5 if children 
reported symptoms of upper respiratory infection on the day of lung function measurements. 
 
Moshammer et al (Moshammer, Hutter et al. 2006) followed up 163 children with fortnightly 
lung function measurements. In single pollutant models, PM2.5 was associated with decrements 
in PEF (-0.41%)  and FEV1 (-0.23%) for a 10 ug/m3 increase in PM2.5. In a two pollutant model 
with NO2, effects were smaller (positive for FEV1) and were no longer significant.  
 
In a panel study, 861 children with persistent asthma from seven US urban communities kept 
two week asthma diaries every six month for two years (O'Connor, Neas et al. 2008). In single 
pollutant models, there were significant associations between lag 0-4 PM2.5 (13.2 ug/m3 
increase) and FEV1 (-1.47%, 95%CI: -2.0 to -0.94%), PEF (-1.10%, 95%CI: -1.65 to -0.56%) and 
missed school days (OR=1.33, 95%CI: 1.06-1.66) but not with days with asthma symptoms 
(cough, wheeze) and nights with asthma.  In three pollutant models with O3 and NO2, only the 
PEF effects remained significant.  
 
In a study from Mexico, Escamilla-Nunez et al (Escamilla-Nunez, Barraza-Villarreal et al. 2008) 
recruited 147 asthmatic children and 50 healthy children in a panel study of symptoms (wheeze 
and cough) and asthma medication use (preventers and relievers).  In single pollutant models, 
there was no association between PM2.5 and cough, wheeze or medication use. In three 
pollutant models (with O3 and NO2), PM2.5 was associated with wheeze only at lag 0. In children 
without asthma, there were no associations between PM2.5 and cough, wheeze or medication 
use. 
 
In a Canadian study of children with doctor diagnosed asthma , Dales et al (Dales, Chen et al. 
2009) found a significant association between PM2.5 and evening FEV1 in both single pollutant 
models (0.54% decrease in FEV1, 95%CI: 0.06-1.02% decrease, 6.0 ug/m3 increase in PM2.5). The 
association persisted in two pollutant models with ozone, NO2 and SO2. There were no effects 
of ozone, NO2 and SO2 on morning FEV1. There were also no effects of PM2.5, ozone, NO2 and 
SO2 on evening FEV1, PEF and symptoms (cough, wheeze, difficulty breathing and chest 
tightness).  
 
In Sydney, in a panel study of 125 symptomatic children conducted in 1994, there was a 
significant association between PM10 and doctor visits for asthma in both single pollution and 
three pollution (with ozone and NO2) models but not between PM10 and evening symptoms 
(cough and wheeze) and evening medication use for asthma (Jalaludin, O'Toole et al. 2004a). In 
the same study, there was no association between PM10 and PEF in population regression 
models (Jalaludin, Chey et al. 2000).  
 
In the Sydney panel study, the effects of bushfire PM on lung function (Jalaludin, Smith et al. 
2000) and on symptoms and medication use (Jalaludin, O'Toole et al. 2004b) were also 
investigated. There were no associations between daily PM10 and PEF except in a subgroup of 
children without bronchial hyper-reactivity where there was a negative association between 
PM10 and PEF.  In single pollutant models, the non-bushfire fraction of PM10 was associated 
with wet cough (lag 0, lag 2, lag 0-4), dry cough (lag 0, lag 0-4) and wheeze (lag 0-2, lag 0-4). 
There were no associations with asthma medication use.  
 
In another study investigating the effects of biomass PM, Johnston et al  (Johnston, Webby et al. 
2006) conducted a panel study of children and adults in Darwin over a period of seven months 
to determine the effects of deliberate landscape burnings on children’s symptoms, medication 
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use, missed school or work, and whether they saw a health care professional for asthma. In 
children, both PM2.5 and PM10 were significantly associated with becoming symptomatic (5 
ug/m3 increase in PM2.5: OR=1.148, 95%CI: 1.042-1.264; 10 ug/m3 increase in PM10: OR=1.247, 
95%CI: 1.058-1.468). There were no associations between PM and asthma attacks, medication 
use, missed school and seeing a health care professional for asthma.    
 
In a panel study of high school students from Christchurch, New Zealand, where PM10 is 
mainly from wood burning, small effects were seen in only children with asthma (Epton, 
Dawson et al. 2008). In this group of children, outdoor PM10 had small effects on evening PEF 
and cough. 
 
 
The ACHAPS study did not find any adverse effects of PM on lung function in single pollution 
models and a few associations with PM10 and symptoms (mainly cough and wheeze with ORs 
between 1.017 to 1.02 for a 1 ug/m3 increase in PM10). These effect estimates are much smaller 
than the pooled estimates from the meta-analysis conducted by Ward and Ayres (Ward and 
Ayres 2004). 
 
 
3.4.2. Ozone 
 
Most panel studies (where children have been undertaking their normal activities) have 
demonstrated decrements in PEF ranging from 0.2% to 2.2% for a 50 ppb increase in ambient 
ozone concentration  
(Krzyzanowski, Quackenboss et al. 1992; Neas, Dockery et al. 1995; Romieu, Meneses et al. 1996; 
Romieu, Meneses et al. 1997; Gold, Damokosh et al. 1999; Neas, Dockery et al. 1999). However, 
Hoek et al (Hoek, Brunekreef et al. 1993) found a 4% decrease in PEF, one study found no 
change in PEF (Vedal, Schenker et al. 1987) and another study demonstrated a non-significant 
2.4% increase in PEF (Gielen, van der Zee et al. 1997) for a 50 ppb increase in ambient ozone 
concentration.   
 
The effects of ozone are greater in those studies undertaken in summer camps in the US. In 
some of these studies, a 50 ppb increase in ambient ozone concentration was associated with 
about a 5% decrease in PEF (Raizenne, Burnett et al. 1989; Studnicka, Frischer et al. 1995; 
Thurston, Lippmann et al. 1997; Galizia and Kinney 1999).  
 
Mortimer et al (Mortimer, Neas et al. 2002) studied 846 children with asthma recruited from 
eight US urban centres focusing on the effects of ozone on lung function and symptoms.  A 15 
ppb increase in 5-day average 8-hr ozone was associated with a 0.59% (95%CI: 0.13-1.05%) 
decrease in morning PEF. There were no effects of individual daily lags (lag 1 to lag 6) and 
cumulative lag 1-4 ozone on morning PEF. A four day moving average ozone was significantly 
associated with any morning symptoms (cough, chest tightness, wheeze) (OR=1.16, 95%CI: 
1.02-1.30). There were no significant associations with evening PEF or evening symptoms.   
 
In a study of 21 children with mild asthma, Delfino et al (Delfino, Gong et al. 2003), did not find 
significant associations between ozone (1-hr maximum) and morning PEF, evening PEF and 
‘bothersome or more severe’ asthma symptoms.  
 
 148 
 
Lewis et al (Lewis, Robins et al. 2005) studied 86 children with asthma with daily diaries. There 
were no associations between O3 and FEV1 for the children who were not taking maintenance 
corticosteroids. However, in those children taking maintenance corticosteroids for their asthma, 
there was a significant decrease in FEV1 (beta=-3.95, 95%CI: -6.78 to -1.12; lag 2 O3 8-hr). 
Adverse effects of ozone were also more likely if children reported symptoms of upper 
respiratory infection on the day of lung function measurements. 
 
In an eight city panel study analysis from the US (Schildcrout, Sheppard et al. 2006), there were 
no significant associations between warm season ozone and  asthma symptoms and medication 
use.  
 
In a panel study, 861 children with persistent asthma from seven US urban communities kept 
two week asthma diaries every six month for two years (O'Connor, Neas et al. 2008). In single 
pollutant models, there were no significant associations between lag 0-4 ozone and FEV1, PEF, 
days with asthma symptoms (cough, wheeze), nights with asthma and missed school days. In 
three pollutant models with PM2.5 and NO2, ozone (lag 0-4 26.7 ppb) was now associated with 
decrements in PEF (-1.48%, 95%CI: -2.50 to -0.45%).  
 
In a study from Mexico, Escamilla-Nunez et al (Escamilla-Nunez, Barraza-Villarreal et al. 2008) 
recruited 147 asthmatic children and 50 healthy children in a panel study of symptoms (wheeze 
and cough) and asthma medication use (preventers and relievers).  In single pollutant models, 
all metrics of ozone (lag 0, lag 1, lag 2, lag 0-2, lag 0-3, lag 0-4) were significantly associated with 
cough, wheeze and reliever medication use.  In three pollutant models (with PM2.5 and NO2), 
ozone effects were mainly seen with cough and wheeze. In children without asthma, there were 
no associations between ozone and cough, wheeze or medication use. 
 
In Sydney, in a panel study of 125 symptomatic children conducted in 1994, there was a 
significant association between ozone and evening PEF in population regression models but not 
in GEE models. The association remained significant in two pollution models (ozone with PM10 
or with NO2) and in three pollution models (ozone with PM10 and NO2) (Jalaludin, Chey et al. 
2000).  In the same panel study, Jalaludin et al (Jalaludin, O'Toole et al. 2004) were not able to 
demonstrate relationships between ambient ozone and asthma symptoms, medication use and 
doctor visits for asthma.   
 
 
The ACHAPS study was not able to demonstrate any adverse effects of ambient ozone on 
children’s lung function, symptoms or medication use. In fact we see the opposite effect where 
ambient ozone appears to have a protective effect on symptoms of cough and wheeze. In a sub-
analysis restricted to the warm season (when ozone concentration would be higher), the results 
were similar to those obtained when the analyses were conducted regardless of the season.    
 
 
3.4.3. Nitrogen dioxide 
 
In a study from the United Kingdom, children with a history of asthma exposed to higher levels 
of NO2 (> 28 ug/m3) were more likely to experience an episode of asthma within seven days of 
an upper respiratory infection (OR=1.9, 95%CI: 1.1-3.4) compared to children exposed to lower 
levels of NO2 (≤8 ug/m3) (Linaker, Coggon et al. 2000).  
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Mortimer et al (Mortimer, Neas et al. 2002) studied 846 children with asthma recruited from 
eight US urban centres focusing on the effects of ozone on lung function and symptoms.  
However, in further analysis, they demonstrated associations between average lag 1 to lag 6 
NO2 and any morning asthma symptoms of cough, chest tightness or wheeze (OR=1.48, 95%CI: 
1.02-2.16) in single pollutant models for a 20 ppb change in NO2. Effects were no longer 
significant in two pollutant models (with ozone), three pollutant models (with ozone and SO2) 
and four pollutant models (ozone, SO2 and PM10). There were no significant associations with 
morning or evening PEF or evening symptoms.  
 
In a study of 21 children with mild asthma, Delfino et al (Delfino, Gong et al. 2003), found 
significant associations between 1-hr and 8-hr NO2 and ‘bothersome or more severe’ asthma 
symptoms but there were no associations between 1-hr NO2 and morning PEF and evening 
PEF.  
 
Schildcrout et al (Schildcrout, Sheppard et al. 2006), in a panel study of 990 children in eight 
cities in the US, found associations between NO2 and any asthma symptoms (lag 2 NO2: 
OR=1.09, 95%CI: 1.03-1.15; lag 0-2 NO2: OR=1.04, 95%CI: 1.01-1.07; 20 ppb change in NO2) and 
with the use of rescue inhalers (lag 2 NO2: RR=1.05, 95%CI: 1.01-1.09; lag 0-2 NO2: RR=1.03, 
95%CI: 1.01-1.05; 20 ppb change in NO2).   
 
Moshammer et al (Moshammer, Hutter et al. 2006) followed up 163 children with fortnightly 
lung function measurements. In single pollutant models, NO2 was associated with decrements 
in FEV1 of about 1% for a 10 ug/m3 increase in NO2. In a two pollutant model with PM2.5, the 
effect on FEV1 was similar. 
 
In a panel study, 861 children with persistent asthma from seven US urban communities kept 
two week asthma diaries every six month for two years (O'Connor, Neas et al. 2008). In single 
pollutant models, there were significant associations between lag 0-4 NO2 (20.4 ppb) and FEV1 (-
1.36, 95%CI: -1.92 to -0.80), PEF (-1.66, 95%CI: -2.24 to -1.08), night asthma (37%, 95%CI: 8-73%) 
and missed school days (OR=1.67, 95%CI: 1.18-2.36). There were no associations with days with 
asthma symptoms (cough and wheeze). In three pollutant models with PM2.5 and ozone, the 
adverse NO2 effects on FEV1 and PEF remained significant; however, associations with night 
asthma and missed school days were now non-significant and associations with days of cough 
and wheeze became significant.   
 
In a study from Mexico, Escamilla-Nunez et al (Escamilla-Nunez, Barraza-Villarreal et al. 2008) 
recruited 147 asthmatic children and 50 healthy children in a panel study of symptoms (wheeze 
and cough) and asthma medication use (preventers and relievers).  In single pollutant models, 
all metrics of NO2 (lag 0, lag 1, lag 2, lag 0-2, lag 0-3, lag 0-4) were significantly associated with 
cough, wheeze and reliever medication use.  In three pollutant models (with PM2.5 and O3), NO2 
effects were mainly seen with cough and reliever medication use. In children without asthma, 
an association was observed only between lag 0-1 NO2 and cough. 
 
A Sydney panel study of 125 symptomatic children conducted in 1994, showed no association 
between NO2 and evening PEF in single pollutant models and in two pollutant models with 
ozone (Jalaludin, Chey et al. 2000). In the same panel study, Jalaludin et al (Jalaludin, O'Toole et 
al. 2004) were able to demonstrate relationships between ambient NO2 and prevalence of 
evening wet cough but not with other evening symptoms  (wheeze and dry cough), medication 
use (inhaled relievers and preventers) and doctor visits for asthma.   
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In the ACHAPS study, the most consistent results were seen with NO2.  Consistent 
relationships between NO2 and night symptoms (cough, wheeze and shortness of breath) and 
effects were greater for NO2 24-hr than for NO2 1-hr. There were also more consistent 
relationships between NO2 and day time  symptoms and effects were greater for NO2 24-hr than 
for NO2 1-hr. Children were also more likely to use more reliever medications for asthma on 
days with higher NO2 concentrations. 
 
 
3.4.4. Sulphur dioxide 
 
Mortimer et al (Mortimer, Neas et al. 2002) studied 846 children with asthma recruited from 
eight US urban centres focusing on the effects of ozone on lung function and symptoms.  
However, in further analysis, they demonstrated associations between average lag 1 and lag 2 
SO2 and any morning asthma symptoms of cough, chest tightness or wheeze (OR=1.19, 95%CI: 
1.06-1.35) in single pollutant models for a 20 ppb change in SO2. Significant effects remained in 
two pollutant models (with ozone) and three pollutant models (with ozone and NO2) but not in 
four pollutant models (with ozone, NO2 and PM10). There were no significant associations with 
morning or evening PEF or evening symptoms.  
 
In a study of 21 children with mild asthma, Delfino et al (Delfino, Gong et al. 2003), found 
significant associations between 1-hr and 8-hr SO2 and ‘bothersome or more severe’ asthma 
symptoms and with 1-hr SO2 and evening PEF. There were no associations between 1-hr SO2 
and morning PEF.  
 
In an eight city panel study analysis of 990 children from the US (Schildcrout, Sheppard et al. 
2006), there were no significant associations between SO2 and  asthma symptoms and 
medication use.  
 
In a panel study, 861 children with persistent asthma from seven US urban communities kept 
two week asthma diaries every six month for two years (O'Connor, Neas et al. 2008). In single 
pollutant models, there were significant associations between lag 0-4 SO2 (12.4 ppb) and FEV1 (-
1.60, 95%CI: -2.54 to -0.67) and PEF (-2.14, 95%CI: -3.08 to -1.19) but not with days with asthma 
symptoms (cough, wheeze), nights with asthma and missed school days. Multi-pollutant 
analyses were not conducted for SO2.   
 
Dales et al (Dales, Chen et al. 2009) in a panel study of 182 children did not find associations 
between SO2 and FEV1 and PEF, but however found an association between SO2 and chest 
tightness (OR=1.30, 95%CI: 1.06-1.58; highest quartile SO2 [≥8.8 ppb] versus lowest quartile SO2 
[<2.3 ppb]).  
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In the ACHAPS study, in single pollutant models, mainly beneficial effects were seen except for 
lag 1 SO2 1-hr and nighttime reliever medication use. In a restricted analysis for the effects of 
SO2 after excluding children from Port Pirie, a significant negative association was seen 
between SO2 1-hr and morning PEF. The beneficial effects on day time symptoms were now no 
longer apparent. In fact, there were now adverse effects especially with cough and runny nose. 
Children also tended to use more preventer medication for symptoms on days with higher SO2 
1-hr levels.   
 
 
3.4.5. Carbon monoxide 
 
In a study of 21 children with mild asthma, Delfino et al (Delfino, Gong et al. 2003), found no 
significant associations between 1-hr and 8-hr CO and ‘bothersome or more severe’ asthma 
symptoms and between 1-hr CO and morning PEF or evening PEF.  
 
In an eight city panel study analysis from the US, 990 children were studied (Schildcrout, 
Sheppard et al. 2006) for the effects of air pollution on asthma symptoms and medication use. In 
single pollutant models, CO was associated with asthma symptoms (OR=1.08, 95%CI: 1.01-1.14 
for 1 ppm CO) and rescue asthma inhalers (OR=1.07, 95%CI: 1.01-1.13 for 1 ppm CO).  
 
In a panel study, 861 children with persistent asthma from seven US urban communities kept 
two week asthma diaries every six month for two years (O'Connor, Neas et al. 2008). In single 
pollutant models, there were significant associations between lag 0-4 CO (872 ppb) and 
increased days with asthma symptoms (cough and wheeze) (26%, 95%CI: 3-55%) and nights 
with asthma (35%, 95%CI: 7-71%), but not with FEV1, PEF and missed school days. Multi-
pollutant analyses were not conducted for CO.   
 
There are no published Australian panel studies that have investigated the effects of ambient 
CO on childrens’ respiratory health. However, in a birth cohort followed-up over five years 
(follow-up at age 6 weeks, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years),  Rodriguez et 
al (Rodriguez, Tonkin et al. 2007) investigated the effects of ambient air pollutants (lag 0, lag 5 
and lag 0-5 for CO, NO2, O3, PM2.5 and BSP) on symptoms of respiratory illness such as 
runny/blocked nose, cough, wheeze and fever. There were significant associations between lag 
5 and lag 0-4 CO 8-hr and runny/blocked nose and wheeze with the estimates slightly larger for 
lag 5 (runny blocked nose: OR=1.380, 95%CI: 1.028-1.853; wheeze: OR=1.136, 95%CI: 1.016-
1.260) compared to lag 0-4.  
 
 
The ACHAPS study did not find associations between CO and lung function. There were three 
negative associations with symptoms (night cough, night shortness of breath and day wheeze). 
As only 17 of the 27 AQMs monitored for CO, we had a smaller sample size for the CO analyses 
which may made it more difficult to detect small effects. 
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3.5. Methodological issues 
 
3.5.1. Measurement of lung function 
 
In this study, lung function (PEF and FEV1) was measured using a Mini-Wright Digital 
electronic peak flow meter. The electronic peak flow meters were given to each child and they 
recorded three successive measurements in the morning and three successive measurements in 
the evening. The highest PEF and FEV1 from these three successive measurements were 
automatically stored in the electronic peak flow device with a date and time stamp. The use of 
an electronic peak flow meter where measurements are automatically stored for the researcher 
to download at a later time avoids the problem of under or over reporting.  
 
Peak flow meters are widely used in longitudinal studies because they are portable and 
relatively inexpensive, allowing frequent measures of lung function at low cost. Furthermore, 
the PEFs obtained from the mini Wright peak flow meter are comparable with those derived 
from spirometry (Lebowitz 1982; Sanz, Martorell et al. 1990; Thurston, Lippmann et al. 1997; 
Lippmann and Spektor 1998).  It has also been demonstrated that individual peak flow meters 
are highly reproducible (r=0.999) (Morrill, Dickey et al. 1981).   
 
In a paper relevant to this current study, Lippmann et al. (Lippmann and Spektor 1998) 
reported that, in 91 children aged eight to 15 years, there was about a 9% underestimation of 
PEF measured by mini Wright peak flow meters compared to PEFs derived from spirometry. 
However, when both spirometry PEF and mini Wright PEF were regressed on average ozone 
concentration in the previous hour, the coefficients were similar (-6.780.73 mL/sec/ppb ozone 
and -6.630.76 mL/sec/ppb ozone respectively). The authors suggested that the mini Wright 
peak flow meter is a convenient and effective tool for characterising changes in PEF associated 
with exposure to ambient ozone.   
 
There has also been a view that PEF is a measure of the function of the large airways (Vedal, 
Schenker et al. 1987) and PEF may not be able to detect changes in the small airways associated 
with asthma. In a cross-sectional study to determine chronic effects of air pollution on lung 
function in children and adults, larger reductions in PEF than in either FVC or FEV1 were found 
(Schwartz 1989), suggesting that PEF might be a more sensitive indicator of the effects of air 
pollution on airways. 
 
In summary, it has been demonstrated that the PEF, as measured by a mini Wright peak flow 
meter, is both accurate and reproducible and can be used in epidemiological studies to measure 
lung function. The mini Wright peak flow meter is a convenient and effective tool for 
characterising changes in PEF associated with exposure to ambient air pollution. 
3.5.2. Fixed site air pollution monitoring 
 
In this study, air quality data from fixed site ambient air quality monitoring stations were used 
to characterise individual exposure to ambient air pollutants. There have been concerns that the 
use of such fixed site ambient ozone monitoring stations may not adequately characterise the 
actual personal exposure to ambient air pollutants especially as people spend a large proportion 
of their time indoors where the air pollution concentrations can be much lower than ambient 
concentrations. 
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However, any misclassification of exposure would bias the results towards the null (Neas, 
Dockery et al. 1995; Romieu, Meneses et al. 1996). Similarly, any misreporting of lung function 
and symptoms in asthma diaries by children would be non-differential as parents and children 
would generally not know the days that were high ambient air pollution days at the time of 
recording and hence any subsequent bias would be towards the null (Romieu, Meneses et al. 
1996). 
 
Therefore, any measurement bias in exposure that might have operated in this study would 
have biased the results towards the null, and any significant association would indicate a real 
effect. 
3.5.3. Accuracy of diary keeping 
 
A longitudinal study where the subjects are required to measure their lung function with a peak 
flow meter and complete an asthma dairy twice a day for a 5-6 week period represents a 
significant burden on the subjects and their families. It is likely that, despite instructions to not 
complete diaries retrospectively, there would be children in the study who during the study 
period would have incorrectly reported their symptoms and medication use in the diary.   
 
However, this incorrect reporting is most likely to be non-differential and hence any associated 
bias would be towards the null. However, in multivariate models, where there may also be non-
differential errors in the assessment of the exposure, the effect could be less predictable 
(Naeher, Holford et al. 1999). 
 
Missing data are also a recognised problem in studies that rely on self-reporting of symptoms. 
Neas et al. (Neas, Dockery et al. 1995) have suggested that if missing data (lung function, 
symptoms and medication use) are not correlated with ambient pollution levels, then it implies 
that the missing data occurred at random and hence would not lead to bias. It is unlikely that 
children and parents would be aware of high air pollution days and therefore any misreported 
data or missing data would most likely bias the results towards the null and minimise the 
potential for type 1 error. 
3.5.4. Learning effect 
 
Many investigators have excluded the first few days of observations and sometimes up to two 
weeks of observations to exclude a learning effect in the use of the peak flow meter. It has been 
assumed that the recorded lung function for a period of time up to a week could be inaccurate 
because the children are still learning the proper use of the peak flow meters.  Although there 
appears to be some theoretical justification for this, some investigators have not detected a 
learning effect (Neas, Dockery et al. 1995; Studnicka, Frischer et al. 1995; Scarlett, Abbott et al. 
1996; Naeher, Holford et al. 1999).  However, in this study, the first three days of diary data 
were discarded so as to account for any possible learning effect. 
3.5.5. Hours spent outdoors doing vigorous physical activity 
 
Exposure to ambient ozone not only depends on the concentration of the ambient air pollutants 
but also on the number of hours spent outdoors and on the activity level whilst outdoors. 
Therefore, it would seem desirable to control for the effects of both the number of hours spent 
outdoors and activity levels. 
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Krzyzanowski et al. (Krzyzanowski, Quackenboss et al. 1992) have suggested that only 
measuring the number of hours spent outdoors, without also measuring the specific hours the 
subjects were indoors/outdoors, was not a good measure of total ambient exposure. Linn et al. 
(Linn, Shamoo et al. 1996) did attempt to measure time spent outdoors and activity levels 
(completing a questionnaire before each time spirometry was performed) in their longitudinal 
study of school children. However, about 25% of the questionnaires demonstrated 
inconsistencies in reported activity levels for successive days, so these data were not used to 
calculate the overall ambient ozone exposures, and only the number of hours spent outdoors 
was used as a measure of ambient ozone exposure.    
 
Dales et al (Dales, Chen et al. 2009) in a panel study of 182 primary school children 
investigating the effects of air pollutants on FEV1, found that associations were no different 
between those children who spent at least two hours daily outdoors and those who spent less 
than two hours daily outdoors. 
 
In the study, participating children were asked to report, on each day, the number of hours 
spent outdoors doing vigorous physical activity and we used this as a covariate in the 
regression models. 
3.5.6. Effects of temperature  
 
There are issues about the shape of the relationship between temperature and lung function, 
that is, whether the relationship is linear or non-linear. Neas et al. (Neas, Dockery et al. 1995) 
have suggested that when there is a narrow temperature range (11ºC to 29ºC in their study), the 
temperature effect was likely to be linear. In this current study there were no compelling 
reasons to model mean daily temperature as anything other than a continuous variable. During 
this study, the median mean daily temperature was also in a narrow range (15ºC to 23ºC) and a 
linear relationship would be expected between temperature and lung function.   
3.5.7. Single-pollutant versus multi-pollutant models 
 
As well as single pollutant models, multi-pollutant models were also constructed. The Air 
Pollution on Health: European Approach (APHEA) project was a multinational program to 
determine the associations between air pollution and short term health effects (number of daily 
deaths and number of daily hospital admissions) (Katsouyanni, Zmirou et al. 1995). One of its 
aims was also to develop and standardise the methodology for the detection of short term 
effects in the analysis of epidemiological time-series data. As many air pollutants are often 
moderately to strongly correlated with each other, the APHEA protocol therefore recommends 
caution when modelling the effects of air pollution in multi-pollutant models (Katsouyanni, 
Schwartz et al. 1996; Schwartz, Spix et al. 1996), as in such models, collinearity can lead to 
unstable regression coefficients.   
 
Across all the 27 AQMs, there was moderate correlation between PM10 and PM2.5 (r=0.65). There 
were very high correlations among the three metrics for ozone (r=0.94-0.99), the two metrics for 
SO2 (r=0.90) and the two metrics for NO2 (r=0.84). Otherwise, the correlations between air 
pollutants were generally weak. The lack of strong correlations among the air pollutants 
enabled two pollutant models to be constructed to identify the independent effects of air 
pollutants.   
3.5.8. Collinearity among the independent variables 
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Collinearity among the independent or explanatory variables is an important issue in air 
pollution research. There are often moderate to strong correlations among the air pollution and 
meteorological variables, especially between ambient ozone concentration and temperature. In 
the United States, there is also often a moderate to strong correlation between ambient ozone 
and ambient PM10 concentrations. When strong collinearity exists between two variables it is 
not possible to determine the independent effects of each of those two variables.  
 
This is one of the main reasons why the APHEA protocol recommends caution when modelling 
the effects of air pollution in multi-pollutant models (Katsouyanni, Schwartz et al. 1996; 
Schwartz, Spix et al. 1996)  as multi-pollutant models, where collinearity exist, can lead to 
unstable regression coefficients.   
 
In this study, we centred the temperature variable so as to avoid collinearity between the air 
pollutants and daily mean temperature.  
3.5.9. Multiple comparisons 
 
Although many tests of association were conducted in this study, corrections for multiple 
comparisons (for example, Bonferroni’s correction) were not employed. It has been strongly 
argued by Rothman (Rothman and Greenland 1998) that no adjustments for multiple 
comparisons need be made even if a large number of comparisons are reported at the one time, 
provided all results are reported (both negative and positive results, that is, both non-significant 
and significant results). Therefore, corrections for multiple comparisons were not employed. 
Subsequently, all results need to be reviewed critically, and any significant result should be 
considered suggestive only, unless or until supported by other published studies. 
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Part D 
 
Conclusions 
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Despite the fact that there are some inconsistencies in the international literature on the effects 
of air pollution on children’s respiratory health, the weight of the evidence does appear to 
suggest that the adverse effects of air pollution are real.  
 
Inconsistencies in study findings may be attributed to: 
 
 intrinsic differences between cities or regions in terms of climates, pollutant mixes, or 
particulate chemistry, all of which may modify or confound observed associations, or 
make separation of individual effects variously difficult 
 
 differences between populations at risk in terms of inherent susceptibility, outdoor and 
indoor exposures, and time activity 
 
 study designs: experimental studies in relation to air pollution and children cannot be 
performed, so evidence relies on a variety of study designs from ecological designs 
(considered the weakest in terms of scientific evidence of causality) to prospective 
designs (considered the strongest); however, all studies will be subject to confounding to 
some degree 
 
 differing metrics for air pollutants, ranging from individualised monitors to routine 
fixed monitors to proxy measures such as distance to heavy traffic roads 
 
 differing health outcomes and methods of ascertainment 
 
 differing statistical analyses, despite development of protocols such as APHEA. 
 
In considering these factors, one needs to separate issues of bias (attributed to uncontrolled 
confounding; for example, from those of imprecision (attributed to random error in measuring 
exposure, for example). The latter are less of a concern since they would act to attenuate 
associations and result in conservative findings.  Bias is a far more contentious issue since 
findings could be invalid; that is, either over- or under-stated.   
 
Somewhat paradoxically, though, consistent findings in different settings, with different 
confounding factors, argues for evidence of a real effect – if a given finding is due to 
confounding or use of a specific methodological approach, why should it be replicated in 
another environment with different confounders or methodology? 
 
Perhaps the single most influential study of air pollution and child health is the SCCHS, which 
most recently has shown consistent adverse effects of measured air pollutants on lung function 
growth on prospectively gathered data.  Other outcomes include supportive evidence from 
cross-sectional analyses including traffic density studies, demonstrated health improvement 
when children move from a higher to a lower pollution area, and implication of air pollution in 
onset of asthma, as opposed to exacerbation. 
 
Many panel studies have demonstrated adverse effects of air pollutants on lung function, 
respiratory symptoms and medication use for asthma and, in most cases, these effects are small. 
For example, panel studies conducted in summer camps in the US where children are 
physically active outdoors show, on average, about a 5% decrease in PEF for a 50 ppb increase 
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in ambient O3 concentration.  Panel studies where children are engaging in their normal daily 
activities show smaller decrements in lung function.  
 
Although the decreases found in lung function are relatively small and may be clinically 
unimportant, Hoek et al. (Hoek, Dockery et al., 1998) demonstrated some interesting outcomes 
in relation to exposure to ambient PM10.  A 10 g/m3 increase in PM10 was associated with only 
a 0.07% decrease in population PEF but with a 3% increase in the prevalence of PEF more than 
20% below the median which would be clinically significant.  The authors suggest that there 
was a shift in the whole PEF distribution to the left.  Therefore, in population terms, even a 
small decrease in average lung function might have important effects at the extreme ends of the 
distribution (Rose and Day, 1990), and an unexpected large population impact.   
 
Asthma is the most common chronic disease in childhood in Australia.  The International Study 
on Asthma and Allergies in Childhood Steering Committee (ISAAC, 1998) reported that, in 
Australia, the prevalence of asthma in children aged 13–14 years was about 30%.  More recent 
data suggest that 16-26% of children will ever have a diagnosis of asthma and that 18-23% of 
children have current asthma (AIHW Australian Centre for Asthma Monitoring, 2008). 
Therefore, this is a large group of children susceptible to the respiratory effects of ambient air 
pollution.  
 
It is thought that air pollutants may affect the airways of children with asthma by acting as 
secondary or trigger factors in children with airway hyperresponsiveness, by functioning as 
primary factors to initiate and increase airway inflammation, thereby leading to airway 
hyperresponsiveness, by having a direct toxic effect on the airways leading to asthma-like 
symptoms in normal individuals, or by affecting the immune system resulting in sensitisation 
or increased allergic responses in the airways (Barnes 1994). 
 
Children and infants may be particularly at increased risk from ambient air pollution for a 
number of reasons including the following:  
 In the first few months after birth, an infant’s metabolic pathways are still developing 
and due to this biochemical immaturity, an infant cannot detoxify and excrete toxins as 
well as adults (Tamburlini, Ehrenstein et al., 2002).  
 Infants and children inhale and retain larger amounts of air pollution per unit of body 
weight than adults. 
 The narrow bronchioles of young children are more likely to be constricted in response 
to environmental irritants than the bronchioles of adults.  
 Children’s normal growth may be affected when exposed to pollutants at critical periods 
(Mathieu-Nolf, 2002). 
 Children spend more time outdoors than adults and, hence, are more exposed to 
ambient air pollutants (Bates, 1995; Mathieu-Nolf, 2002).  
 
Exposure to ambient air pollution can also have long term impacts.  There is increasing 
evidence that maternal exposure to ambient air pollutants is associated with adverse pregnancy 
outcomes, in particular, risk of low birth weight, foetal growth restriction, and pre-term 
delivery (Glinianaia, Rankin et al., 2004; Mannes, Jalaludin et al., 2005; Sram, Binkova et al., 
2005; Jalaludin, Mannes et al., 2007; Ritz and Wilhelm, 2008), and recent qualitative reviews 
have concluded these effects are likely to be causal (WHO, 2005).  This more recent evidence is 
of concern as birth weight is an important predictor of perinatal and infant mortality 
(McCormick, 1985), childhood morbidity and disability (Pharoah, Cooke et al., 1990) and 
chronic diseases later in life, such as cardiovascular disease and diabetes  (Robinson, 2001; 
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Barker, 2004).  Thus, contribution of air pollution, as a risk factor, to the burden of disease has 
important public health implications.  
 
Children exposed to long-term air pollution can also be adversely affected.  The cohort studies 
to date have mainly focused on the effects of air pollution on lung growth in children and have 
found associations between ambient air pollutants and reduced lung growth (Frischer, 
Studnicka et al., 1999; Gauderman et al., 2000, 2002, 2004; Horak, Studnicka et al., 2002).  
Children recruited in these studies have generally been from grade one at school and onwards 
(6-7 years plus).  One study (Gehring, Cyrys et al., 2002) has also investigated the effects of air 
pollution on lung growth or the development of asthma in younger children.  There are also 
some studies that have used a birth cohort to investigate the effects of air pollution on the 
incidence of asthma and allergies (Brauer, Hoek et al., 2002; Brauer, Hoek et al., 2007; 
Rodriguez, Tonkin et al., 2007).  There is now growing evidence that there are chronic effects of 
air pollution on children’s respiratory health. 
 
Therefore, a continuing question remains about the chronic effects of ambient air pollutant 
exposure on lung function in children.  As children’s lungs are still growing and maturing, 
long-term exposure to ambient air pollutants may result in pathophysiological changes that 
may continue into adult life.  The effects of long-term exposure (over years) to air pollutants on 
pulmonary function and lung growth have been increasingly studied.  However, there is an 
urgent need for further studies on the chronic adverse health effects of ambient air pollutants on 
not only lung function and lung growth, but also on other health outcomes such as 
cardiovascular disease and diabetes.   
 
Although air pollution levels are relatively low in most regions of Australia, they may not be 
low enough to prevent adverse health effects, findings that have implications for the future 
revisions of the Australian air quality guidelines.  Major reductions in the combustion emissions 
(PM, CO, NO2 and precursors of ambient O3; that is, oxides of nitrogen and reactive organic 
chemicals) will be required to counter the expected increase in air pollution as a result of the 
demands of a growing population.  While current control measures are mainly targeted at 
motor vehicles, these measures need to be supplemented by urban design and transport 
demand strategies to lower and maintain those lower levels of ambient air pollutants.   
 
An important question is whether exposure to air pollution control should revolve around 
setting air quality limits; for example, NEPMs in Australia or National Ambient Air Quality 
Standards in the US, or whether an option would be to take the exposure-reduction approach 
(Laxen and Moorcroft 2005).  In Australia, the current approach is to set NEPMs and require 
jurisdictions to meet the NEPMs.  There are no requirements for jurisdictions to take measures 
to reduce exposure where concentrations are already below the NEPM.  Such a regulatory 
measure is reasonable for air pollutants that have an established threshold for adverse health 
effects.  However, many air pollutants do not have a threshold (for example, PM and O3) 
(World Health Organisation, 2006, 2008) and levels even below the NEPM have been 
demonstrated to have adverse health effects.  The exposure-reduction approach, which aims to 
shift the exposure of the whole population, seems a reasonable way to reduce the whole 
community’s exposure to ambient air pollution.  
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